<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:cc="http://web.resource.org/cc/"
 xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:admin="http://webns.net/mvcb/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel rdf:about="https://www.mdpi.com/rss/journal/viruses">
		<title>Viruses</title>
		<description>Latest open access articles published in Viruses at https://www.mdpi.com/journal/viruses</description>
		<link>https://www.mdpi.com/journal/viruses</link>
		<admin:generatorAgent rdf:resource="https://www.mdpi.com/journal/viruses"/>
		<admin:errorReportsTo rdf:resource="mailto:support@mdpi.com"/>
		<dc:publisher>MDPI</dc:publisher>
		<dc:language>en</dc:language>
		<dc:rights>Creative Commons Attribution (CC-BY)</dc:rights>
						<prism:copyright>MDPI</prism:copyright>
		<prism:rightsAgent>support@mdpi.com</prism:rightsAgent>
		<image rdf:resource="https://pub.mdpi-res.com/img/design/mdpi-pub-logo.png?13cf3b5bd783e021?1778581344"/>
				<items>
			<rdf:Seq>
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/554" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/553" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/552" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/551" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/550" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/549" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/548" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/547" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/546" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/545" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/544" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/543" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/542" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/541" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/540" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/539" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/538" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/537" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/536" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/535" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/534" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/533" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/532" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/531" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/530" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/529" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/528" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/527" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/526" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/524" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/525" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/523" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/522" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/521" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/517" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/519" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/520" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/518" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/516" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/515" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/513" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/514" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/512" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/511" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/510" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/509" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/508" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/507" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/506" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/505" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/504" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/503" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/502" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/501" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/500" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/499" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/498" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/497" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/496" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/495" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/494" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/493" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/492" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/491" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/490" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/489" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/488" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/487" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/486" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/485" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/484" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/5/483" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/482" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/481" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/480" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/479" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/478" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/477" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/476" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/475" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/474" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/473" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/472" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/471" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/470" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/469" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/468" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/467" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/466" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/465" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/464" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/463" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/462" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/461" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/460" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/459" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/458" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/457" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/456" />
            				<rdf:li rdf:resource="https://www.mdpi.com/1999-4915/18/4/455" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="https://creativecommons.org/licenses/by/4.0/" />
	</channel>

        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/554">

	<title>Viruses, Vol. 18, Pages 554: Emerging Trends in HIV-1 Sub-Subtype A6 in Belgium: Transmission Dynamics, Drug Resistance, and Subtyping Tool Evaluation</title>
	<link>https://www.mdpi.com/1999-4915/18/5/554</link>
	<description>The international spread of HIV-1 sub-subtype A6 raises concerns due to its association with contraindications for long-acting injectable formulations of cabotegravir (LA-CAB) and rilpivirine (LA-RPV). This study investigated its increasing proportion in Belgium, assessing transmission dynamics and potential migration links. Additionally, genotypic drug resistance in the Belgian HIV-1 sub-subtype A6 population were analyzed and four automatic subtyping tools were compared. A dataset of 4764 HIV-1 protease and reverse transcriptase (RT) sequences from newly diagnosed, treatment-na&amp;amp;iuml;ve individuals in Belgium (2013&amp;amp;ndash;2022) was analyzed. A combination of phylogenetic analysis and online subtyping tools identified 136 sub-subtype A6 sequences. The increase in the proportion of HIV-1 sub-subtype A6 observed in Belgium since 2020 reflects changing transmission patterns, especially among Belgium-born men having sex with men, and cannot be solely linked to the recent influx of Ukrainian migrants. Of these sub-subtype A6 sequences, less than 10% showed LA-CAB + LA-RPV resistance, mainly due to E138A within RT. HIVdb and ANRS reliably assessed resistance in this therapy-na&amp;amp;iuml;ve cohort, and HIVdb, COMET, and SmartGene&amp;amp;reg; produced concordant subtyping results. While algorithm choice has little impact at low resistance prevalence, further research is necessary and HIVdb and ANRS remain more suitable for ongoing clinical and research use.</description>
	<pubDate>2026-05-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 554: Emerging Trends in HIV-1 Sub-Subtype A6 in Belgium: Transmission Dynamics, Drug Resistance, and Subtyping Tool Evaluation</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/554">doi: 10.3390/v18050554</a></p>
	<p>Authors:
		Virginie Mortier
		Laurent Debaisieux
		Deborah De Geyter
		Marie-Luce Delforge
		Melissa Depypere
		Géraldine Dessilly
		Benoît Kabamba-Mukadi
		Khalid El Moussaoui
		Samy Mzougui
		Ben Serrien
		Karolien Stoffels
		Dominique Van Beckhoven
		Ellen Van Cutsem
		Dorien Van den Bossche
		Sigi Van den Wijngaert
		Fien Vanroye
		Elizaveta Padalko
		Chris Verhofstede
		Kristel Van Laethem
		</p>
	<p>The international spread of HIV-1 sub-subtype A6 raises concerns due to its association with contraindications for long-acting injectable formulations of cabotegravir (LA-CAB) and rilpivirine (LA-RPV). This study investigated its increasing proportion in Belgium, assessing transmission dynamics and potential migration links. Additionally, genotypic drug resistance in the Belgian HIV-1 sub-subtype A6 population were analyzed and four automatic subtyping tools were compared. A dataset of 4764 HIV-1 protease and reverse transcriptase (RT) sequences from newly diagnosed, treatment-na&amp;amp;iuml;ve individuals in Belgium (2013&amp;amp;ndash;2022) was analyzed. A combination of phylogenetic analysis and online subtyping tools identified 136 sub-subtype A6 sequences. The increase in the proportion of HIV-1 sub-subtype A6 observed in Belgium since 2020 reflects changing transmission patterns, especially among Belgium-born men having sex with men, and cannot be solely linked to the recent influx of Ukrainian migrants. Of these sub-subtype A6 sequences, less than 10% showed LA-CAB + LA-RPV resistance, mainly due to E138A within RT. HIVdb and ANRS reliably assessed resistance in this therapy-na&amp;amp;iuml;ve cohort, and HIVdb, COMET, and SmartGene&amp;amp;reg; produced concordant subtyping results. While algorithm choice has little impact at low resistance prevalence, further research is necessary and HIVdb and ANRS remain more suitable for ongoing clinical and research use.</p>
	]]></content:encoded>

	<dc:title>Emerging Trends in HIV-1 Sub-Subtype A6 in Belgium: Transmission Dynamics, Drug Resistance, and Subtyping Tool Evaluation</dc:title>
			<dc:creator>Virginie Mortier</dc:creator>
			<dc:creator>Laurent Debaisieux</dc:creator>
			<dc:creator>Deborah De Geyter</dc:creator>
			<dc:creator>Marie-Luce Delforge</dc:creator>
			<dc:creator>Melissa Depypere</dc:creator>
			<dc:creator>Géraldine Dessilly</dc:creator>
			<dc:creator>Benoît Kabamba-Mukadi</dc:creator>
			<dc:creator>Khalid El Moussaoui</dc:creator>
			<dc:creator>Samy Mzougui</dc:creator>
			<dc:creator>Ben Serrien</dc:creator>
			<dc:creator>Karolien Stoffels</dc:creator>
			<dc:creator>Dominique Van Beckhoven</dc:creator>
			<dc:creator>Ellen Van Cutsem</dc:creator>
			<dc:creator>Dorien Van den Bossche</dc:creator>
			<dc:creator>Sigi Van den Wijngaert</dc:creator>
			<dc:creator>Fien Vanroye</dc:creator>
			<dc:creator>Elizaveta Padalko</dc:creator>
			<dc:creator>Chris Verhofstede</dc:creator>
			<dc:creator>Kristel Van Laethem</dc:creator>
		<dc:identifier>doi: 10.3390/v18050554</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-12</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>554</prism:startingPage>
		<prism:doi>10.3390/v18050554</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/554</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/553">

	<title>Viruses, Vol. 18, Pages 553: Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence</title>
	<link>https://www.mdpi.com/1999-4915/18/5/553</link>
	<description>The gut microbiota, often referred to as the &amp;amp;ldquo;forgotten organ&amp;amp;rdquo;, plays an indispensable role in maintaining host physiological metabolism, immune function, and nutrient absorption. Moreover, the gut microbiome serves as a critical biological barrier against viral infections and is increasingly recognized as a potential target to augment antiviral therapies. Recent studies have revealed that microbial ligands and metabolites derived from the gut microbiota are pivotal in modulating respiratory immune responses, providing compelling evidence of the complex interaction network between microorganisms and the host, particularly the signaling pathways linking the gut to distal organs such as the lungs. This review examines the communication and regulatory mechanisms between the gut microbiota and pulmonary mucosal surfaces during influenza virus infection, emphasizing how gut microbial communities and probiotics influence host immune responses, promote the production of immune-related molecules, and enhance antiviral defenses. The aim is to provide comprehensive insights into the gut&amp;amp;ndash;lung axis and its implications for respiratory health.</description>
	<pubDate>2026-05-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 553: Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/553">doi: 10.3390/v18050553</a></p>
	<p>Authors:
		Feihu Guan
		Jie Zhang
		Ye Tian
		Bofan Fu
		Ji Liu
		Yafen Song
		Aoyang Yan
		Bing Zhang
		Ling Chen
		Min Zhang
		Pengfei Du
		Lei Wang
		Xiaoyue Yang
		Sifan Guo
		Chenghuai Yang
		Hui Zhang
		Qianyi Zhang
		</p>
	<p>The gut microbiota, often referred to as the &amp;amp;ldquo;forgotten organ&amp;amp;rdquo;, plays an indispensable role in maintaining host physiological metabolism, immune function, and nutrient absorption. Moreover, the gut microbiome serves as a critical biological barrier against viral infections and is increasingly recognized as a potential target to augment antiviral therapies. Recent studies have revealed that microbial ligands and metabolites derived from the gut microbiota are pivotal in modulating respiratory immune responses, providing compelling evidence of the complex interaction network between microorganisms and the host, particularly the signaling pathways linking the gut to distal organs such as the lungs. This review examines the communication and regulatory mechanisms between the gut microbiota and pulmonary mucosal surfaces during influenza virus infection, emphasizing how gut microbial communities and probiotics influence host immune responses, promote the production of immune-related molecules, and enhance antiviral defenses. The aim is to provide comprehensive insights into the gut&amp;amp;ndash;lung axis and its implications for respiratory health.</p>
	]]></content:encoded>

	<dc:title>Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence</dc:title>
			<dc:creator>Feihu Guan</dc:creator>
			<dc:creator>Jie Zhang</dc:creator>
			<dc:creator>Ye Tian</dc:creator>
			<dc:creator>Bofan Fu</dc:creator>
			<dc:creator>Ji Liu</dc:creator>
			<dc:creator>Yafen Song</dc:creator>
			<dc:creator>Aoyang Yan</dc:creator>
			<dc:creator>Bing Zhang</dc:creator>
			<dc:creator>Ling Chen</dc:creator>
			<dc:creator>Min Zhang</dc:creator>
			<dc:creator>Pengfei Du</dc:creator>
			<dc:creator>Lei Wang</dc:creator>
			<dc:creator>Xiaoyue Yang</dc:creator>
			<dc:creator>Sifan Guo</dc:creator>
			<dc:creator>Chenghuai Yang</dc:creator>
			<dc:creator>Hui Zhang</dc:creator>
			<dc:creator>Qianyi Zhang</dc:creator>
		<dc:identifier>doi: 10.3390/v18050553</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-12</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>553</prism:startingPage>
		<prism:doi>10.3390/v18050553</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/553</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/552">

	<title>Viruses, Vol. 18, Pages 552: Dynamics of Paraspeckle Components in Herpes Simplex Virus 1 (HSV-1)-Infected Human Neuronal Cells</title>
	<link>https://www.mdpi.com/1999-4915/18/5/552</link>
	<description>Paraspeckles are subnuclear ribonucleoprotein condensates that regulate host stress responses, including those triggered by viral infection. In vitro studies using non-neuronal cells have shown the involvement of specific paraspeckle components in facilitating the replication of certain viruses, including Herpes Simplex Virus 1 (HSV-1), but these processes have not been investigated in human neuronal cells, which represent a relevant target of the virus. We employed human neural precursor cells (NPCs), neurons, and brain organoids derived from hiPSCs to investigate the previously unexplored dynamics of paraspeckle components in HSV-1-infected human neuronal cells. Our results reveal cell-type-specific differences in the expression of paraspeckle genes in response to HSV-1 infection. Unlike other viruses, HSV-1 orchestrates a previously unreported redistribution of paraspeckle proteins, leading to their accumulation in viral replication compartments (VRCs). Importantly, the expression of the paraspeckle proteins NONO and SFPQ correlates with HSV-1 permissiveness in human neuronal cells and may be required to establish a nuclear environment favoring viral transcription/replication. This enhances our understanding of how stress-response pathways in cells can be exploited by viruses in a cell-type-specific manner.</description>
	<pubDate>2026-05-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 552: Dynamics of Paraspeckle Components in Herpes Simplex Virus 1 (HSV-1)-Infected Human Neuronal Cells</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/552">doi: 10.3390/v18050552</a></p>
	<p>Authors:
		Carolina Filipponi
		David C. Bloom
		Carlo Gambotto
		Callen T. Wallace
		Jadranka Milosevic
		Simon C. Watkins
		Shane Buckley
		Maribeth A. Wesesky
		Vishwajit L. Nimgaonkar
		Leonardo D’Aiuto
		</p>
	<p>Paraspeckles are subnuclear ribonucleoprotein condensates that regulate host stress responses, including those triggered by viral infection. In vitro studies using non-neuronal cells have shown the involvement of specific paraspeckle components in facilitating the replication of certain viruses, including Herpes Simplex Virus 1 (HSV-1), but these processes have not been investigated in human neuronal cells, which represent a relevant target of the virus. We employed human neural precursor cells (NPCs), neurons, and brain organoids derived from hiPSCs to investigate the previously unexplored dynamics of paraspeckle components in HSV-1-infected human neuronal cells. Our results reveal cell-type-specific differences in the expression of paraspeckle genes in response to HSV-1 infection. Unlike other viruses, HSV-1 orchestrates a previously unreported redistribution of paraspeckle proteins, leading to their accumulation in viral replication compartments (VRCs). Importantly, the expression of the paraspeckle proteins NONO and SFPQ correlates with HSV-1 permissiveness in human neuronal cells and may be required to establish a nuclear environment favoring viral transcription/replication. This enhances our understanding of how stress-response pathways in cells can be exploited by viruses in a cell-type-specific manner.</p>
	]]></content:encoded>

	<dc:title>Dynamics of Paraspeckle Components in Herpes Simplex Virus 1 (HSV-1)-Infected Human Neuronal Cells</dc:title>
			<dc:creator>Carolina Filipponi</dc:creator>
			<dc:creator>David C. Bloom</dc:creator>
			<dc:creator>Carlo Gambotto</dc:creator>
			<dc:creator>Callen T. Wallace</dc:creator>
			<dc:creator>Jadranka Milosevic</dc:creator>
			<dc:creator>Simon C. Watkins</dc:creator>
			<dc:creator>Shane Buckley</dc:creator>
			<dc:creator>Maribeth A. Wesesky</dc:creator>
			<dc:creator>Vishwajit L. Nimgaonkar</dc:creator>
			<dc:creator>Leonardo D’Aiuto</dc:creator>
		<dc:identifier>doi: 10.3390/v18050552</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-12</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>552</prism:startingPage>
		<prism:doi>10.3390/v18050552</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/552</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/551">

	<title>Viruses, Vol. 18, Pages 551: Special Issue: Microscopy Methods for Virus Research</title>
	<link>https://www.mdpi.com/1999-4915/18/5/551</link>
	<description>Significant advances in microscopy methods for biomedical applications have been made in the past two decades, and these methods are now being actively pursued for virus research [...]</description>
	<pubDate>2026-05-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 551: Special Issue: Microscopy Methods for Virus Research</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/551">doi: 10.3390/v18050551</a></p>
	<p>Authors:
		Krishanu Ray
		</p>
	<p>Significant advances in microscopy methods for biomedical applications have been made in the past two decades, and these methods are now being actively pursued for virus research [...]</p>
	]]></content:encoded>

	<dc:title>Special Issue: Microscopy Methods for Virus Research</dc:title>
			<dc:creator>Krishanu Ray</dc:creator>
		<dc:identifier>doi: 10.3390/v18050551</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-12</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>551</prism:startingPage>
		<prism:doi>10.3390/v18050551</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/551</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/550">

	<title>Viruses, Vol. 18, Pages 550: Microglial-Derived IGF-1 Serves as a Regulator for Neuroimmune Homeostasis During Viral-Induced Demyelination</title>
	<link>https://www.mdpi.com/1999-4915/18/5/550</link>
	<description>This study investigated the role of microglia-derived insulin-like growth factor 1 (IGF-1) in modulating host defense and disease progression in a viral model of neuroinflammation and demyelination. Intracranial infection of susceptible mice with the glial-tropic JHM strain of mouse hepatitis virus (JHMV) induces acute encephalomyelitis, followed by an immune-mediated demyelinating disease that mimics many clinical and histologic features of multiple sclerosis (MS). Utilizing an inducible fractalkine receptor (Cx3cr1) promoter-driven Cre-loxP recombinant system, we performed timed ablation of Igf1 in microglia to assess its impact on the central nervous system (CNS) response to JHMV. While the loss of microglial IGF-1 did not impair the control of viral replication, it significantly exacerbated spinal cord demyelination. CyTOF and imaging mass cytometry analysis of spinal cords indicated increased myelin damage was associated with increased accumulation of CD8+Ly6C+ effector T cells and reduced expression of TREM2 that impaired transition into a disease-associated microglia (DAM) phenotype capable of sensing and potentially mitigating myelin damage. Collectively, these findings argue that microglial IGF-1 is a non-redundant coordinator of the CNS immune responses that occur in response to CNS viral infection.</description>
	<pubDate>2026-05-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 550: Microglial-Derived IGF-1 Serves as a Regulator for Neuroimmune Homeostasis During Viral-Induced Demyelination</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/550">doi: 10.3390/v18050550</a></p>
	<p>Authors:
		Vanessa M. Scarfone
		Collin Pachow
		Pauline U. Nguyen
		Anita Lakatos
		Jamie-Jean De La Torre
		Alisa Xie
		Kellie Fernandez
		Charlene Collado
		Kaitlin Murray
		Roberto Tinoco
		Craig M. Walsh
		Trevor Owens
		Agnieszka Wlodarczyk
		Thomas E. Lane
		</p>
	<p>This study investigated the role of microglia-derived insulin-like growth factor 1 (IGF-1) in modulating host defense and disease progression in a viral model of neuroinflammation and demyelination. Intracranial infection of susceptible mice with the glial-tropic JHM strain of mouse hepatitis virus (JHMV) induces acute encephalomyelitis, followed by an immune-mediated demyelinating disease that mimics many clinical and histologic features of multiple sclerosis (MS). Utilizing an inducible fractalkine receptor (Cx3cr1) promoter-driven Cre-loxP recombinant system, we performed timed ablation of Igf1 in microglia to assess its impact on the central nervous system (CNS) response to JHMV. While the loss of microglial IGF-1 did not impair the control of viral replication, it significantly exacerbated spinal cord demyelination. CyTOF and imaging mass cytometry analysis of spinal cords indicated increased myelin damage was associated with increased accumulation of CD8+Ly6C+ effector T cells and reduced expression of TREM2 that impaired transition into a disease-associated microglia (DAM) phenotype capable of sensing and potentially mitigating myelin damage. Collectively, these findings argue that microglial IGF-1 is a non-redundant coordinator of the CNS immune responses that occur in response to CNS viral infection.</p>
	]]></content:encoded>

	<dc:title>Microglial-Derived IGF-1 Serves as a Regulator for Neuroimmune Homeostasis During Viral-Induced Demyelination</dc:title>
			<dc:creator>Vanessa M. Scarfone</dc:creator>
			<dc:creator>Collin Pachow</dc:creator>
			<dc:creator>Pauline U. Nguyen</dc:creator>
			<dc:creator>Anita Lakatos</dc:creator>
			<dc:creator>Jamie-Jean De La Torre</dc:creator>
			<dc:creator>Alisa Xie</dc:creator>
			<dc:creator>Kellie Fernandez</dc:creator>
			<dc:creator>Charlene Collado</dc:creator>
			<dc:creator>Kaitlin Murray</dc:creator>
			<dc:creator>Roberto Tinoco</dc:creator>
			<dc:creator>Craig M. Walsh</dc:creator>
			<dc:creator>Trevor Owens</dc:creator>
			<dc:creator>Agnieszka Wlodarczyk</dc:creator>
			<dc:creator>Thomas E. Lane</dc:creator>
		<dc:identifier>doi: 10.3390/v18050550</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-09</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>550</prism:startingPage>
		<prism:doi>10.3390/v18050550</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/550</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/549">

	<title>Viruses, Vol. 18, Pages 549: Intersecting Epidemics: A Multilevel Syndemic Analysis of a Chikungunya Virus Epidemic in Colombia Through Clinical, Biological, and Socioeconomic Factors</title>
	<link>https://www.mdpi.com/1999-4915/18/5/549</link>
	<description>This study applied a syndemic framework to chikungunya virus (CHIKV) infection during the 2014&amp;amp;ndash;2015 Colombian epidemic, integrating biological and social determinants. Methods: A community-based cohort of 279 serologically confirmed adults from six cities was analyzed. Clinical, sociodemographic, and cytokine data were evaluated using multilevel and multivariate statistical approaches. Results: Among 279 patients, 141 (50. 5%) met World Health Organization (WHO) criteria for acute CHIKV infection. The cohort was predominantly female and of lower socioeconomic status (SES). The most frequent manifestations were arthralgia (91%), fatigue (58%), fever (50.5%), myalgia (45.9%), and rash (45.2%). Multivariate models identified IL-15, IL-17A, IL-12p40, MCP-1, and MIP-1&amp;amp;alpha; as significant correlates of fever, rash, and myalgia. Socioeconomic and ethnic factors influenced cytokine expression; Caucasian patients showed higher proinflammatory cytokine levels than Afro-American patients. Lower SES was associated with greater symptom burden. Network analyses revealed distinct immune signatures linking biological responses with clinical and demographic variables. Conclusion: Immune responses, clinical manifestations, and social disadvantages interact significantly in CHIKV infection. These findings support a syndemic model in which socioeconomic vulnerability amplifies disease impact, highlighting the need for integrated biosociological public health strategies, particularly targeting populations with low socioeconomic status.</description>
	<pubDate>2026-05-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 549: Intersecting Epidemics: A Multilevel Syndemic Analysis of a Chikungunya Virus Epidemic in Colombia Through Clinical, Biological, and Socioeconomic Factors</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/549">doi: 10.3390/v18050549</a></p>
	<p>Authors:
		Juan C. Rueda
		Ana María Santos
		Ignacio Angarita
		Ingris Peláez-Ballesta
		Alfonso Gastelum
		Igor Rueda
		Jaime Cortés-Ramos
		Cristian Astudillo
		Daniel Rincón-Sierra
		Karina Guzmán
		Jesús Giovanny Ballesteros
		Juan Manuel Bello
		John Londono
		</p>
	<p>This study applied a syndemic framework to chikungunya virus (CHIKV) infection during the 2014&amp;amp;ndash;2015 Colombian epidemic, integrating biological and social determinants. Methods: A community-based cohort of 279 serologically confirmed adults from six cities was analyzed. Clinical, sociodemographic, and cytokine data were evaluated using multilevel and multivariate statistical approaches. Results: Among 279 patients, 141 (50. 5%) met World Health Organization (WHO) criteria for acute CHIKV infection. The cohort was predominantly female and of lower socioeconomic status (SES). The most frequent manifestations were arthralgia (91%), fatigue (58%), fever (50.5%), myalgia (45.9%), and rash (45.2%). Multivariate models identified IL-15, IL-17A, IL-12p40, MCP-1, and MIP-1&amp;amp;alpha; as significant correlates of fever, rash, and myalgia. Socioeconomic and ethnic factors influenced cytokine expression; Caucasian patients showed higher proinflammatory cytokine levels than Afro-American patients. Lower SES was associated with greater symptom burden. Network analyses revealed distinct immune signatures linking biological responses with clinical and demographic variables. Conclusion: Immune responses, clinical manifestations, and social disadvantages interact significantly in CHIKV infection. These findings support a syndemic model in which socioeconomic vulnerability amplifies disease impact, highlighting the need for integrated biosociological public health strategies, particularly targeting populations with low socioeconomic status.</p>
	]]></content:encoded>

	<dc:title>Intersecting Epidemics: A Multilevel Syndemic Analysis of a Chikungunya Virus Epidemic in Colombia Through Clinical, Biological, and Socioeconomic Factors</dc:title>
			<dc:creator>Juan C. Rueda</dc:creator>
			<dc:creator>Ana María Santos</dc:creator>
			<dc:creator>Ignacio Angarita</dc:creator>
			<dc:creator>Ingris Peláez-Ballesta</dc:creator>
			<dc:creator>Alfonso Gastelum</dc:creator>
			<dc:creator>Igor Rueda</dc:creator>
			<dc:creator>Jaime Cortés-Ramos</dc:creator>
			<dc:creator>Cristian Astudillo</dc:creator>
			<dc:creator>Daniel Rincón-Sierra</dc:creator>
			<dc:creator>Karina Guzmán</dc:creator>
			<dc:creator>Jesús Giovanny Ballesteros</dc:creator>
			<dc:creator>Juan Manuel Bello</dc:creator>
			<dc:creator>John Londono</dc:creator>
		<dc:identifier>doi: 10.3390/v18050549</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-09</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>549</prism:startingPage>
		<prism:doi>10.3390/v18050549</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/549</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/548">

	<title>Viruses, Vol. 18, Pages 548: Application of a Blood&amp;ndash;Brain Barrier Organ-on-a-Chip Model for Assessment of Countermeasure Efficiency Against Eastern Equine Encephalitis Virus</title>
	<link>https://www.mdpi.com/1999-4915/18/5/548</link>
	<description>Infection by neurotropic alphaviruses such as the Eastern equine encephalitis virus (EEEV) causes extensive inflammation in the central nervous system and tissue damage, including disruption of the blood&amp;amp;ndash;brain barrier (BBB). Neuroinflammation and BBB disruption following infection are critical pathological considerations for the development of robust countermeasure strategies. Encephalitic disease resulting from EEEV infection currently lacks FDA-approved therapeutic intervention strategies, thus exposing a major capability gap in the ability to address the global health burden that could result from alphavirus infections. In this manuscript, we present a gravity-flow Neurovascular Unit (gNVU) model of the human BBB that may be used for modeling EEEV-induced neuropathology and evaluating countermeasures. The data generated using this model show that EEEV infection causes a time-dependent disruption of BBB integrity and increases the inflammatory load in a manner that correlates with an increase in the viral load. The data also show that the route of introduction of the pathogen has an impact on the pathology measured, with infection through the brain side eliciting a greater inflammatory outcome than infection through the vascular route. Overall, the included data support the utility of this organ-on-a-chip (OOC) platform of the human BBB in understanding encephalitic disease caused by neurotropic viruses and evaluation of therapeutic intervention strategies.</description>
	<pubDate>2026-05-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 548: Application of a Blood&amp;ndash;Brain Barrier Organ-on-a-Chip Model for Assessment of Countermeasure Efficiency Against Eastern Equine Encephalitis Virus</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/548">doi: 10.3390/v18050548</a></p>
	<p>Authors:
		Niloufar A. Boghdeh-Olson
		Michael D. Barrera
		Clayton M. Britt
		David K. Schaffer
		Jacquelyn A. Brown
		John P. Wikswo
		Aarthi Narayanan
		</p>
	<p>Infection by neurotropic alphaviruses such as the Eastern equine encephalitis virus (EEEV) causes extensive inflammation in the central nervous system and tissue damage, including disruption of the blood&amp;amp;ndash;brain barrier (BBB). Neuroinflammation and BBB disruption following infection are critical pathological considerations for the development of robust countermeasure strategies. Encephalitic disease resulting from EEEV infection currently lacks FDA-approved therapeutic intervention strategies, thus exposing a major capability gap in the ability to address the global health burden that could result from alphavirus infections. In this manuscript, we present a gravity-flow Neurovascular Unit (gNVU) model of the human BBB that may be used for modeling EEEV-induced neuropathology and evaluating countermeasures. The data generated using this model show that EEEV infection causes a time-dependent disruption of BBB integrity and increases the inflammatory load in a manner that correlates with an increase in the viral load. The data also show that the route of introduction of the pathogen has an impact on the pathology measured, with infection through the brain side eliciting a greater inflammatory outcome than infection through the vascular route. Overall, the included data support the utility of this organ-on-a-chip (OOC) platform of the human BBB in understanding encephalitic disease caused by neurotropic viruses and evaluation of therapeutic intervention strategies.</p>
	]]></content:encoded>

	<dc:title>Application of a Blood&amp;amp;ndash;Brain Barrier Organ-on-a-Chip Model for Assessment of Countermeasure Efficiency Against Eastern Equine Encephalitis Virus</dc:title>
			<dc:creator>Niloufar A. Boghdeh-Olson</dc:creator>
			<dc:creator>Michael D. Barrera</dc:creator>
			<dc:creator>Clayton M. Britt</dc:creator>
			<dc:creator>David K. Schaffer</dc:creator>
			<dc:creator>Jacquelyn A. Brown</dc:creator>
			<dc:creator>John P. Wikswo</dc:creator>
			<dc:creator>Aarthi Narayanan</dc:creator>
		<dc:identifier>doi: 10.3390/v18050548</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-09</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>548</prism:startingPage>
		<prism:doi>10.3390/v18050548</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/548</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/547">

	<title>Viruses, Vol. 18, Pages 547: Hypoxia-Enhanced N110 Glycosylation of Hemagglutinin Promotes H3N2 Influenza Virus Fitness by Modulating Receptor Binding and Immune Evasion</title>
	<link>https://www.mdpi.com/1999-4915/18/5/547</link>
	<description>The hemagglutinin (HA) of influenza A/H3N2 virus evolves rapidly, with glycosylation driving immune evasion. However, how host microenvironmental cues influence this process remains poorly understood. We identified a novel N-linked glycosylation site at position 110 (N110) in contemporary H3N2 viruses (NSS genotype) that enhances viral fitness by increasing receptor-binding signal, HA cleavage, and replication. Remarkably, hypoxia, which mimics the respiratory tract microenvironment, significantly augments N110 glycosylation. Mechanistically, we identified the B4GAT1-B4GALT1 complex as the key mediator of this modification. Hypoxia upregulates their expression and strengthens their interaction with HA. In ferret models, N110-glycosylated viruses exhibit heightened pathogenicity and evade ancestral antibodies. Furthermore, immunization with N110-containing HA confers broad-spectrum protection, whereas reciprocal immunization is ineffective. Our findings reveal hypoxia-driven glycosylation as a previously unrecognized mechanism of H3N2 adaptation, providing critical insights for vaccine efficacy and highlighting the importance of integrating microenvironmental factors into future antiviral strategies.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 547: Hypoxia-Enhanced N110 Glycosylation of Hemagglutinin Promotes H3N2 Influenza Virus Fitness by Modulating Receptor Binding and Immune Evasion</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/547">doi: 10.3390/v18050547</a></p>
	<p>Authors:
		Ting Zhang
		Yihui Fang
		Jie Liu
		Ao Guo
		Bin Yuan
		Yanan Zhang
		Lihua Ding
		Qinong Ye
		</p>
	<p>The hemagglutinin (HA) of influenza A/H3N2 virus evolves rapidly, with glycosylation driving immune evasion. However, how host microenvironmental cues influence this process remains poorly understood. We identified a novel N-linked glycosylation site at position 110 (N110) in contemporary H3N2 viruses (NSS genotype) that enhances viral fitness by increasing receptor-binding signal, HA cleavage, and replication. Remarkably, hypoxia, which mimics the respiratory tract microenvironment, significantly augments N110 glycosylation. Mechanistically, we identified the B4GAT1-B4GALT1 complex as the key mediator of this modification. Hypoxia upregulates their expression and strengthens their interaction with HA. In ferret models, N110-glycosylated viruses exhibit heightened pathogenicity and evade ancestral antibodies. Furthermore, immunization with N110-containing HA confers broad-spectrum protection, whereas reciprocal immunization is ineffective. Our findings reveal hypoxia-driven glycosylation as a previously unrecognized mechanism of H3N2 adaptation, providing critical insights for vaccine efficacy and highlighting the importance of integrating microenvironmental factors into future antiviral strategies.</p>
	]]></content:encoded>

	<dc:title>Hypoxia-Enhanced N110 Glycosylation of Hemagglutinin Promotes H3N2 Influenza Virus Fitness by Modulating Receptor Binding and Immune Evasion</dc:title>
			<dc:creator>Ting Zhang</dc:creator>
			<dc:creator>Yihui Fang</dc:creator>
			<dc:creator>Jie Liu</dc:creator>
			<dc:creator>Ao Guo</dc:creator>
			<dc:creator>Bin Yuan</dc:creator>
			<dc:creator>Yanan Zhang</dc:creator>
			<dc:creator>Lihua Ding</dc:creator>
			<dc:creator>Qinong Ye</dc:creator>
		<dc:identifier>doi: 10.3390/v18050547</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>547</prism:startingPage>
		<prism:doi>10.3390/v18050547</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/547</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/546">

	<title>Viruses, Vol. 18, Pages 546: NLR Inflammasomes in Viral Infections: From Molecular Mechanisms to Therapeutic Interventions</title>
	<link>https://www.mdpi.com/1999-4915/18/5/546</link>
	<description>The innate immune system serves as the primary barrier against viral invasion, utilizing pattern recognition receptors (PRRs) to orchestrate a rapid defense. Among these, the nucleotide-binding domain and leucine-rich repeat (NLR) containing proteins function as central signaling scaffolds, assembling into multiprotein complexes known as inflammasomes. These complexes drive the maturation of pro-inflammatory cytokines IL-1&amp;amp;beta; and IL-18, and initiate gasdermin D (GSDMD)-mediated pyroptosis, a lytic cell death pathway that eliminates intracellular replication niches. This comprehensive review synthesizes the diversified landscape of inflammasome activation during viral infections, extending beyond the canonical NLRP3 inflammasome to include specialized sensors such as NLRP6, NLRP9, NLRP1, NLRP12, and NLRC4. We critically evaluate the evolutionary &amp;amp;ldquo;arms race&amp;amp;rdquo; between host defenses and viral pathogens, detailing the sophisticated immune evasion strategies employed by viruses&amp;amp;mdash;ranging from the expression of decoy proteins and direct proteolytic cleavage of immune sensors to the manipulation of post-translational modifications (PTMs). Furthermore, we discuss the dual nature of inflammasome activation, which balances protective viral clearance against pathological hyperinflammation, and provide an exhaustive analysis of novel therapeutic strategies, including direct NLR inhibitors and downstream cytokine blockers, currently navigating clinical transition.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 546: NLR Inflammasomes in Viral Infections: From Molecular Mechanisms to Therapeutic Interventions</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/546">doi: 10.3390/v18050546</a></p>
	<p>Authors:
		Shiyuan Hou
		Xing Shen
		Danni Sun
		Yulin An
		Yuxuan Zhou
		Xing Sun
		Shuhan Wang
		Xinyue Liu
		Mengting Zhu
		Shuai Zhao
		Ziyu Liu
		Xingan Wu
		Rongrong Liu
		</p>
	<p>The innate immune system serves as the primary barrier against viral invasion, utilizing pattern recognition receptors (PRRs) to orchestrate a rapid defense. Among these, the nucleotide-binding domain and leucine-rich repeat (NLR) containing proteins function as central signaling scaffolds, assembling into multiprotein complexes known as inflammasomes. These complexes drive the maturation of pro-inflammatory cytokines IL-1&amp;amp;beta; and IL-18, and initiate gasdermin D (GSDMD)-mediated pyroptosis, a lytic cell death pathway that eliminates intracellular replication niches. This comprehensive review synthesizes the diversified landscape of inflammasome activation during viral infections, extending beyond the canonical NLRP3 inflammasome to include specialized sensors such as NLRP6, NLRP9, NLRP1, NLRP12, and NLRC4. We critically evaluate the evolutionary &amp;amp;ldquo;arms race&amp;amp;rdquo; between host defenses and viral pathogens, detailing the sophisticated immune evasion strategies employed by viruses&amp;amp;mdash;ranging from the expression of decoy proteins and direct proteolytic cleavage of immune sensors to the manipulation of post-translational modifications (PTMs). Furthermore, we discuss the dual nature of inflammasome activation, which balances protective viral clearance against pathological hyperinflammation, and provide an exhaustive analysis of novel therapeutic strategies, including direct NLR inhibitors and downstream cytokine blockers, currently navigating clinical transition.</p>
	]]></content:encoded>

	<dc:title>NLR Inflammasomes in Viral Infections: From Molecular Mechanisms to Therapeutic Interventions</dc:title>
			<dc:creator>Shiyuan Hou</dc:creator>
			<dc:creator>Xing Shen</dc:creator>
			<dc:creator>Danni Sun</dc:creator>
			<dc:creator>Yulin An</dc:creator>
			<dc:creator>Yuxuan Zhou</dc:creator>
			<dc:creator>Xing Sun</dc:creator>
			<dc:creator>Shuhan Wang</dc:creator>
			<dc:creator>Xinyue Liu</dc:creator>
			<dc:creator>Mengting Zhu</dc:creator>
			<dc:creator>Shuai Zhao</dc:creator>
			<dc:creator>Ziyu Liu</dc:creator>
			<dc:creator>Xingan Wu</dc:creator>
			<dc:creator>Rongrong Liu</dc:creator>
		<dc:identifier>doi: 10.3390/v18050546</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>546</prism:startingPage>
		<prism:doi>10.3390/v18050546</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/546</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/545">

	<title>Viruses, Vol. 18, Pages 545: Identification of Cyclin L1 as a Host Factor Regulating Hepatitis B Virus Replication</title>
	<link>https://www.mdpi.com/1999-4915/18/5/545</link>
	<description>Background and Aims: Understanding regulatory interactions between hepatitis B virus (HBV) and host factors is essential for the development of next generation host-directed antiviral therapies and the achievement of a functional HBV cure. Here, we investigated HBV-induced alterations in host gene expression in primary human hepatocytes (PHH) to identify host factors exploited by the virus for replication and persistence. Whole-transcriptome sequencing (WTS) of HBV-infected PHH identified host pathways with potential roles in the HBV life cycle. RNA interference-based functional screening of dysregulated candidate genes identified cyclin L1 (CCNL1) as a key host factor. RNAi-mediated knockdown of CCNL1 reduced HBV gene expression, including hepatitis B surface antigen (HBsAg). Mechanistically, CCNL1 regulates phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (RNAPII) at serine 2 (S2), consistent with a role in transcriptional regulation. CCNL1 knockdown further reduced the binding of total and phospho- (Ser2/Ser5) RNAPII, pan-acetylated histone H3 (H3ac), and H3K27ac to HBV covalently closed circular DNA (cccDNA), indicating impaired cccDNA-dependent transcription. In addition, CCNL1 expression was elevated in chronic hepatitis B patients compared with those with resolved infection. Collectively, these data demonstrate that CCNL1 promotes HBV transcription and replication through modulation of RNAPII phosphorylation and chromatin-associated transcriptional activity, identifying CCNL1 as a potential host susceptibility factor for HBV. Importance: Hepatitis B virus infection remains a major threat to human health in areas with high prevalence. There is need to fully understand the complex interactions between the virus and human host factors/processes to support ongoing efforts to develop anti-HBV therapies that can be used with existing therapies to achieve a better cure. HBV relies on host cellular factors and biological processes to establish and maintain efficient infection, making host&amp;amp;ndash;virus interactions attractive targets for therapeutic intervention. Thus, identifying host factors that support and/or restrict HBV infection is essential for understanding the molecular basis of chronic HBV infection and for developing host-targeting anti-HBV drugs. This study identifies cyclin L1 (CCNL1) as a host susceptibility factor that promotes HBV transcription and replication through regulation of RNA polymerase II activity and or post-transcriptional mechanisms.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 545: Identification of Cyclin L1 as a Host Factor Regulating Hepatitis B Virus Replication</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/545">doi: 10.3390/v18050545</a></p>
	<p>Authors:
		Collins Oduor Owino
		Balakrishnan Chakrapani Narmada
		Gian Yi Lin
		Pauline Poh Kim Aw
		Nivrithi Ganesh
		Jovi Tan Siying
		Marie-Laure Plissonnier
		Thangavelu Thangavelu Matan
		Niranjan Shirgaonkar
		Pablo Bifani
		Massimo Levrero
		Giridharan Periyasamy
		Seng Gee Lim
		Ramanuj DasGupta
		</p>
	<p>Background and Aims: Understanding regulatory interactions between hepatitis B virus (HBV) and host factors is essential for the development of next generation host-directed antiviral therapies and the achievement of a functional HBV cure. Here, we investigated HBV-induced alterations in host gene expression in primary human hepatocytes (PHH) to identify host factors exploited by the virus for replication and persistence. Whole-transcriptome sequencing (WTS) of HBV-infected PHH identified host pathways with potential roles in the HBV life cycle. RNA interference-based functional screening of dysregulated candidate genes identified cyclin L1 (CCNL1) as a key host factor. RNAi-mediated knockdown of CCNL1 reduced HBV gene expression, including hepatitis B surface antigen (HBsAg). Mechanistically, CCNL1 regulates phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (RNAPII) at serine 2 (S2), consistent with a role in transcriptional regulation. CCNL1 knockdown further reduced the binding of total and phospho- (Ser2/Ser5) RNAPII, pan-acetylated histone H3 (H3ac), and H3K27ac to HBV covalently closed circular DNA (cccDNA), indicating impaired cccDNA-dependent transcription. In addition, CCNL1 expression was elevated in chronic hepatitis B patients compared with those with resolved infection. Collectively, these data demonstrate that CCNL1 promotes HBV transcription and replication through modulation of RNAPII phosphorylation and chromatin-associated transcriptional activity, identifying CCNL1 as a potential host susceptibility factor for HBV. Importance: Hepatitis B virus infection remains a major threat to human health in areas with high prevalence. There is need to fully understand the complex interactions between the virus and human host factors/processes to support ongoing efforts to develop anti-HBV therapies that can be used with existing therapies to achieve a better cure. HBV relies on host cellular factors and biological processes to establish and maintain efficient infection, making host&amp;amp;ndash;virus interactions attractive targets for therapeutic intervention. Thus, identifying host factors that support and/or restrict HBV infection is essential for understanding the molecular basis of chronic HBV infection and for developing host-targeting anti-HBV drugs. This study identifies cyclin L1 (CCNL1) as a host susceptibility factor that promotes HBV transcription and replication through regulation of RNA polymerase II activity and or post-transcriptional mechanisms.</p>
	]]></content:encoded>

	<dc:title>Identification of Cyclin L1 as a Host Factor Regulating Hepatitis B Virus Replication</dc:title>
			<dc:creator>Collins Oduor Owino</dc:creator>
			<dc:creator>Balakrishnan Chakrapani Narmada</dc:creator>
			<dc:creator>Gian Yi Lin</dc:creator>
			<dc:creator>Pauline Poh Kim Aw</dc:creator>
			<dc:creator>Nivrithi Ganesh</dc:creator>
			<dc:creator>Jovi Tan Siying</dc:creator>
			<dc:creator>Marie-Laure Plissonnier</dc:creator>
			<dc:creator>Thangavelu Thangavelu Matan</dc:creator>
			<dc:creator>Niranjan Shirgaonkar</dc:creator>
			<dc:creator>Pablo Bifani</dc:creator>
			<dc:creator>Massimo Levrero</dc:creator>
			<dc:creator>Giridharan Periyasamy</dc:creator>
			<dc:creator>Seng Gee Lim</dc:creator>
			<dc:creator>Ramanuj DasGupta</dc:creator>
		<dc:identifier>doi: 10.3390/v18050545</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>545</prism:startingPage>
		<prism:doi>10.3390/v18050545</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/545</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/544">

	<title>Viruses, Vol. 18, Pages 544: Current Challenges and Potential Strategies to Enhance Efficacy of Oral Phage Therapy in Food Animals: A Systematic Review with Quantitative Analysis</title>
	<link>https://www.mdpi.com/1999-4915/18/5/544</link>
	<description>Phage therapy has enormous potential in combating bacterial resistance in food animals. However, its application via the oral route remains limited due to challenges associated with the gastrointestinal tract (GIT) environment and a lack of rigorous clinical trial evidence. Therefore, we systematically searched in Google Scholar, PubMed, Scopus, and Web of Science databases following PRISMA guidelines and finally identified 111 articles on oral phage therapy in food animals from where we summarized the key physiological and chemical factors of the gut environment hindering the effectiveness of oral phage therapy (OPT), examined the methods used to evaluate phage stability in the GI environment, and highlighted potential strategies to mitigate these challenges. In addition, we performed quantitative analysis to visualize in vitro pH and thermal stability patterns of phages targeting bacteria isolated from food animals and variability in buffer and incubation period across stability studies. The GIT consists of several anatomically and functionally distinct segments, where complex interactions occur among digestive enzymes, gastric acids, electrolytes, commensal microbiota, and mucosal immune components. The acidic pH of the stomach is a major barrier to successful oral phage delivery. According to our analysis of pH stability testing data from the reviewed studies, most phages targeting antimicrobial-resistant bacteria in food animals remained stable at pH 5&amp;amp;ndash;9 and inactivated under highly acidic (pH &amp;amp;le; 2) or highly alkaline (pH &amp;amp;ge; 11) conditions. In addition, phages are susceptible to high temperatures (above 60 &amp;amp;deg;C), digestive enzymes (e.g., pepsin, trypsin, lipases), bile salts, and host immune responses. Several in vitro laboratory techniques are available to assess phage stability under simulated GI conditions, but variations occur in the assessment protocols. Microencapsulation using alginate and chitosan has been used to protect phages from the adverse GI environment. Additionally, enteric-coated capsules, antacids, co-encapsulation with acid-neutralizing agents, consumption of alkaline water, and daily phage administration are suggested to improve phage survival and efficacy. For the successful clinical implementation of OPT in food animals, future research should focus on elucidating the molecular and physicochemical determinants of phage stability, understanding the humoral immune response to OPT, standardizing laboratory protocol for assessing phage viability, improving the scalability of encapsulation methods, and exploring other potential delivery techniques.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 544: Current Challenges and Potential Strategies to Enhance Efficacy of Oral Phage Therapy in Food Animals: A Systematic Review with Quantitative Analysis</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/544">doi: 10.3390/v18050544</a></p>
	<p>Authors:
		Md Ashiqur Rahman
		Rebecca Abraham
		David J. Hampson
		Sam Abraham
		Jasim M. Uddin
		</p>
	<p>Phage therapy has enormous potential in combating bacterial resistance in food animals. However, its application via the oral route remains limited due to challenges associated with the gastrointestinal tract (GIT) environment and a lack of rigorous clinical trial evidence. Therefore, we systematically searched in Google Scholar, PubMed, Scopus, and Web of Science databases following PRISMA guidelines and finally identified 111 articles on oral phage therapy in food animals from where we summarized the key physiological and chemical factors of the gut environment hindering the effectiveness of oral phage therapy (OPT), examined the methods used to evaluate phage stability in the GI environment, and highlighted potential strategies to mitigate these challenges. In addition, we performed quantitative analysis to visualize in vitro pH and thermal stability patterns of phages targeting bacteria isolated from food animals and variability in buffer and incubation period across stability studies. The GIT consists of several anatomically and functionally distinct segments, where complex interactions occur among digestive enzymes, gastric acids, electrolytes, commensal microbiota, and mucosal immune components. The acidic pH of the stomach is a major barrier to successful oral phage delivery. According to our analysis of pH stability testing data from the reviewed studies, most phages targeting antimicrobial-resistant bacteria in food animals remained stable at pH 5&amp;amp;ndash;9 and inactivated under highly acidic (pH &amp;amp;le; 2) or highly alkaline (pH &amp;amp;ge; 11) conditions. In addition, phages are susceptible to high temperatures (above 60 &amp;amp;deg;C), digestive enzymes (e.g., pepsin, trypsin, lipases), bile salts, and host immune responses. Several in vitro laboratory techniques are available to assess phage stability under simulated GI conditions, but variations occur in the assessment protocols. Microencapsulation using alginate and chitosan has been used to protect phages from the adverse GI environment. Additionally, enteric-coated capsules, antacids, co-encapsulation with acid-neutralizing agents, consumption of alkaline water, and daily phage administration are suggested to improve phage survival and efficacy. For the successful clinical implementation of OPT in food animals, future research should focus on elucidating the molecular and physicochemical determinants of phage stability, understanding the humoral immune response to OPT, standardizing laboratory protocol for assessing phage viability, improving the scalability of encapsulation methods, and exploring other potential delivery techniques.</p>
	]]></content:encoded>

	<dc:title>Current Challenges and Potential Strategies to Enhance Efficacy of Oral Phage Therapy in Food Animals: A Systematic Review with Quantitative Analysis</dc:title>
			<dc:creator>Md Ashiqur Rahman</dc:creator>
			<dc:creator>Rebecca Abraham</dc:creator>
			<dc:creator>David J. Hampson</dc:creator>
			<dc:creator>Sam Abraham</dc:creator>
			<dc:creator>Jasim M. Uddin</dc:creator>
		<dc:identifier>doi: 10.3390/v18050544</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>544</prism:startingPage>
		<prism:doi>10.3390/v18050544</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/544</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/543">

	<title>Viruses, Vol. 18, Pages 543: Decoding the Structural Complexity of Viral RNAs with SHAPE to Guide Antiviral Therapeutics</title>
	<link>https://www.mdpi.com/1999-4915/18/5/543</link>
	<description>RNA viruses encode multiple layers of regulatory information within their genomes, extending beyond their protein-coding sequences. Through local secondary structures and long-range RNA&amp;amp;ndash;RNA interactions, viral RNAs control essential steps of the viral life cycle, including translation, replication, genome cyclization, packaging, and evasion of host defenses. Over the last two decades, chemical probing approaches&amp;amp;mdash;particularly Selective 2&amp;amp;prime;-Hydroxyl Acylation analyzed by a primer extension (SHAPE) and its high-throughput derivatives&amp;amp;mdash;have transformed our ability to investigate these structures at a single nucleotide resolution and on a genome-wide scale. These technologies have revealed that viral genomes are highly structured and contain numerous functional RNA elements within untranslated regions as well as coding sequences. In this review, we summarize the main experimental strategies used to profile viral RNA architecture, with a focus on SHAPE-based methodologies and complementary approaches. We then discuss the major classes of functional RNA structures identified across diverse viral families, focusing on elements involved in translation and replication, such as internal ribosome entry sites (IRES) and cyclization elements, as well as other functional structures, including XRN1-resistant and frameshifting elements. Finally, we examine how structure-guided analyses are opening new avenues for antiviral intervention, including antisense oligonucleotides, small molecules, and RNA-degrading chimeras. Together, these advances highlight the viral RNA structure as both a key determinant of virus biology and a promising target for therapeutic innovation.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 543: Decoding the Structural Complexity of Viral RNAs with SHAPE to Guide Antiviral Therapeutics</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/543">doi: 10.3390/v18050543</a></p>
	<p>Authors:
		 Broglia
		 Canale
		 Vandelli
		 Tartaglia
		 Delli Ponti
		</p>
	<p>RNA viruses encode multiple layers of regulatory information within their genomes, extending beyond their protein-coding sequences. Through local secondary structures and long-range RNA&amp;amp;ndash;RNA interactions, viral RNAs control essential steps of the viral life cycle, including translation, replication, genome cyclization, packaging, and evasion of host defenses. Over the last two decades, chemical probing approaches&amp;amp;mdash;particularly Selective 2&amp;amp;prime;-Hydroxyl Acylation analyzed by a primer extension (SHAPE) and its high-throughput derivatives&amp;amp;mdash;have transformed our ability to investigate these structures at a single nucleotide resolution and on a genome-wide scale. These technologies have revealed that viral genomes are highly structured and contain numerous functional RNA elements within untranslated regions as well as coding sequences. In this review, we summarize the main experimental strategies used to profile viral RNA architecture, with a focus on SHAPE-based methodologies and complementary approaches. We then discuss the major classes of functional RNA structures identified across diverse viral families, focusing on elements involved in translation and replication, such as internal ribosome entry sites (IRES) and cyclization elements, as well as other functional structures, including XRN1-resistant and frameshifting elements. Finally, we examine how structure-guided analyses are opening new avenues for antiviral intervention, including antisense oligonucleotides, small molecules, and RNA-degrading chimeras. Together, these advances highlight the viral RNA structure as both a key determinant of virus biology and a promising target for therapeutic innovation.</p>
	]]></content:encoded>

	<dc:title>Decoding the Structural Complexity of Viral RNAs with SHAPE to Guide Antiviral Therapeutics</dc:title>
			<dc:creator> Broglia</dc:creator>
			<dc:creator> Canale</dc:creator>
			<dc:creator> Vandelli</dc:creator>
			<dc:creator> Tartaglia</dc:creator>
			<dc:creator> Delli Ponti</dc:creator>
		<dc:identifier>doi: 10.3390/v18050543</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>543</prism:startingPage>
		<prism:doi>10.3390/v18050543</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/543</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/542">

	<title>Viruses, Vol. 18, Pages 542: Mucosal Dynamics Contributing to Innate Immune Responses to HIV in the Human Female Genital Tract</title>
	<link>https://www.mdpi.com/1999-4915/18/5/542</link>
	<description>HIV is primarily acquired in women at the female genital mucosa through heterosexual contact. Mucosal immune cells reside adjacent to, within, below, and distant from the epithelium that lines the surface of the female genital tract (FGT) mucosa. Innate immune cells play dual roles in HIV acquisition, both poised to rapidly recognize and respond to HIV, but are also capable of promoting HIV infection locally and distantly in the lymph nodes. In this review we emphasize recent human research on the roles of specific innate immune cells in HIV pathogenesis in the FGT, including dendritic cells, macrophages, neutrophils and innate lymphoid cells. We review how FGT mucosal dynamics, including anatomical compartmentalization, menstrual cycle regulation, reproductive history, menopause and chronological aging contribute to tissue conditioning of these cells and changes in HIV susceptibility in women throughout their lives.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 542: Mucosal Dynamics Contributing to Innate Immune Responses to HIV in the Human Female Genital Tract</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/542">doi: 10.3390/v18050542</a></p>
	<p>Authors:
		Genna E. Moldovan
		Gabriel P. Faber
		Marta Rodriguez-Garcia
		</p>
	<p>HIV is primarily acquired in women at the female genital mucosa through heterosexual contact. Mucosal immune cells reside adjacent to, within, below, and distant from the epithelium that lines the surface of the female genital tract (FGT) mucosa. Innate immune cells play dual roles in HIV acquisition, both poised to rapidly recognize and respond to HIV, but are also capable of promoting HIV infection locally and distantly in the lymph nodes. In this review we emphasize recent human research on the roles of specific innate immune cells in HIV pathogenesis in the FGT, including dendritic cells, macrophages, neutrophils and innate lymphoid cells. We review how FGT mucosal dynamics, including anatomical compartmentalization, menstrual cycle regulation, reproductive history, menopause and chronological aging contribute to tissue conditioning of these cells and changes in HIV susceptibility in women throughout their lives.</p>
	]]></content:encoded>

	<dc:title>Mucosal Dynamics Contributing to Innate Immune Responses to HIV in the Human Female Genital Tract</dc:title>
			<dc:creator>Genna E. Moldovan</dc:creator>
			<dc:creator>Gabriel P. Faber</dc:creator>
			<dc:creator>Marta Rodriguez-Garcia</dc:creator>
		<dc:identifier>doi: 10.3390/v18050542</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>542</prism:startingPage>
		<prism:doi>10.3390/v18050542</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/542</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/541">

	<title>Viruses, Vol. 18, Pages 541: Evaluating the Role of Anopheles Mosquitoes in the Global Spread of Arboviruses: A Review of Laboratory-Confirmed Viral Competence</title>
	<link>https://www.mdpi.com/1999-4915/18/5/541</link>
	<description>Mosquito-borne diseases are a major global health concern, infecting up to 700 million people annually and causing over one million deaths. Of the several genera of biting mosquitoes, species of Anopheles are mostly studied for their ability (vector competence) to transmit Plasmodium protozoan parasites, some species of which cause malaria. More than 480 species of Anopheles have been described worldwide, and about 70 of these are responsible for Plasmodium spp. transmission. However, the focus on Anopheles as vectors of Plasmodium has led to a relative lack of study about the ability of Anopheles to transmit viruses. Some Anopheles species have been experimentally confirmed as competent for various arboviruses. In most cases, they are secondary vectors, with relatively low competence, contributing to overall transmission while other species of mosquito or other vectors are responsible for sustained transmission. Although secondary vectors may contribute less to transmission, they may play important epidemiological roles by extending transmission seasons and/or providing a means of overwintering viruses. Here, we conducted a review of scientific repositories to build a database of known Anopheles competence for arboviruses. After exclusions, we retained 427 laboratory-confirmed studies from 7343 papers reviewed. Our analysis suggests some Anopheles spp. could contribute to arbovirus overwintering in temperate regions.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 541: Evaluating the Role of Anopheles Mosquitoes in the Global Spread of Arboviruses: A Review of Laboratory-Confirmed Viral Competence</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/541">doi: 10.3390/v18050541</a></p>
	<p>Authors:
		Rosheen Sungeni Mthawanji
		Matthew Baylis
		Maya Wardeh
		Marcus S. C. Blagrove
		</p>
	<p>Mosquito-borne diseases are a major global health concern, infecting up to 700 million people annually and causing over one million deaths. Of the several genera of biting mosquitoes, species of Anopheles are mostly studied for their ability (vector competence) to transmit Plasmodium protozoan parasites, some species of which cause malaria. More than 480 species of Anopheles have been described worldwide, and about 70 of these are responsible for Plasmodium spp. transmission. However, the focus on Anopheles as vectors of Plasmodium has led to a relative lack of study about the ability of Anopheles to transmit viruses. Some Anopheles species have been experimentally confirmed as competent for various arboviruses. In most cases, they are secondary vectors, with relatively low competence, contributing to overall transmission while other species of mosquito or other vectors are responsible for sustained transmission. Although secondary vectors may contribute less to transmission, they may play important epidemiological roles by extending transmission seasons and/or providing a means of overwintering viruses. Here, we conducted a review of scientific repositories to build a database of known Anopheles competence for arboviruses. After exclusions, we retained 427 laboratory-confirmed studies from 7343 papers reviewed. Our analysis suggests some Anopheles spp. could contribute to arbovirus overwintering in temperate regions.</p>
	]]></content:encoded>

	<dc:title>Evaluating the Role of Anopheles Mosquitoes in the Global Spread of Arboviruses: A Review of Laboratory-Confirmed Viral Competence</dc:title>
			<dc:creator>Rosheen Sungeni Mthawanji</dc:creator>
			<dc:creator>Matthew Baylis</dc:creator>
			<dc:creator>Maya Wardeh</dc:creator>
			<dc:creator>Marcus S. C. Blagrove</dc:creator>
		<dc:identifier>doi: 10.3390/v18050541</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>541</prism:startingPage>
		<prism:doi>10.3390/v18050541</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/541</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/540">

	<title>Viruses, Vol. 18, Pages 540: Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors</title>
	<link>https://www.mdpi.com/1999-4915/18/5/540</link>
	<description>HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) are central to modern antiretroviral therapy (ART) because of their high potency and durable effect on viral suppression. However, drug resistance mutations (DRMs) within HIV-1 IN emerge, which can compromise long-term treatment efficacy. Many distinct DRMs that arise under INSTI therapy have been extensively tabulated in public repositories and literature. However, the timelines over which they emerge, accumulate, and consolidate in patients have not been systematically integrated across clinical and experimental studies. In this review, we synthesize current evidence on the temporal evolution of DRMs within HIV-1 IN by examining mutational kinetic data from viruses derived from people living with HIV/AIDS (PLWH) and from in vitro selection experiments. We compare experimental timelines to recent computational predictions derived from Potts-based fitness landscapes coupled with kinetic Monte Carlo simulations and identify reproducible kinetic classes that distinguish fast-, intermediate-, and slow-emerging DRMs. Rapidly emerging DRMs such as E92Q and N155H typically appear early under drug pressure and often represent low-barrier adaptive responses, whereas the most clinically consequential mutations, such as Q148H/K/R, G140A/S, and E138K, arise only after extended therapy and generally require compensatory mutational backgrounds to persist. Although absolute emergence times vary substantially between in vivo and in vitro systems, consistent temporal trends across datasets support the existence of underlying epistatic constraints that shape drug resistance evolution. Understanding DRM timelines is clinically relevant because it provides a framework for interpreting resistance detected at virological failure, informs optimal timing of resistance testing, and may enable earlier identification of high-risk evolutionary trajectories before durable resistance is established.</description>
	<pubDate>2026-05-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 540: Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/540">doi: 10.3390/v18050540</a></p>
	<p>Authors:
		Indrani Choudhuri
		Jocelyn G. Olvera
		Avik Biswas
		Allan Haldane
		Ronald M. Levy
		Dmitry Lyumkis
		</p>
	<p>HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) are central to modern antiretroviral therapy (ART) because of their high potency and durable effect on viral suppression. However, drug resistance mutations (DRMs) within HIV-1 IN emerge, which can compromise long-term treatment efficacy. Many distinct DRMs that arise under INSTI therapy have been extensively tabulated in public repositories and literature. However, the timelines over which they emerge, accumulate, and consolidate in patients have not been systematically integrated across clinical and experimental studies. In this review, we synthesize current evidence on the temporal evolution of DRMs within HIV-1 IN by examining mutational kinetic data from viruses derived from people living with HIV/AIDS (PLWH) and from in vitro selection experiments. We compare experimental timelines to recent computational predictions derived from Potts-based fitness landscapes coupled with kinetic Monte Carlo simulations and identify reproducible kinetic classes that distinguish fast-, intermediate-, and slow-emerging DRMs. Rapidly emerging DRMs such as E92Q and N155H typically appear early under drug pressure and often represent low-barrier adaptive responses, whereas the most clinically consequential mutations, such as Q148H/K/R, G140A/S, and E138K, arise only after extended therapy and generally require compensatory mutational backgrounds to persist. Although absolute emergence times vary substantially between in vivo and in vitro systems, consistent temporal trends across datasets support the existence of underlying epistatic constraints that shape drug resistance evolution. Understanding DRM timelines is clinically relevant because it provides a framework for interpreting resistance detected at virological failure, informs optimal timing of resistance testing, and may enable earlier identification of high-risk evolutionary trajectories before durable resistance is established.</p>
	]]></content:encoded>

	<dc:title>Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors</dc:title>
			<dc:creator>Indrani Choudhuri</dc:creator>
			<dc:creator>Jocelyn G. Olvera</dc:creator>
			<dc:creator>Avik Biswas</dc:creator>
			<dc:creator>Allan Haldane</dc:creator>
			<dc:creator>Ronald M. Levy</dc:creator>
			<dc:creator>Dmitry Lyumkis</dc:creator>
		<dc:identifier>doi: 10.3390/v18050540</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-08</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>540</prism:startingPage>
		<prism:doi>10.3390/v18050540</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/540</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/539">

	<title>Viruses, Vol. 18, Pages 539: Factors Associated with Antiretroviral Therapy Re-Engagement Among Men Who Have Sex with Men in South Africa: A Multi-District Analysis</title>
	<link>https://www.mdpi.com/1999-4915/18/5/539</link>
	<description>Men who have sex with men (MSM) are among of the key population groups that have been disproportionately affected by the HIV epidemic globally. Hence, MSM living with HIV may experience unique challenges leading to their disengagement from and re-engagement with care. This study aimed to identify factors associated with ART re-engagement among MSM in selected districts of South African provinces. A retrospective observational study design was followed, utilising MSM routine programme data from 1 January 2018 to 31 December 2022. The programme enrolled 3337 MSM aged 16 years or older who resided in the selected provinces/districts. Descriptive statistics characterised participants&amp;amp;rsquo; baseline profiles. Binary logistic regression identified factors associated with re-engagement with ART. Data analysis was done using SPSS version 31.0.1.0; p &amp;amp;lt; 0.05 was considered statistically significant. The district was the only statistically significant predictor of re-engagement among MSM, wherein eThekwini district had lower odds of re-engagement (aOR = 0.248, 95% CI: 0.144&amp;amp;ndash;0.428, p &amp;amp;lt; 0.001). This represented a 75% reduction in the likelihood of re-engagement compared to the City of Tshwane. There was no association between being re-initiated on ART and HIV testing modality (aOR = 7.299, 95% CI: 0.567&amp;amp;ndash;94.037, p = 0.127). Future studies should longitudinally and qualitatively investigate specific programme and contextual factors driving district-level variation in re-engagement, while incorporating individual-level factors.</description>
	<pubDate>2026-05-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 539: Factors Associated with Antiretroviral Therapy Re-Engagement Among Men Who Have Sex with Men in South Africa: A Multi-District Analysis</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/539">doi: 10.3390/v18050539</a></p>
	<p>Authors:
		Betty Sebati
		Anthony Brown
		</p>
	<p>Men who have sex with men (MSM) are among of the key population groups that have been disproportionately affected by the HIV epidemic globally. Hence, MSM living with HIV may experience unique challenges leading to their disengagement from and re-engagement with care. This study aimed to identify factors associated with ART re-engagement among MSM in selected districts of South African provinces. A retrospective observational study design was followed, utilising MSM routine programme data from 1 January 2018 to 31 December 2022. The programme enrolled 3337 MSM aged 16 years or older who resided in the selected provinces/districts. Descriptive statistics characterised participants&amp;amp;rsquo; baseline profiles. Binary logistic regression identified factors associated with re-engagement with ART. Data analysis was done using SPSS version 31.0.1.0; p &amp;amp;lt; 0.05 was considered statistically significant. The district was the only statistically significant predictor of re-engagement among MSM, wherein eThekwini district had lower odds of re-engagement (aOR = 0.248, 95% CI: 0.144&amp;amp;ndash;0.428, p &amp;amp;lt; 0.001). This represented a 75% reduction in the likelihood of re-engagement compared to the City of Tshwane. There was no association between being re-initiated on ART and HIV testing modality (aOR = 7.299, 95% CI: 0.567&amp;amp;ndash;94.037, p = 0.127). Future studies should longitudinally and qualitatively investigate specific programme and contextual factors driving district-level variation in re-engagement, while incorporating individual-level factors.</p>
	]]></content:encoded>

	<dc:title>Factors Associated with Antiretroviral Therapy Re-Engagement Among Men Who Have Sex with Men in South Africa: A Multi-District Analysis</dc:title>
			<dc:creator>Betty Sebati</dc:creator>
			<dc:creator>Anthony Brown</dc:creator>
		<dc:identifier>doi: 10.3390/v18050539</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-07</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-07</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>539</prism:startingPage>
		<prism:doi>10.3390/v18050539</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/539</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/538">

	<title>Viruses, Vol. 18, Pages 538: A Prolonged Norovirus Infection and the Molecular Evolution of Human Norovirus Within-Host in a Child with Burkitt Lymphoma</title>
	<link>https://www.mdpi.com/1999-4915/18/5/538</link>
	<description>It has been reported that chronic infection of human norovirus (HuNoV) may potentially serve as a reservoir for viral variants with the possibility to evade population immunity or alter the binding sites of HBGA receptors. In this study, a child diagnosed with Burkitt lymphoma and positive for HuNoV determined by real-time PCR (qPCR) firstly in 15 August 2016, was followed up until 20 March 2018, and 26 fecal specimens and one vomitus were collected to trace the evolutionary characteristics of HuNoV by phylogenetic analysis, meta-genomics next-generation sequencing (mNGS), and temporal evolutionary analysis of VP1 among 23 specimens positive for HuNoV. There were 15 specimens with partial RdRp gene sequences forming an independent cluster with sequences of GII.P31, 14 with the region C sequences and 11 with P domain sequences of VP1 gene clustered together with HuNoV GII.4 Sydney_2012. All these sequences showed that mutations accumulated nearly in a time order, and more mutations were shown in the key epitopes A&amp;amp;ndash;E or near the binding sites for HBGA in subdomain P2 with higher evolutionary rates. Analysis of NGS data identified intra-host viral quasi-species, and two genome sequences of the same length from mNGS were assembled from N705, with mutations located in the region of subdomain P2 (1171 nt&amp;amp;ndash;1202 nt) which led to five amino acid mutations. In conclusion, the accumulated mutations of HuNoV, especially in subdomain P2, were explored in a child with Burkitt lymphoma, and the sequencing of HuNoV from immunocompromised individuals was proven critical for monitoring intra-host quasi-species evolution and potential variant emergence, providing basic data for clinical infection control.</description>
	<pubDate>2026-05-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 538: A Prolonged Norovirus Infection and the Molecular Evolution of Human Norovirus Within-Host in a Child with Burkitt Lymphoma</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/538">doi: 10.3390/v18050538</a></p>
	<p>Authors:
		Liping Jia
		Ri De
		Zeng Li
		Zhenzhi Han
		Liying Liu
		Huijin Dong
		Shunqiao Feng
		Rong Liu
		Linqing Zhao
		</p>
	<p>It has been reported that chronic infection of human norovirus (HuNoV) may potentially serve as a reservoir for viral variants with the possibility to evade population immunity or alter the binding sites of HBGA receptors. In this study, a child diagnosed with Burkitt lymphoma and positive for HuNoV determined by real-time PCR (qPCR) firstly in 15 August 2016, was followed up until 20 March 2018, and 26 fecal specimens and one vomitus were collected to trace the evolutionary characteristics of HuNoV by phylogenetic analysis, meta-genomics next-generation sequencing (mNGS), and temporal evolutionary analysis of VP1 among 23 specimens positive for HuNoV. There were 15 specimens with partial RdRp gene sequences forming an independent cluster with sequences of GII.P31, 14 with the region C sequences and 11 with P domain sequences of VP1 gene clustered together with HuNoV GII.4 Sydney_2012. All these sequences showed that mutations accumulated nearly in a time order, and more mutations were shown in the key epitopes A&amp;amp;ndash;E or near the binding sites for HBGA in subdomain P2 with higher evolutionary rates. Analysis of NGS data identified intra-host viral quasi-species, and two genome sequences of the same length from mNGS were assembled from N705, with mutations located in the region of subdomain P2 (1171 nt&amp;amp;ndash;1202 nt) which led to five amino acid mutations. In conclusion, the accumulated mutations of HuNoV, especially in subdomain P2, were explored in a child with Burkitt lymphoma, and the sequencing of HuNoV from immunocompromised individuals was proven critical for monitoring intra-host quasi-species evolution and potential variant emergence, providing basic data for clinical infection control.</p>
	]]></content:encoded>

	<dc:title>A Prolonged Norovirus Infection and the Molecular Evolution of Human Norovirus Within-Host in a Child with Burkitt Lymphoma</dc:title>
			<dc:creator>Liping Jia</dc:creator>
			<dc:creator>Ri De</dc:creator>
			<dc:creator>Zeng Li</dc:creator>
			<dc:creator>Zhenzhi Han</dc:creator>
			<dc:creator>Liying Liu</dc:creator>
			<dc:creator>Huijin Dong</dc:creator>
			<dc:creator>Shunqiao Feng</dc:creator>
			<dc:creator>Rong Liu</dc:creator>
			<dc:creator>Linqing Zhao</dc:creator>
		<dc:identifier>doi: 10.3390/v18050538</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-07</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-07</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>538</prism:startingPage>
		<prism:doi>10.3390/v18050538</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/538</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/537">

	<title>Viruses, Vol. 18, Pages 537: Evaluation of Antigen Productivity and Inactivation Kinetics of a Recombinant Foot-and-Mouth Disease SAT1 Vaccine Strain</title>
	<link>https://www.mdpi.com/1999-4915/18/5/537</link>
	<description>The Republic of Korea has implemented routine vaccination against foot-and-mouth disease virus (FMDV) in livestock using a bivalent vaccine comprising serotypes O and A following the massive FMD outbreak in 2010, while antigens for the remaining serotypes are maintained in overseas antigen banks. The recent geographic expansion of FMDV Southern African Territories 1 (SAT1) beyond Africa underscores the need for enhanced preparedness in previously unaffected regions. In this study, we evaluated the SAT1 BOT-R strain as a candidate vaccine seed for potential domestic vaccine production by optimizing antigen production conditions, assessing scalability, determining virus inactivation parameters, and examining immunogenicity in pigs. Optimal antigen yield was achieved at 20 h&amp;amp;minus;24 h post infection with a multiplicity of infection of 0.005&amp;amp;minus;0.01, with production remaining stable under mildly alkaline conditions. Antigen productivity was consistently maintained during scale-up from shake flasks to a bioreactor, yielding up to 9.5 &amp;amp;mu;g/mL. Complete virus inactivation was achieved using binary ethylenimine at 2 mM for 24 h at 26 &amp;amp;deg;C. Vaccines formulated from both flask- and bioreactor-derived antigens elicited comparable neutralizing antibody responses in pigs, reaching a median titer of 1:500 following booster immunization. Collectively, these findings demonstrate that the SAT1 BOT-R strain is a viable and scalable candidate for SAT1 antigen banking and future domestic vaccine production, providing a practical framework for strengthening national preparedness against potential incursions of FMDV SAT1.</description>
	<pubDate>2026-05-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 537: Evaluation of Antigen Productivity and Inactivation Kinetics of a Recombinant Foot-and-Mouth Disease SAT1 Vaccine Strain</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/537">doi: 10.3390/v18050537</a></p>
	<p>Authors:
		Jae Young Kim
		Sun Young Park
		Gyeongmin Lee
		Seung-A Hwangbo
		Giyoun Cho
		Jong-Hyeon Park
		Young-Joon Ko
		</p>
	<p>The Republic of Korea has implemented routine vaccination against foot-and-mouth disease virus (FMDV) in livestock using a bivalent vaccine comprising serotypes O and A following the massive FMD outbreak in 2010, while antigens for the remaining serotypes are maintained in overseas antigen banks. The recent geographic expansion of FMDV Southern African Territories 1 (SAT1) beyond Africa underscores the need for enhanced preparedness in previously unaffected regions. In this study, we evaluated the SAT1 BOT-R strain as a candidate vaccine seed for potential domestic vaccine production by optimizing antigen production conditions, assessing scalability, determining virus inactivation parameters, and examining immunogenicity in pigs. Optimal antigen yield was achieved at 20 h&amp;amp;minus;24 h post infection with a multiplicity of infection of 0.005&amp;amp;minus;0.01, with production remaining stable under mildly alkaline conditions. Antigen productivity was consistently maintained during scale-up from shake flasks to a bioreactor, yielding up to 9.5 &amp;amp;mu;g/mL. Complete virus inactivation was achieved using binary ethylenimine at 2 mM for 24 h at 26 &amp;amp;deg;C. Vaccines formulated from both flask- and bioreactor-derived antigens elicited comparable neutralizing antibody responses in pigs, reaching a median titer of 1:500 following booster immunization. Collectively, these findings demonstrate that the SAT1 BOT-R strain is a viable and scalable candidate for SAT1 antigen banking and future domestic vaccine production, providing a practical framework for strengthening national preparedness against potential incursions of FMDV SAT1.</p>
	]]></content:encoded>

	<dc:title>Evaluation of Antigen Productivity and Inactivation Kinetics of a Recombinant Foot-and-Mouth Disease SAT1 Vaccine Strain</dc:title>
			<dc:creator>Jae Young Kim</dc:creator>
			<dc:creator>Sun Young Park</dc:creator>
			<dc:creator>Gyeongmin Lee</dc:creator>
			<dc:creator>Seung-A Hwangbo</dc:creator>
			<dc:creator>Giyoun Cho</dc:creator>
			<dc:creator>Jong-Hyeon Park</dc:creator>
			<dc:creator>Young-Joon Ko</dc:creator>
		<dc:identifier>doi: 10.3390/v18050537</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-06</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-06</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>537</prism:startingPage>
		<prism:doi>10.3390/v18050537</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/537</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/536">

	<title>Viruses, Vol. 18, Pages 536: Efficient Plasmid-Based Rescue of T7 RNA Polymerase-Driven Calicivirus Reverse Genetics Systems in Mammalian Cells Using Vaccinia Virus RNA-Capping Enzymes</title>
	<link>https://www.mdpi.com/1999-4915/18/5/536</link>
	<description>The caliciviruses include important human and animal pathogens such as norovirus, sapovirus and feline calicivirus. Viral reverse genetics is performed to understand the fundamental biology of these viruses, as well as a potential route to generate live-attenuated vaccines. Calicivirus reverse genetics systems have typically relied on either the production of in vitro-transcribed RNA or plasmid-based rescue, either from a mammalian promoter or through supplementing with helper enzymes through means of a helper virus. Here, we present a novel system integrating vaccinia capping enzymes D1R and D12L encoded on plasmids as part of a system for murine norovirus (MNV) reverse genetics. The addition of D1R, D12L and T7 RNA polymerase-expressing plasmids increases the viral titres of rescued MNV in both BSR-T7 cells and transgenic BSR-T7 cells expressing murine CD300LF (BSR-T7CD300LF), and viral protein abundance. When the murine norovirus receptor is expressed in BSR-T7CD300LF, viral titres increased 100&amp;amp;ndash;1000-fold compared to standard BSR-T7 cells. This system offers a robust, increased throughput means of assessing viral mutants over parallel in vitro transcription and capping reactions for multiple mutants, without requiring a helper virus.</description>
	<pubDate>2026-05-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 536: Efficient Plasmid-Based Rescue of T7 RNA Polymerase-Driven Calicivirus Reverse Genetics Systems in Mammalian Cells Using Vaccinia Virus RNA-Capping Enzymes</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/536">doi: 10.3390/v18050536</a></p>
	<p>Authors:
		Frazer J. T. Buchanan
		Markella Loi
		Charlotte Chim
		ShuXian Zhou
		Rebekah Penrice-Randal
		Leandro X. Neves
		Maximilian Erdmann
		Edward Emmott
		</p>
	<p>The caliciviruses include important human and animal pathogens such as norovirus, sapovirus and feline calicivirus. Viral reverse genetics is performed to understand the fundamental biology of these viruses, as well as a potential route to generate live-attenuated vaccines. Calicivirus reverse genetics systems have typically relied on either the production of in vitro-transcribed RNA or plasmid-based rescue, either from a mammalian promoter or through supplementing with helper enzymes through means of a helper virus. Here, we present a novel system integrating vaccinia capping enzymes D1R and D12L encoded on plasmids as part of a system for murine norovirus (MNV) reverse genetics. The addition of D1R, D12L and T7 RNA polymerase-expressing plasmids increases the viral titres of rescued MNV in both BSR-T7 cells and transgenic BSR-T7 cells expressing murine CD300LF (BSR-T7CD300LF), and viral protein abundance. When the murine norovirus receptor is expressed in BSR-T7CD300LF, viral titres increased 100&amp;amp;ndash;1000-fold compared to standard BSR-T7 cells. This system offers a robust, increased throughput means of assessing viral mutants over parallel in vitro transcription and capping reactions for multiple mutants, without requiring a helper virus.</p>
	]]></content:encoded>

	<dc:title>Efficient Plasmid-Based Rescue of T7 RNA Polymerase-Driven Calicivirus Reverse Genetics Systems in Mammalian Cells Using Vaccinia Virus RNA-Capping Enzymes</dc:title>
			<dc:creator>Frazer J. T. Buchanan</dc:creator>
			<dc:creator>Markella Loi</dc:creator>
			<dc:creator>Charlotte Chim</dc:creator>
			<dc:creator>ShuXian Zhou</dc:creator>
			<dc:creator>Rebekah Penrice-Randal</dc:creator>
			<dc:creator>Leandro X. Neves</dc:creator>
			<dc:creator>Maximilian Erdmann</dc:creator>
			<dc:creator>Edward Emmott</dc:creator>
		<dc:identifier>doi: 10.3390/v18050536</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-04</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-04</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>536</prism:startingPage>
		<prism:doi>10.3390/v18050536</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/536</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/535">

	<title>Viruses, Vol. 18, Pages 535: Bat-Borne Viruses and Pandemic Risk: Could Europe Be an Emergence Hotspot?</title>
	<link>https://www.mdpi.com/1999-4915/18/5/535</link>
	<description>The recent SARS-CoV-2 pandemic&amp;amp;mdash;which had significant worldwide health, economic, and other effects&amp;amp;mdash;indicated the need to monitor zoonotic viruses with pandemic potential. The aim of this review is to assess bat-borne viruses as a potential pandemic risk, with a particular focus on Europe. The presence and activity of bats, as well as diseases emerging in humans in various regions of the world, point to their importance in the context of a possible outbreak of future epidemics. The rate of genetic change observed among viruses requires constant scrutiny on all continents, including Europe. Bats are a considerable source of many zoonotic viruses, including coronaviruses, filoviruses and paramyxoviruses. Among viruses associated with bats, RNA viruses are the dominant ones, characterized by high pathogenicity and often leading to interspecies transmission. The majority (about 80%) of RNA viruses were identified in bats from three families: Vespertilionidae, Rhinolophidae and Pteropodidae. Understanding how viruses are transmitted in the environment and the role of reservoir organisms and intermediate hosts is crucial to determining the level of epidemic risk. This review discuses viruses identified in bats globally, with a special focus on Europe, and evaluates their potential to cause epidemics.</description>
	<pubDate>2026-05-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 535: Bat-Borne Viruses and Pandemic Risk: Could Europe Be an Emergence Hotspot?</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/535">doi: 10.3390/v18050535</a></p>
	<p>Authors:
		Krzysztof Skowron
		Justyna Bauza-Kaszewska
		Anna Budzyńska
		Natalia Wiktorczyk-Kapischke
		Julia Czuba
		Ewa Wałecka-Zacharska
		Kacper Wnuk
		Mariusz Zapadka
		Krzysztof Kasprzyk
		Katarzyna Grudlewska-Buda
		</p>
	<p>The recent SARS-CoV-2 pandemic&amp;amp;mdash;which had significant worldwide health, economic, and other effects&amp;amp;mdash;indicated the need to monitor zoonotic viruses with pandemic potential. The aim of this review is to assess bat-borne viruses as a potential pandemic risk, with a particular focus on Europe. The presence and activity of bats, as well as diseases emerging in humans in various regions of the world, point to their importance in the context of a possible outbreak of future epidemics. The rate of genetic change observed among viruses requires constant scrutiny on all continents, including Europe. Bats are a considerable source of many zoonotic viruses, including coronaviruses, filoviruses and paramyxoviruses. Among viruses associated with bats, RNA viruses are the dominant ones, characterized by high pathogenicity and often leading to interspecies transmission. The majority (about 80%) of RNA viruses were identified in bats from three families: Vespertilionidae, Rhinolophidae and Pteropodidae. Understanding how viruses are transmitted in the environment and the role of reservoir organisms and intermediate hosts is crucial to determining the level of epidemic risk. This review discuses viruses identified in bats globally, with a special focus on Europe, and evaluates their potential to cause epidemics.</p>
	]]></content:encoded>

	<dc:title>Bat-Borne Viruses and Pandemic Risk: Could Europe Be an Emergence Hotspot?</dc:title>
			<dc:creator>Krzysztof Skowron</dc:creator>
			<dc:creator>Justyna Bauza-Kaszewska</dc:creator>
			<dc:creator>Anna Budzyńska</dc:creator>
			<dc:creator>Natalia Wiktorczyk-Kapischke</dc:creator>
			<dc:creator>Julia Czuba</dc:creator>
			<dc:creator>Ewa Wałecka-Zacharska</dc:creator>
			<dc:creator>Kacper Wnuk</dc:creator>
			<dc:creator>Mariusz Zapadka</dc:creator>
			<dc:creator>Krzysztof Kasprzyk</dc:creator>
			<dc:creator>Katarzyna Grudlewska-Buda</dc:creator>
		<dc:identifier>doi: 10.3390/v18050535</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-02</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-02</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>535</prism:startingPage>
		<prism:doi>10.3390/v18050535</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/535</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/534">

	<title>Viruses, Vol. 18, Pages 534: Phage Therapy Beyond Static Pharmaceuticals: A Framework for Controlled Evolutionary Platforms</title>
	<link>https://www.mdpi.com/1999-4915/18/5/534</link>
	<description>Rising antimicrobial resistance has revived global interest in phage therapy, yet its transition to standard clinical practice remains slow. This challenge is not solely due to a lack of efficacy. Instead, we face a fundamental conceptual barrier caused by an &amp;amp;ldquo;evaluation mismatch.&amp;amp;rdquo; Traditional regulations treat phages as static chemical molecules&amp;amp;mdash;like taking a &amp;amp;ldquo;snapshot.&amp;amp;rdquo; However, biologically, phages are dynamic, evolving populations&amp;amp;mdash;more like a living &amp;amp;ldquo;movie.&amp;amp;rdquo; In this review, we use Schr&amp;amp;ouml;dinger&amp;amp;rsquo;s cat metaphor to explain this reality: phage variability is not a defect, but an essential feature. To bridge this gap, we propose a Controlled Evolutionary Platform. By distinguishing between a fixed &amp;amp;ldquo;Safety Core&amp;amp;rdquo; and a fluctuating &amp;amp;ldquo;Adaptive Periphery,&amp;amp;rdquo; we can manage viral evolution rather than trying to stop it. Ultimately, to integrate phages into modern medicine, we must redefine &amp;amp;ldquo;consistency&amp;amp;rdquo;: shifting our focus from preserving a fixed genetic sequence to ensuring the reliable performance of population dynamics.</description>
	<pubDate>2026-05-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 534: Phage Therapy Beyond Static Pharmaceuticals: A Framework for Controlled Evolutionary Platforms</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/534">doi: 10.3390/v18050534</a></p>
	<p>Authors:
		Hidetomo Iwano
		Jumpei Fujiki
		Tomohiro Nakamura
		</p>
	<p>Rising antimicrobial resistance has revived global interest in phage therapy, yet its transition to standard clinical practice remains slow. This challenge is not solely due to a lack of efficacy. Instead, we face a fundamental conceptual barrier caused by an &amp;amp;ldquo;evaluation mismatch.&amp;amp;rdquo; Traditional regulations treat phages as static chemical molecules&amp;amp;mdash;like taking a &amp;amp;ldquo;snapshot.&amp;amp;rdquo; However, biologically, phages are dynamic, evolving populations&amp;amp;mdash;more like a living &amp;amp;ldquo;movie.&amp;amp;rdquo; In this review, we use Schr&amp;amp;ouml;dinger&amp;amp;rsquo;s cat metaphor to explain this reality: phage variability is not a defect, but an essential feature. To bridge this gap, we propose a Controlled Evolutionary Platform. By distinguishing between a fixed &amp;amp;ldquo;Safety Core&amp;amp;rdquo; and a fluctuating &amp;amp;ldquo;Adaptive Periphery,&amp;amp;rdquo; we can manage viral evolution rather than trying to stop it. Ultimately, to integrate phages into modern medicine, we must redefine &amp;amp;ldquo;consistency&amp;amp;rdquo;: shifting our focus from preserving a fixed genetic sequence to ensuring the reliable performance of population dynamics.</p>
	]]></content:encoded>

	<dc:title>Phage Therapy Beyond Static Pharmaceuticals: A Framework for Controlled Evolutionary Platforms</dc:title>
			<dc:creator>Hidetomo Iwano</dc:creator>
			<dc:creator>Jumpei Fujiki</dc:creator>
			<dc:creator>Tomohiro Nakamura</dc:creator>
		<dc:identifier>doi: 10.3390/v18050534</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-01</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-01</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>534</prism:startingPage>
		<prism:doi>10.3390/v18050534</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/534</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/533">

	<title>Viruses, Vol. 18, Pages 533: Minimal Genome, Maximal Effect: How Polyomavirus Genomes Are Capable of Complex Pathogenesis</title>
	<link>https://www.mdpi.com/1999-4915/18/5/533</link>
	<description>The Polyomaviridae family contains members known for achieving high seroprevalence within their target species despite a limited genomic economy. Minimalism, by definition, allows for the clarification and streamlining of purpose via the removal of unnecessary or distracting components. Among viruses, Simian Vacuolating Virus 40 (SV40) and other polyomaviruses are master minimalists, achieving efficient replication and persistence with compact genomes of approximately 5 kb in length. This review examines how polyomaviruses employ limited genetic material and simple structure to participate in complex functions and interactions, highlighting minimalism as both an evolutionary and functional advantage. Polyomaviruses make the most of their compact genomes in each stage of the viral lifecycle through the production of multifunctional early proteins and cis-regulatory elements, utilization of alternative splicing and host infrastructure, and organization of compact structural proteins. This allows for the successful replication and proliferation of virions while also reducing evolutionary pressure and promoting host immune evasion. Examination of the implications of polyomaviral minimalism illustrates that genome economy is not a constraint, but rather a driver of biological sophistication.</description>
	<pubDate>2026-05-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 533: Minimal Genome, Maximal Effect: How Polyomavirus Genomes Are Capable of Complex Pathogenesis</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/533">doi: 10.3390/v18050533</a></p>
	<p>Authors:
		Michaela Lano
		Barry Milavetz
		</p>
	<p>The Polyomaviridae family contains members known for achieving high seroprevalence within their target species despite a limited genomic economy. Minimalism, by definition, allows for the clarification and streamlining of purpose via the removal of unnecessary or distracting components. Among viruses, Simian Vacuolating Virus 40 (SV40) and other polyomaviruses are master minimalists, achieving efficient replication and persistence with compact genomes of approximately 5 kb in length. This review examines how polyomaviruses employ limited genetic material and simple structure to participate in complex functions and interactions, highlighting minimalism as both an evolutionary and functional advantage. Polyomaviruses make the most of their compact genomes in each stage of the viral lifecycle through the production of multifunctional early proteins and cis-regulatory elements, utilization of alternative splicing and host infrastructure, and organization of compact structural proteins. This allows for the successful replication and proliferation of virions while also reducing evolutionary pressure and promoting host immune evasion. Examination of the implications of polyomaviral minimalism illustrates that genome economy is not a constraint, but rather a driver of biological sophistication.</p>
	]]></content:encoded>

	<dc:title>Minimal Genome, Maximal Effect: How Polyomavirus Genomes Are Capable of Complex Pathogenesis</dc:title>
			<dc:creator>Michaela Lano</dc:creator>
			<dc:creator>Barry Milavetz</dc:creator>
		<dc:identifier>doi: 10.3390/v18050533</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-05-01</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-05-01</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>533</prism:startingPage>
		<prism:doi>10.3390/v18050533</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/533</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/532">

	<title>Viruses, Vol. 18, Pages 532: Isolation and Genomic Characterization of a Lytic Bacteriophage Against Multidrug-Resistant E. coli</title>
	<link>https://www.mdpi.com/1999-4915/18/5/532</link>
	<description>Antimicrobial resistance (AMR) has become a major concern in the treatment of bacterial infections, and bacteriophage therapy has emerged as a promising alternative to antibiotics. Bacteriophages are highly specific to their bacterial hosts; hence, isolating phages indigenous to a specific region offers a significant advantage against various pathogen strains. We have isolated a cocktail of bacteriophages against pathogenic E. coli from sewage water at a primary healthcare centre. Characterisation of the isolated phages demonstrated their stability across a broad pH and temperature range, strong lytic activity, and effective biofilm degradation, with no cross-reactivity with Staphylococcus aureus (S. aureus). Genomic analysis and phylogenetic studies indicated that the largest phage (by genome size) in the cocktail belongs to the genus Vequintavirus (myoviruses, rV5-like phages), and its genome sequence has been deposited in NCBI (Accession ID: PX741096). The phage genome was linear, with headful (PAC) packaging, encoded lysis proteins, and lacked antibiotic-resistant or major lysogeny-associated genes, collectively suggesting a lytic lifestyle. These findings emphasize the therapeutic potential of rV5-like phages and underscore the critical need to establish phage banks in India to improve disease management.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 532: Isolation and Genomic Characterization of a Lytic Bacteriophage Against Multidrug-Resistant E. coli</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/532">doi: 10.3390/v18050532</a></p>
	<p>Authors:
		Ramesh Kumpatla
		Vinaya Kruthi Vitala
		Arunasree M. Kalle
		</p>
	<p>Antimicrobial resistance (AMR) has become a major concern in the treatment of bacterial infections, and bacteriophage therapy has emerged as a promising alternative to antibiotics. Bacteriophages are highly specific to their bacterial hosts; hence, isolating phages indigenous to a specific region offers a significant advantage against various pathogen strains. We have isolated a cocktail of bacteriophages against pathogenic E. coli from sewage water at a primary healthcare centre. Characterisation of the isolated phages demonstrated their stability across a broad pH and temperature range, strong lytic activity, and effective biofilm degradation, with no cross-reactivity with Staphylococcus aureus (S. aureus). Genomic analysis and phylogenetic studies indicated that the largest phage (by genome size) in the cocktail belongs to the genus Vequintavirus (myoviruses, rV5-like phages), and its genome sequence has been deposited in NCBI (Accession ID: PX741096). The phage genome was linear, with headful (PAC) packaging, encoded lysis proteins, and lacked antibiotic-resistant or major lysogeny-associated genes, collectively suggesting a lytic lifestyle. These findings emphasize the therapeutic potential of rV5-like phages and underscore the critical need to establish phage banks in India to improve disease management.</p>
	]]></content:encoded>

	<dc:title>Isolation and Genomic Characterization of a Lytic Bacteriophage Against Multidrug-Resistant E. coli</dc:title>
			<dc:creator>Ramesh Kumpatla</dc:creator>
			<dc:creator>Vinaya Kruthi Vitala</dc:creator>
			<dc:creator>Arunasree M. Kalle</dc:creator>
		<dc:identifier>doi: 10.3390/v18050532</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>532</prism:startingPage>
		<prism:doi>10.3390/v18050532</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/532</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/531">

	<title>Viruses, Vol. 18, Pages 531: Methodological Approaches to Dengue Virus Detection in Wastewater: A Systematic Review and Meta-Analysis of Positivity Rate</title>
	<link>https://www.mdpi.com/1999-4915/18/5/531</link>
	<description>Dengue fever, with a high proportion of asymptomatic infections, poses a major global public health challenge that traditional surveillance systems frequently underestimate. Wastewater-based epidemiology (WBE) has emerged as a promising approach to monitoring infectious diseases beyond enteric viruses. Dengue virus is shed in urine, feces, and saliva, providing a biological basis for wastewater detection alongside clinical surveillance. This systematic review and meta-analysis synthesize current evidence on dengue virus (DENV) detection in wastewater and evaluate methodological factors influencing detection success in WBE. A systematic literature search using selected databases and predetermined keywords, followed by eligibility screening, resulted in ten studies being included, covering community surveillance and experimental trials. DENV ribonucleic acids (RNA) were most consistently detected and enriched in wastewater solids, indicating this matrix as the most reliable for surveillance. Among concentration methods, ultrafiltration achieved the highest viral recovery efficiency, while reverse transcription digital polymerase chain reaction (RT-dPCR) demonstrated superior sensitivity and precision compared to those of reverse transcription quantitative polymerase chain reaction (RT-qPCR), particularly at low viral concentrations. Storage at &amp;amp;minus;80 &amp;amp;deg;C was critical for preserving RNA integrity. The meta-analysis yielded a pooled DENV positivity rate of 24% (95% CI: 20&amp;amp;ndash;28%) after exclusion of outliers. Overall, solid-phase analysis combined with RT-dPCR represents the most sensitive methodological approach across the included studies. Harmonized protocols are needed to support future translation of dengue WBE into community surveillance as current evidence mainly demonstrates methodological feasibility and provides a technical foundation for future public health integration. Therefore, further longitudinal and multi-site validation is required to establish its broader applicability for dengue surveillance.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 531: Methodological Approaches to Dengue Virus Detection in Wastewater: A Systematic Review and Meta-Analysis of Positivity Rate</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/531">doi: 10.3390/v18050531</a></p>
	<p>Authors:
		Siti Aishah Rashid
		Sakshaleni Rajendiran
		Nurul Farehah Shahrir
		Nurul Athirah Naserrudin
		Terence Tan Yew Chin
		Janice Chan Sue Wen
		Imanul Hassan Abdul Shukor
		Nurul Amalina Khairul Hasni
		</p>
	<p>Dengue fever, with a high proportion of asymptomatic infections, poses a major global public health challenge that traditional surveillance systems frequently underestimate. Wastewater-based epidemiology (WBE) has emerged as a promising approach to monitoring infectious diseases beyond enteric viruses. Dengue virus is shed in urine, feces, and saliva, providing a biological basis for wastewater detection alongside clinical surveillance. This systematic review and meta-analysis synthesize current evidence on dengue virus (DENV) detection in wastewater and evaluate methodological factors influencing detection success in WBE. A systematic literature search using selected databases and predetermined keywords, followed by eligibility screening, resulted in ten studies being included, covering community surveillance and experimental trials. DENV ribonucleic acids (RNA) were most consistently detected and enriched in wastewater solids, indicating this matrix as the most reliable for surveillance. Among concentration methods, ultrafiltration achieved the highest viral recovery efficiency, while reverse transcription digital polymerase chain reaction (RT-dPCR) demonstrated superior sensitivity and precision compared to those of reverse transcription quantitative polymerase chain reaction (RT-qPCR), particularly at low viral concentrations. Storage at &amp;amp;minus;80 &amp;amp;deg;C was critical for preserving RNA integrity. The meta-analysis yielded a pooled DENV positivity rate of 24% (95% CI: 20&amp;amp;ndash;28%) after exclusion of outliers. Overall, solid-phase analysis combined with RT-dPCR represents the most sensitive methodological approach across the included studies. Harmonized protocols are needed to support future translation of dengue WBE into community surveillance as current evidence mainly demonstrates methodological feasibility and provides a technical foundation for future public health integration. Therefore, further longitudinal and multi-site validation is required to establish its broader applicability for dengue surveillance.</p>
	]]></content:encoded>

	<dc:title>Methodological Approaches to Dengue Virus Detection in Wastewater: A Systematic Review and Meta-Analysis of Positivity Rate</dc:title>
			<dc:creator>Siti Aishah Rashid</dc:creator>
			<dc:creator>Sakshaleni Rajendiran</dc:creator>
			<dc:creator>Nurul Farehah Shahrir</dc:creator>
			<dc:creator>Nurul Athirah Naserrudin</dc:creator>
			<dc:creator>Terence Tan Yew Chin</dc:creator>
			<dc:creator>Janice Chan Sue Wen</dc:creator>
			<dc:creator>Imanul Hassan Abdul Shukor</dc:creator>
			<dc:creator>Nurul Amalina Khairul Hasni</dc:creator>
		<dc:identifier>doi: 10.3390/v18050531</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>531</prism:startingPage>
		<prism:doi>10.3390/v18050531</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/531</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/530">

	<title>Viruses, Vol. 18, Pages 530: Respiratory Syncytial Virus-Associated Severe Acute Respiratory Infections in Hospitalized Patients at a University Hospital Center in Rabat, Morocco: An Epidemiological Overview</title>
	<link>https://www.mdpi.com/1999-4915/18/5/530</link>
	<description>Respiratory syncytial virus (RSV) imposes a substantial burden of severe acute respiratory infection (SARI), especially in young children and the elderly. Methods: We describe RSV epidemiology among hospitalized SARI patients at the Ibn Sina University Hospital Center (Rabat, Morocco) from 1 January 2021, to 31 December 2025, using multiplex PCR (BioFire&amp;amp;reg; RP2.1plus or Xpert&amp;amp;reg; SARS-CoV-2/Flu/RSV). Results: Among 4604SARI samples, RSV prevalence was 16.1% (739/4604), predominantly pediatric (88.6%, p &amp;amp;lt; 0.001), with peak burden in infants &amp;amp;lt;6 months (70.4% of cases, p &amp;amp;lt; 0.001). Pediatric prevalence was 28.3% (655/2316) vs. 3.8% (84/2204) in adults (p &amp;amp;lt; 0.001), with predominance in the elderly &amp;amp;ge;60 years (51/1041, 4.9%). Co-infections occurred in 46.7% (310/665) of FilmArray-tested positives (total = 665), led by rhinovirus/enterovirus (198/310, 63.9%), and were significantly higher in children (48.5%, p &amp;amp;lt; 0.001). RSV peaked in winter (51.6%), except for summer dominance in 2021 (52.5%), reflecting COVID-19 non-pharmaceutical intervention effects. Conclusions: These data establish Morocco&amp;amp;rsquo;s first comprehensive RSV surveillance baseline, highlighting post-pandemic epidemiological shifts. As maternal vaccines and monoclonal antibodies emerge, these data inform optimal implementation in low- and middle-income countries (LMICs).</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 530: Respiratory Syncytial Virus-Associated Severe Acute Respiratory Infections in Hospitalized Patients at a University Hospital Center in Rabat, Morocco: An Epidemiological Overview</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/530">doi: 10.3390/v18050530</a></p>
	<p>Authors:
		Ghizlane El-Amin
		Naima El Hafidi
		Soumia Benchekroun
		Mahraoui Chafiq
		Amal Zouaki
		Nora Touyar
		Najat Bouihat
		Salma Ech-Cherif El Kettani
		Saad Harrak
		Larbi Ed-Dafali
		Aziza Bentalha
		Mustapha Alilou
		Hamza El Hamzaoui
		Amina Barkat
		Ilham Elouardighi
		Tarek Dendane
		Khalid Abidi
		Jihane Bel Ayachi
		Naoufal Madani
		Redouane Abouqal
		Hicham Harmouche
		Mouna Maamar
		Rachid El Jaoudi
		Mourad Feindiri
		Myriam Seffar
		Mohamed Bouskraoui
		Hakima Kabbaj
		</p>
	<p>Respiratory syncytial virus (RSV) imposes a substantial burden of severe acute respiratory infection (SARI), especially in young children and the elderly. Methods: We describe RSV epidemiology among hospitalized SARI patients at the Ibn Sina University Hospital Center (Rabat, Morocco) from 1 January 2021, to 31 December 2025, using multiplex PCR (BioFire&amp;amp;reg; RP2.1plus or Xpert&amp;amp;reg; SARS-CoV-2/Flu/RSV). Results: Among 4604SARI samples, RSV prevalence was 16.1% (739/4604), predominantly pediatric (88.6%, p &amp;amp;lt; 0.001), with peak burden in infants &amp;amp;lt;6 months (70.4% of cases, p &amp;amp;lt; 0.001). Pediatric prevalence was 28.3% (655/2316) vs. 3.8% (84/2204) in adults (p &amp;amp;lt; 0.001), with predominance in the elderly &amp;amp;ge;60 years (51/1041, 4.9%). Co-infections occurred in 46.7% (310/665) of FilmArray-tested positives (total = 665), led by rhinovirus/enterovirus (198/310, 63.9%), and were significantly higher in children (48.5%, p &amp;amp;lt; 0.001). RSV peaked in winter (51.6%), except for summer dominance in 2021 (52.5%), reflecting COVID-19 non-pharmaceutical intervention effects. Conclusions: These data establish Morocco&amp;amp;rsquo;s first comprehensive RSV surveillance baseline, highlighting post-pandemic epidemiological shifts. As maternal vaccines and monoclonal antibodies emerge, these data inform optimal implementation in low- and middle-income countries (LMICs).</p>
	]]></content:encoded>

	<dc:title>Respiratory Syncytial Virus-Associated Severe Acute Respiratory Infections in Hospitalized Patients at a University Hospital Center in Rabat, Morocco: An Epidemiological Overview</dc:title>
			<dc:creator>Ghizlane El-Amin</dc:creator>
			<dc:creator>Naima El Hafidi</dc:creator>
			<dc:creator>Soumia Benchekroun</dc:creator>
			<dc:creator>Mahraoui Chafiq</dc:creator>
			<dc:creator>Amal Zouaki</dc:creator>
			<dc:creator>Nora Touyar</dc:creator>
			<dc:creator>Najat Bouihat</dc:creator>
			<dc:creator>Salma Ech-Cherif El Kettani</dc:creator>
			<dc:creator>Saad Harrak</dc:creator>
			<dc:creator>Larbi Ed-Dafali</dc:creator>
			<dc:creator>Aziza Bentalha</dc:creator>
			<dc:creator>Mustapha Alilou</dc:creator>
			<dc:creator>Hamza El Hamzaoui</dc:creator>
			<dc:creator>Amina Barkat</dc:creator>
			<dc:creator>Ilham Elouardighi</dc:creator>
			<dc:creator>Tarek Dendane</dc:creator>
			<dc:creator>Khalid Abidi</dc:creator>
			<dc:creator>Jihane Bel Ayachi</dc:creator>
			<dc:creator>Naoufal Madani</dc:creator>
			<dc:creator>Redouane Abouqal</dc:creator>
			<dc:creator>Hicham Harmouche</dc:creator>
			<dc:creator>Mouna Maamar</dc:creator>
			<dc:creator>Rachid El Jaoudi</dc:creator>
			<dc:creator>Mourad Feindiri</dc:creator>
			<dc:creator>Myriam Seffar</dc:creator>
			<dc:creator>Mohamed Bouskraoui</dc:creator>
			<dc:creator>Hakima Kabbaj</dc:creator>
		<dc:identifier>doi: 10.3390/v18050530</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>530</prism:startingPage>
		<prism:doi>10.3390/v18050530</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/530</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/529">

	<title>Viruses, Vol. 18, Pages 529: Changing Patterns of HCV Genotype Distribution in a Migration-Affected Region of Turkey: A Retrospective Hospital-Based Study (2014&amp;ndash;2021)</title>
	<link>https://www.mdpi.com/1999-4915/18/5/529</link>
	<description>Hepatitis C virus (HCV) infection is still a major worldwide health concern. It is distinguished by a high degree of genetic variation that affects the course of the illness and the effectiveness of treatment. The epidemiological profile of HCV is prone to rapid change in areas where there is significant human migration, like Turkey. The purpose of this study was to evaluate the impact of long-term migration on local viral diversity by analyzing the distribution and temporal trends of HCV genotypes among Turkish citizens and asylum seekers in Kayseri, Turkey, over an eight-year period. From January 2014 to December 2021. 1173 HCV RNA-positive patients at Kayseri City Training and Research Hospital were the subject of a retrospective analysis. Genotypes were determined using the Abbott RealTime HCV Genotype II assay and Montania 4896 assay (Anatolia Geneworks, T&amp;amp;uuml;rkiye). The most prevalent genotypes were Genotype 1b (48.3%, 95% CI: 45.5&amp;amp;ndash;51.2%), Genotype 4 (25.0%, 95% CI: 22.5&amp;amp;ndash;27.5%), and Genotype 1a (10.3%, 95% CI: 8.6&amp;amp;ndash;12.1%). Turkish patients exhibited the highest prevalence of Genotype 1b (98.2%), while asylum seekers demonstrated greater relative burdens of Genotype 4 (8.5% of total GT4) and Genotype 5 (83.3% of total GT5). Genotype 3a emerged in 2018, with a predominance in males (73.9%). The Cochran&amp;amp;ndash;Armitage trend test revealed statistically significant increasing trends for Genotype 3 (Z = 3.572, p = 0.0004) and Genotype 3a (Z = 2.600, p = 0.009). This eight-year retrospective study demonstrates that the HCV genotype distribution in Kayseri has undergone significant changes in the context of migration and demographic shifts. The statistically significant increasing trends of Genotypes 3 and 3a, particularly among younger male populations, suggest evolving transmission dynamics. These findings underscore the necessity of demographically targeted and culturally appropriate screening and treatment strategies for both resident and migrant populations to achieve HCV elimination goals.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 529: Changing Patterns of HCV Genotype Distribution in a Migration-Affected Region of Turkey: A Retrospective Hospital-Based Study (2014&amp;ndash;2021)</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/529">doi: 10.3390/v18050529</a></p>
	<p>Authors:
		Yasemin Ay Altintop
		Esma Saatçi
		</p>
	<p>Hepatitis C virus (HCV) infection is still a major worldwide health concern. It is distinguished by a high degree of genetic variation that affects the course of the illness and the effectiveness of treatment. The epidemiological profile of HCV is prone to rapid change in areas where there is significant human migration, like Turkey. The purpose of this study was to evaluate the impact of long-term migration on local viral diversity by analyzing the distribution and temporal trends of HCV genotypes among Turkish citizens and asylum seekers in Kayseri, Turkey, over an eight-year period. From January 2014 to December 2021. 1173 HCV RNA-positive patients at Kayseri City Training and Research Hospital were the subject of a retrospective analysis. Genotypes were determined using the Abbott RealTime HCV Genotype II assay and Montania 4896 assay (Anatolia Geneworks, T&amp;amp;uuml;rkiye). The most prevalent genotypes were Genotype 1b (48.3%, 95% CI: 45.5&amp;amp;ndash;51.2%), Genotype 4 (25.0%, 95% CI: 22.5&amp;amp;ndash;27.5%), and Genotype 1a (10.3%, 95% CI: 8.6&amp;amp;ndash;12.1%). Turkish patients exhibited the highest prevalence of Genotype 1b (98.2%), while asylum seekers demonstrated greater relative burdens of Genotype 4 (8.5% of total GT4) and Genotype 5 (83.3% of total GT5). Genotype 3a emerged in 2018, with a predominance in males (73.9%). The Cochran&amp;amp;ndash;Armitage trend test revealed statistically significant increasing trends for Genotype 3 (Z = 3.572, p = 0.0004) and Genotype 3a (Z = 2.600, p = 0.009). This eight-year retrospective study demonstrates that the HCV genotype distribution in Kayseri has undergone significant changes in the context of migration and demographic shifts. The statistically significant increasing trends of Genotypes 3 and 3a, particularly among younger male populations, suggest evolving transmission dynamics. These findings underscore the necessity of demographically targeted and culturally appropriate screening and treatment strategies for both resident and migrant populations to achieve HCV elimination goals.</p>
	]]></content:encoded>

	<dc:title>Changing Patterns of HCV Genotype Distribution in a Migration-Affected Region of Turkey: A Retrospective Hospital-Based Study (2014&amp;amp;ndash;2021)</dc:title>
			<dc:creator>Yasemin Ay Altintop</dc:creator>
			<dc:creator>Esma Saatçi</dc:creator>
		<dc:identifier>doi: 10.3390/v18050529</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>529</prism:startingPage>
		<prism:doi>10.3390/v18050529</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/529</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/528">

	<title>Viruses, Vol. 18, Pages 528: Association of Initial Chest CT Findings, CT Severity Score and Clinical Parameters with ICU Admission in Hospitalized COVID-19 Patients</title>
	<link>https://www.mdpi.com/1999-4915/18/5/528</link>
	<description>The aim of this study was to evaluate the association between baseline clinical and CT characteristics and to identify factors associated with intensive care unit (ICU) admission in hospitalized COVID-19 patients. This retrospective study included 176 adult patients with laboratory-confirmed SARS-CoV-2 infection hospitalized at the COVID Hospital of the Clinical Hospital Center Kosovska Mitrovica during 2021&amp;amp;ndash;2022 (Delta and Omicron variants). Patients were divided into two groups according to intensive care unit requirement: those treated in a general inpatient ward (No ICU) and those requiring ICU admission (ICU group). Demographic and clinical characteristics, lifestyle factors, CT findings, CT severity score (CTSS) values, and therapeutic interventions were compared between groups. Of the total cohort, 113 patients (64%) were hospitalized in a general inpatient ward, while 63 (36%) required intensive care unit admission. Independent predictors of ICU admission identified in the multivariate logistic regression analysis were obesity (B = 2.96, p &amp;amp;lt; 0.001), dyspnea (B = 1.51, p = 0.041), higher CT severity score (B = 0.68, p &amp;amp;lt; 0.001), and lower glucose levels (B = &amp;amp;minus;0.27, p = 0.014). Furthermore, for each one-point increase in the CTSS, the odds of ICU admission nearly doubled (OR = 1.97). Total CT score values above the cut-off point (15.0) demonstrated significant reliability in discriminating the need for ICU transfer in patients with COVID-19. These findings suggest that combined clinical and radiological assessment at hospital admission may facilitate early identification of patients at high risk of requiring ICU care, with the CT severity score representing the strongest radiological predictor.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 528: Association of Initial Chest CT Findings, CT Severity Score and Clinical Parameters with ICU Admission in Hospitalized COVID-19 Patients</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/528">doi: 10.3390/v18050528</a></p>
	<p>Authors:
		Aleksandra Milenkovic
		Simon Nikolic
		Jelena Aritonovic Pribakovic
		Branislava Radovic
		Aleksandra Ilic
		Milica Stevanovic
		Sara Kovacevic
		Kristina Bulatovic
		Jelena Milovanovic
		Arijeta Kostic
		Aleksandra Janicevic
		</p>
	<p>The aim of this study was to evaluate the association between baseline clinical and CT characteristics and to identify factors associated with intensive care unit (ICU) admission in hospitalized COVID-19 patients. This retrospective study included 176 adult patients with laboratory-confirmed SARS-CoV-2 infection hospitalized at the COVID Hospital of the Clinical Hospital Center Kosovska Mitrovica during 2021&amp;amp;ndash;2022 (Delta and Omicron variants). Patients were divided into two groups according to intensive care unit requirement: those treated in a general inpatient ward (No ICU) and those requiring ICU admission (ICU group). Demographic and clinical characteristics, lifestyle factors, CT findings, CT severity score (CTSS) values, and therapeutic interventions were compared between groups. Of the total cohort, 113 patients (64%) were hospitalized in a general inpatient ward, while 63 (36%) required intensive care unit admission. Independent predictors of ICU admission identified in the multivariate logistic regression analysis were obesity (B = 2.96, p &amp;amp;lt; 0.001), dyspnea (B = 1.51, p = 0.041), higher CT severity score (B = 0.68, p &amp;amp;lt; 0.001), and lower glucose levels (B = &amp;amp;minus;0.27, p = 0.014). Furthermore, for each one-point increase in the CTSS, the odds of ICU admission nearly doubled (OR = 1.97). Total CT score values above the cut-off point (15.0) demonstrated significant reliability in discriminating the need for ICU transfer in patients with COVID-19. These findings suggest that combined clinical and radiological assessment at hospital admission may facilitate early identification of patients at high risk of requiring ICU care, with the CT severity score representing the strongest radiological predictor.</p>
	]]></content:encoded>

	<dc:title>Association of Initial Chest CT Findings, CT Severity Score and Clinical Parameters with ICU Admission in Hospitalized COVID-19 Patients</dc:title>
			<dc:creator>Aleksandra Milenkovic</dc:creator>
			<dc:creator>Simon Nikolic</dc:creator>
			<dc:creator>Jelena Aritonovic Pribakovic</dc:creator>
			<dc:creator>Branislava Radovic</dc:creator>
			<dc:creator>Aleksandra Ilic</dc:creator>
			<dc:creator>Milica Stevanovic</dc:creator>
			<dc:creator>Sara Kovacevic</dc:creator>
			<dc:creator>Kristina Bulatovic</dc:creator>
			<dc:creator>Jelena Milovanovic</dc:creator>
			<dc:creator>Arijeta Kostic</dc:creator>
			<dc:creator>Aleksandra Janicevic</dc:creator>
		<dc:identifier>doi: 10.3390/v18050528</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>528</prism:startingPage>
		<prism:doi>10.3390/v18050528</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/528</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/527">

	<title>Viruses, Vol. 18, Pages 527: Enterovirus Testing in Hand, Foot, and Mouth Disease and Herpangina: A Highly Sensitive Single-Round VP4&amp;ndash;VP2 Reverse-Transcription Polymerase Chain Reaction Assay with a Redesigned Reverse Primer</title>
	<link>https://www.mdpi.com/1999-4915/18/5/527</link>
	<description>Molecular typing of enteroviruses (EVs) is essential for surveillance of hand, foot, and mouth disease (HFMD). Conventional reverse-transcription polymerase chain reaction (RT-PCR) targeting the VP4&amp;amp;ndash;VP2 region can be insufficiently sensitive, reducing the detectability of Enterovirus A (EV-A). We developed a single-round RT-PCR assay using a modified reverse primer design (C3R) for rapid EV detection and genotyping. Sensitivity was evaluated using EV-A71 and poliovirus type 1 reference strains, across 60 EV-positive clinical specimens. The C3R-based assay showed ~1000-fold higher sensitivity for EV-A71 than for conventional assays (limit of detection: 6.6 copies/reaction). The assay detected 98.3% (59/60) of clinical specimens in a single-round format, whereas the conventional assay detected only 45.0% (27/60) and showed a marked decline in detection at higher Ct values. The C3R-based assay maintained complete detection for clinical specimens with Ct values below 40. The majority of the amplified products yielded high-quality sequences suitable for genotyping. This C3R-based RT-PCR overcomes sensitivity limitations of existing protocols and provides reliable genotyping from low-viral-load specimens, supporting its use in routine diagnostics and large-scale HFMD surveillance.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 527: Enterovirus Testing in Hand, Foot, and Mouth Disease and Herpangina: A Highly Sensitive Single-Round VP4&amp;ndash;VP2 Reverse-Transcription Polymerase Chain Reaction Assay with a Redesigned Reverse Primer</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/527">doi: 10.3390/v18050527</a></p>
	<p>Authors:
		Tsuguto Fujimoto
		Miki Ogi
		Kazuhiro Kitakawa
		Takako Sano
		Yorihiro Nishimura
		Kouichi Kitamura
		Minami Kikuchi Ueno
		Minetaro Arita
		</p>
	<p>Molecular typing of enteroviruses (EVs) is essential for surveillance of hand, foot, and mouth disease (HFMD). Conventional reverse-transcription polymerase chain reaction (RT-PCR) targeting the VP4&amp;amp;ndash;VP2 region can be insufficiently sensitive, reducing the detectability of Enterovirus A (EV-A). We developed a single-round RT-PCR assay using a modified reverse primer design (C3R) for rapid EV detection and genotyping. Sensitivity was evaluated using EV-A71 and poliovirus type 1 reference strains, across 60 EV-positive clinical specimens. The C3R-based assay showed ~1000-fold higher sensitivity for EV-A71 than for conventional assays (limit of detection: 6.6 copies/reaction). The assay detected 98.3% (59/60) of clinical specimens in a single-round format, whereas the conventional assay detected only 45.0% (27/60) and showed a marked decline in detection at higher Ct values. The C3R-based assay maintained complete detection for clinical specimens with Ct values below 40. The majority of the amplified products yielded high-quality sequences suitable for genotyping. This C3R-based RT-PCR overcomes sensitivity limitations of existing protocols and provides reliable genotyping from low-viral-load specimens, supporting its use in routine diagnostics and large-scale HFMD surveillance.</p>
	]]></content:encoded>

	<dc:title>Enterovirus Testing in Hand, Foot, and Mouth Disease and Herpangina: A Highly Sensitive Single-Round VP4&amp;amp;ndash;VP2 Reverse-Transcription Polymerase Chain Reaction Assay with a Redesigned Reverse Primer</dc:title>
			<dc:creator>Tsuguto Fujimoto</dc:creator>
			<dc:creator>Miki Ogi</dc:creator>
			<dc:creator>Kazuhiro Kitakawa</dc:creator>
			<dc:creator>Takako Sano</dc:creator>
			<dc:creator>Yorihiro Nishimura</dc:creator>
			<dc:creator>Kouichi Kitamura</dc:creator>
			<dc:creator>Minami Kikuchi Ueno</dc:creator>
			<dc:creator>Minetaro Arita</dc:creator>
		<dc:identifier>doi: 10.3390/v18050527</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>527</prism:startingPage>
		<prism:doi>10.3390/v18050527</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/527</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/526">

	<title>Viruses, Vol. 18, Pages 526: Isolation of Bacteriophages with Lytic Activity from Biological Samples of Left Ventricular Assist Device Patients: An In Vitro Study</title>
	<link>https://www.mdpi.com/1999-4915/18/5/526</link>
	<description>Percutaneous cable infection of left ventricular assist device (LVAD) patients is a significant source of morbidity, often caused by biofilm-producing or multidrug-resistant bacteria. We hypothesized that bacteriophage viruses can be identified from biological samples of patients with active driveline infection. Six patients with local percutaneous lead infections were enrolled. Microbiological samples were collected from the infected wound and other skin regions. The isolated viral strains and phages from wastewater samples were then tested against the pathogen bacterial cultures in vitro. Biofilm disruption assay and genetic analysis of the strains were also performed. Bacteriophages with lytic activity could be identified from samples of two patients. One patient contained four strains showing strong efficacy against his own Staphylococcus epidermidis. Furthermore, this bacterium was susceptible to phages identified from another patient and strains from wastewater samples. Genomic analysis suggested lysogenic lifestyle of the phages. However, none of them have shown any microbiological signs of lysogeny. In conclusion, we have been able to prove in vitro lytic activity of bacteriophages originating from the same LVAD patient. We also found effective phages in biological samples of other patients and wastewater samples, suggesting that patients implanted in the same center may share bacteriophage flora.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 526: Isolation of Bacteriophages with Lytic Activity from Biological Samples of Left Ventricular Assist Device Patients: An In Vitro Study</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/526">doi: 10.3390/v18050526</a></p>
	<p>Authors:
		Balazs Sax
		Adam Koppanyi
		Katalin Kristof
		Akos Kiraly
		Gyula Prinz
		Istvan Hartyanszky
		Gergely Gyorgy Nagy
		Istvan Nemet
		Fanni Temesvari-Kis
		Balazs Kiss
		Bela Merkely
		</p>
	<p>Percutaneous cable infection of left ventricular assist device (LVAD) patients is a significant source of morbidity, often caused by biofilm-producing or multidrug-resistant bacteria. We hypothesized that bacteriophage viruses can be identified from biological samples of patients with active driveline infection. Six patients with local percutaneous lead infections were enrolled. Microbiological samples were collected from the infected wound and other skin regions. The isolated viral strains and phages from wastewater samples were then tested against the pathogen bacterial cultures in vitro. Biofilm disruption assay and genetic analysis of the strains were also performed. Bacteriophages with lytic activity could be identified from samples of two patients. One patient contained four strains showing strong efficacy against his own Staphylococcus epidermidis. Furthermore, this bacterium was susceptible to phages identified from another patient and strains from wastewater samples. Genomic analysis suggested lysogenic lifestyle of the phages. However, none of them have shown any microbiological signs of lysogeny. In conclusion, we have been able to prove in vitro lytic activity of bacteriophages originating from the same LVAD patient. We also found effective phages in biological samples of other patients and wastewater samples, suggesting that patients implanted in the same center may share bacteriophage flora.</p>
	]]></content:encoded>

	<dc:title>Isolation of Bacteriophages with Lytic Activity from Biological Samples of Left Ventricular Assist Device Patients: An In Vitro Study</dc:title>
			<dc:creator>Balazs Sax</dc:creator>
			<dc:creator>Adam Koppanyi</dc:creator>
			<dc:creator>Katalin Kristof</dc:creator>
			<dc:creator>Akos Kiraly</dc:creator>
			<dc:creator>Gyula Prinz</dc:creator>
			<dc:creator>Istvan Hartyanszky</dc:creator>
			<dc:creator>Gergely Gyorgy Nagy</dc:creator>
			<dc:creator>Istvan Nemet</dc:creator>
			<dc:creator>Fanni Temesvari-Kis</dc:creator>
			<dc:creator>Balazs Kiss</dc:creator>
			<dc:creator>Bela Merkely</dc:creator>
		<dc:identifier>doi: 10.3390/v18050526</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>526</prism:startingPage>
		<prism:doi>10.3390/v18050526</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/526</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/524">

	<title>Viruses, Vol. 18, Pages 524: Dual Aspect of the Pandemic on the African Continent: Viral Distribution and Shifting Demographic Susceptibility to SARS-CoV-2</title>
	<link>https://www.mdpi.com/1999-4915/18/5/524</link>
	<description>SARS-CoV-2, the causative agent of COVID-19, emerged in late 2019 and rapidly developed into a global health crisis. In this study, we analysed 173,194 SARS-CoV-2 genomes from the GISAID database to explore the intra-continental dynamics and distribution of variants across Africa between 2020 and 2024. We have identified 1377 distinct lineages, which were classified by clade to assess associations with infection and mortality rate. So, we conducted a Shannon entropy analysis to confirm the diversity and we applied a Correspondence Analysis (CA). Our findings revealed that one of the deadliest in Africa during the Delta wave, lineage AY.45 predominated in the South Africa cluster, whereas AY.34.1 drove transmission in the Atlantic West Africa cluster, underscoring regional heterogeneity. Furthermore, early in the pandemic, men exhibited a 39% higher risk of infection compared to women (aOR: 1.39, 95% CI [1.34&amp;amp;ndash;1.45]), particularly in association with clade G. By contrast, later stages were dominated by clade GRA, which disproportionately affected the elderly (&amp;amp;ge;70 years; aOR: 1.39, 95% CI [1.33&amp;amp;ndash;1.45]) and children (0&amp;amp;ndash;9 years; aOR: 1.26, 95% CI [1.20&amp;amp;ndash;1.33]). Our analysis highlighted that the pandemic on the African continent unfolded as a mosaic of epidemics shaped by diverse variants and regional epidemiological contexts. These findings emphasize the importance of genomic surveillance to capture local epidemic signatures and inform region-specific public health strategies.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 524: Dual Aspect of the Pandemic on the African Continent: Viral Distribution and Shifting Demographic Susceptibility to SARS-CoV-2</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/524">doi: 10.3390/v18050524</a></p>
	<p>Authors:
		Julia Cyrielle Andeko
		Sonia Etenna Lekana-Douki
		Gabriel Falque
		Nadine N’dilimabaka
		Jean-Bernard Lekana-Douki
		</p>
	<p>SARS-CoV-2, the causative agent of COVID-19, emerged in late 2019 and rapidly developed into a global health crisis. In this study, we analysed 173,194 SARS-CoV-2 genomes from the GISAID database to explore the intra-continental dynamics and distribution of variants across Africa between 2020 and 2024. We have identified 1377 distinct lineages, which were classified by clade to assess associations with infection and mortality rate. So, we conducted a Shannon entropy analysis to confirm the diversity and we applied a Correspondence Analysis (CA). Our findings revealed that one of the deadliest in Africa during the Delta wave, lineage AY.45 predominated in the South Africa cluster, whereas AY.34.1 drove transmission in the Atlantic West Africa cluster, underscoring regional heterogeneity. Furthermore, early in the pandemic, men exhibited a 39% higher risk of infection compared to women (aOR: 1.39, 95% CI [1.34&amp;amp;ndash;1.45]), particularly in association with clade G. By contrast, later stages were dominated by clade GRA, which disproportionately affected the elderly (&amp;amp;ge;70 years; aOR: 1.39, 95% CI [1.33&amp;amp;ndash;1.45]) and children (0&amp;amp;ndash;9 years; aOR: 1.26, 95% CI [1.20&amp;amp;ndash;1.33]). Our analysis highlighted that the pandemic on the African continent unfolded as a mosaic of epidemics shaped by diverse variants and regional epidemiological contexts. These findings emphasize the importance of genomic surveillance to capture local epidemic signatures and inform region-specific public health strategies.</p>
	]]></content:encoded>

	<dc:title>Dual Aspect of the Pandemic on the African Continent: Viral Distribution and Shifting Demographic Susceptibility to SARS-CoV-2</dc:title>
			<dc:creator>Julia Cyrielle Andeko</dc:creator>
			<dc:creator>Sonia Etenna Lekana-Douki</dc:creator>
			<dc:creator>Gabriel Falque</dc:creator>
			<dc:creator>Nadine N’dilimabaka</dc:creator>
			<dc:creator>Jean-Bernard Lekana-Douki</dc:creator>
		<dc:identifier>doi: 10.3390/v18050524</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>524</prism:startingPage>
		<prism:doi>10.3390/v18050524</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/524</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/525">

	<title>Viruses, Vol. 18, Pages 525: Emergence and Evolution of Triple Reassortant Highly Pathogenic Avian Influenza A(H5N1) Virus, Argentina, 2025</title>
	<link>https://www.mdpi.com/1999-4915/18/5/525</link>
	<description>The H5N1 subtype of highly pathogenic avian influenza (HPAI) poses a major zoonotic threat due to its high fatality rate and capacity for cross species transmission. In early 2025, Argentina detected a novel triple reassortant A(H5N1) virus in Chaco Province, combining Eurasian, North American, and South American lineage segments. Genomic analyses of subsequent outbreaks in Buenos Aires and Entre R&amp;amp;iacute;os confirmed persistence of this reassortant and additional HA substitutions (T204K, P251S) potentially linked to increased mammalian receptor affinity. Although PB2 sequences lacked canonical mammalian-adaptive markers (E627K, Q591K, D701N), all contained I292M, a mutation associated with human adaptation. Phylogenetic analyses revealed distinct genotypes and increasing divergence. These findings indicate ongoing viral evolution and adaptation within Argentina, emphasizing the urgent need for sustained genomic surveillance, timely data sharing, and integrated One Health strategies to mitigate zoonotic and socioeconomic risks associated with H5N1 spread in South America.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 525: Emergence and Evolution of Triple Reassortant Highly Pathogenic Avian Influenza A(H5N1) Virus, Argentina, 2025</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/525">doi: 10.3390/v18050525</a></p>
	<p>Authors:
		Estefania Benedetti
		Maria Carolina Artuso
		Alex Byrne
		Maria de Belen Garibotto
		Martín Avaro
		Luana Piccini
		Ariana Chamorro
		Marcelo Sciorra
		Vanina Marchione
		Mara Russo
		Maria Elena Dattero
		Erika Macias Machicado
		Monica Galiano
		Nicola Lewis
		Andrea Pontoriero
		</p>
	<p>The H5N1 subtype of highly pathogenic avian influenza (HPAI) poses a major zoonotic threat due to its high fatality rate and capacity for cross species transmission. In early 2025, Argentina detected a novel triple reassortant A(H5N1) virus in Chaco Province, combining Eurasian, North American, and South American lineage segments. Genomic analyses of subsequent outbreaks in Buenos Aires and Entre R&amp;amp;iacute;os confirmed persistence of this reassortant and additional HA substitutions (T204K, P251S) potentially linked to increased mammalian receptor affinity. Although PB2 sequences lacked canonical mammalian-adaptive markers (E627K, Q591K, D701N), all contained I292M, a mutation associated with human adaptation. Phylogenetic analyses revealed distinct genotypes and increasing divergence. These findings indicate ongoing viral evolution and adaptation within Argentina, emphasizing the urgent need for sustained genomic surveillance, timely data sharing, and integrated One Health strategies to mitigate zoonotic and socioeconomic risks associated with H5N1 spread in South America.</p>
	]]></content:encoded>

	<dc:title>Emergence and Evolution of Triple Reassortant Highly Pathogenic Avian Influenza A(H5N1) Virus, Argentina, 2025</dc:title>
			<dc:creator>Estefania Benedetti</dc:creator>
			<dc:creator>Maria Carolina Artuso</dc:creator>
			<dc:creator>Alex Byrne</dc:creator>
			<dc:creator>Maria de Belen Garibotto</dc:creator>
			<dc:creator>Martín Avaro</dc:creator>
			<dc:creator>Luana Piccini</dc:creator>
			<dc:creator>Ariana Chamorro</dc:creator>
			<dc:creator>Marcelo Sciorra</dc:creator>
			<dc:creator>Vanina Marchione</dc:creator>
			<dc:creator>Mara Russo</dc:creator>
			<dc:creator>Maria Elena Dattero</dc:creator>
			<dc:creator>Erika Macias Machicado</dc:creator>
			<dc:creator>Monica Galiano</dc:creator>
			<dc:creator>Nicola Lewis</dc:creator>
			<dc:creator>Andrea Pontoriero</dc:creator>
		<dc:identifier>doi: 10.3390/v18050525</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>525</prism:startingPage>
		<prism:doi>10.3390/v18050525</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/525</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/523">

	<title>Viruses, Vol. 18, Pages 523: A Review of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection in Botswana</title>
	<link>https://www.mdpi.com/1999-4915/18/5/523</link>
	<description>Hepatitis B virus (HBV) remains a leading cause of chronic liver disease worldwide, contributing to cirrhosis and hepatocellular carcinoma. Sub-Saharan Africa accounts for an estimated 68% of incident HBV infections, where co-infection with human immunodeficiency virus (HIV) is common and associated with poorer clinical outcomes. In Botswana, limited HBV screening and the absence of established HBV management guidelines persist despite reported HIV-HBV co-infection rates ranging from 1.1% to 10.6%. This scoping review aimed to summarise existing research on HBV and HIV-HBV co-infection in Botswana and assess clinical and policy implications. Following PRISMA methodology, searches were conducted across PubMed, Google Scholar, Semantic Scholar, and Consensus databases. Thirty eligible peer-reviewed studies were identified and evaluated for prevalence data, virological characteristics, genotypes, mutations, treatment outcomes, vaccination programs, and the availability of guidelines. Findings indicate intermediate-to-high HBV and HIV-HBV disease burden, substantial occult HBV infection, and gaps in diagnostic and preventive practices. The lack of routine screening, deficient infant birth-dose and adult vaccination, and established treatment pathways likely increase the risk of HBV-associated morbidity and mortality. Strengthened public health interventions, including expanded testing, enhanced vaccination coverage, and prevention of mother-to-child transmission strategies, are recommended to improve disease control and clinical outcomes in Botswana.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 523: A Review of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection in Botswana</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/523">doi: 10.3390/v18050523</a></p>
	<p>Authors:
		Linda Mpofu-Dobo
		Kebaneilwe Lebani
		Jason T. Blackard
		Sikhulile Moyo
		Motswedi Anderson
		Simani Gaseitsiwe
		</p>
	<p>Hepatitis B virus (HBV) remains a leading cause of chronic liver disease worldwide, contributing to cirrhosis and hepatocellular carcinoma. Sub-Saharan Africa accounts for an estimated 68% of incident HBV infections, where co-infection with human immunodeficiency virus (HIV) is common and associated with poorer clinical outcomes. In Botswana, limited HBV screening and the absence of established HBV management guidelines persist despite reported HIV-HBV co-infection rates ranging from 1.1% to 10.6%. This scoping review aimed to summarise existing research on HBV and HIV-HBV co-infection in Botswana and assess clinical and policy implications. Following PRISMA methodology, searches were conducted across PubMed, Google Scholar, Semantic Scholar, and Consensus databases. Thirty eligible peer-reviewed studies were identified and evaluated for prevalence data, virological characteristics, genotypes, mutations, treatment outcomes, vaccination programs, and the availability of guidelines. Findings indicate intermediate-to-high HBV and HIV-HBV disease burden, substantial occult HBV infection, and gaps in diagnostic and preventive practices. The lack of routine screening, deficient infant birth-dose and adult vaccination, and established treatment pathways likely increase the risk of HBV-associated morbidity and mortality. Strengthened public health interventions, including expanded testing, enhanced vaccination coverage, and prevention of mother-to-child transmission strategies, are recommended to improve disease control and clinical outcomes in Botswana.</p>
	]]></content:encoded>

	<dc:title>A Review of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection in Botswana</dc:title>
			<dc:creator>Linda Mpofu-Dobo</dc:creator>
			<dc:creator>Kebaneilwe Lebani</dc:creator>
			<dc:creator>Jason T. Blackard</dc:creator>
			<dc:creator>Sikhulile Moyo</dc:creator>
			<dc:creator>Motswedi Anderson</dc:creator>
			<dc:creator>Simani Gaseitsiwe</dc:creator>
		<dc:identifier>doi: 10.3390/v18050523</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>523</prism:startingPage>
		<prism:doi>10.3390/v18050523</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/523</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/522">

	<title>Viruses, Vol. 18, Pages 522: Identification and Characterization of a Novel Bovine Adenovirus Which Represents a Distinct Evolutionary Branch</title>
	<link>https://www.mdpi.com/1999-4915/18/5/522</link>
	<description>Bovine adenovirus (BAdV) is associated with respiratory and enteric diseases in cattle. In this study, the complete genomic sequence of a novel BAdV strain (named BAdV/LN/CHN/2023) was sequenced and annotated using the next-generation sequencing (NGS) technology. The viral genome comprises 32,391 base pairs with a GC content of 44.93%, encoding 33 predicted open reading frames (ORFs), consistent with the genomic organization of mastadenoviruses. Comparative genomic analysis confirmed that BAdV/LN/CHN/2023 contains conserved structural and functional motifs characteristic of the genus Mastadenovirus. Phylogenetic analysis revealed that BAdV/LN/CHN/2023 shares low similarity with all currently recognized bovine mastadenoviruses classified by the International Committee on Taxonomy of Viruses (ICTV). In addition, an open reading frame (ORF) encoding the 146R protein was annotated in this strain; this feature has not been identified in any previously recognized bovine mastadenoviruses. This study presents the first full-length genomic sequence of a putative BAdV-11 strain, and based on ICTV criteria, we propose that this strain represents a novel mastadenovirus species, supported by phylogenetic distance and genomic divergence. Our findings expand the known genetic diversity of BAdVs and contribute to a better understanding of their evolutionary relationships.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 522: Identification and Characterization of a Novel Bovine Adenovirus Which Represents a Distinct Evolutionary Branch</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/522">doi: 10.3390/v18050522</a></p>
	<p>Authors:
		Jinyu Sui
		Suchun Wang
		Zihao Pan
		Kaicheng Wang
		</p>
	<p>Bovine adenovirus (BAdV) is associated with respiratory and enteric diseases in cattle. In this study, the complete genomic sequence of a novel BAdV strain (named BAdV/LN/CHN/2023) was sequenced and annotated using the next-generation sequencing (NGS) technology. The viral genome comprises 32,391 base pairs with a GC content of 44.93%, encoding 33 predicted open reading frames (ORFs), consistent with the genomic organization of mastadenoviruses. Comparative genomic analysis confirmed that BAdV/LN/CHN/2023 contains conserved structural and functional motifs characteristic of the genus Mastadenovirus. Phylogenetic analysis revealed that BAdV/LN/CHN/2023 shares low similarity with all currently recognized bovine mastadenoviruses classified by the International Committee on Taxonomy of Viruses (ICTV). In addition, an open reading frame (ORF) encoding the 146R protein was annotated in this strain; this feature has not been identified in any previously recognized bovine mastadenoviruses. This study presents the first full-length genomic sequence of a putative BAdV-11 strain, and based on ICTV criteria, we propose that this strain represents a novel mastadenovirus species, supported by phylogenetic distance and genomic divergence. Our findings expand the known genetic diversity of BAdVs and contribute to a better understanding of their evolutionary relationships.</p>
	]]></content:encoded>

	<dc:title>Identification and Characterization of a Novel Bovine Adenovirus Which Represents a Distinct Evolutionary Branch</dc:title>
			<dc:creator>Jinyu Sui</dc:creator>
			<dc:creator>Suchun Wang</dc:creator>
			<dc:creator>Zihao Pan</dc:creator>
			<dc:creator>Kaicheng Wang</dc:creator>
		<dc:identifier>doi: 10.3390/v18050522</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>522</prism:startingPage>
		<prism:doi>10.3390/v18050522</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/522</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/521">

	<title>Viruses, Vol. 18, Pages 521: 3D Single-Virus Tracking: Advances in Methodology and Labeling Strategies Towards Probing the Virus&amp;ndash;Epithelium Interaction</title>
	<link>https://www.mdpi.com/1999-4915/18/5/521</link>
	<description>The epithelium represents the first line of defense against viral infection, yet the precise mechanisms by which viruses penetrate this complex barrier remain incompletely understood. Single-virus tracking (SVT) has emerged as a powerful fluorescence microscopy approach to directly visualize viral dynamics with nanometer spatial precision and millisecond temporal resolution. In this review, we survey recent progress in SVT methodologies, from image-based approaches to active feedback techniques, and assess their capacity to resolve viral behavior in physiologically relevant epithelial models. We further evaluate advances in virus labeling strategies&amp;amp;mdash;including fluorescent proteins, organic dyes, and nanoparticles&amp;amp;mdash;that enable prolonged observation while preserving infectivity. By integrating developments in optical instrumentation and molecular labeling, SVT is increasingly capable of capturing critical processes, including extracellular diffusion, receptor engagement, internalization, and trans-epithelial transport. Finally, we discuss current challenges, including limited penetration depth, photobleaching, and the complexity of 3D epithelial tissues, and outline future opportunities to extend SVT towards in situ and tissue-level studies. Together, these advances position SVT as a transformative tool to illuminate virus&amp;amp;ndash;epithelium interactions and guide therapeutic strategies.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 521: 3D Single-Virus Tracking: Advances in Methodology and Labeling Strategies Towards Probing the Virus&amp;ndash;Epithelium Interaction</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/521">doi: 10.3390/v18050521</a></p>
	<p>Authors:
		Yuxin Lin
		Haoting Lin
		Donggeng Yu
		Kevin Welsher
		</p>
	<p>The epithelium represents the first line of defense against viral infection, yet the precise mechanisms by which viruses penetrate this complex barrier remain incompletely understood. Single-virus tracking (SVT) has emerged as a powerful fluorescence microscopy approach to directly visualize viral dynamics with nanometer spatial precision and millisecond temporal resolution. In this review, we survey recent progress in SVT methodologies, from image-based approaches to active feedback techniques, and assess their capacity to resolve viral behavior in physiologically relevant epithelial models. We further evaluate advances in virus labeling strategies&amp;amp;mdash;including fluorescent proteins, organic dyes, and nanoparticles&amp;amp;mdash;that enable prolonged observation while preserving infectivity. By integrating developments in optical instrumentation and molecular labeling, SVT is increasingly capable of capturing critical processes, including extracellular diffusion, receptor engagement, internalization, and trans-epithelial transport. Finally, we discuss current challenges, including limited penetration depth, photobleaching, and the complexity of 3D epithelial tissues, and outline future opportunities to extend SVT towards in situ and tissue-level studies. Together, these advances position SVT as a transformative tool to illuminate virus&amp;amp;ndash;epithelium interactions and guide therapeutic strategies.</p>
	]]></content:encoded>

	<dc:title>3D Single-Virus Tracking: Advances in Methodology and Labeling Strategies Towards Probing the Virus&amp;amp;ndash;Epithelium Interaction</dc:title>
			<dc:creator>Yuxin Lin</dc:creator>
			<dc:creator>Haoting Lin</dc:creator>
			<dc:creator>Donggeng Yu</dc:creator>
			<dc:creator>Kevin Welsher</dc:creator>
		<dc:identifier>doi: 10.3390/v18050521</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>521</prism:startingPage>
		<prism:doi>10.3390/v18050521</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/521</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/517">

	<title>Viruses, Vol. 18, Pages 517: Development and Evaluation of Molecular Diagnostic Tests for SARS-CoV-2 at English NHS Sites Throughout the COVID-19 Pandemic</title>
	<link>https://www.mdpi.com/1999-4915/18/5/517</link>
	<description>The COVID-19 pandemic placed unprecedented pressure on diagnostic services worldwide. The first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the UK were confirmed on 31 January 2020, prompting National Health Service (NHS) laboratories to scale diagnostic procedures. The demand for testing rapidly exceeded historical norms for respiratory virus diagnostics, necessitating substantial government investment in consumables, assay development, and workforce expansion. This review presents a retrospective evaluation of SARS-CoV-2 diagnostic platforms deployed within the Norfolk and Norwich University Hospital (NNUH) trust and compares them with those implemented by other regional laboratories during the pandemic. It examines the molecular mechanisms, performance, scalability, and specificity of the multiple molecular testing approaches to optimise workflow based on the evolving technology. The integration of complementary platforms through a stratified testing strategy enabled high-throughput population screening while preserving diagnostic resolution for complex respiratory cases, substantially improving laboratory efficiency and resilience. The emerging diagnostic methodologies, RT-LAMP and CRISPR-based assays, are described, and we discuss their potential roles in future outbreaks. We critically evaluate the overall preparedness of UK health services for the COVID-19 pandemic and highlight key priorities for future pandemic preparedness at both local and national levels.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 517: Development and Evaluation of Molecular Diagnostic Tests for SARS-CoV-2 at English NHS Sites Throughout the COVID-19 Pandemic</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/517">doi: 10.3390/v18050517</a></p>
	<p>Authors:
		Luke D. Griffith
		Samir Dervisevic
		Penny P. Powell
		</p>
	<p>The COVID-19 pandemic placed unprecedented pressure on diagnostic services worldwide. The first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the UK were confirmed on 31 January 2020, prompting National Health Service (NHS) laboratories to scale diagnostic procedures. The demand for testing rapidly exceeded historical norms for respiratory virus diagnostics, necessitating substantial government investment in consumables, assay development, and workforce expansion. This review presents a retrospective evaluation of SARS-CoV-2 diagnostic platforms deployed within the Norfolk and Norwich University Hospital (NNUH) trust and compares them with those implemented by other regional laboratories during the pandemic. It examines the molecular mechanisms, performance, scalability, and specificity of the multiple molecular testing approaches to optimise workflow based on the evolving technology. The integration of complementary platforms through a stratified testing strategy enabled high-throughput population screening while preserving diagnostic resolution for complex respiratory cases, substantially improving laboratory efficiency and resilience. The emerging diagnostic methodologies, RT-LAMP and CRISPR-based assays, are described, and we discuss their potential roles in future outbreaks. We critically evaluate the overall preparedness of UK health services for the COVID-19 pandemic and highlight key priorities for future pandemic preparedness at both local and national levels.</p>
	]]></content:encoded>

	<dc:title>Development and Evaluation of Molecular Diagnostic Tests for SARS-CoV-2 at English NHS Sites Throughout the COVID-19 Pandemic</dc:title>
			<dc:creator>Luke D. Griffith</dc:creator>
			<dc:creator>Samir Dervisevic</dc:creator>
			<dc:creator>Penny P. Powell</dc:creator>
		<dc:identifier>doi: 10.3390/v18050517</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>517</prism:startingPage>
		<prism:doi>10.3390/v18050517</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/517</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/519">

	<title>Viruses, Vol. 18, Pages 519: Genomic Diversity of Vaginal Lactobacillus crispatus Prophages from South African Women</title>
	<link>https://www.mdpi.com/1999-4915/18/5/519</link>
	<description>Lactobacillus crispatus is widely associated with optimal sexual and reproductive health outcomes. While L. crispatus genomes commonly harbor prophages, little is known about their genomic diversity and potential inducibility by clinically relevant compounds. We induced and characterized four bacteriophages from four L. crispatus strains isolated from vaginal secretions of South African adolescents. Sequenced viral DNA from induced phages was assembled, and their respective genomes were annotated and compared to bacteriophage reference genomes. All the phage genomes range in size from 42.9 to 48.3 kbp. Of the four phages, UC101 and UC164 shared &amp;amp;lt;90% pairwise intergenomic similarity to reference phages, suggesting that they represent new species. To explore factors potentially associated with prophage activation, L. crispatus strains were exposed to physiological concentrations of copper ions and tenofovir, selected based on their common use by women in Africa and reported associations with altered vaginal bacterial community composition. The presence of phage-like particles following exposure to copper ions (2.0 &amp;amp;times; 10&amp;amp;minus;6 M&amp;amp;ndash;3.0 &amp;amp;times; 10&amp;amp;minus;6 M) and tenofovir (500 ng/mL) was observed by transmission electron microscopy, suggesting possible prophage activation under these conditions. This study provides new insights into the genomic diversity of inducible L. crispatus phages and presents hypothesis-generating evidence regarding their potential inducibility using copper ions and tenofovir.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 519: Genomic Diversity of Vaginal Lactobacillus crispatus Prophages from South African Women</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/519">doi: 10.3390/v18050519</a></p>
	<p>Authors:
		Adijat Ozohu Jimoh
		Anika Chicken
		Brandon Maust
		Colin Feng
		Seth Rakoff-Nahoum
		Jo-Ann S. Passmore
		Brian R. Kullin
		Simona Kraberger
		Fatima Aysha Hussain
		Heather B. Jaspan
		Arvind Varsani
		Anna-Ursula Happel
		</p>
	<p>Lactobacillus crispatus is widely associated with optimal sexual and reproductive health outcomes. While L. crispatus genomes commonly harbor prophages, little is known about their genomic diversity and potential inducibility by clinically relevant compounds. We induced and characterized four bacteriophages from four L. crispatus strains isolated from vaginal secretions of South African adolescents. Sequenced viral DNA from induced phages was assembled, and their respective genomes were annotated and compared to bacteriophage reference genomes. All the phage genomes range in size from 42.9 to 48.3 kbp. Of the four phages, UC101 and UC164 shared &amp;amp;lt;90% pairwise intergenomic similarity to reference phages, suggesting that they represent new species. To explore factors potentially associated with prophage activation, L. crispatus strains were exposed to physiological concentrations of copper ions and tenofovir, selected based on their common use by women in Africa and reported associations with altered vaginal bacterial community composition. The presence of phage-like particles following exposure to copper ions (2.0 &amp;amp;times; 10&amp;amp;minus;6 M&amp;amp;ndash;3.0 &amp;amp;times; 10&amp;amp;minus;6 M) and tenofovir (500 ng/mL) was observed by transmission electron microscopy, suggesting possible prophage activation under these conditions. This study provides new insights into the genomic diversity of inducible L. crispatus phages and presents hypothesis-generating evidence regarding their potential inducibility using copper ions and tenofovir.</p>
	]]></content:encoded>

	<dc:title>Genomic Diversity of Vaginal Lactobacillus crispatus Prophages from South African Women</dc:title>
			<dc:creator>Adijat Ozohu Jimoh</dc:creator>
			<dc:creator>Anika Chicken</dc:creator>
			<dc:creator>Brandon Maust</dc:creator>
			<dc:creator>Colin Feng</dc:creator>
			<dc:creator>Seth Rakoff-Nahoum</dc:creator>
			<dc:creator>Jo-Ann S. Passmore</dc:creator>
			<dc:creator>Brian R. Kullin</dc:creator>
			<dc:creator>Simona Kraberger</dc:creator>
			<dc:creator>Fatima Aysha Hussain</dc:creator>
			<dc:creator>Heather B. Jaspan</dc:creator>
			<dc:creator>Arvind Varsani</dc:creator>
			<dc:creator>Anna-Ursula Happel</dc:creator>
		<dc:identifier>doi: 10.3390/v18050519</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>519</prism:startingPage>
		<prism:doi>10.3390/v18050519</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/519</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/520">

	<title>Viruses, Vol. 18, Pages 520: Shifting Epicenters: The Dynamic Regional Dispersal of SARS-CoV-2 Omicron in Poland</title>
	<link>https://www.mdpi.com/1999-4915/18/5/520</link>
	<description>The evolution and spatial dissemination of SARS-CoV-2 Omicron subvariants have been characterized by rapid lineage replacement and complex transmission dynamics influenced by regional connectivity. This study presents a comprehensive discrete phylogeographic analysis of 90,136 SARS-CoV-2 sequences collected in Poland from 2022 to 2024 to reconstruct the dispersal dynamics of major Omicron lineages, including BA.1, BA.2, BA.5, CH.1, XBB.1, and JN.1. Utilizing Bayesian statistical frameworks, we identified significant viral transitions between the 16 Polish voivodeships and established variant-specific dominance windows ranging from 2 to 4 months. Our findings reveal a highly dynamic epidemic landscape with shifting regional epicenters. The initial BA.1 wave was primarily driven by the Mazovian voivodeship, accounting for 36.1% of outward migration events. This pattern shifted dramatically with the rise in BA.2, which was centered in the industrial Silesian region in the south-west, a densely populated area with strong economic ties to neighboring countries, potentially reflecting a different introduction or transmission dynamic. Furthermore, the epidemic landscape continued to reconfigure during the BA.5 wave, marked by the emergence of new transmission hubs in eastern border regions such as Lublin. Subsequent lineages exhibited distinct geographic signatures: BA.5 spread broadly along the Baltic-central corridor, CH.1 was centered in the north-east, XBB.1 re-emerged in the west-central region of Greater Poland, and JN.1 was driven overwhelmingly by Lesser Poland. These transitions highlight that regional transmission hubs are transient and influenced by local factors such as population density, cross-border mobility, and socio-economic connectivity. This study underscores the critical value of dense genomic surveillance in identifying evolving dispersal routes to inform adaptive, region-specific public health interventions.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 520: Shifting Epicenters: The Dynamic Regional Dispersal of SARS-CoV-2 Omicron in Poland</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/520">doi: 10.3390/v18050520</a></p>
	<p>Authors:
		Marcin Horecki
		Karol Serwin
		Miłosz Parczewski
		</p>
	<p>The evolution and spatial dissemination of SARS-CoV-2 Omicron subvariants have been characterized by rapid lineage replacement and complex transmission dynamics influenced by regional connectivity. This study presents a comprehensive discrete phylogeographic analysis of 90,136 SARS-CoV-2 sequences collected in Poland from 2022 to 2024 to reconstruct the dispersal dynamics of major Omicron lineages, including BA.1, BA.2, BA.5, CH.1, XBB.1, and JN.1. Utilizing Bayesian statistical frameworks, we identified significant viral transitions between the 16 Polish voivodeships and established variant-specific dominance windows ranging from 2 to 4 months. Our findings reveal a highly dynamic epidemic landscape with shifting regional epicenters. The initial BA.1 wave was primarily driven by the Mazovian voivodeship, accounting for 36.1% of outward migration events. This pattern shifted dramatically with the rise in BA.2, which was centered in the industrial Silesian region in the south-west, a densely populated area with strong economic ties to neighboring countries, potentially reflecting a different introduction or transmission dynamic. Furthermore, the epidemic landscape continued to reconfigure during the BA.5 wave, marked by the emergence of new transmission hubs in eastern border regions such as Lublin. Subsequent lineages exhibited distinct geographic signatures: BA.5 spread broadly along the Baltic-central corridor, CH.1 was centered in the north-east, XBB.1 re-emerged in the west-central region of Greater Poland, and JN.1 was driven overwhelmingly by Lesser Poland. These transitions highlight that regional transmission hubs are transient and influenced by local factors such as population density, cross-border mobility, and socio-economic connectivity. This study underscores the critical value of dense genomic surveillance in identifying evolving dispersal routes to inform adaptive, region-specific public health interventions.</p>
	]]></content:encoded>

	<dc:title>Shifting Epicenters: The Dynamic Regional Dispersal of SARS-CoV-2 Omicron in Poland</dc:title>
			<dc:creator>Marcin Horecki</dc:creator>
			<dc:creator>Karol Serwin</dc:creator>
			<dc:creator>Miłosz Parczewski</dc:creator>
		<dc:identifier>doi: 10.3390/v18050520</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>520</prism:startingPage>
		<prism:doi>10.3390/v18050520</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/520</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/518">

	<title>Viruses, Vol. 18, Pages 518: Oncolytic Viruses for Cancer Therapy in Dogs</title>
	<link>https://www.mdpi.com/1999-4915/18/5/518</link>
	<description>Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. This systematic review summarizes current knowledge on the application of oncolytic viruses (OVs) in canine cancer treatment, focusing on their mechanisms of action, safety profiles, and clinical efficacy. We evaluate diverse OV platforms, including myxoma virus, reovirus, vesicular stomatitis virus, canine adenoviruses, vaccinia virus, Sendai virus, and Newcastle disease virus, across preclinical and clinical studies in dogs with various malignancies. While several OVs have demonstrated favorable tolerability and modest antitumor activity, key challenges such as pre-existing immunity, optimization of dosing regimens, and rational combination strategies remain to be addressed. This review emphasizes the translational significance of canine studies for both veterinary and human oncology, underscoring the critical need for rigorously designed clinical trials to refine virotherapy protocols and expand therapeutic options for canine cancer patients.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 518: Oncolytic Viruses for Cancer Therapy in Dogs</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/518">doi: 10.3390/v18050518</a></p>
	<p>Authors:
		Daria O. Neymysheva
		Galina V. Ilyinskaya
		Viktoria A. Sarkisova
		Elena A. Mukhina
		Sofia A. Romanen-kova
		Peter M. Chumakov
		</p>
	<p>Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. This systematic review summarizes current knowledge on the application of oncolytic viruses (OVs) in canine cancer treatment, focusing on their mechanisms of action, safety profiles, and clinical efficacy. We evaluate diverse OV platforms, including myxoma virus, reovirus, vesicular stomatitis virus, canine adenoviruses, vaccinia virus, Sendai virus, and Newcastle disease virus, across preclinical and clinical studies in dogs with various malignancies. While several OVs have demonstrated favorable tolerability and modest antitumor activity, key challenges such as pre-existing immunity, optimization of dosing regimens, and rational combination strategies remain to be addressed. This review emphasizes the translational significance of canine studies for both veterinary and human oncology, underscoring the critical need for rigorously designed clinical trials to refine virotherapy protocols and expand therapeutic options for canine cancer patients.</p>
	]]></content:encoded>

	<dc:title>Oncolytic Viruses for Cancer Therapy in Dogs</dc:title>
			<dc:creator>Daria O. Neymysheva</dc:creator>
			<dc:creator>Galina V. Ilyinskaya</dc:creator>
			<dc:creator>Viktoria A. Sarkisova</dc:creator>
			<dc:creator>Elena A. Mukhina</dc:creator>
			<dc:creator>Sofia A. Romanen-kova</dc:creator>
			<dc:creator>Peter M. Chumakov</dc:creator>
		<dc:identifier>doi: 10.3390/v18050518</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>518</prism:startingPage>
		<prism:doi>10.3390/v18050518</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/518</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/516">

	<title>Viruses, Vol. 18, Pages 516: Hepatitis Free Hospital: Retrospective Results of an In-Hospital Project of Hepatitis C Virus Micro-Elimination</title>
	<link>https://www.mdpi.com/1999-4915/18/5/516</link>
	<description>National HCV screening, a cost-effective program in Italy, is supported by the Italian Ministry of Health. Free-of-charge screening was approved for people who use drugs, prisoners and the 1969&amp;amp;ndash;1989 general population birth cohort. However, the benefits of extending hospital-based screening irrespective of age, in terms of case detection and linkage to care, remain unclear. We assessed a streamlined in-hospital pathway at San Giuseppe Hospital (Milan), between 2021 and 2024, with anti-HCV screening for all admissions and HCV-RNA confirmation when indicated. Anti-HCV seroprevalence among 18,218 screened patients was 1.9% (medical wards 3.8%, surgical 1.4%). Viremia was detected in 23/75 tested (31%); 78% linked to care and 30% initiated treatment. Notably, 91% of viremic patients were born before 1969 indicating hospital-based screening effectively identifies HCV infections in older cohorts missed by national screening programs. Systematic screening implementation across hospital wards represents a pragmatic micro-elimination strategy for Italy and similar epidemiological contexts, advancing 2030 elimination targets.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 516: Hepatitis Free Hospital: Retrospective Results of an In-Hospital Project of Hepatitis C Virus Micro-Elimination</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/516">doi: 10.3390/v18050516</a></p>
	<p>Authors:
		Federica Cerini
		Loreta A. Kondili
		Chiara Masellis
		Agostino Cosenza
		Carmelo Selvaggio
		Maria Grazia Rumi
		</p>
	<p>National HCV screening, a cost-effective program in Italy, is supported by the Italian Ministry of Health. Free-of-charge screening was approved for people who use drugs, prisoners and the 1969&amp;amp;ndash;1989 general population birth cohort. However, the benefits of extending hospital-based screening irrespective of age, in terms of case detection and linkage to care, remain unclear. We assessed a streamlined in-hospital pathway at San Giuseppe Hospital (Milan), between 2021 and 2024, with anti-HCV screening for all admissions and HCV-RNA confirmation when indicated. Anti-HCV seroprevalence among 18,218 screened patients was 1.9% (medical wards 3.8%, surgical 1.4%). Viremia was detected in 23/75 tested (31%); 78% linked to care and 30% initiated treatment. Notably, 91% of viremic patients were born before 1969 indicating hospital-based screening effectively identifies HCV infections in older cohorts missed by national screening programs. Systematic screening implementation across hospital wards represents a pragmatic micro-elimination strategy for Italy and similar epidemiological contexts, advancing 2030 elimination targets.</p>
	]]></content:encoded>

	<dc:title>Hepatitis Free Hospital: Retrospective Results of an In-Hospital Project of Hepatitis C Virus Micro-Elimination</dc:title>
			<dc:creator>Federica Cerini</dc:creator>
			<dc:creator>Loreta A. Kondili</dc:creator>
			<dc:creator>Chiara Masellis</dc:creator>
			<dc:creator>Agostino Cosenza</dc:creator>
			<dc:creator>Carmelo Selvaggio</dc:creator>
			<dc:creator>Maria Grazia Rumi</dc:creator>
		<dc:identifier>doi: 10.3390/v18050516</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>516</prism:startingPage>
		<prism:doi>10.3390/v18050516</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/516</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/515">

	<title>Viruses, Vol. 18, Pages 515: Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity</title>
	<link>https://www.mdpi.com/1999-4915/18/5/515</link>
	<description>Background &amp;amp;amp; Aim: The entry of Hepatitis D Virus (HDV) depends on HBV surface proteins (HBsAg) composed of three isoforms: large-, middle, and small HBsAg. Here, we investigate the levels of total HBsAg and HBsAg isoforms and their correlations with HDV-RNA, HBcrAg, and transaminases in the setting of untreated chronic hepatitis D (CHD). Methods: This study includes 316 HBeAg-negative patients: 192 CHD and 124 with chronic hepatitis B (CHB) as a control group. HBsAg isoforms were quantified by ad hoc-designed ELISAs. Results: The composition of HBsAg isoforms varied between the two groups of patients, with remarkably higher small HBsAg, middle-HBsAg, and large HBsAg in CHD than in CHB. This data was confirmed by multivariable analysis (p &amp;amp;lt; 0.0001). Among CHD, HBsAg isoforms positively correlated with HDV-RNA (p &amp;amp;lt; 0.0001) and HBcrAg (p &amp;amp;lt; 0.0001) but not with HBV-DNA. The results were confirmed by stratifying patients according to HDV-RNA (&amp;amp;lt; or &amp;amp;gt;1000 IU/mL) and HBcrAg (&amp;amp;lt; or &amp;amp;gt;3 logU/mL). Furthermore, CHD patients with ALT &amp;amp;gt; upper limit of normal presented significantly higher S-HBsAg and M-HBsAg levels. Conclusions: CHD is characterized by a more elevated HBsAg isoform production, paralleling HDV-RNA and HBcrAg release. This may suggest a preferential recruitment of HBsAg isoforms in HDV virions at the expense of HBV virions. The association of HBsAg isoforms with higher ALT also suggests their potential contribution in supporting HDV-induced pro-inflammatory stimuli.</description>
	<pubDate>2026-04-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 515: Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/515">doi: 10.3390/v18050515</a></p>
	<p>Authors:
		Stefano D’Anna
		Lorenzo Piermatteo
		Alessia Magnapera
		Ilaria Grossi
		Caterina Tramontozzi
		Antonella Olivero
		Leonardo Duca
		Giulia Torre
		Elisabetta Teti
		Andrea Di Lorenzo
		Vincenzo Malagnino
		Marco Iannetta
		Sandro Grelli
		Pierpaolo Paba
		Ada Bertoli
		Francesca Ceccherini-Silberstein
		Leonardo Baiocchi
		Simona Francioso
		Ilaria Lenci
		Michele Milella
		Annalisa Saracino
		Alessia Ciancio
		Giuseppina Brancaccio
		Loredana Sarmati
		Pietro Lampertico
		Mario Rizzetto
		Gian Paolo Caviglia
		Romina Salpini
		Valentina Svicher
		</p>
	<p>Background &amp;amp;amp; Aim: The entry of Hepatitis D Virus (HDV) depends on HBV surface proteins (HBsAg) composed of three isoforms: large-, middle, and small HBsAg. Here, we investigate the levels of total HBsAg and HBsAg isoforms and their correlations with HDV-RNA, HBcrAg, and transaminases in the setting of untreated chronic hepatitis D (CHD). Methods: This study includes 316 HBeAg-negative patients: 192 CHD and 124 with chronic hepatitis B (CHB) as a control group. HBsAg isoforms were quantified by ad hoc-designed ELISAs. Results: The composition of HBsAg isoforms varied between the two groups of patients, with remarkably higher small HBsAg, middle-HBsAg, and large HBsAg in CHD than in CHB. This data was confirmed by multivariable analysis (p &amp;amp;lt; 0.0001). Among CHD, HBsAg isoforms positively correlated with HDV-RNA (p &amp;amp;lt; 0.0001) and HBcrAg (p &amp;amp;lt; 0.0001) but not with HBV-DNA. The results were confirmed by stratifying patients according to HDV-RNA (&amp;amp;lt; or &amp;amp;gt;1000 IU/mL) and HBcrAg (&amp;amp;lt; or &amp;amp;gt;3 logU/mL). Furthermore, CHD patients with ALT &amp;amp;gt; upper limit of normal presented significantly higher S-HBsAg and M-HBsAg levels. Conclusions: CHD is characterized by a more elevated HBsAg isoform production, paralleling HDV-RNA and HBcrAg release. This may suggest a preferential recruitment of HBsAg isoforms in HDV virions at the expense of HBV virions. The association of HBsAg isoforms with higher ALT also suggests their potential contribution in supporting HDV-induced pro-inflammatory stimuli.</p>
	]]></content:encoded>

	<dc:title>Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity</dc:title>
			<dc:creator>Stefano D’Anna</dc:creator>
			<dc:creator>Lorenzo Piermatteo</dc:creator>
			<dc:creator>Alessia Magnapera</dc:creator>
			<dc:creator>Ilaria Grossi</dc:creator>
			<dc:creator>Caterina Tramontozzi</dc:creator>
			<dc:creator>Antonella Olivero</dc:creator>
			<dc:creator>Leonardo Duca</dc:creator>
			<dc:creator>Giulia Torre</dc:creator>
			<dc:creator>Elisabetta Teti</dc:creator>
			<dc:creator>Andrea Di Lorenzo</dc:creator>
			<dc:creator>Vincenzo Malagnino</dc:creator>
			<dc:creator>Marco Iannetta</dc:creator>
			<dc:creator>Sandro Grelli</dc:creator>
			<dc:creator>Pierpaolo Paba</dc:creator>
			<dc:creator>Ada Bertoli</dc:creator>
			<dc:creator>Francesca Ceccherini-Silberstein</dc:creator>
			<dc:creator>Leonardo Baiocchi</dc:creator>
			<dc:creator>Simona Francioso</dc:creator>
			<dc:creator>Ilaria Lenci</dc:creator>
			<dc:creator>Michele Milella</dc:creator>
			<dc:creator>Annalisa Saracino</dc:creator>
			<dc:creator>Alessia Ciancio</dc:creator>
			<dc:creator>Giuseppina Brancaccio</dc:creator>
			<dc:creator>Loredana Sarmati</dc:creator>
			<dc:creator>Pietro Lampertico</dc:creator>
			<dc:creator>Mario Rizzetto</dc:creator>
			<dc:creator>Gian Paolo Caviglia</dc:creator>
			<dc:creator>Romina Salpini</dc:creator>
			<dc:creator>Valentina Svicher</dc:creator>
		<dc:identifier>doi: 10.3390/v18050515</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-30</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>515</prism:startingPage>
		<prism:doi>10.3390/v18050515</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/515</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/513">

	<title>Viruses, Vol. 18, Pages 513: Co-Feeding Transmission of Tick-Borne Viruses</title>
	<link>https://www.mdpi.com/1999-4915/18/5/513</link>
	<description>Tick-borne viruses (TBVs) are a diverse group of arthropod-borne pathogens maintained in complex transmission cycles involving both tick vectors and vertebrate hosts. Among the known TBV transmission routes, co-feeding transmission, in which virus is transferred from an infected tick to an uninfected tick feeding on the same vertebrate host even in the absence of a detectable viremia, represents an important route that contributes to viral maintenance in nature. Although co-feeding transmission has been demonstrated across multiple vector, host, and virus combinations, the mechanisms governing this transmission route remain poorly defined. This review synthesizes current understanding of co-feeding transmission and highlights the importance of ecological and immunological factors that shape this process in nature. Specifically, we emphasize the role of the cutaneous microenvironment at the tick co-feeding site, where localized viral replication and tick salivary factors create conditions favorable for virus transfer between co-feeding ticks. We also highlight the requirements for co-feeding transmission to occur in nature and across seasons. Together, these insights support a model in which localized skin infection is a central feature of co-feeding transmission while underscoring key gaps in our understanding of the cellular and molecular mechanisms that govern this process.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 513: Co-Feeding Transmission of Tick-Borne Viruses</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/513">doi: 10.3390/v18050513</a></p>
	<p>Authors:
		Sarah C. Macon-Foley
		Meghan E. Hermance
		</p>
	<p>Tick-borne viruses (TBVs) are a diverse group of arthropod-borne pathogens maintained in complex transmission cycles involving both tick vectors and vertebrate hosts. Among the known TBV transmission routes, co-feeding transmission, in which virus is transferred from an infected tick to an uninfected tick feeding on the same vertebrate host even in the absence of a detectable viremia, represents an important route that contributes to viral maintenance in nature. Although co-feeding transmission has been demonstrated across multiple vector, host, and virus combinations, the mechanisms governing this transmission route remain poorly defined. This review synthesizes current understanding of co-feeding transmission and highlights the importance of ecological and immunological factors that shape this process in nature. Specifically, we emphasize the role of the cutaneous microenvironment at the tick co-feeding site, where localized viral replication and tick salivary factors create conditions favorable for virus transfer between co-feeding ticks. We also highlight the requirements for co-feeding transmission to occur in nature and across seasons. Together, these insights support a model in which localized skin infection is a central feature of co-feeding transmission while underscoring key gaps in our understanding of the cellular and molecular mechanisms that govern this process.</p>
	]]></content:encoded>

	<dc:title>Co-Feeding Transmission of Tick-Borne Viruses</dc:title>
			<dc:creator>Sarah C. Macon-Foley</dc:creator>
			<dc:creator>Meghan E. Hermance</dc:creator>
		<dc:identifier>doi: 10.3390/v18050513</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>513</prism:startingPage>
		<prism:doi>10.3390/v18050513</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/513</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/514">

	<title>Viruses, Vol. 18, Pages 514: Rapid Construction and Characterization of Infectious cDNA Clones and Reporter Viruses of Enteroviruses, Including Enterovirus A71 and Coxsackievirus B5, with Systematic Identification of Critical Determinants for Successful Reporter Virus Generation</title>
	<link>https://www.mdpi.com/1999-4915/18/5/514</link>
	<description>Enteroviruses are positive-sense single-stranded RNA viruses and common pathogens that are responsible for diverse public health diseases. To facilitate the study of the virus biology and pathogenesis of enterovirus, we developed a rapid method for construction of the enteroviral cDNA clones including enterovirus A71 (EV-A71) and coxsackievirus B5 (CVB5). As described for EV-A71, the full-length cDNA of CVB5 was amplified by long-distance PCR and cloned into a T7 promoter-containing plasmid using directional seamless cloning technology. The virus was successfully rescued by single transfection into cells stably expressing T7 polymerase and exhibited characteristics similar to the parental virus. Next, through systematic construction and the optimization of the EV-A71 and CVB5 reporter viruses, we successfully generated two novel reporter virus panels with high virus titers, rapid replication, and relatively stable genetic inheritance across passages using the new fluorescence proteins mScarlet3-H and the smallest miRFP670nano3. Analysis of critical determinants for the reporter virus construction revealed that reporter gene sizes, genomic insertion sites, and the usage of protease recognition sites are crucial parameters. The EV-A71 and CVB5 reporter viruses enable antiviral drug evaluation, as demonstrated by our identification of gemcitabine as a broad-spectrum inhibitor of both viruses. These systems also facilitate the functional interrogation of host factors, exemplified by our discovery that METTL3 promotes EV-A71 and CVB5 replication. These reverse genetic tools, including infectious cDNA clones and reporter viruses, will advance basic enterovirus biology and accelerate antiviral drug discovery.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 514: Rapid Construction and Characterization of Infectious cDNA Clones and Reporter Viruses of Enteroviruses, Including Enterovirus A71 and Coxsackievirus B5, with Systematic Identification of Critical Determinants for Successful Reporter Virus Generation</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/514">doi: 10.3390/v18050514</a></p>
	<p>Authors:
		Hao Zheng
		Tong Zhao
		Meixian Fu
		Zirui Niu
		Yifan Xing
		Xia Cai
		Jian-Er Long
		</p>
	<p>Enteroviruses are positive-sense single-stranded RNA viruses and common pathogens that are responsible for diverse public health diseases. To facilitate the study of the virus biology and pathogenesis of enterovirus, we developed a rapid method for construction of the enteroviral cDNA clones including enterovirus A71 (EV-A71) and coxsackievirus B5 (CVB5). As described for EV-A71, the full-length cDNA of CVB5 was amplified by long-distance PCR and cloned into a T7 promoter-containing plasmid using directional seamless cloning technology. The virus was successfully rescued by single transfection into cells stably expressing T7 polymerase and exhibited characteristics similar to the parental virus. Next, through systematic construction and the optimization of the EV-A71 and CVB5 reporter viruses, we successfully generated two novel reporter virus panels with high virus titers, rapid replication, and relatively stable genetic inheritance across passages using the new fluorescence proteins mScarlet3-H and the smallest miRFP670nano3. Analysis of critical determinants for the reporter virus construction revealed that reporter gene sizes, genomic insertion sites, and the usage of protease recognition sites are crucial parameters. The EV-A71 and CVB5 reporter viruses enable antiviral drug evaluation, as demonstrated by our identification of gemcitabine as a broad-spectrum inhibitor of both viruses. These systems also facilitate the functional interrogation of host factors, exemplified by our discovery that METTL3 promotes EV-A71 and CVB5 replication. These reverse genetic tools, including infectious cDNA clones and reporter viruses, will advance basic enterovirus biology and accelerate antiviral drug discovery.</p>
	]]></content:encoded>

	<dc:title>Rapid Construction and Characterization of Infectious cDNA Clones and Reporter Viruses of Enteroviruses, Including Enterovirus A71 and Coxsackievirus B5, with Systematic Identification of Critical Determinants for Successful Reporter Virus Generation</dc:title>
			<dc:creator>Hao Zheng</dc:creator>
			<dc:creator>Tong Zhao</dc:creator>
			<dc:creator>Meixian Fu</dc:creator>
			<dc:creator>Zirui Niu</dc:creator>
			<dc:creator>Yifan Xing</dc:creator>
			<dc:creator>Xia Cai</dc:creator>
			<dc:creator>Jian-Er Long</dc:creator>
		<dc:identifier>doi: 10.3390/v18050514</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>514</prism:startingPage>
		<prism:doi>10.3390/v18050514</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/514</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/512">

	<title>Viruses, Vol. 18, Pages 512: Discordant Immune&amp;ndash;Virologic Responses During Antiretroviral Therapy: Immune Dysregulation Patterns, CD4/CD8 Ratio Inversion, and Clinical Predictors in a Romanian HIV Cohort</title>
	<link>https://www.mdpi.com/1999-4915/18/5/512</link>
	<description>(1) Background: Despite the success of combination antiretroviral therapy (cART), immune recovery in treated HIV infection remains heterogeneous, and discordant immune&amp;amp;ndash;virologic responses persist in a substantial proportion of people living with HIV (PLWH). These patterns may reflect ongoing immune dysregulation despite effective viral suppression. This study aimed to characterize discordant treatment classifications, evaluate immune imbalance using the CD4/CD8 ratio, identify associated clinical predictors, and assess opportunistic infection burden in a Romanian cohort of people living with HIV receiving long-term cART. (2) Methods: A retrospective cross-sectional study was conducted in 462 adults with HIV-1 infection receiving cART at the &amp;amp;ldquo;Prof. Dr. Matei Bal&amp;amp;#537;&amp;amp;rdquo; National Institute of Infectious Diseases, Bucharest (2018&amp;amp;ndash;2021). PLWH were classified as concordant responders (CR), immunological discordant responders (ID), or virological discordant responders (VD) based on plasma HIV-1 RNA and CD4+ T-cell count thresholds. Immune dysregulation was assessed using the CD4/CD8 ratio. Multinomial logistic, logistic, and negative binomial regression models were used to identify predictors of discordant responses, severe CD4/CD8 ratio inversion, and opportunistic infection burden. (3) Results: Discordant responses were observed in 30.7% of PLWH (14.5% ID, 16.2% VD). CD4/CD8 ratio inversion occurred in 71.2% and severe inversion in 40.0%. Significant differences across clinical classification groups were found for CD4+T-cell counts (H = 153.62, p &amp;amp;lt; 0.001, &amp;amp;epsilon;2 = 0.33) and CD4/CD8 ratio (H = 115.10, p &amp;amp;lt; 0.001, &amp;amp;epsilon;2 = 0.25), while CD8+ counts were similar (p = 0.571). Male sex was associated with both ID and VD, and severe CD4/CD8 inversion was strongly associated with ID. Opportunistic infection burden was associated with duration of HIV infection and CDC stage. (4) Conclusions: Discordant immune&amp;amp;ndash;virologic responses remain frequent during long-term cART and are characterized by persistent immune imbalance reflected by CD4/CD8 ratio inversion. The CD4/CD8 ratio may provide clinically relevant information on immune recovery beyond CD4+ T-cell counts.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 512: Discordant Immune&amp;ndash;Virologic Responses During Antiretroviral Therapy: Immune Dysregulation Patterns, CD4/CD8 Ratio Inversion, and Clinical Predictors in a Romanian HIV Cohort</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/512">doi: 10.3390/v18050512</a></p>
	<p>Authors:
		Ruxandra-Cristina Marin
		Radu Dumitru Moleriu
		Gabriela S. Bungau
		Delia Mirela Tit
		Călin Muntean
		</p>
	<p>(1) Background: Despite the success of combination antiretroviral therapy (cART), immune recovery in treated HIV infection remains heterogeneous, and discordant immune&amp;amp;ndash;virologic responses persist in a substantial proportion of people living with HIV (PLWH). These patterns may reflect ongoing immune dysregulation despite effective viral suppression. This study aimed to characterize discordant treatment classifications, evaluate immune imbalance using the CD4/CD8 ratio, identify associated clinical predictors, and assess opportunistic infection burden in a Romanian cohort of people living with HIV receiving long-term cART. (2) Methods: A retrospective cross-sectional study was conducted in 462 adults with HIV-1 infection receiving cART at the &amp;amp;ldquo;Prof. Dr. Matei Bal&amp;amp;#537;&amp;amp;rdquo; National Institute of Infectious Diseases, Bucharest (2018&amp;amp;ndash;2021). PLWH were classified as concordant responders (CR), immunological discordant responders (ID), or virological discordant responders (VD) based on plasma HIV-1 RNA and CD4+ T-cell count thresholds. Immune dysregulation was assessed using the CD4/CD8 ratio. Multinomial logistic, logistic, and negative binomial regression models were used to identify predictors of discordant responses, severe CD4/CD8 ratio inversion, and opportunistic infection burden. (3) Results: Discordant responses were observed in 30.7% of PLWH (14.5% ID, 16.2% VD). CD4/CD8 ratio inversion occurred in 71.2% and severe inversion in 40.0%. Significant differences across clinical classification groups were found for CD4+T-cell counts (H = 153.62, p &amp;amp;lt; 0.001, &amp;amp;epsilon;2 = 0.33) and CD4/CD8 ratio (H = 115.10, p &amp;amp;lt; 0.001, &amp;amp;epsilon;2 = 0.25), while CD8+ counts were similar (p = 0.571). Male sex was associated with both ID and VD, and severe CD4/CD8 inversion was strongly associated with ID. Opportunistic infection burden was associated with duration of HIV infection and CDC stage. (4) Conclusions: Discordant immune&amp;amp;ndash;virologic responses remain frequent during long-term cART and are characterized by persistent immune imbalance reflected by CD4/CD8 ratio inversion. The CD4/CD8 ratio may provide clinically relevant information on immune recovery beyond CD4+ T-cell counts.</p>
	]]></content:encoded>

	<dc:title>Discordant Immune&amp;amp;ndash;Virologic Responses During Antiretroviral Therapy: Immune Dysregulation Patterns, CD4/CD8 Ratio Inversion, and Clinical Predictors in a Romanian HIV Cohort</dc:title>
			<dc:creator>Ruxandra-Cristina Marin</dc:creator>
			<dc:creator>Radu Dumitru Moleriu</dc:creator>
			<dc:creator>Gabriela S. Bungau</dc:creator>
			<dc:creator>Delia Mirela Tit</dc:creator>
			<dc:creator>Călin Muntean</dc:creator>
		<dc:identifier>doi: 10.3390/v18050512</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>512</prism:startingPage>
		<prism:doi>10.3390/v18050512</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/512</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/511">

	<title>Viruses, Vol. 18, Pages 511: Unraveling the Rectal Virome: Microbial Crosstalk, Immune Modulation, and Clinical Outcomes in People with and Vulnerable to HIV</title>
	<link>https://www.mdpi.com/1999-4915/18/5/511</link>
	<description>The rectal mucosa houses a large number of viruses with important roles in shaping the local microbial communities and modulating immune responses, which could influence host susceptibility to infection and other diseases. Unique composition of the gut microbiome, including the predominance of clinically significant eukaryotic viruses like herpesviruses, cytomegalovirus, and human papillomavirus, has been described in both people with HIV (PWH) and men who have sex with men (MSM) vulnerable to HIV. Despite these insights, the rectal virome and the clinical implications of virome&amp;amp;ndash;bacteriome&amp;amp;ndash;immune interactions in the rectal mucosa remain poorly understood. In this review, we synthesize existing data on the composition of the rectal virome, its interactions with the bacteriome and the immune system, and implications on clinical outcomes in people living with or vulnerable to HIV. We also highlight the gaps and research needed to further explore and unravel these relationships.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 511: Unraveling the Rectal Virome: Microbial Crosstalk, Immune Modulation, and Clinical Outcomes in People with and Vulnerable to HIV</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/511">doi: 10.3390/v18050511</a></p>
	<p>Authors:
		Ruth S. Bako
		Colleen F. Kelley
		</p>
	<p>The rectal mucosa houses a large number of viruses with important roles in shaping the local microbial communities and modulating immune responses, which could influence host susceptibility to infection and other diseases. Unique composition of the gut microbiome, including the predominance of clinically significant eukaryotic viruses like herpesviruses, cytomegalovirus, and human papillomavirus, has been described in both people with HIV (PWH) and men who have sex with men (MSM) vulnerable to HIV. Despite these insights, the rectal virome and the clinical implications of virome&amp;amp;ndash;bacteriome&amp;amp;ndash;immune interactions in the rectal mucosa remain poorly understood. In this review, we synthesize existing data on the composition of the rectal virome, its interactions with the bacteriome and the immune system, and implications on clinical outcomes in people living with or vulnerable to HIV. We also highlight the gaps and research needed to further explore and unravel these relationships.</p>
	]]></content:encoded>

	<dc:title>Unraveling the Rectal Virome: Microbial Crosstalk, Immune Modulation, and Clinical Outcomes in People with and Vulnerable to HIV</dc:title>
			<dc:creator>Ruth S. Bako</dc:creator>
			<dc:creator>Colleen F. Kelley</dc:creator>
		<dc:identifier>doi: 10.3390/v18050511</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>511</prism:startingPage>
		<prism:doi>10.3390/v18050511</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/511</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/510">

	<title>Viruses, Vol. 18, Pages 510: Clinical Presentation, Etiology, and Outcomes of HIV-Associated Cardiomyopathy: A Systematic Review of Published Case Reports</title>
	<link>https://www.mdpi.com/1999-4915/18/5/510</link>
	<description>HIV-associated cardiomyopathy is a significant cause of morbidity and mortality among people living with HIV, contributing to heart failure, arrhythmia, and sudden cardiac death. Despite its clinical importance, its individual-patient clinical spectrum has not been systematically synthesized. We conducted a systematic review of published English-language case reports and small case series describing cardiomyopathy in HIV-infected individuals. Etiologies were classified using a framework distinguishing cardiomyopathy arising from uncontrolled HIV from that occurring despite virologic control. Stratified analyses examined temporal trends and geographic differences. We identified 99 patients (75 male, 20 female, 4 unspecified) from 27 countries (80% high-income). Median age was 35 years (IQR 28&amp;amp;ndash;45). Among 52 patients with CD4 data, median was 154 cells/&amp;amp;micro;L (IQR 84&amp;amp;ndash;391); 52% had CD4 &amp;amp;lt; 200. Systolic dysfunction was present in 94% with echocardiographic data. Uncontrolled HIV phenotypes predominated (64%), but controlled phenotypes (21%)&amp;amp;mdash;including drug-induced cardiomyopathy (n = 19, predominantly zidovudine-associated) and autoimmune or inflammatory mechanisms (n = 13)&amp;amp;mdash;were substantial. Mortality declined across eras: 65% pre-ART, 32% early ART, 21% modern ART. Recovery occurred in 58%. HIV-associated cardiomyopathy is heterogeneous with improving outcomes across treatment eras. Systematic etiologic evaluation is warranted in all affected patients. The near absence of data from sub-Saharan Africa represents a critical gap.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 510: Clinical Presentation, Etiology, and Outcomes of HIV-Associated Cardiomyopathy: A Systematic Review of Published Case Reports</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/510">doi: 10.3390/v18050510</a></p>
	<p>Authors:
		Omar Hozayen
		Joseph Hozayen
		Benjamin J. Behers
		Anas Abu Jad
		Bashar Roumia
		Matthew W. Miller
		Christoph A. Stephenson-Moe
		Nicolas Riveros
		Manuel Rosario
		Karen M. Hamad
		</p>
	<p>HIV-associated cardiomyopathy is a significant cause of morbidity and mortality among people living with HIV, contributing to heart failure, arrhythmia, and sudden cardiac death. Despite its clinical importance, its individual-patient clinical spectrum has not been systematically synthesized. We conducted a systematic review of published English-language case reports and small case series describing cardiomyopathy in HIV-infected individuals. Etiologies were classified using a framework distinguishing cardiomyopathy arising from uncontrolled HIV from that occurring despite virologic control. Stratified analyses examined temporal trends and geographic differences. We identified 99 patients (75 male, 20 female, 4 unspecified) from 27 countries (80% high-income). Median age was 35 years (IQR 28&amp;amp;ndash;45). Among 52 patients with CD4 data, median was 154 cells/&amp;amp;micro;L (IQR 84&amp;amp;ndash;391); 52% had CD4 &amp;amp;lt; 200. Systolic dysfunction was present in 94% with echocardiographic data. Uncontrolled HIV phenotypes predominated (64%), but controlled phenotypes (21%)&amp;amp;mdash;including drug-induced cardiomyopathy (n = 19, predominantly zidovudine-associated) and autoimmune or inflammatory mechanisms (n = 13)&amp;amp;mdash;were substantial. Mortality declined across eras: 65% pre-ART, 32% early ART, 21% modern ART. Recovery occurred in 58%. HIV-associated cardiomyopathy is heterogeneous with improving outcomes across treatment eras. Systematic etiologic evaluation is warranted in all affected patients. The near absence of data from sub-Saharan Africa represents a critical gap.</p>
	]]></content:encoded>

	<dc:title>Clinical Presentation, Etiology, and Outcomes of HIV-Associated Cardiomyopathy: A Systematic Review of Published Case Reports</dc:title>
			<dc:creator>Omar Hozayen</dc:creator>
			<dc:creator>Joseph Hozayen</dc:creator>
			<dc:creator>Benjamin J. Behers</dc:creator>
			<dc:creator>Anas Abu Jad</dc:creator>
			<dc:creator>Bashar Roumia</dc:creator>
			<dc:creator>Matthew W. Miller</dc:creator>
			<dc:creator>Christoph A. Stephenson-Moe</dc:creator>
			<dc:creator>Nicolas Riveros</dc:creator>
			<dc:creator>Manuel Rosario</dc:creator>
			<dc:creator>Karen M. Hamad</dc:creator>
		<dc:identifier>doi: 10.3390/v18050510</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>510</prism:startingPage>
		<prism:doi>10.3390/v18050510</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/510</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/509">

	<title>Viruses, Vol. 18, Pages 509: Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2</title>
	<link>https://www.mdpi.com/1999-4915/18/5/509</link>
	<description>Dengue virus (DENV) and SARS-CoV-2 are emerging viral pathogens that share overlapping clinical features, including fever, fatigue, and respiratory symptoms, complicating differential diagnosis in endemic regions. Their co-circulation has increased the risk of co-infections, which may result in unpredictable disease progression, increased morbidity, and mortality. This overlap presents a significant challenge in managing outbreaks, as both viruses pose a major public health threat. Vaccines and direct-acting antivirals may be rendered ineffective by viral mutations, making it difficult to address evolving strains. Host-directed antivirals offer a promising alternative, potentially maintaining efficacy against a multitude of variants. Both DENV and SARS-CoV-2 rely on host proteases for viral maturation and entry, with furin playing a crucial role in viral glycoprotein cleavage. In DENV, furin cleaves the prM protein, facilitating virion maturation, while in SARS-CoV-2, the polybasic furin cleavage site in the spike protein enhances viral entry. This makes furin a compelling pan-viral target, where inhibiting furin could reduce viral fitness without relying on viral mutations. This review highlights the therapeutic rationale for targeting furin and discusses luteolin, a furin inhibitor showing antiviral activity against both viruses. Furin-targeted therapies may offer a durable antiviral strategy effective across DENV serotypes, SARS-CoV-2 variants, and co-infection settings.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 509: Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/509">doi: 10.3390/v18050509</a></p>
	<p>Authors:
		Lina Shalaby
		Yaman Al-Haneedi
		Alaa Abdelhamid
		Hadi Yassine
		Mohamed M. Emara
		</p>
	<p>Dengue virus (DENV) and SARS-CoV-2 are emerging viral pathogens that share overlapping clinical features, including fever, fatigue, and respiratory symptoms, complicating differential diagnosis in endemic regions. Their co-circulation has increased the risk of co-infections, which may result in unpredictable disease progression, increased morbidity, and mortality. This overlap presents a significant challenge in managing outbreaks, as both viruses pose a major public health threat. Vaccines and direct-acting antivirals may be rendered ineffective by viral mutations, making it difficult to address evolving strains. Host-directed antivirals offer a promising alternative, potentially maintaining efficacy against a multitude of variants. Both DENV and SARS-CoV-2 rely on host proteases for viral maturation and entry, with furin playing a crucial role in viral glycoprotein cleavage. In DENV, furin cleaves the prM protein, facilitating virion maturation, while in SARS-CoV-2, the polybasic furin cleavage site in the spike protein enhances viral entry. This makes furin a compelling pan-viral target, where inhibiting furin could reduce viral fitness without relying on viral mutations. This review highlights the therapeutic rationale for targeting furin and discusses luteolin, a furin inhibitor showing antiviral activity against both viruses. Furin-targeted therapies may offer a durable antiviral strategy effective across DENV serotypes, SARS-CoV-2 variants, and co-infection settings.</p>
	]]></content:encoded>

	<dc:title>Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2</dc:title>
			<dc:creator>Lina Shalaby</dc:creator>
			<dc:creator>Yaman Al-Haneedi</dc:creator>
			<dc:creator>Alaa Abdelhamid</dc:creator>
			<dc:creator>Hadi Yassine</dc:creator>
			<dc:creator>Mohamed M. Emara</dc:creator>
		<dc:identifier>doi: 10.3390/v18050509</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>509</prism:startingPage>
		<prism:doi>10.3390/v18050509</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/509</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/508">

	<title>Viruses, Vol. 18, Pages 508: Rotavirus Prevalence, Genetic Diversity, and Co-Infections During the 2023&amp;ndash;2024 Cholera Outbreak in Zambia: Insights from Multi-Pathogen Diagnostics</title>
	<link>https://www.mdpi.com/1999-4915/18/5/508</link>
	<description>During Zambia&amp;amp;rsquo;s 2023&amp;amp;ndash;2024 cholera outbreak, reliance on single-pathogen diagnostics risked overlooking co-circulating enteric pathogens. This study estimated the prevalence of rotavirus and described co-detected enteropathogens and rotavirus genotypes among patients admitted with suspected cholera. A sub-analysis was conducted on diarrhoeal stool specimens collected from patients who met the syndromic suspected cholera case definition. Samples were tested using the Bosphore&amp;amp;reg; Gastroenteritis Panel v2, a multiplex PCR enteric panel, to detect rotavirus and other gastrointestinal pathogens. Rotavirus-positive specimens with sufficient viral load were further genotyped by RT-PCR targeting of the VP7 and VP4 genes. Among 319 suspected cholera admissions, rotavirus was detected in 18 patients (5.6%; 95% CI 3.4&amp;amp;ndash;8.8%), predominantly in children aged &amp;amp;lt;5 years (27.8%, 5/18) and 6&amp;amp;ndash;17 years (27.8%, 5/18). Co-infection was common, with 17/18 (94.4%) of rotavirus-positive samples showing co-infection with at least one additional enteric pathogen, most frequently Campylobacter. Genotyping was successful in five samples and revealed heterogenous circulating strains, including G1P[8], G2P[4], G3P[6], G12P[6], and G1P[6]. Rotavirus accounted for a modest proportion of suspected cholera admissions and was frequently detected in mixed enteric infections, underscoring the value of multi-pathogen diagnostics and continued molecular surveillance during outbreak response.</description>
	<pubDate>2026-04-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 508: Rotavirus Prevalence, Genetic Diversity, and Co-Infections During the 2023&amp;ndash;2024 Cholera Outbreak in Zambia: Insights from Multi-Pathogen Diagnostics</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/508">doi: 10.3390/v18050508</a></p>
	<p>Authors:
		Adriace Chauwa
		Samuel Bosomprah
		Bernard Phiri
		Natasha M. Laban
		Dhvani H. Kuntawala
		Dennis Ngosa
		Harriet Ng’ombe
		Fraser Liswaniso
		Chaluma C. Luchen
		Mutinta Muchimba
		Innocent Mwape
		Bertha T. Nzangwa
		Sekayi F. Tigere
		Kennedy Chibesa
		Suwilanji Silwamba
		Michelo Simuyandi
		Nyuma Mbewe
		Roma Chilengi
		Caroline Chisenga
		</p>
	<p>During Zambia&amp;amp;rsquo;s 2023&amp;amp;ndash;2024 cholera outbreak, reliance on single-pathogen diagnostics risked overlooking co-circulating enteric pathogens. This study estimated the prevalence of rotavirus and described co-detected enteropathogens and rotavirus genotypes among patients admitted with suspected cholera. A sub-analysis was conducted on diarrhoeal stool specimens collected from patients who met the syndromic suspected cholera case definition. Samples were tested using the Bosphore&amp;amp;reg; Gastroenteritis Panel v2, a multiplex PCR enteric panel, to detect rotavirus and other gastrointestinal pathogens. Rotavirus-positive specimens with sufficient viral load were further genotyped by RT-PCR targeting of the VP7 and VP4 genes. Among 319 suspected cholera admissions, rotavirus was detected in 18 patients (5.6%; 95% CI 3.4&amp;amp;ndash;8.8%), predominantly in children aged &amp;amp;lt;5 years (27.8%, 5/18) and 6&amp;amp;ndash;17 years (27.8%, 5/18). Co-infection was common, with 17/18 (94.4%) of rotavirus-positive samples showing co-infection with at least one additional enteric pathogen, most frequently Campylobacter. Genotyping was successful in five samples and revealed heterogenous circulating strains, including G1P[8], G2P[4], G3P[6], G12P[6], and G1P[6]. Rotavirus accounted for a modest proportion of suspected cholera admissions and was frequently detected in mixed enteric infections, underscoring the value of multi-pathogen diagnostics and continued molecular surveillance during outbreak response.</p>
	]]></content:encoded>

	<dc:title>Rotavirus Prevalence, Genetic Diversity, and Co-Infections During the 2023&amp;amp;ndash;2024 Cholera Outbreak in Zambia: Insights from Multi-Pathogen Diagnostics</dc:title>
			<dc:creator>Adriace Chauwa</dc:creator>
			<dc:creator>Samuel Bosomprah</dc:creator>
			<dc:creator>Bernard Phiri</dc:creator>
			<dc:creator>Natasha M. Laban</dc:creator>
			<dc:creator>Dhvani H. Kuntawala</dc:creator>
			<dc:creator>Dennis Ngosa</dc:creator>
			<dc:creator>Harriet Ng’ombe</dc:creator>
			<dc:creator>Fraser Liswaniso</dc:creator>
			<dc:creator>Chaluma C. Luchen</dc:creator>
			<dc:creator>Mutinta Muchimba</dc:creator>
			<dc:creator>Innocent Mwape</dc:creator>
			<dc:creator>Bertha T. Nzangwa</dc:creator>
			<dc:creator>Sekayi F. Tigere</dc:creator>
			<dc:creator>Kennedy Chibesa</dc:creator>
			<dc:creator>Suwilanji Silwamba</dc:creator>
			<dc:creator>Michelo Simuyandi</dc:creator>
			<dc:creator>Nyuma Mbewe</dc:creator>
			<dc:creator>Roma Chilengi</dc:creator>
			<dc:creator>Caroline Chisenga</dc:creator>
		<dc:identifier>doi: 10.3390/v18050508</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-29</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-29</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>508</prism:startingPage>
		<prism:doi>10.3390/v18050508</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/508</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/507">

	<title>Viruses, Vol. 18, Pages 507: The Value of Hepatitis E Screening Sensitivity: Lookback Investigation in German Blood Donors</title>
	<link>https://www.mdpi.com/1999-4915/18/5/507</link>
	<description>Hepatitis E virus (HEV) is the leading cause of hepatitis globally and poses particular risks for immunocompromised individuals. Mandatory screening of blood donations for HEV RNA and retrospective individual testing of previous donations (lookback investigations) following a reactive result have been implemented in several countries to protect these patients. This includes Germany, where a sensitivity limit of 2000 IU/mL applies to index donations. In total, 334 HEV RNA-positive blood donations were detected at our blood donation service between 2018 and 2024. Lookback testing was applied in 211 cases, revealing previous HEV RNA-positive donations in 23.1% of donors (n = 48, 76 donations). Although 16 of these retrospectively tested HEV RNA-positive donations have already been transfused, no transfusion-transmitted HEV infection has been reported. The HEV RNA viral load in the lookback donation was below 50 IU/mL in 72.4% of cases. Routine testing effectively prevents highly viremic blood products entering the supply, significantly reducing the infection risk. While the administration of virus particles with low-viremic products cannot be ruled out, the remaining risk appears to be minimal and has been deemed so far acceptable for the safety of blood products. The lookback strategy further supports the screening strategy by retrospectively identifying blood products from low-viremic donations and enabling appropriate risk management.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 507: The Value of Hepatitis E Screening Sensitivity: Lookback Investigation in German Blood Donors</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/507">doi: 10.3390/v18050507</a></p>
	<p>Authors:
		Ricarda Plümers
		Jens Dreier
		Attila Mandl
		Cornelius Knabbe
		Tanja Vollmer
		</p>
	<p>Hepatitis E virus (HEV) is the leading cause of hepatitis globally and poses particular risks for immunocompromised individuals. Mandatory screening of blood donations for HEV RNA and retrospective individual testing of previous donations (lookback investigations) following a reactive result have been implemented in several countries to protect these patients. This includes Germany, where a sensitivity limit of 2000 IU/mL applies to index donations. In total, 334 HEV RNA-positive blood donations were detected at our blood donation service between 2018 and 2024. Lookback testing was applied in 211 cases, revealing previous HEV RNA-positive donations in 23.1% of donors (n = 48, 76 donations). Although 16 of these retrospectively tested HEV RNA-positive donations have already been transfused, no transfusion-transmitted HEV infection has been reported. The HEV RNA viral load in the lookback donation was below 50 IU/mL in 72.4% of cases. Routine testing effectively prevents highly viremic blood products entering the supply, significantly reducing the infection risk. While the administration of virus particles with low-viremic products cannot be ruled out, the remaining risk appears to be minimal and has been deemed so far acceptable for the safety of blood products. The lookback strategy further supports the screening strategy by retrospectively identifying blood products from low-viremic donations and enabling appropriate risk management.</p>
	]]></content:encoded>

	<dc:title>The Value of Hepatitis E Screening Sensitivity: Lookback Investigation in German Blood Donors</dc:title>
			<dc:creator>Ricarda Plümers</dc:creator>
			<dc:creator>Jens Dreier</dc:creator>
			<dc:creator>Attila Mandl</dc:creator>
			<dc:creator>Cornelius Knabbe</dc:creator>
			<dc:creator>Tanja Vollmer</dc:creator>
		<dc:identifier>doi: 10.3390/v18050507</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>507</prism:startingPage>
		<prism:doi>10.3390/v18050507</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/507</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/506">

	<title>Viruses, Vol. 18, Pages 506: Presence of EBV and HHV-7 Genomic Sequences in Saliva and Virus-Specific Antibodies in Sera of Oral Lichen Planus and Aphthous Stomatitis Patients: A Comparative Observational Study</title>
	<link>https://www.mdpi.com/1999-4915/18/5/506</link>
	<description>The presence of human herpesviruses is frequently detected in the oral cavity, yet their disease-specific role in chronic inflammatory oral mucosal disorders remains uncertain. This comparative observational study investigated Epstein&amp;amp;ndash;Barr virus (EBV) and human herpesvirus-7 (HHV-7) genomic sequences in saliva and virus-specific antibodies in serum among patients with oral lichen planus (OLP; n = 35), aphthous stomatitis (AS; n = 31), and healthy controls (n = 34). Salivary viral loads were quantified using real-time PCR, while EBV and HHV-7-specific IgG and IgM antibodies were measured using ELISA-based assays. EBV and HHV-7 DNA in saliva were commonly detected across all groups, demonstrating high baseline shedding and marked interindividual variability. Although EBV IgG levels were higher in OLP compared with AS in univariate analysis, multivariate regression revealed that age, rather than disease status, was the primary determinant of EBV IgG levels. After adjustment for age, sex, and discomfort, neither EBV nor HHV-7 salivary loads showed independent associations with OLP or AS. HHV-7 salivary loads were uniformly distributed among groups. These findings suggest that salivary detection of EBV and HHV-7 reflects widespread latent infection rather than disease-specific activity in OLP or AS. Longitudinal and tissue-based studies integrating immunological profiling are warranted to clarify whether herpesvirus reactivation contributes to disease severity in defined patient subgroups.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 506: Presence of EBV and HHV-7 Genomic Sequences in Saliva and Virus-Specific Antibodies in Sera of Oral Lichen Planus and Aphthous Stomatitis Patients: A Comparative Observational Study</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/506">doi: 10.3390/v18050506</a></p>
	<p>Authors:
		Jagriti Kakar
		Liba Sokolovska
		Maksims Zolovs
		Modra Murovska
		Ingrīda Čēma
		</p>
	<p>The presence of human herpesviruses is frequently detected in the oral cavity, yet their disease-specific role in chronic inflammatory oral mucosal disorders remains uncertain. This comparative observational study investigated Epstein&amp;amp;ndash;Barr virus (EBV) and human herpesvirus-7 (HHV-7) genomic sequences in saliva and virus-specific antibodies in serum among patients with oral lichen planus (OLP; n = 35), aphthous stomatitis (AS; n = 31), and healthy controls (n = 34). Salivary viral loads were quantified using real-time PCR, while EBV and HHV-7-specific IgG and IgM antibodies were measured using ELISA-based assays. EBV and HHV-7 DNA in saliva were commonly detected across all groups, demonstrating high baseline shedding and marked interindividual variability. Although EBV IgG levels were higher in OLP compared with AS in univariate analysis, multivariate regression revealed that age, rather than disease status, was the primary determinant of EBV IgG levels. After adjustment for age, sex, and discomfort, neither EBV nor HHV-7 salivary loads showed independent associations with OLP or AS. HHV-7 salivary loads were uniformly distributed among groups. These findings suggest that salivary detection of EBV and HHV-7 reflects widespread latent infection rather than disease-specific activity in OLP or AS. Longitudinal and tissue-based studies integrating immunological profiling are warranted to clarify whether herpesvirus reactivation contributes to disease severity in defined patient subgroups.</p>
	]]></content:encoded>

	<dc:title>Presence of EBV and HHV-7 Genomic Sequences in Saliva and Virus-Specific Antibodies in Sera of Oral Lichen Planus and Aphthous Stomatitis Patients: A Comparative Observational Study</dc:title>
			<dc:creator>Jagriti Kakar</dc:creator>
			<dc:creator>Liba Sokolovska</dc:creator>
			<dc:creator>Maksims Zolovs</dc:creator>
			<dc:creator>Modra Murovska</dc:creator>
			<dc:creator>Ingrīda Čēma</dc:creator>
		<dc:identifier>doi: 10.3390/v18050506</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>506</prism:startingPage>
		<prism:doi>10.3390/v18050506</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/506</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/505">

	<title>Viruses, Vol. 18, Pages 505: Langat Virus Infection Can Be Demonstrated in Both Tick Salivary Glands and Midgut Within 24 Hours of Blood Feeding</title>
	<link>https://www.mdpi.com/1999-4915/18/5/505</link>
	<description>The detailed mechanism and sequence by which tick-borne flaviviruses (TBFVs), such as Langat virus (LGTV), infect and disseminate in arthropod hosts remain undefined. To begin characterizing these processes, we used artificial membrane feeding chambers to feed adult Ixodes scapularis ticks with blood containing LGTV. At 24, 48, 72, and 96 hours (h) after attachment, we removed and dissected the partially fed ticks to obtain the midgut and salivary glands. Histology confirmed infection in cells of the digestive epithelium lineage; infection was noted in midgut generative cells and the more differentiated functional digestive cells over the course of feeding. The viral envelope (E) protein, nonstructural protein 3 (NS3), and double-stranded RNA (dsRNA) were readily detected in these cells by 48 h after infection. Parallel analysis indicated that cells in salivary gland acini were also infected by 48 h, where virus target cells appeared to be the granular cells in acini types II and III. Thus, both salivary glands and midgut showed direct evidence of infection by 48 h. Although viral staining was not observed at 24 h, when organs were removed at 24 h and individually cultured ex vivo, the virus was detected. Taken together, our results provide evidence of LGTV infection in both the salivary glands and midgut within the first 24 h of a blood meal. The findings should prompt a reevaluation of the systemic dissemination of TBFV in infected ticks.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 505: Langat Virus Infection Can Be Demonstrated in Both Tick Salivary Glands and Midgut Within 24 Hours of Blood Feeding</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/505">doi: 10.3390/v18050505</a></p>
	<p>Authors:
		Missiani Ochwoto
		Danielle K. Offerdahl
		Edwin O. Ogola
		Barbara C. Weck
		Dan Long
		Greg A. Saturday
		Marshall E. Bloom
		</p>
	<p>The detailed mechanism and sequence by which tick-borne flaviviruses (TBFVs), such as Langat virus (LGTV), infect and disseminate in arthropod hosts remain undefined. To begin characterizing these processes, we used artificial membrane feeding chambers to feed adult Ixodes scapularis ticks with blood containing LGTV. At 24, 48, 72, and 96 hours (h) after attachment, we removed and dissected the partially fed ticks to obtain the midgut and salivary glands. Histology confirmed infection in cells of the digestive epithelium lineage; infection was noted in midgut generative cells and the more differentiated functional digestive cells over the course of feeding. The viral envelope (E) protein, nonstructural protein 3 (NS3), and double-stranded RNA (dsRNA) were readily detected in these cells by 48 h after infection. Parallel analysis indicated that cells in salivary gland acini were also infected by 48 h, where virus target cells appeared to be the granular cells in acini types II and III. Thus, both salivary glands and midgut showed direct evidence of infection by 48 h. Although viral staining was not observed at 24 h, when organs were removed at 24 h and individually cultured ex vivo, the virus was detected. Taken together, our results provide evidence of LGTV infection in both the salivary glands and midgut within the first 24 h of a blood meal. The findings should prompt a reevaluation of the systemic dissemination of TBFV in infected ticks.</p>
	]]></content:encoded>

	<dc:title>Langat Virus Infection Can Be Demonstrated in Both Tick Salivary Glands and Midgut Within 24 Hours of Blood Feeding</dc:title>
			<dc:creator>Missiani Ochwoto</dc:creator>
			<dc:creator>Danielle K. Offerdahl</dc:creator>
			<dc:creator>Edwin O. Ogola</dc:creator>
			<dc:creator>Barbara C. Weck</dc:creator>
			<dc:creator>Dan Long</dc:creator>
			<dc:creator>Greg A. Saturday</dc:creator>
			<dc:creator>Marshall E. Bloom</dc:creator>
		<dc:identifier>doi: 10.3390/v18050505</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>505</prism:startingPage>
		<prism:doi>10.3390/v18050505</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/505</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/504">

	<title>Viruses, Vol. 18, Pages 504: Dynamic Changes in Host Immune Response During Crimean&amp;ndash;Congo Hemorrhagic Fever and Severe Fever with Thrombocytopenia Syndrome in Mice</title>
	<link>https://www.mdpi.com/1999-4915/18/5/504</link>
	<description>Crimean&amp;amp;ndash;Congo hemorrhagic fever virus (CCHFV) and severe fever with thrombocytopenia syndrome virus (SFTSV) are tick-borne pathogens that cause severe illness and high mortality. Early diagnosis is critical, particularly in resource-limited settings, to enable timely intervention. Host gene expression profiling offers a promising approach to identify potential biomarkers for early detection, disease staging, and logical treatment decision-making. Using a transient IFN-&amp;amp;alpha;/&amp;amp;beta; receptor-suppressed mouse model, we performed targeted transcriptomic analysis on blood samples collected at 2, 3, and 4 days after CCHFV or SFTSV challenge. A significant increase in viral load and changes in gene expression were observed as early as two days post-challenge. CCHFV induced a progressively evolving interferon-driven response, while SFTSV triggered rapid, sustained immune activation. Affected targets included interferon-stimulated genes, chemokines, cytokines, Toll-like receptors, and genes associated with viral evasion and innate immune response. Despite shared expression patterns, unique genes were identified as potential biomarkers to distinguish between CCHFV and SFTSV infections. Differential gene expression revealed distinct immune response dynamics, with suppression of critical immune regulatory genes suggesting transcriptional signatures associated with viral evasion mechanisms contributing to disease severity. These findings provide a comparative analysis of molecular pathways and gene expression changes, offering critical insights for biomarker discovery, effective triage, and evaluation of appropriate medical intervention.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 504: Dynamic Changes in Host Immune Response During Crimean&amp;ndash;Congo Hemorrhagic Fever and Severe Fever with Thrombocytopenia Syndrome in Mice</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/504">doi: 10.3390/v18050504</a></p>
	<p>Authors:
		Doreswamy Kenchegowda
		Brian D. Carey
		Joshua Shamblin
		Collin J. Fitzpatrick
		Danielle L. Porier
		Susan Coyne
		Jeffrey Koehler
		Candace D. Blancett
		Christina E. Douglas
		Cheryl Taylor-Howell
		Aura R. Garrison
		Christopher P. Stefan
		Charles J. Shoemaker
		Joseph W. Golden
		</p>
	<p>Crimean&amp;amp;ndash;Congo hemorrhagic fever virus (CCHFV) and severe fever with thrombocytopenia syndrome virus (SFTSV) are tick-borne pathogens that cause severe illness and high mortality. Early diagnosis is critical, particularly in resource-limited settings, to enable timely intervention. Host gene expression profiling offers a promising approach to identify potential biomarkers for early detection, disease staging, and logical treatment decision-making. Using a transient IFN-&amp;amp;alpha;/&amp;amp;beta; receptor-suppressed mouse model, we performed targeted transcriptomic analysis on blood samples collected at 2, 3, and 4 days after CCHFV or SFTSV challenge. A significant increase in viral load and changes in gene expression were observed as early as two days post-challenge. CCHFV induced a progressively evolving interferon-driven response, while SFTSV triggered rapid, sustained immune activation. Affected targets included interferon-stimulated genes, chemokines, cytokines, Toll-like receptors, and genes associated with viral evasion and innate immune response. Despite shared expression patterns, unique genes were identified as potential biomarkers to distinguish between CCHFV and SFTSV infections. Differential gene expression revealed distinct immune response dynamics, with suppression of critical immune regulatory genes suggesting transcriptional signatures associated with viral evasion mechanisms contributing to disease severity. These findings provide a comparative analysis of molecular pathways and gene expression changes, offering critical insights for biomarker discovery, effective triage, and evaluation of appropriate medical intervention.</p>
	]]></content:encoded>

	<dc:title>Dynamic Changes in Host Immune Response During Crimean&amp;amp;ndash;Congo Hemorrhagic Fever and Severe Fever with Thrombocytopenia Syndrome in Mice</dc:title>
			<dc:creator>Doreswamy Kenchegowda</dc:creator>
			<dc:creator>Brian D. Carey</dc:creator>
			<dc:creator>Joshua Shamblin</dc:creator>
			<dc:creator>Collin J. Fitzpatrick</dc:creator>
			<dc:creator>Danielle L. Porier</dc:creator>
			<dc:creator>Susan Coyne</dc:creator>
			<dc:creator>Jeffrey Koehler</dc:creator>
			<dc:creator>Candace D. Blancett</dc:creator>
			<dc:creator>Christina E. Douglas</dc:creator>
			<dc:creator>Cheryl Taylor-Howell</dc:creator>
			<dc:creator>Aura R. Garrison</dc:creator>
			<dc:creator>Christopher P. Stefan</dc:creator>
			<dc:creator>Charles J. Shoemaker</dc:creator>
			<dc:creator>Joseph W. Golden</dc:creator>
		<dc:identifier>doi: 10.3390/v18050504</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>504</prism:startingPage>
		<prism:doi>10.3390/v18050504</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/504</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/503">

	<title>Viruses, Vol. 18, Pages 503: CHIKV-Infected Human Dermal Fibroblasts Mount an IFN&amp;beta; Transcriptional Response Independent of TBK1/IKK&amp;epsilon; Signaling That Fails to Prevent Lethal Infection</title>
	<link>https://www.mdpi.com/1999-4915/18/5/503</link>
	<description>Chikungunya virus (CHIKV) is an alphavirus that infects dermal fibroblasts as a primary target cell during natural mosquito-borne transmission. While primary human dermal fibroblasts (hDFs) have been implicated as a key source of type I interferon (IFN-I) during CHIKV infection, the dynamics of this response and its sufficiency for antiviral protection remain incompletely understood. Here, we systematically characterize in vitro CHIKV infection of primary hDFs, evaluating the effects of single-passage viral stock origin (mammalian- vs. mosquito-propagated), donor variability, and multiplicity of infection (MOI) on infection kinetics and innate immune induction. We demonstrate that hDFs support high-titered CHIKV replication at both MOI 1 and 0.01, resulting in universal cell death by 72 hpi despite robust IFN&amp;amp;beta; transcript induction&amp;amp;mdash;reaching up to ~2800-fold over mock&amp;amp;mdash;and secretion of pro-inflammatory cytokines, including IFN&amp;amp;alpha;2, TNF&amp;amp;alpha;, IL-1&amp;amp;beta;, and IL-8. Notably, IFN&amp;amp;beta; protein levels remained below 10 pg/mL under all infection conditions, revealing a disconnect between transcriptional and translational responses, suggesting CHIKV-mediated translational suppression. Pharmacological inhibition of TBK1/IKK&amp;amp;epsilon; via amlexanox did not suppress IFN&amp;amp;beta; transcript induction at any tested concentration, suggesting that canonical PRR signaling through this node&amp;amp;mdash;including both RIG-I/MAVS and TLR3/TRIF pathways&amp;amp;mdash;is not the major driver of the observed transcriptional response. In contrast, co-inoculation with exogenous IFN&amp;amp;beta; as low as 20 pg/mL activated IFNAR signaling, robustly upregulated interferon-stimulated genes (ISGs), and fully rescued hDFs from otherwise lethal infection. Together, these findings demonstrate that CHIKV-infected hDFs mount a transcriptionally robust but translationally insufficient innate immune response and that the transcriptional response appears to operate independently of TBK1/IKK&amp;amp;epsilon;. These results have direct implications for understanding how the skin microenvironment may modulate early CHIKV pathogenesis and suggest that paracrine IFN&amp;amp;beta; signaling from neighboring cell types may be critical for fibroblast survival during natural infection.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 503: CHIKV-Infected Human Dermal Fibroblasts Mount an IFN&amp;beta; Transcriptional Response Independent of TBK1/IKK&amp;epsilon; Signaling That Fails to Prevent Lethal Infection</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/503">doi: 10.3390/v18050503</a></p>
	<p>Authors:
		Meagan M. Taylor
		Rosemary W. Roberts
		Jonathan O. Rayner
		</p>
	<p>Chikungunya virus (CHIKV) is an alphavirus that infects dermal fibroblasts as a primary target cell during natural mosquito-borne transmission. While primary human dermal fibroblasts (hDFs) have been implicated as a key source of type I interferon (IFN-I) during CHIKV infection, the dynamics of this response and its sufficiency for antiviral protection remain incompletely understood. Here, we systematically characterize in vitro CHIKV infection of primary hDFs, evaluating the effects of single-passage viral stock origin (mammalian- vs. mosquito-propagated), donor variability, and multiplicity of infection (MOI) on infection kinetics and innate immune induction. We demonstrate that hDFs support high-titered CHIKV replication at both MOI 1 and 0.01, resulting in universal cell death by 72 hpi despite robust IFN&amp;amp;beta; transcript induction&amp;amp;mdash;reaching up to ~2800-fold over mock&amp;amp;mdash;and secretion of pro-inflammatory cytokines, including IFN&amp;amp;alpha;2, TNF&amp;amp;alpha;, IL-1&amp;amp;beta;, and IL-8. Notably, IFN&amp;amp;beta; protein levels remained below 10 pg/mL under all infection conditions, revealing a disconnect between transcriptional and translational responses, suggesting CHIKV-mediated translational suppression. Pharmacological inhibition of TBK1/IKK&amp;amp;epsilon; via amlexanox did not suppress IFN&amp;amp;beta; transcript induction at any tested concentration, suggesting that canonical PRR signaling through this node&amp;amp;mdash;including both RIG-I/MAVS and TLR3/TRIF pathways&amp;amp;mdash;is not the major driver of the observed transcriptional response. In contrast, co-inoculation with exogenous IFN&amp;amp;beta; as low as 20 pg/mL activated IFNAR signaling, robustly upregulated interferon-stimulated genes (ISGs), and fully rescued hDFs from otherwise lethal infection. Together, these findings demonstrate that CHIKV-infected hDFs mount a transcriptionally robust but translationally insufficient innate immune response and that the transcriptional response appears to operate independently of TBK1/IKK&amp;amp;epsilon;. These results have direct implications for understanding how the skin microenvironment may modulate early CHIKV pathogenesis and suggest that paracrine IFN&amp;amp;beta; signaling from neighboring cell types may be critical for fibroblast survival during natural infection.</p>
	]]></content:encoded>

	<dc:title>CHIKV-Infected Human Dermal Fibroblasts Mount an IFN&amp;amp;beta; Transcriptional Response Independent of TBK1/IKK&amp;amp;epsilon; Signaling That Fails to Prevent Lethal Infection</dc:title>
			<dc:creator>Meagan M. Taylor</dc:creator>
			<dc:creator>Rosemary W. Roberts</dc:creator>
			<dc:creator>Jonathan O. Rayner</dc:creator>
		<dc:identifier>doi: 10.3390/v18050503</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>503</prism:startingPage>
		<prism:doi>10.3390/v18050503</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/503</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/502">

	<title>Viruses, Vol. 18, Pages 502: Genotype Diversity of Highly Pathogenic Avian Influenza H5N1 Clade 2.3.4.4b in Pennsylvania Poultry During Disease Outbreak from April 2022 to March 2023</title>
	<link>https://www.mdpi.com/1999-4915/18/5/502</link>
	<description>The 2022 highly pathogenic avian influenza (HPAI) outbreak of H5N1 clade 2.3.4.4b was one of the major avian influenza outbreaks, leading to multiple spillover events infecting domestic and wild bird flocks, as well as mammals. The sustained spread was a result of viral circulation in wild birds across migratory flyways in North America. Pennsylvania has a significant poultry population that supports both retail and live bird markets. The state also features migratory bird stopovers on the Atlantic flyway, increasing exposure to HPAI infections. This study investigates clinical presentation and sequence data from H5N1 clade 2.3.4.4b viruses during the 2022 outbreak in Pennsylvania. Eight different H5N1 clade 2.3.4.4b genotypes were detected (A1, B1.1, B1.2, B1.3, B2.2, B3.3, B3.5, and one minor genotype) during the first year. The earliest detection was genotype A1, a fully Eurasian virus, in commercial poultry in April 2022. All other genotypes identified were reassortants of A1 with North American avian influenza gene segments (denoted with &amp;amp;ldquo;B&amp;amp;rdquo;). Genotype B3.3 was a rare genotype prior to the initial spillover into the live bird market system, but remained predominant among backyard flocks in Pennsylvania and surrounding states until September 2023. Genotype B3.3 has not been detected in migratory waterfowl since, suggesting the genotype has waned and is no longer in circulation. This study sheds light on the genotype diversity of H5N1 during the 2022 outbreak in Pennsylvania poultry, contributing to the understanding of virus evolution and its potential impacts.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 502: Genotype Diversity of Highly Pathogenic Avian Influenza H5N1 Clade 2.3.4.4b in Pennsylvania Poultry During Disease Outbreak from April 2022 to March 2023</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/502">doi: 10.3390/v18050502</a></p>
	<p>Authors:
		Deepanker Tewari
		Manoj K. Sekhwal
		Chrislyn Nicholson
		Mary L. Killian
		Corey Zellers
		Julia Livengood
		Kristina Lantz
		Mia Torchetti
		Alex Hamberg
		</p>
	<p>The 2022 highly pathogenic avian influenza (HPAI) outbreak of H5N1 clade 2.3.4.4b was one of the major avian influenza outbreaks, leading to multiple spillover events infecting domestic and wild bird flocks, as well as mammals. The sustained spread was a result of viral circulation in wild birds across migratory flyways in North America. Pennsylvania has a significant poultry population that supports both retail and live bird markets. The state also features migratory bird stopovers on the Atlantic flyway, increasing exposure to HPAI infections. This study investigates clinical presentation and sequence data from H5N1 clade 2.3.4.4b viruses during the 2022 outbreak in Pennsylvania. Eight different H5N1 clade 2.3.4.4b genotypes were detected (A1, B1.1, B1.2, B1.3, B2.2, B3.3, B3.5, and one minor genotype) during the first year. The earliest detection was genotype A1, a fully Eurasian virus, in commercial poultry in April 2022. All other genotypes identified were reassortants of A1 with North American avian influenza gene segments (denoted with &amp;amp;ldquo;B&amp;amp;rdquo;). Genotype B3.3 was a rare genotype prior to the initial spillover into the live bird market system, but remained predominant among backyard flocks in Pennsylvania and surrounding states until September 2023. Genotype B3.3 has not been detected in migratory waterfowl since, suggesting the genotype has waned and is no longer in circulation. This study sheds light on the genotype diversity of H5N1 during the 2022 outbreak in Pennsylvania poultry, contributing to the understanding of virus evolution and its potential impacts.</p>
	]]></content:encoded>

	<dc:title>Genotype Diversity of Highly Pathogenic Avian Influenza H5N1 Clade 2.3.4.4b in Pennsylvania Poultry During Disease Outbreak from April 2022 to March 2023</dc:title>
			<dc:creator>Deepanker Tewari</dc:creator>
			<dc:creator>Manoj K. Sekhwal</dc:creator>
			<dc:creator>Chrislyn Nicholson</dc:creator>
			<dc:creator>Mary L. Killian</dc:creator>
			<dc:creator>Corey Zellers</dc:creator>
			<dc:creator>Julia Livengood</dc:creator>
			<dc:creator>Kristina Lantz</dc:creator>
			<dc:creator>Mia Torchetti</dc:creator>
			<dc:creator>Alex Hamberg</dc:creator>
		<dc:identifier>doi: 10.3390/v18050502</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>502</prism:startingPage>
		<prism:doi>10.3390/v18050502</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/502</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/501">

	<title>Viruses, Vol. 18, Pages 501: Isolation and Molecular Analysis of Negeviruses in Mosquitoes (Diptera: Culicidae) from an Environmental Protection Area in the Brazilian Amazon</title>
	<link>https://www.mdpi.com/1999-4915/18/5/501</link>
	<description>Mosquitoes are recognized as the arthropod group with the greatest vectorial capacity, and the viruses they transmit constitute a significant concern in the context of global One Health. In addition, these insects act as hosts for a wide diversity of insect-specific viruses (ISVs), which exclusively infect arthropods. Expanding knowledge of ISVs is particularly relevant, given their potential influence on arbovirus replication and their role in elucidating the evolutionary processes that shape virus&amp;amp;ndash;vector interactions. In this study, we report the isolation and molecular analysis of three negeviruses associated with different mosquito species of the genera Culex, Coquillettidia, Mansonia, and Ochlerotatus, collected in Bel&amp;amp;eacute;m, Par&amp;amp;aacute; State, in the Brazilian Amazon: Loreto virus, Wallerfield virus, and a putative new species, designated Terra firme virus. Eleven pools exhibited cellular alterations consistent with cytopathic effects in invertebrate C6/36 cells but showed no evidence of replication in vertebrate Vero cells. Notably, simultaneous infections by two or three negeviruses were detected in some mosquito pools, indicating the occurrence of multiple viral infections within individual samples. Genomic analyses revealed that the isolated strains share conserved domains with previously described isolates from other countries. Phylogenetic inferences demonstrated that the investigated strains are classified within the clades Nelorpivirus and Sandewavirus. Taken together, these findings expand the currently known diversity of the negevirus group and contribute to a more comprehensive understanding of its host range and geographic distribution.</description>
	<pubDate>2026-04-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 501: Isolation and Molecular Analysis of Negeviruses in Mosquitoes (Diptera: Culicidae) from an Environmental Protection Area in the Brazilian Amazon</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/501">doi: 10.3390/v18050501</a></p>
	<p>Authors:
		Bruna Alves Ramos
		Daniel Damous Dias
		Joaquim Pinto Nunes-Neto
		José Wilson Rosa Junior
		Durval Bertram Rodrigues Vieira
		Valéria Lima Carvalho
		Ana Lúcia Monteiro Wanzeller
		Eliana Vieira Pinto da Silva
		Maria Nazaré Oliveira Freitas
		Landeson Junior Leopoldino Barros
		Maissa Maia Santos
		Jamilla Augusta de Souza Pantoja
		Ercília de Jesus Gonçalves
		Ana Claudia da Silva Ribeiro
		Ana Cecília Ribeiro Cruz
		Sandro Patroca Silva
		Carine Fortes Aragão
		Alexandre do Rosário Casseb
		Livia Caricio Martins
		</p>
	<p>Mosquitoes are recognized as the arthropod group with the greatest vectorial capacity, and the viruses they transmit constitute a significant concern in the context of global One Health. In addition, these insects act as hosts for a wide diversity of insect-specific viruses (ISVs), which exclusively infect arthropods. Expanding knowledge of ISVs is particularly relevant, given their potential influence on arbovirus replication and their role in elucidating the evolutionary processes that shape virus&amp;amp;ndash;vector interactions. In this study, we report the isolation and molecular analysis of three negeviruses associated with different mosquito species of the genera Culex, Coquillettidia, Mansonia, and Ochlerotatus, collected in Bel&amp;amp;eacute;m, Par&amp;amp;aacute; State, in the Brazilian Amazon: Loreto virus, Wallerfield virus, and a putative new species, designated Terra firme virus. Eleven pools exhibited cellular alterations consistent with cytopathic effects in invertebrate C6/36 cells but showed no evidence of replication in vertebrate Vero cells. Notably, simultaneous infections by two or three negeviruses were detected in some mosquito pools, indicating the occurrence of multiple viral infections within individual samples. Genomic analyses revealed that the isolated strains share conserved domains with previously described isolates from other countries. Phylogenetic inferences demonstrated that the investigated strains are classified within the clades Nelorpivirus and Sandewavirus. Taken together, these findings expand the currently known diversity of the negevirus group and contribute to a more comprehensive understanding of its host range and geographic distribution.</p>
	]]></content:encoded>

	<dc:title>Isolation and Molecular Analysis of Negeviruses in Mosquitoes (Diptera: Culicidae) from an Environmental Protection Area in the Brazilian Amazon</dc:title>
			<dc:creator>Bruna Alves Ramos</dc:creator>
			<dc:creator>Daniel Damous Dias</dc:creator>
			<dc:creator>Joaquim Pinto Nunes-Neto</dc:creator>
			<dc:creator>José Wilson Rosa Junior</dc:creator>
			<dc:creator>Durval Bertram Rodrigues Vieira</dc:creator>
			<dc:creator>Valéria Lima Carvalho</dc:creator>
			<dc:creator>Ana Lúcia Monteiro Wanzeller</dc:creator>
			<dc:creator>Eliana Vieira Pinto da Silva</dc:creator>
			<dc:creator>Maria Nazaré Oliveira Freitas</dc:creator>
			<dc:creator>Landeson Junior Leopoldino Barros</dc:creator>
			<dc:creator>Maissa Maia Santos</dc:creator>
			<dc:creator>Jamilla Augusta de Souza Pantoja</dc:creator>
			<dc:creator>Ercília de Jesus Gonçalves</dc:creator>
			<dc:creator>Ana Claudia da Silva Ribeiro</dc:creator>
			<dc:creator>Ana Cecília Ribeiro Cruz</dc:creator>
			<dc:creator>Sandro Patroca Silva</dc:creator>
			<dc:creator>Carine Fortes Aragão</dc:creator>
			<dc:creator>Alexandre do Rosário Casseb</dc:creator>
			<dc:creator>Livia Caricio Martins</dc:creator>
		<dc:identifier>doi: 10.3390/v18050501</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-25</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-25</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>501</prism:startingPage>
		<prism:doi>10.3390/v18050501</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/501</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/500">

	<title>Viruses, Vol. 18, Pages 500: Annual Dynamics and Functional Traits of Viral Communities in Tropical Intertidal Sands of Sanya Bay</title>
	<link>https://www.mdpi.com/1999-4915/18/5/500</link>
	<description>Viruses are key regulators of marine microbial communities, yet their temporal dynamics in tropical intertidal sediments remain poorly characterized. We conducted a year-long metagenomic survey of sandy intertidal sediments in Sanya Bay (60 monthly samples from five sites) to examine viral taxonomy, community structure, lytic proteins, and auxiliary metabolic genes (AMGs). Within the classifiable fraction, the assemblages were consistently dominated by Assiduviridae. However, NMDS analysis revealed a significant overall seasonal shift, with October&amp;amp;ndash;December samples separating from the rest of the year. Co-occurrence network analysis identified five co-occurrence modules with distinct temporal patterns, alongside a concurrent decline in module abundance and lytic proteins in October. Functional annotation showed that cysteine and methionine metabolism, primarily driven by DNA methyltransferases, was identified as a highly represented AMG category among the annotated functions, while other pathways displayed seasonal variability. Collectively, these findings suggest that although characterized by a classifiable fraction dominated by Assiduviridae, the highly complex tropical intertidal viral communities undergo substantial seasonal reorganization in structure and functional potential.</description>
	<pubDate>2026-04-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 500: Annual Dynamics and Functional Traits of Viral Communities in Tropical Intertidal Sands of Sanya Bay</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/500">doi: 10.3390/v18050500</a></p>
	<p>Authors:
		Zijia Wang
		Zongminghan Liu
		Juntao Zeng
		Jiwei Li
		Jiahao Cheng
		Xiaoxue Qi
		Jingwen Li
		Shijie Bai
		</p>
	<p>Viruses are key regulators of marine microbial communities, yet their temporal dynamics in tropical intertidal sediments remain poorly characterized. We conducted a year-long metagenomic survey of sandy intertidal sediments in Sanya Bay (60 monthly samples from five sites) to examine viral taxonomy, community structure, lytic proteins, and auxiliary metabolic genes (AMGs). Within the classifiable fraction, the assemblages were consistently dominated by Assiduviridae. However, NMDS analysis revealed a significant overall seasonal shift, with October&amp;amp;ndash;December samples separating from the rest of the year. Co-occurrence network analysis identified five co-occurrence modules with distinct temporal patterns, alongside a concurrent decline in module abundance and lytic proteins in October. Functional annotation showed that cysteine and methionine metabolism, primarily driven by DNA methyltransferases, was identified as a highly represented AMG category among the annotated functions, while other pathways displayed seasonal variability. Collectively, these findings suggest that although characterized by a classifiable fraction dominated by Assiduviridae, the highly complex tropical intertidal viral communities undergo substantial seasonal reorganization in structure and functional potential.</p>
	]]></content:encoded>

	<dc:title>Annual Dynamics and Functional Traits of Viral Communities in Tropical Intertidal Sands of Sanya Bay</dc:title>
			<dc:creator>Zijia Wang</dc:creator>
			<dc:creator>Zongminghan Liu</dc:creator>
			<dc:creator>Juntao Zeng</dc:creator>
			<dc:creator>Jiwei Li</dc:creator>
			<dc:creator>Jiahao Cheng</dc:creator>
			<dc:creator>Xiaoxue Qi</dc:creator>
			<dc:creator>Jingwen Li</dc:creator>
			<dc:creator>Shijie Bai</dc:creator>
		<dc:identifier>doi: 10.3390/v18050500</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-25</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-25</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>500</prism:startingPage>
		<prism:doi>10.3390/v18050500</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/500</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/499">

	<title>Viruses, Vol. 18, Pages 499: Real-World Utilization of the HCV Care Cascade Before and After Implementation of a Program to Streamline Care and Promote Treatment</title>
	<link>https://www.mdpi.com/1999-4915/18/5/499</link>
	<description>Objectives: The World Health Organization (WHO) goal of eradicating hepatitis C virus (HCV) infection by 2030 has encouraged healthcare providers to implement proactive strategies to improve diagnosis and treatment. The aims of this retrospective cohort study were to assess a program designed to improve the HCV care cascade and facilitate access to treatment, within a national healthcare provider in Israel, Maccabi Healthcare Services (MHS). Methods: Included were adult patients newly diagnosed with HCV infection before and after the implementation of a screening and care optimization program. Patients diagnosed in 2017 served as the reference group (RG), while those diagnosed in 2019 (following the program implementation) comprised the intervention group (IG). Study outcomes included completion of HCV laboratory testing, time to consultation with gastroenterologist/hepatologist (GE), and initiation of treatment with direct-acting antivirals (DAAs). Results: The study sample included 356 HCV Ab+ patients in the RG (median age = 46 years; 41% females), and 328 in the IG (median age = 48 years; 39% females). Compared to RG, IG demonstrated higher rates of patient visiting GE visit (78.1% vs. 63%) and initiating DAA treatment (66.3% vs. 35.5%). Conclusions: Implementation of a restructured HCV care cascade was associated with a greater proportion of patients receiving expert consultation and higher DAA treatment uptake, important steps towards HCV eradication.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 499: Real-World Utilization of the HCV Care Cascade Before and After Implementation of a Program to Streamline Care and Promote Treatment</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/499">doi: 10.3390/v18050499</a></p>
	<p>Authors:
		Daniella Rahamim-Cohen
		Ayelet Aviva Basson
		Clara Weil
		Izana Kaplan-Lavi
		Odelia Tassa-Liani
		Yael Topol
		Gabriel Chodick
		Bar Cohen
		Limor Adler
		Shirley Shapiro Ben David
		</p>
	<p>Objectives: The World Health Organization (WHO) goal of eradicating hepatitis C virus (HCV) infection by 2030 has encouraged healthcare providers to implement proactive strategies to improve diagnosis and treatment. The aims of this retrospective cohort study were to assess a program designed to improve the HCV care cascade and facilitate access to treatment, within a national healthcare provider in Israel, Maccabi Healthcare Services (MHS). Methods: Included were adult patients newly diagnosed with HCV infection before and after the implementation of a screening and care optimization program. Patients diagnosed in 2017 served as the reference group (RG), while those diagnosed in 2019 (following the program implementation) comprised the intervention group (IG). Study outcomes included completion of HCV laboratory testing, time to consultation with gastroenterologist/hepatologist (GE), and initiation of treatment with direct-acting antivirals (DAAs). Results: The study sample included 356 HCV Ab+ patients in the RG (median age = 46 years; 41% females), and 328 in the IG (median age = 48 years; 39% females). Compared to RG, IG demonstrated higher rates of patient visiting GE visit (78.1% vs. 63%) and initiating DAA treatment (66.3% vs. 35.5%). Conclusions: Implementation of a restructured HCV care cascade was associated with a greater proportion of patients receiving expert consultation and higher DAA treatment uptake, important steps towards HCV eradication.</p>
	]]></content:encoded>

	<dc:title>Real-World Utilization of the HCV Care Cascade Before and After Implementation of a Program to Streamline Care and Promote Treatment</dc:title>
			<dc:creator>Daniella Rahamim-Cohen</dc:creator>
			<dc:creator>Ayelet Aviva Basson</dc:creator>
			<dc:creator>Clara Weil</dc:creator>
			<dc:creator>Izana Kaplan-Lavi</dc:creator>
			<dc:creator>Odelia Tassa-Liani</dc:creator>
			<dc:creator>Yael Topol</dc:creator>
			<dc:creator>Gabriel Chodick</dc:creator>
			<dc:creator>Bar Cohen</dc:creator>
			<dc:creator>Limor Adler</dc:creator>
			<dc:creator>Shirley Shapiro Ben David</dc:creator>
		<dc:identifier>doi: 10.3390/v18050499</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>499</prism:startingPage>
		<prism:doi>10.3390/v18050499</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/499</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/498">

	<title>Viruses, Vol. 18, Pages 498: Genomic Surveillance of BVDV in Southern Brazil: What Changed After a Decade in Rio Grande do Sul?</title>
	<link>https://www.mdpi.com/1999-4915/18/5/498</link>
	<description>Bovine viral diarrhea virus (BVDV) is a major cattle pathogen associated with significant economic losses worldwide. In Brazil, the high genetic diversity of circulating strains represents an additional challenge for disease control. To update the molecular epidemiology of BVDV in southern Brazil, 16,198 bovine serum samples collected in 2020 through a national surveillance program were screened for pestivirus RNA by RT-qPCR. Forty-nine samples (0.36%) were positive and subjected to partial sequencing of the 5&amp;amp;prime;UTR and Npro regions. Phylogenetic analysis identified BVDV-1a (25/49; 51%), BVDV-1b (1/49; 2%), BVDV-1d (7/49; 14%), and BVDV-2b (16/49; 33%), with no detection of HoBiPeV. When compared descriptively with data from 2010 in the same region, BVDV-1a remained the most frequent subgenotype, while BVDV-2b also represented a substantial proportion of detections, contrasting with other regions worldwide. Although the two datasets are not directly comparable, and no statistically significant differences were observed, these findings provide an updated overview of circulating BVDV subgenotypes in Rio Grande do Sul. The absence of HoBiPeV contrasts with reports from other regions of Brazil and suggests a distinct regional pattern of pestivirus circulation. Overall, the results reinforce the importance of continuous genomic surveillance to monitor changes in viral diversity and support control strategies in cattle populations.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 498: Genomic Surveillance of BVDV in Southern Brazil: What Changed After a Decade in Rio Grande do Sul?</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/498">doi: 10.3390/v18050498</a></p>
	<p>Authors:
		Leticia F. Baumbach
		Raquel S. Alves
		Laura J. Camargo
		Eduardo O. Sanguinet
		Leticia S. Santos
		Lucas Marian
		Gabriela E. Birlem
		Roberto Schroeder
		Fabiano Barreto
		João Marcos N. Costa
		Renata A. Casagrande
		Matheus N. Weber
		Cláudio W. Canal
		</p>
	<p>Bovine viral diarrhea virus (BVDV) is a major cattle pathogen associated with significant economic losses worldwide. In Brazil, the high genetic diversity of circulating strains represents an additional challenge for disease control. To update the molecular epidemiology of BVDV in southern Brazil, 16,198 bovine serum samples collected in 2020 through a national surveillance program were screened for pestivirus RNA by RT-qPCR. Forty-nine samples (0.36%) were positive and subjected to partial sequencing of the 5&amp;amp;prime;UTR and Npro regions. Phylogenetic analysis identified BVDV-1a (25/49; 51%), BVDV-1b (1/49; 2%), BVDV-1d (7/49; 14%), and BVDV-2b (16/49; 33%), with no detection of HoBiPeV. When compared descriptively with data from 2010 in the same region, BVDV-1a remained the most frequent subgenotype, while BVDV-2b also represented a substantial proportion of detections, contrasting with other regions worldwide. Although the two datasets are not directly comparable, and no statistically significant differences were observed, these findings provide an updated overview of circulating BVDV subgenotypes in Rio Grande do Sul. The absence of HoBiPeV contrasts with reports from other regions of Brazil and suggests a distinct regional pattern of pestivirus circulation. Overall, the results reinforce the importance of continuous genomic surveillance to monitor changes in viral diversity and support control strategies in cattle populations.</p>
	]]></content:encoded>

	<dc:title>Genomic Surveillance of BVDV in Southern Brazil: What Changed After a Decade in Rio Grande do Sul?</dc:title>
			<dc:creator>Leticia F. Baumbach</dc:creator>
			<dc:creator>Raquel S. Alves</dc:creator>
			<dc:creator>Laura J. Camargo</dc:creator>
			<dc:creator>Eduardo O. Sanguinet</dc:creator>
			<dc:creator>Leticia S. Santos</dc:creator>
			<dc:creator>Lucas Marian</dc:creator>
			<dc:creator>Gabriela E. Birlem</dc:creator>
			<dc:creator>Roberto Schroeder</dc:creator>
			<dc:creator>Fabiano Barreto</dc:creator>
			<dc:creator>João Marcos N. Costa</dc:creator>
			<dc:creator>Renata A. Casagrande</dc:creator>
			<dc:creator>Matheus N. Weber</dc:creator>
			<dc:creator>Cláudio W. Canal</dc:creator>
		<dc:identifier>doi: 10.3390/v18050498</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>498</prism:startingPage>
		<prism:doi>10.3390/v18050498</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/498</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/497">

	<title>Viruses, Vol. 18, Pages 497: Whole-Genome Phylogenetic Characterization of Human Parainfluenza Virus Type 4 Circulating in St. Petersburg, Russia</title>
	<link>https://www.mdpi.com/1999-4915/18/5/497</link>
	<description>Human parainfluenza virus type 4 (hPIV4) remains poorly characterized compared with other hPIV serotypes and information on its genomic diversity is particularly limited for Russia and Eastern Europe. In this study, we report the first complete genome sequences of hPIV4 isolates from Russia and place them in the context of global hPIV4 genetic diversity. Eight hPIV4 viruses were isolated in cell culture from respiratory samples collected from hospitalized children in Saint Petersburg between 2017/2018 and 2023/2024. Complete viral genomes were recovered using a metagenomic whole-genome amplification approach based on SMART-9N technology. Phylogenetic analysis of 178 complete hPIV4 genomes showed clear separation into hPIV4a (n = 132) and hPIV4b (n = 46) subtypes. Based on genetic distance approach, hPIV4a formed two major clusters, with the dominant cluster B subdivided into four subclusters (B1&amp;amp;ndash;B4); and subcluster B4 further resolved into four genetic lineages. All Russian isolates belonged to the subcluster B4 and were distributed among multiple co-circulating lineages. In contrast, hPIV4b genomes segregated into three distinct clusters, reflecting structured genetic diversity within the subtype. Collectively, this study provides, to the best of our knowledge, the first p-distance-based framework for hPIV4 whole-genome classification and contributes new complete genome sequences for an underrepresented region.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 497: Whole-Genome Phylogenetic Characterization of Human Parainfluenza Virus Type 4 Circulating in St. Petersburg, Russia</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/497">doi: 10.3390/v18050497</a></p>
	<p>Authors:
		Oula Mansour
		Artem V. Fadeev
		Alexander A. Perederiy
		Andrey D. Ksenafontov
		Anastasiia Y. Boyarintseva
		Daria M. Danilenko
		Dmitry A. Lioznov
		Andrey B. Komissarov
		</p>
	<p>Human parainfluenza virus type 4 (hPIV4) remains poorly characterized compared with other hPIV serotypes and information on its genomic diversity is particularly limited for Russia and Eastern Europe. In this study, we report the first complete genome sequences of hPIV4 isolates from Russia and place them in the context of global hPIV4 genetic diversity. Eight hPIV4 viruses were isolated in cell culture from respiratory samples collected from hospitalized children in Saint Petersburg between 2017/2018 and 2023/2024. Complete viral genomes were recovered using a metagenomic whole-genome amplification approach based on SMART-9N technology. Phylogenetic analysis of 178 complete hPIV4 genomes showed clear separation into hPIV4a (n = 132) and hPIV4b (n = 46) subtypes. Based on genetic distance approach, hPIV4a formed two major clusters, with the dominant cluster B subdivided into four subclusters (B1&amp;amp;ndash;B4); and subcluster B4 further resolved into four genetic lineages. All Russian isolates belonged to the subcluster B4 and were distributed among multiple co-circulating lineages. In contrast, hPIV4b genomes segregated into three distinct clusters, reflecting structured genetic diversity within the subtype. Collectively, this study provides, to the best of our knowledge, the first p-distance-based framework for hPIV4 whole-genome classification and contributes new complete genome sequences for an underrepresented region.</p>
	]]></content:encoded>

	<dc:title>Whole-Genome Phylogenetic Characterization of Human Parainfluenza Virus Type 4 Circulating in St. Petersburg, Russia</dc:title>
			<dc:creator>Oula Mansour</dc:creator>
			<dc:creator>Artem V. Fadeev</dc:creator>
			<dc:creator>Alexander A. Perederiy</dc:creator>
			<dc:creator>Andrey D. Ksenafontov</dc:creator>
			<dc:creator>Anastasiia Y. Boyarintseva</dc:creator>
			<dc:creator>Daria M. Danilenko</dc:creator>
			<dc:creator>Dmitry A. Lioznov</dc:creator>
			<dc:creator>Andrey B. Komissarov</dc:creator>
		<dc:identifier>doi: 10.3390/v18050497</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>497</prism:startingPage>
		<prism:doi>10.3390/v18050497</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/497</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/496">

	<title>Viruses, Vol. 18, Pages 496: SARS-CoV-2 N Protein Hijacks the m6A Reader YTHDF2 to Suppress Antiviral Gene Expression</title>
	<link>https://www.mdpi.com/1999-4915/18/5/496</link>
	<description>The m6A RNA methylation pathway plays a critical role in host antiviral defense. Host cells employ m6A readers such as YTHDF2 to regulate viral RNA fate through diverse mechanisms, including degradation, translational control, and immune recognition. However, we found that YTHDF2 is essential for SARS-CoV-2 replication, suggesting that a virus may exploit this host machinery to its advantage. Through integrative RNA-proteome analysis, we identified the SARS-CoV-2 nucleocapsid (N) transcript as the most heavily m6A-modified viral transcript and a direct interactor of YTHDF2. The N protein forms a complex with YTHDF2 in the cytoplasm and redirects this host RNA decay machinery toward host antiviral transcripts. N suppresses ISG15, IFIT1, MX1 and pro-inflammatory cytokines in a largely YTHDF2-dependent manner, an effect that is lost in YTHDF2-knockout cells. These findings reveal a viral immune evasion strategy wherein a viral protein actively hijacks an m6A reader to silence antiviral gene expression, establishing the N-YTHDF2 axis as a therapeutic target against SARS-CoV-2 and other coronaviruses.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 496: SARS-CoV-2 N Protein Hijacks the m6A Reader YTHDF2 to Suppress Antiviral Gene Expression</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/496">doi: 10.3390/v18050496</a></p>
	<p>Authors:
		Peihan Wu
		Shuai Wang
		Xu Li
		</p>
	<p>The m6A RNA methylation pathway plays a critical role in host antiviral defense. Host cells employ m6A readers such as YTHDF2 to regulate viral RNA fate through diverse mechanisms, including degradation, translational control, and immune recognition. However, we found that YTHDF2 is essential for SARS-CoV-2 replication, suggesting that a virus may exploit this host machinery to its advantage. Through integrative RNA-proteome analysis, we identified the SARS-CoV-2 nucleocapsid (N) transcript as the most heavily m6A-modified viral transcript and a direct interactor of YTHDF2. The N protein forms a complex with YTHDF2 in the cytoplasm and redirects this host RNA decay machinery toward host antiviral transcripts. N suppresses ISG15, IFIT1, MX1 and pro-inflammatory cytokines in a largely YTHDF2-dependent manner, an effect that is lost in YTHDF2-knockout cells. These findings reveal a viral immune evasion strategy wherein a viral protein actively hijacks an m6A reader to silence antiviral gene expression, establishing the N-YTHDF2 axis as a therapeutic target against SARS-CoV-2 and other coronaviruses.</p>
	]]></content:encoded>

	<dc:title>SARS-CoV-2 N Protein Hijacks the m6A Reader YTHDF2 to Suppress Antiviral Gene Expression</dc:title>
			<dc:creator>Peihan Wu</dc:creator>
			<dc:creator>Shuai Wang</dc:creator>
			<dc:creator>Xu Li</dc:creator>
		<dc:identifier>doi: 10.3390/v18050496</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>496</prism:startingPage>
		<prism:doi>10.3390/v18050496</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/496</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/495">

	<title>Viruses, Vol. 18, Pages 495: From Envelope to Encephalopathy: How HIV-1 gp120 Drives Neurocognitive Decline</title>
	<link>https://www.mdpi.com/1999-4915/18/5/495</link>
	<description>Although neurons are not productively infected by HIV-1, the envelope glycoprotein gp120, detectable in cerebrospinal fluid independently of active viral replication, gains intraneuronal access via lipid raft-mediated endocytosis, macropinocytosis, and retrograde axonal transport, contributing to persistent neurobiological dysfunction within the central nervous system. Once internalized, gp120 is associated with neuronal dysfunction involving convergent pathways, including excitotoxic calcium dysregulation, mitochondrial and metabolic failure, and inflammatory and senescence-associated amplification. These pathways converge on suppression of CREB and BDNF signaling, dismantling the transcriptional and neurotrophic programs required for synaptic maintenance and cognitive resilience. Extracellular vesicle-mediated dissemination and microRNA reprogramming extend gp120-associated neurobiological effects beyond sites of receptor engagement, while gut-derived metabolites, particularly quinolinic acid, lower the excitotoxic threshold through synergistic activation of NMDA receptors. Together, these mechanisms define HAND as a network disorder in which gp120 contributes to persistent neurocognitive dysfunction beyond active viral replication, identifying convergent therapeutic nodes where combination strategies targeting excitotoxicity, mitochondrial dysfunction, and neuroinflammation offer the most promising path toward durable neuroprotection.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 495: From Envelope to Encephalopathy: How HIV-1 gp120 Drives Neurocognitive Decline</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/495">doi: 10.3390/v18050495</a></p>
	<p>Authors:
		Maryline Santerre
		Jenny Shrestha
		Charles N. S. Allen
		Natalia Shcherbik
		Bassel E. Sawaya
		</p>
	<p>Although neurons are not productively infected by HIV-1, the envelope glycoprotein gp120, detectable in cerebrospinal fluid independently of active viral replication, gains intraneuronal access via lipid raft-mediated endocytosis, macropinocytosis, and retrograde axonal transport, contributing to persistent neurobiological dysfunction within the central nervous system. Once internalized, gp120 is associated with neuronal dysfunction involving convergent pathways, including excitotoxic calcium dysregulation, mitochondrial and metabolic failure, and inflammatory and senescence-associated amplification. These pathways converge on suppression of CREB and BDNF signaling, dismantling the transcriptional and neurotrophic programs required for synaptic maintenance and cognitive resilience. Extracellular vesicle-mediated dissemination and microRNA reprogramming extend gp120-associated neurobiological effects beyond sites of receptor engagement, while gut-derived metabolites, particularly quinolinic acid, lower the excitotoxic threshold through synergistic activation of NMDA receptors. Together, these mechanisms define HAND as a network disorder in which gp120 contributes to persistent neurocognitive dysfunction beyond active viral replication, identifying convergent therapeutic nodes where combination strategies targeting excitotoxicity, mitochondrial dysfunction, and neuroinflammation offer the most promising path toward durable neuroprotection.</p>
	]]></content:encoded>

	<dc:title>From Envelope to Encephalopathy: How HIV-1 gp120 Drives Neurocognitive Decline</dc:title>
			<dc:creator>Maryline Santerre</dc:creator>
			<dc:creator>Jenny Shrestha</dc:creator>
			<dc:creator>Charles N. S. Allen</dc:creator>
			<dc:creator>Natalia Shcherbik</dc:creator>
			<dc:creator>Bassel E. Sawaya</dc:creator>
		<dc:identifier>doi: 10.3390/v18050495</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>495</prism:startingPage>
		<prism:doi>10.3390/v18050495</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/495</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/494">

	<title>Viruses, Vol. 18, Pages 494: Polymorphisms for Defence and Virulence in the Arabidopsis thaliana&amp;ndash;Cucumber mosaic virus Interaction Are Expressed in the Host&amp;rsquo;s Native Habitat</title>
	<link>https://www.mdpi.com/1999-4915/18/5/494</link>
	<description>Plant defences are assumed to evolve in response to the negative effects of virus infection on plant fitness (virulence), and to drive plant&amp;amp;ndash;virus coevolution. However, viruses are not always antagonistic symbionts of plants, and the expression of defence traits is environment-dependent. Thus, understanding plant&amp;amp;ndash;virus interactions requires analysing the expression of defence traits in the host&amp;amp;rsquo;s native habitat. Here we analyse the effect of cucumber mosaic virus (CMV) infection, and the expression of resistance and tolerance in the native habitat of a wild Arabidopsis thaliana population. Plants from ten genotypes from that population, which have been shown to differ in resistance and tolerance to CMV in a greenhouse, were inoculated with an Arabidopsis isolate of CMV and transplanted to their habitat. Resistance was rated based on virus accumulation in leaves, and tolerance was rated based on the effect of infection on plant fecundity relative to virus accumulation. Consistent with the greenhouse assays, virulence depended on the host genotype, and polymorphisms for resistance and tolerance were expressed in the field, supporting the validity of the conclusions from the greenhouse assays. Our results also support theoretical predictions on the relationships between pathogen multiplication and virulence and between resistance and tolerance.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 494: Polymorphisms for Defence and Virulence in the Arabidopsis thaliana&amp;ndash;Cucumber mosaic virus Interaction Are Expressed in the Host&amp;rsquo;s Native Habitat</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/494">doi: 10.3390/v18050494</a></p>
	<p>Authors:
		Israel Pagán
		Rafael de Andrés-Torán
		Nuria Montes
		Aurora Fraile
		Fernando García-Arenal
		</p>
	<p>Plant defences are assumed to evolve in response to the negative effects of virus infection on plant fitness (virulence), and to drive plant&amp;amp;ndash;virus coevolution. However, viruses are not always antagonistic symbionts of plants, and the expression of defence traits is environment-dependent. Thus, understanding plant&amp;amp;ndash;virus interactions requires analysing the expression of defence traits in the host&amp;amp;rsquo;s native habitat. Here we analyse the effect of cucumber mosaic virus (CMV) infection, and the expression of resistance and tolerance in the native habitat of a wild Arabidopsis thaliana population. Plants from ten genotypes from that population, which have been shown to differ in resistance and tolerance to CMV in a greenhouse, were inoculated with an Arabidopsis isolate of CMV and transplanted to their habitat. Resistance was rated based on virus accumulation in leaves, and tolerance was rated based on the effect of infection on plant fecundity relative to virus accumulation. Consistent with the greenhouse assays, virulence depended on the host genotype, and polymorphisms for resistance and tolerance were expressed in the field, supporting the validity of the conclusions from the greenhouse assays. Our results also support theoretical predictions on the relationships between pathogen multiplication and virulence and between resistance and tolerance.</p>
	]]></content:encoded>

	<dc:title>Polymorphisms for Defence and Virulence in the Arabidopsis thaliana&amp;amp;ndash;Cucumber mosaic virus Interaction Are Expressed in the Host&amp;amp;rsquo;s Native Habitat</dc:title>
			<dc:creator>Israel Pagán</dc:creator>
			<dc:creator>Rafael de Andrés-Torán</dc:creator>
			<dc:creator>Nuria Montes</dc:creator>
			<dc:creator>Aurora Fraile</dc:creator>
			<dc:creator>Fernando García-Arenal</dc:creator>
		<dc:identifier>doi: 10.3390/v18050494</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>494</prism:startingPage>
		<prism:doi>10.3390/v18050494</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/494</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/493">

	<title>Viruses, Vol. 18, Pages 493: Flavivirus-Induced ER Stress and Unfolded Protein Response: A Central Hub Linking Lipid Droplet Remodeling and Viral Replication</title>
	<link>https://www.mdpi.com/1999-4915/18/5/493</link>
	<description>Endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) represent fundamental cellular adaptive mechanisms that maintain protein homeostasis and metabolic balance. Many RNA viruses, particularly flaviviruses such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), yellow fever virus (YFV), and Japanese encephalitis virus (JEV), extensively remodel the ER to establish replication compartments and assemble progeny virions. This massive reorganization disrupts ER homeostasis, leading to UPR activation. Emerging evidence reveals that flaviviruses not only trigger but also manipulate the three UPR branches&amp;amp;mdash;PERK, IRE1, and ATF6&amp;amp;mdash;to optimize viral translation, replication, and egress. In parallel, flavivirus infection profoundly alters host lipid metabolism and promotes dynamic changes in lipid droplets (LDs), key organelles that mediate lipid storage and serve as scaffolds for viral replication and assembly. The UPR intimately connects to LD biogenesis through transcriptional and translational programs mediated by XBP1, ATF4, and ATF6, thereby coupling ER stress responses to lipid remodeling and energy homeostasis. This intricate crosstalk between UPR and LDs creates a metabolic and structural niche favorable for viral replication but detrimental to host cell integrity. This review provides a comprehensive analysis of the molecular mechanisms by which flaviviruses exploit ER stress and the UPR to reprogram lipid metabolism and LD dynamics. We highlight the dual role of UPR signaling in promoting adaptive lipid synthesis and initiating cell death under prolonged stress, discuss recent insights into ER&amp;amp;ndash;LD interactions during flavivirus infection, and explore therapeutic opportunities targeting UPR&amp;amp;ndash;lipid metabolic pathways as broad-spectrum antiviral strategies. Understanding this interconnected network will advance our knowledge of viral pathogenesis and identify new avenues for host-directed antiviral intervention.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 493: Flavivirus-Induced ER Stress and Unfolded Protein Response: A Central Hub Linking Lipid Droplet Remodeling and Viral Replication</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/493">doi: 10.3390/v18050493</a></p>
	<p>Authors:
		Imaan Muhammad
		Kaci Craft
		Shaokai Pei
		Ruth Cruz-Cosme
		Qiyi Tang
		</p>
	<p>Endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) represent fundamental cellular adaptive mechanisms that maintain protein homeostasis and metabolic balance. Many RNA viruses, particularly flaviviruses such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), yellow fever virus (YFV), and Japanese encephalitis virus (JEV), extensively remodel the ER to establish replication compartments and assemble progeny virions. This massive reorganization disrupts ER homeostasis, leading to UPR activation. Emerging evidence reveals that flaviviruses not only trigger but also manipulate the three UPR branches&amp;amp;mdash;PERK, IRE1, and ATF6&amp;amp;mdash;to optimize viral translation, replication, and egress. In parallel, flavivirus infection profoundly alters host lipid metabolism and promotes dynamic changes in lipid droplets (LDs), key organelles that mediate lipid storage and serve as scaffolds for viral replication and assembly. The UPR intimately connects to LD biogenesis through transcriptional and translational programs mediated by XBP1, ATF4, and ATF6, thereby coupling ER stress responses to lipid remodeling and energy homeostasis. This intricate crosstalk between UPR and LDs creates a metabolic and structural niche favorable for viral replication but detrimental to host cell integrity. This review provides a comprehensive analysis of the molecular mechanisms by which flaviviruses exploit ER stress and the UPR to reprogram lipid metabolism and LD dynamics. We highlight the dual role of UPR signaling in promoting adaptive lipid synthesis and initiating cell death under prolonged stress, discuss recent insights into ER&amp;amp;ndash;LD interactions during flavivirus infection, and explore therapeutic opportunities targeting UPR&amp;amp;ndash;lipid metabolic pathways as broad-spectrum antiviral strategies. Understanding this interconnected network will advance our knowledge of viral pathogenesis and identify new avenues for host-directed antiviral intervention.</p>
	]]></content:encoded>

	<dc:title>Flavivirus-Induced ER Stress and Unfolded Protein Response: A Central Hub Linking Lipid Droplet Remodeling and Viral Replication</dc:title>
			<dc:creator>Imaan Muhammad</dc:creator>
			<dc:creator>Kaci Craft</dc:creator>
			<dc:creator>Shaokai Pei</dc:creator>
			<dc:creator>Ruth Cruz-Cosme</dc:creator>
			<dc:creator>Qiyi Tang</dc:creator>
		<dc:identifier>doi: 10.3390/v18050493</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>493</prism:startingPage>
		<prism:doi>10.3390/v18050493</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/493</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/492">

	<title>Viruses, Vol. 18, Pages 492: Functional Analysis of the Halastavi &amp;aacute;rva Virus (HalV) Internal Ribosome Entry Site</title>
	<link>https://www.mdpi.com/1999-4915/18/5/492</link>
	<description>Viral internal ribosome entry sites (IRESs) are specialized RNA structures that facilitate cap-independent translation as a strategy to usurp the host translational machinery. The Type 6 IRESs are the most streamlined mechanism to date, as they adopt a three pseudoknot RNA structure to initiate factorless translation initiation by directly recruiting the ribosome and drive translation. The Halastavi &amp;amp;aacute;rva virus (HalV) IRES represents the most minimalistic subclass identified to date, whereby the IRES lacks specific pseudoknot domains that bind to the 40S subunit but instead recruits pre-assembled 80S ribosomes via a mechanism that is not fully understood. Here, we examined cellular conditions that can support HalV IRES translation. We demonstrated that the HalV IRES is translationally active in insect Sf21 lysates and Drosophila S2 cells, but inactive in mammalian RRL and wheat germ extract. Cells treated with heat shock or serum starvation suppressed HalV IRES activity, whereas virus infection robustly enhanced HalV IRES-mediated translation. Finally, the HalV IRES can support viral translation and replication using a heterologous viral replicon. These findings highlight the context-specific cellular conditions that allow ribosome assembly and translation by a factorless minimalist IRES.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 492: Functional Analysis of the Halastavi &amp;aacute;rva Virus (HalV) Internal Ribosome Entry Site</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/492">doi: 10.3390/v18050492</a></p>
	<p>Authors:
		Subash Chapagain
		Lauren F. Woodburn
		Natalie C. J. Strynadka
		Eric Jan
		</p>
	<p>Viral internal ribosome entry sites (IRESs) are specialized RNA structures that facilitate cap-independent translation as a strategy to usurp the host translational machinery. The Type 6 IRESs are the most streamlined mechanism to date, as they adopt a three pseudoknot RNA structure to initiate factorless translation initiation by directly recruiting the ribosome and drive translation. The Halastavi &amp;amp;aacute;rva virus (HalV) IRES represents the most minimalistic subclass identified to date, whereby the IRES lacks specific pseudoknot domains that bind to the 40S subunit but instead recruits pre-assembled 80S ribosomes via a mechanism that is not fully understood. Here, we examined cellular conditions that can support HalV IRES translation. We demonstrated that the HalV IRES is translationally active in insect Sf21 lysates and Drosophila S2 cells, but inactive in mammalian RRL and wheat germ extract. Cells treated with heat shock or serum starvation suppressed HalV IRES activity, whereas virus infection robustly enhanced HalV IRES-mediated translation. Finally, the HalV IRES can support viral translation and replication using a heterologous viral replicon. These findings highlight the context-specific cellular conditions that allow ribosome assembly and translation by a factorless minimalist IRES.</p>
	]]></content:encoded>

	<dc:title>Functional Analysis of the Halastavi &amp;amp;aacute;rva Virus (HalV) Internal Ribosome Entry Site</dc:title>
			<dc:creator>Subash Chapagain</dc:creator>
			<dc:creator>Lauren F. Woodburn</dc:creator>
			<dc:creator>Natalie C. J. Strynadka</dc:creator>
			<dc:creator>Eric Jan</dc:creator>
		<dc:identifier>doi: 10.3390/v18050492</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>492</prism:startingPage>
		<prism:doi>10.3390/v18050492</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/492</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/491">

	<title>Viruses, Vol. 18, Pages 491: A Household Cluster of Tick-Borne Encephalitis in Belgium in 2025: Is the Epidemiology Evolving?</title>
	<link>https://www.mdpi.com/1999-4915/18/5/491</link>
	<description>Despite serological evidence of tick-borne encephalitis virus (TBEV) circulation in Belgian animals since 2007, confirmed autochthonous human infection was only first documented in 2020. We review the current national epidemiologic situation and investigate a household cluster of confirmed autochthonous cases identified in 2025. A cohabiting couple experienced a near-simultaneous onset of meningoencephalitis and tested positive for TBEV-specific IgM and IgG, with confirmation by PRNT90. One patient reported a recent tick bite, and both patients reported consumption of unpasteurized milk and goat cheese, suggesting possible alimentary transmission. The identification of Case 2, who lacked neurological symptoms at presentation and was only tested due to the index case, illustrates the risk of missed diagnoses and supports the notion that human TBEV infection is likely underdiagnosed in Belgium. These findings underscore the need to increase clinical awareness, strengthen surveillance, and reinforce prevention strategies. TBE should be considered in the differential diagnosis of patients presenting with non-specific fever or neurological syndromes such as meningoencephalitis, particularly during the spring-to-autumn tick activity season.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 491: A Household Cluster of Tick-Borne Encephalitis in Belgium in 2025: Is the Epidemiology Evolving?</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/491">doi: 10.3390/v18050491</a></p>
	<p>Authors:
		Hélène Boogaerts
		Janne Tollenaere
		Kim Bekelaar
		Els Oris
		Sarah Resseler
		Baptist Declerck
		Dorien Van den Bossche
		Marjan Van Esbroeck
		Deborah Steensels
		</p>
	<p>Despite serological evidence of tick-borne encephalitis virus (TBEV) circulation in Belgian animals since 2007, confirmed autochthonous human infection was only first documented in 2020. We review the current national epidemiologic situation and investigate a household cluster of confirmed autochthonous cases identified in 2025. A cohabiting couple experienced a near-simultaneous onset of meningoencephalitis and tested positive for TBEV-specific IgM and IgG, with confirmation by PRNT90. One patient reported a recent tick bite, and both patients reported consumption of unpasteurized milk and goat cheese, suggesting possible alimentary transmission. The identification of Case 2, who lacked neurological symptoms at presentation and was only tested due to the index case, illustrates the risk of missed diagnoses and supports the notion that human TBEV infection is likely underdiagnosed in Belgium. These findings underscore the need to increase clinical awareness, strengthen surveillance, and reinforce prevention strategies. TBE should be considered in the differential diagnosis of patients presenting with non-specific fever or neurological syndromes such as meningoencephalitis, particularly during the spring-to-autumn tick activity season.</p>
	]]></content:encoded>

	<dc:title>A Household Cluster of Tick-Borne Encephalitis in Belgium in 2025: Is the Epidemiology Evolving?</dc:title>
			<dc:creator>Hélène Boogaerts</dc:creator>
			<dc:creator>Janne Tollenaere</dc:creator>
			<dc:creator>Kim Bekelaar</dc:creator>
			<dc:creator>Els Oris</dc:creator>
			<dc:creator>Sarah Resseler</dc:creator>
			<dc:creator>Baptist Declerck</dc:creator>
			<dc:creator>Dorien Van den Bossche</dc:creator>
			<dc:creator>Marjan Van Esbroeck</dc:creator>
			<dc:creator>Deborah Steensels</dc:creator>
		<dc:identifier>doi: 10.3390/v18050491</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>491</prism:startingPage>
		<prism:doi>10.3390/v18050491</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/491</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/490">

	<title>Viruses, Vol. 18, Pages 490: Building a Statewide One Health Network: Report from the Inaugural Pennsylvania One Health Consortium Annual Meeting, 2025</title>
	<link>https://www.mdpi.com/1999-4915/18/5/490</link>
	<description>The inaugural Pennsylvania One Health Consortium Annual Meeting brought together partners from universities, state agencies, public health, veterinary, agriculture, industry, and community organizations to align around a shared One Health agenda. The program highlighted zoonotic threats, antimicrobial stewardship, wildlife and ecosystem health, invasive species, and climate-sensitive hazards. Participants affirmed privacy-preserving data exchange, projects integrating genomic epidemiology with field and environmental surveillance, cross-disciplinary education, and transparent governance, concluding with a phased roadmap for an integrated statewide One Health framework.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 490: Building a Statewide One Health Network: Report from the Inaugural Pennsylvania One Health Consortium Annual Meeting, 2025</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/490">doi: 10.3390/v18050490</a></p>
	<p>Authors:
		Suresh V. Kuchipudi
		Shubhada K. Chothe
		Santhamani Ramasamy
		James S. Holt
		Iulia Vann
		Reginald A. Hoyt
		Andrew M. Hoffman
		Melissa Bilec
		Ananias A. Escalante
		Jennifer R. Fetter
		Sarah States
		Maureen Lichtveld
		</p>
	<p>The inaugural Pennsylvania One Health Consortium Annual Meeting brought together partners from universities, state agencies, public health, veterinary, agriculture, industry, and community organizations to align around a shared One Health agenda. The program highlighted zoonotic threats, antimicrobial stewardship, wildlife and ecosystem health, invasive species, and climate-sensitive hazards. Participants affirmed privacy-preserving data exchange, projects integrating genomic epidemiology with field and environmental surveillance, cross-disciplinary education, and transparent governance, concluding with a phased roadmap for an integrated statewide One Health framework.</p>
	]]></content:encoded>

	<dc:title>Building a Statewide One Health Network: Report from the Inaugural Pennsylvania One Health Consortium Annual Meeting, 2025</dc:title>
			<dc:creator>Suresh V. Kuchipudi</dc:creator>
			<dc:creator>Shubhada K. Chothe</dc:creator>
			<dc:creator>Santhamani Ramasamy</dc:creator>
			<dc:creator>James S. Holt</dc:creator>
			<dc:creator>Iulia Vann</dc:creator>
			<dc:creator>Reginald A. Hoyt</dc:creator>
			<dc:creator>Andrew M. Hoffman</dc:creator>
			<dc:creator>Melissa Bilec</dc:creator>
			<dc:creator>Ananias A. Escalante</dc:creator>
			<dc:creator>Jennifer R. Fetter</dc:creator>
			<dc:creator>Sarah States</dc:creator>
			<dc:creator>Maureen Lichtveld</dc:creator>
		<dc:identifier>doi: 10.3390/v18050490</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Conference Report</prism:section>
	<prism:startingPage>490</prism:startingPage>
		<prism:doi>10.3390/v18050490</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/490</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/489">

	<title>Viruses, Vol. 18, Pages 489: Mapping Molecular Determinants of Antigenicity and Pathogenicity of Infectious Bursal Disease Virus (IBDV): A Scoping Review</title>
	<link>https://www.mdpi.com/1999-4915/18/5/489</link>
	<description>Infectious bursal disease virus (IBDV) is an immunosuppressive pathogen posing a major threat to poultry health worldwide. Its marked phenotypic variability is driven by the rapid evolution of its double-stranded RNA genome, primarily achieved through mutation and reassortment. Although extensive evidence has been generated on molecular determinants of antigenicity and pathogenicity, interpretation is often hindered by heterogeneity and lack of systematicity. This scoping review synthesizes over 35 years of research on amino acid positions influencing IBDV phenotype. A total of 62 studies reporting 107 functionally relevant sites were identified and critically appraised based on evidence type, methodological approach, and ability to infer causality. The results confirmed the central role of VP2, particularly its hypervariable region, while also highlighting the increasingly recognized contribution of other viral proteins. Despite good agreement, comparability across studies was limited by substantial heterogeneity in experimental design and the frequent focus on partial genomic regions. Notably, some molecular markers were context-dependent or inconsistently associated with phenotypic outcomes, underscoring the need for proper interpretation of molecular determinants and for more standardized and comprehensive approaches, including full-genome analyses and reverse genetics. Overall, these findings provide a valuable framework for enhancing molecular diagnostics and supporting the rational design of next-generation vaccines.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 489: Mapping Molecular Determinants of Antigenicity and Pathogenicity of Infectious Bursal Disease Virus (IBDV): A Scoping Review</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/489">doi: 10.3390/v18050489</a></p>
	<p>Authors:
		Francesca Romana Tonellato
		Francesca Poletto
		Cristina Andolfatto
		Claudia Maria Tucciarone
		Giovanni Franzo
		Mattia Cecchinato
		Matteo Legnardi
		</p>
	<p>Infectious bursal disease virus (IBDV) is an immunosuppressive pathogen posing a major threat to poultry health worldwide. Its marked phenotypic variability is driven by the rapid evolution of its double-stranded RNA genome, primarily achieved through mutation and reassortment. Although extensive evidence has been generated on molecular determinants of antigenicity and pathogenicity, interpretation is often hindered by heterogeneity and lack of systematicity. This scoping review synthesizes over 35 years of research on amino acid positions influencing IBDV phenotype. A total of 62 studies reporting 107 functionally relevant sites were identified and critically appraised based on evidence type, methodological approach, and ability to infer causality. The results confirmed the central role of VP2, particularly its hypervariable region, while also highlighting the increasingly recognized contribution of other viral proteins. Despite good agreement, comparability across studies was limited by substantial heterogeneity in experimental design and the frequent focus on partial genomic regions. Notably, some molecular markers were context-dependent or inconsistently associated with phenotypic outcomes, underscoring the need for proper interpretation of molecular determinants and for more standardized and comprehensive approaches, including full-genome analyses and reverse genetics. Overall, these findings provide a valuable framework for enhancing molecular diagnostics and supporting the rational design of next-generation vaccines.</p>
	]]></content:encoded>

	<dc:title>Mapping Molecular Determinants of Antigenicity and Pathogenicity of Infectious Bursal Disease Virus (IBDV): A Scoping Review</dc:title>
			<dc:creator>Francesca Romana Tonellato</dc:creator>
			<dc:creator>Francesca Poletto</dc:creator>
			<dc:creator>Cristina Andolfatto</dc:creator>
			<dc:creator>Claudia Maria Tucciarone</dc:creator>
			<dc:creator>Giovanni Franzo</dc:creator>
			<dc:creator>Mattia Cecchinato</dc:creator>
			<dc:creator>Matteo Legnardi</dc:creator>
		<dc:identifier>doi: 10.3390/v18050489</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>489</prism:startingPage>
		<prism:doi>10.3390/v18050489</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/489</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/488">

	<title>Viruses, Vol. 18, Pages 488: An NS1-F161L Substitution Determines Host-Driven Virulence Enhancement of H5N6 Avian Influenza Virus in Ducks</title>
	<link>https://www.mdpi.com/1999-4915/18/5/488</link>
	<description>H5 subtype avian influenza virus (AIV) can infect both chickens and ducks, leading to substantial economic losses. Nevertheless, certain strains cause silent infections in ducks. In this study, a goose-origin clade 2.3.4.4h H5N6 AIV was isolated, which caused high mortality in mixed-gender white leghorn chickens but no deaths in mixed-gender mallard ducks. After independent serial in vitro passage in duck embryo fibroblasts (DEFs) and in vivo passage in specific-pathogen-free (SPF) ducks, the DEF-passage 10 (P10) virus induced markedly higher mortality rates and viral loads in SPF ducks compared to the DEF-P1 virus and the original parental virus prior to passage. Similarly, the in vivo-passaged P3 and P4 viruses exhibited significantly higher mortality rates than the P1 virus in SPF ducks, with 100% mortality and markedly increased viral titers in the organs. A whole-genome SNP analysis identified seven high-frequency mutations in the M1, NA and NS1 proteins. The NS1-F161L substitution virus exhibited significantly increased mortality rates, viral loads in multiple tissues, and a robustly induced innate immune response in ducks. Furthermore, dynamic evolutionary variations in the NS1 protein among global H5 avian influenza viruses revealed that the NS1-F161L substitution became dominant in clade 2.3.4.4b viruses in 2021 and subsequent years. Collectively, our findings demonstrate that host-driven adaptation can rapidly increase the pathogenicity of H5N6 AIVs in ducks and identify NS1-F161L as a critical virulence marker. These results offer novel insights relevant to the molecular surveillance, virulence prediction, and risk assessment of circulating H5 AIVs in waterfowl.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 488: An NS1-F161L Substitution Determines Host-Driven Virulence Enhancement of H5N6 Avian Influenza Virus in Ducks</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/488">doi: 10.3390/v18050488</a></p>
	<p>Authors:
		Yuwei Wu
		Zhifan Li
		Nuo Xu
		Zijun Lu
		Yurui Dong
		Kunlin Li
		Ying Bian
		Chenzhi Huo
		Tao Qin
		Sujuan Chen
		Hui Yang
		Daxin Peng
		Xiufan Liu
		</p>
	<p>H5 subtype avian influenza virus (AIV) can infect both chickens and ducks, leading to substantial economic losses. Nevertheless, certain strains cause silent infections in ducks. In this study, a goose-origin clade 2.3.4.4h H5N6 AIV was isolated, which caused high mortality in mixed-gender white leghorn chickens but no deaths in mixed-gender mallard ducks. After independent serial in vitro passage in duck embryo fibroblasts (DEFs) and in vivo passage in specific-pathogen-free (SPF) ducks, the DEF-passage 10 (P10) virus induced markedly higher mortality rates and viral loads in SPF ducks compared to the DEF-P1 virus and the original parental virus prior to passage. Similarly, the in vivo-passaged P3 and P4 viruses exhibited significantly higher mortality rates than the P1 virus in SPF ducks, with 100% mortality and markedly increased viral titers in the organs. A whole-genome SNP analysis identified seven high-frequency mutations in the M1, NA and NS1 proteins. The NS1-F161L substitution virus exhibited significantly increased mortality rates, viral loads in multiple tissues, and a robustly induced innate immune response in ducks. Furthermore, dynamic evolutionary variations in the NS1 protein among global H5 avian influenza viruses revealed that the NS1-F161L substitution became dominant in clade 2.3.4.4b viruses in 2021 and subsequent years. Collectively, our findings demonstrate that host-driven adaptation can rapidly increase the pathogenicity of H5N6 AIVs in ducks and identify NS1-F161L as a critical virulence marker. These results offer novel insights relevant to the molecular surveillance, virulence prediction, and risk assessment of circulating H5 AIVs in waterfowl.</p>
	]]></content:encoded>

	<dc:title>An NS1-F161L Substitution Determines Host-Driven Virulence Enhancement of H5N6 Avian Influenza Virus in Ducks</dc:title>
			<dc:creator>Yuwei Wu</dc:creator>
			<dc:creator>Zhifan Li</dc:creator>
			<dc:creator>Nuo Xu</dc:creator>
			<dc:creator>Zijun Lu</dc:creator>
			<dc:creator>Yurui Dong</dc:creator>
			<dc:creator>Kunlin Li</dc:creator>
			<dc:creator>Ying Bian</dc:creator>
			<dc:creator>Chenzhi Huo</dc:creator>
			<dc:creator>Tao Qin</dc:creator>
			<dc:creator>Sujuan Chen</dc:creator>
			<dc:creator>Hui Yang</dc:creator>
			<dc:creator>Daxin Peng</dc:creator>
			<dc:creator>Xiufan Liu</dc:creator>
		<dc:identifier>doi: 10.3390/v18050488</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>488</prism:startingPage>
		<prism:doi>10.3390/v18050488</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/488</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/487">

	<title>Viruses, Vol. 18, Pages 487: Heterologous Sequential mRNA Vaccination of Indian Rhesus Macaques Elicits Broad Binding and Neutralizing Antibody Responses Against Diverse Henipaviruses</title>
	<link>https://www.mdpi.com/1999-4915/18/5/487</link>
	<description>Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are highly pathogenic and often lethal zoonotic viruses with broad species tropism and no approved human vaccines. The emergence of genetically divergent HNVs&amp;amp;mdash;including Ghana virus (GhV), Langya virus (LayV), and Mojiang virus (MojV)&amp;amp;mdash;emphasizes the need for broadly protective countermeasures. Here, we evaluated the antibody (Ab) responses to sequential mRNA vaccines encoding the membrane-bound attachment glycoprotein (gG) from NiV, GhV, and/or LayV in a pilot study with Indian rhesus macaques. Serum binding Ab responses were quantified by ELISA against five soluble gG antigens (NiV, HeV, GhV, LayV, MojV). Functional activity was assessed by neutralization assays using NiV, HeV, and GhV pseudoviruses, and by receptor-blocking ELISA. Sequential vaccination induced high-titer IgG binding against all five HNV gGs with increasing breadth after each dose. Pan-genus regimens elicited moderate neutralizing Ab titers against NiV, HeV, and GhV, whereas the NiV-only regimen elicited potent but narrow neutralization against NiV and HeV. Conversely, the GhV-LayV-GhV regimen elicited strong binding to GhV, LayV, and MojV gG and robust neutralization of GhV pseudovirus, but limited cross-reactivity to NiV and HeV. In this pilot study, we demonstrated that mRNA vaccination can elicit broadly reactive binding and neutralizing Ab responses across phylogenetically distant HNVs. Additionally, we show GhV pseudovirus neutralization for the first time. Collectively, these data provide a foundation for the development of next-generation pan-genus HNV vaccines capable of mitigating future HNV outbreaks.</description>
	<pubDate>2026-04-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 487: Heterologous Sequential mRNA Vaccination of Indian Rhesus Macaques Elicits Broad Binding and Neutralizing Antibody Responses Against Diverse Henipaviruses</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/487">doi: 10.3390/v18050487</a></p>
	<p>Authors:
		Thomas B. Voigt
		Noor Ghosh
		Brandon C. Rosen
		Taylor Newbolt
		Johan J. Louw
		Aaron Yrizarry-Medina
		Christakis Panayiotou
		Jack T. Mauter
		Giovana de Figueiredo Godoy
		Joshua Terao
		Eva G. Rakasz
		Matthew R. Reynolds
		Dawn M. Dudley
		David I. Watkins
		Michael J. Ricciardi
		</p>
	<p>Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are highly pathogenic and often lethal zoonotic viruses with broad species tropism and no approved human vaccines. The emergence of genetically divergent HNVs&amp;amp;mdash;including Ghana virus (GhV), Langya virus (LayV), and Mojiang virus (MojV)&amp;amp;mdash;emphasizes the need for broadly protective countermeasures. Here, we evaluated the antibody (Ab) responses to sequential mRNA vaccines encoding the membrane-bound attachment glycoprotein (gG) from NiV, GhV, and/or LayV in a pilot study with Indian rhesus macaques. Serum binding Ab responses were quantified by ELISA against five soluble gG antigens (NiV, HeV, GhV, LayV, MojV). Functional activity was assessed by neutralization assays using NiV, HeV, and GhV pseudoviruses, and by receptor-blocking ELISA. Sequential vaccination induced high-titer IgG binding against all five HNV gGs with increasing breadth after each dose. Pan-genus regimens elicited moderate neutralizing Ab titers against NiV, HeV, and GhV, whereas the NiV-only regimen elicited potent but narrow neutralization against NiV and HeV. Conversely, the GhV-LayV-GhV regimen elicited strong binding to GhV, LayV, and MojV gG and robust neutralization of GhV pseudovirus, but limited cross-reactivity to NiV and HeV. In this pilot study, we demonstrated that mRNA vaccination can elicit broadly reactive binding and neutralizing Ab responses across phylogenetically distant HNVs. Additionally, we show GhV pseudovirus neutralization for the first time. Collectively, these data provide a foundation for the development of next-generation pan-genus HNV vaccines capable of mitigating future HNV outbreaks.</p>
	]]></content:encoded>

	<dc:title>Heterologous Sequential mRNA Vaccination of Indian Rhesus Macaques Elicits Broad Binding and Neutralizing Antibody Responses Against Diverse Henipaviruses</dc:title>
			<dc:creator>Thomas B. Voigt</dc:creator>
			<dc:creator>Noor Ghosh</dc:creator>
			<dc:creator>Brandon C. Rosen</dc:creator>
			<dc:creator>Taylor Newbolt</dc:creator>
			<dc:creator>Johan J. Louw</dc:creator>
			<dc:creator>Aaron Yrizarry-Medina</dc:creator>
			<dc:creator>Christakis Panayiotou</dc:creator>
			<dc:creator>Jack T. Mauter</dc:creator>
			<dc:creator>Giovana de Figueiredo Godoy</dc:creator>
			<dc:creator>Joshua Terao</dc:creator>
			<dc:creator>Eva G. Rakasz</dc:creator>
			<dc:creator>Matthew R. Reynolds</dc:creator>
			<dc:creator>Dawn M. Dudley</dc:creator>
			<dc:creator>David I. Watkins</dc:creator>
			<dc:creator>Michael J. Ricciardi</dc:creator>
		<dc:identifier>doi: 10.3390/v18050487</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-23</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>487</prism:startingPage>
		<prism:doi>10.3390/v18050487</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/487</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/486">

	<title>Viruses, Vol. 18, Pages 486: Characteristics and Screening Strategies of Hepatitis B in Guangdong Province, China</title>
	<link>https://www.mdpi.com/1999-4915/18/5/486</link>
	<description>Determining the characteristics of hepatitis B virus (HBV) infection in the healthy population and evaluating the effectiveness of detection strategies will facilitate the optimization of hepatitis B screening strategies in the community and accelerate the elimination of HBV infection in China by the end of 2030. Hepatitis B surface antigen (HBsAg)-electrochemiluminescence immunoassays (ECLIAs), HBsAg-rapid diagnostic tests (RDTs), and HBV DNA-nucleic acid tests (NATs) were performed on serum samples from 2721 community-based healthy participants in Guangdong Province. The screening performance of the RDT and NAT and the distribution characteristics of HBsAg and HBV DNA were evaluated. The prevalence rates of HBsAg-ECLIA, HBsAg-RDT and HBV DNA-NAT in Guangdong Province were 6.10% (95% CI: 5.26~7.06), 4.96% (95% CI: 4.21~5.84) and 6.55% (95% CI: 5.64~7.49), respectively, and the prevalence rates for the three methods for individuals aged over 30 years were 11.18%, 10.92% and 12.57%, respectively. When the ECLIA was used as the gold standard, the sensitivities of the RDT, NAT and RDT and NAT in parallel were 80.7% (95% CI: 73.9~86.4), 86.7% (95% CI: 80.6~91.5) and 93.4% (95% CI: 88.5~96.6), respectively, and the sensitivity of the RDT and NAT in parallel was greater than that of the RDT alone (p &amp;amp;lt; 0.001). The parallel RDT and NAT revealed an additional cost&amp;amp;ndash;benefit ratio (ACBR) &amp;amp;lt; 1 for males and individuals aged over 30 years, which indicated that switching from the RDT screening strategy to the RDT and NAT in parallel is more cost effective. Adults aged over 30 years are the main population with hepatitis B infection in Guangdong Province, China, whose prevalence of HBsAg-ECLIA was 11.18%. Single RDT screening is prone to miss individuals with low levels of HBsAg. It is recommended to implement an RDT and NAT in parallel for individuals older than 30 years.</description>
	<pubDate>2026-04-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 486: Characteristics and Screening Strategies of Hepatitis B in Guangdong Province, China</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/486">doi: 10.3390/v18050486</a></p>
	<p>Authors:
		Weizhao Lin
		Xiaoping Shao
		Junjie Wang
		Hongqing Wen
		Jiahong Liu
		Can Xiong
		Zixia Qian
		Wei Zhao
		Jun Liu
		Jiufeng Sun
		</p>
	<p>Determining the characteristics of hepatitis B virus (HBV) infection in the healthy population and evaluating the effectiveness of detection strategies will facilitate the optimization of hepatitis B screening strategies in the community and accelerate the elimination of HBV infection in China by the end of 2030. Hepatitis B surface antigen (HBsAg)-electrochemiluminescence immunoassays (ECLIAs), HBsAg-rapid diagnostic tests (RDTs), and HBV DNA-nucleic acid tests (NATs) were performed on serum samples from 2721 community-based healthy participants in Guangdong Province. The screening performance of the RDT and NAT and the distribution characteristics of HBsAg and HBV DNA were evaluated. The prevalence rates of HBsAg-ECLIA, HBsAg-RDT and HBV DNA-NAT in Guangdong Province were 6.10% (95% CI: 5.26~7.06), 4.96% (95% CI: 4.21~5.84) and 6.55% (95% CI: 5.64~7.49), respectively, and the prevalence rates for the three methods for individuals aged over 30 years were 11.18%, 10.92% and 12.57%, respectively. When the ECLIA was used as the gold standard, the sensitivities of the RDT, NAT and RDT and NAT in parallel were 80.7% (95% CI: 73.9~86.4), 86.7% (95% CI: 80.6~91.5) and 93.4% (95% CI: 88.5~96.6), respectively, and the sensitivity of the RDT and NAT in parallel was greater than that of the RDT alone (p &amp;amp;lt; 0.001). The parallel RDT and NAT revealed an additional cost&amp;amp;ndash;benefit ratio (ACBR) &amp;amp;lt; 1 for males and individuals aged over 30 years, which indicated that switching from the RDT screening strategy to the RDT and NAT in parallel is more cost effective. Adults aged over 30 years are the main population with hepatitis B infection in Guangdong Province, China, whose prevalence of HBsAg-ECLIA was 11.18%. Single RDT screening is prone to miss individuals with low levels of HBsAg. It is recommended to implement an RDT and NAT in parallel for individuals older than 30 years.</p>
	]]></content:encoded>

	<dc:title>Characteristics and Screening Strategies of Hepatitis B in Guangdong Province, China</dc:title>
			<dc:creator>Weizhao Lin</dc:creator>
			<dc:creator>Xiaoping Shao</dc:creator>
			<dc:creator>Junjie Wang</dc:creator>
			<dc:creator>Hongqing Wen</dc:creator>
			<dc:creator>Jiahong Liu</dc:creator>
			<dc:creator>Can Xiong</dc:creator>
			<dc:creator>Zixia Qian</dc:creator>
			<dc:creator>Wei Zhao</dc:creator>
			<dc:creator>Jun Liu</dc:creator>
			<dc:creator>Jiufeng Sun</dc:creator>
		<dc:identifier>doi: 10.3390/v18050486</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-22</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-22</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>486</prism:startingPage>
		<prism:doi>10.3390/v18050486</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/486</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/485">

	<title>Viruses, Vol. 18, Pages 485: Epstein&amp;ndash;Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations</title>
	<link>https://www.mdpi.com/1999-4915/18/5/485</link>
	<description>Epstein&amp;amp;ndash;Barr virus (EBV)-positive primary central nervous system lymphoma (PCNSL) is a rare entity typically associated with profound immunosuppression, most commonly in transplant recipients or individuals with HIV. We report a case of EBV-positive PCNSL arising in a 75-year-old male with myasthenia gravis receiving chronic mycophenolate mofetil (MMF) therapy outside the transplant setting. The patient presented with progressive neurological deficits, and brain magnetic resonance imaging demonstrated multiple enhancing lesions. Stereotactic biopsy revealed diffuse large B-cell lymphoma of non&amp;amp;ndash;germinal center subtype with immunoblastic features and EBV-encoded RNA (EBER) positivity, confirming EBV-positive PCNSL. MMF was discontinued, and the patient was treated with rituximab and high-dose methotrexate, resulting in stable disease. This case highlights that prolonged MMF therapy may confer sufficient immunosuppression to permit EBV-driven lymphoproliferative disease even in non-transplant patients. Early recognition, withdrawal of immunosuppression, and initiation of methotrexate-based chemotherapy can lead to favorable outcomes.</description>
	<pubDate>2026-04-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 485: Epstein&amp;ndash;Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/485">doi: 10.3390/v18050485</a></p>
	<p>Authors:
		Danielle N. Burner
		Giselle Y. López
		Justin T. Low
		Micah A. Luftig
		</p>
	<p>Epstein&amp;amp;ndash;Barr virus (EBV)-positive primary central nervous system lymphoma (PCNSL) is a rare entity typically associated with profound immunosuppression, most commonly in transplant recipients or individuals with HIV. We report a case of EBV-positive PCNSL arising in a 75-year-old male with myasthenia gravis receiving chronic mycophenolate mofetil (MMF) therapy outside the transplant setting. The patient presented with progressive neurological deficits, and brain magnetic resonance imaging demonstrated multiple enhancing lesions. Stereotactic biopsy revealed diffuse large B-cell lymphoma of non&amp;amp;ndash;germinal center subtype with immunoblastic features and EBV-encoded RNA (EBER) positivity, confirming EBV-positive PCNSL. MMF was discontinued, and the patient was treated with rituximab and high-dose methotrexate, resulting in stable disease. This case highlights that prolonged MMF therapy may confer sufficient immunosuppression to permit EBV-driven lymphoproliferative disease even in non-transplant patients. Early recognition, withdrawal of immunosuppression, and initiation of methotrexate-based chemotherapy can lead to favorable outcomes.</p>
	]]></content:encoded>

	<dc:title>Epstein&amp;amp;ndash;Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations</dc:title>
			<dc:creator>Danielle N. Burner</dc:creator>
			<dc:creator>Giselle Y. López</dc:creator>
			<dc:creator>Justin T. Low</dc:creator>
			<dc:creator>Micah A. Luftig</dc:creator>
		<dc:identifier>doi: 10.3390/v18050485</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-22</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-22</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>485</prism:startingPage>
		<prism:doi>10.3390/v18050485</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/485</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/484">

	<title>Viruses, Vol. 18, Pages 484: Targeted and Effective Phage-Based Biocontrol of Black Rot Disease in Broccoli</title>
	<link>https://www.mdpi.com/1999-4915/18/5/484</link>
	<description>Xanthomonas species are Gram-negative bacterial pathogens responsible for diseases in over 400 plant hosts, including numerous economically important crops such as Brassica species. The limited efficacy and environmental concerns associated with chemical control strategies underscore the need for sustainable and targeted alternatives. In this study, we evaluated the suitability and biocontrol efficacy of phages Phi1 and Phi3 to combat Xanthomonas campestris pv. campestris (Xcc) in broccoli plants. Kill-curve assays demonstrated that both phages effectively suppressed Xcc growth across a range of multiplicities of infection. Transmission electron microscopy further confirmed their lytic activity, revealing pronounced structural damage to Xcc cells following phage treatment, accompanied by the subsequent release of phage progeny. To assess host specificity and biosafety, the phages were tested against 41 bacterial isolates that were isolated and taxonomically characterized from broccoli and cauliflower in this study. Neither Phi1 nor Phi3 exhibited lytic activity against any non-target isolate, indicating high host specificity and minimal risk to the native Brassica-associated microbiota. In planta assays demonstrated that the combined application of Phi1 and Phi3 reduced Xcc-induced symptom severity in broccoli plants by 80%. Collectively, these results demonstrate that phages Phi1 and Phi3 represent effective and biologically precise agents for the control of black rot disease in Brassica crops.</description>
	<pubDate>2026-04-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 484: Targeted and Effective Phage-Based Biocontrol of Black Rot Disease in Broccoli</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/484">doi: 10.3390/v18050484</a></p>
	<p>Authors:
		Miloud Sabri
		Khaoula Mektoubi
		Orges Cara
		Roukia Bougheloum
		Angelo De Stradis
		Giuseppe Parrella
		Toufic Elbeaino
		</p>
	<p>Xanthomonas species are Gram-negative bacterial pathogens responsible for diseases in over 400 plant hosts, including numerous economically important crops such as Brassica species. The limited efficacy and environmental concerns associated with chemical control strategies underscore the need for sustainable and targeted alternatives. In this study, we evaluated the suitability and biocontrol efficacy of phages Phi1 and Phi3 to combat Xanthomonas campestris pv. campestris (Xcc) in broccoli plants. Kill-curve assays demonstrated that both phages effectively suppressed Xcc growth across a range of multiplicities of infection. Transmission electron microscopy further confirmed their lytic activity, revealing pronounced structural damage to Xcc cells following phage treatment, accompanied by the subsequent release of phage progeny. To assess host specificity and biosafety, the phages were tested against 41 bacterial isolates that were isolated and taxonomically characterized from broccoli and cauliflower in this study. Neither Phi1 nor Phi3 exhibited lytic activity against any non-target isolate, indicating high host specificity and minimal risk to the native Brassica-associated microbiota. In planta assays demonstrated that the combined application of Phi1 and Phi3 reduced Xcc-induced symptom severity in broccoli plants by 80%. Collectively, these results demonstrate that phages Phi1 and Phi3 represent effective and biologically precise agents for the control of black rot disease in Brassica crops.</p>
	]]></content:encoded>

	<dc:title>Targeted and Effective Phage-Based Biocontrol of Black Rot Disease in Broccoli</dc:title>
			<dc:creator>Miloud Sabri</dc:creator>
			<dc:creator>Khaoula Mektoubi</dc:creator>
			<dc:creator>Orges Cara</dc:creator>
			<dc:creator>Roukia Bougheloum</dc:creator>
			<dc:creator>Angelo De Stradis</dc:creator>
			<dc:creator>Giuseppe Parrella</dc:creator>
			<dc:creator>Toufic Elbeaino</dc:creator>
		<dc:identifier>doi: 10.3390/v18050484</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-22</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-22</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>484</prism:startingPage>
		<prism:doi>10.3390/v18050484</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/484</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/5/483">

	<title>Viruses, Vol. 18, Pages 483: Screening Ticks for Crimean&amp;ndash;Congo Hemorrhagic Fever Virus and Aigai Virus in Greece</title>
	<link>https://www.mdpi.com/1999-4915/18/5/483</link>
	<description>Ixodid ticks are vectors for a plethora of pathogens, including the Crimean&amp;amp;ndash;Congo hemorrhagic fever virus (CCHFV), which causes severe disease in humans. Two autochthonous CCHF human cases were reported in 2025 in Greece. The aim of the present study was to gain a better insight into the geographic distribution and prevalence of CCHFV and the related Aigai virus (AIGV) in ticks in Greece. Therefore, 680 ticks (135 Hyalomma and 545 Rhipicephalus ticks) collected during 2024 from livestock (sheep, goats, cattle) and from the environment were tested for CCHFV and AIGV. AIGV was detected in 12 adult Rhipicephalus bursa ticks (12/511, 2.3%), while all Hyalomma ticks and R. bursa nymphs were negative for both viruses. AIGV-positive ticks were collected in May and June from goats and sheep in two distantly located regional units of Greece. AIGV sequences from partial S RNA segment differ from the prototype AIGV strain (AP-92) by 10.3% and 1.4% at the nucleotide and amino acid level, respectively. Integrated surveillance studies are needed in ticks, humans, wild and domestic animals within a One Health framework to gain a better insight into the epidemiology of CCHF in Greece, while clinical research is needed to elucidate the impact of AIGV in public health.</description>
	<pubDate>2026-04-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 483: Screening Ticks for Crimean&amp;ndash;Congo Hemorrhagic Fever Virus and Aigai Virus in Greece</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/5/483">doi: 10.3390/v18050483</a></p>
	<p>Authors:
		Katerina Tsioka
		Smaragda Sotiraki
		Danai Pervanidou
		Styliani Pappa
		Konstantina Stoikou
		Annita Vakali
		Chrisovaladou-Niki Kefaloudi
		Christina Sapanidou
		Panagiota Ligda
		Angeliki Liakata
		Anastasios Saratsis
		Dimitrios Chatzidimitriou
		Anna Papa
		</p>
	<p>Ixodid ticks are vectors for a plethora of pathogens, including the Crimean&amp;amp;ndash;Congo hemorrhagic fever virus (CCHFV), which causes severe disease in humans. Two autochthonous CCHF human cases were reported in 2025 in Greece. The aim of the present study was to gain a better insight into the geographic distribution and prevalence of CCHFV and the related Aigai virus (AIGV) in ticks in Greece. Therefore, 680 ticks (135 Hyalomma and 545 Rhipicephalus ticks) collected during 2024 from livestock (sheep, goats, cattle) and from the environment were tested for CCHFV and AIGV. AIGV was detected in 12 adult Rhipicephalus bursa ticks (12/511, 2.3%), while all Hyalomma ticks and R. bursa nymphs were negative for both viruses. AIGV-positive ticks were collected in May and June from goats and sheep in two distantly located regional units of Greece. AIGV sequences from partial S RNA segment differ from the prototype AIGV strain (AP-92) by 10.3% and 1.4% at the nucleotide and amino acid level, respectively. Integrated surveillance studies are needed in ticks, humans, wild and domestic animals within a One Health framework to gain a better insight into the epidemiology of CCHF in Greece, while clinical research is needed to elucidate the impact of AIGV in public health.</p>
	]]></content:encoded>

	<dc:title>Screening Ticks for Crimean&amp;amp;ndash;Congo Hemorrhagic Fever Virus and Aigai Virus in Greece</dc:title>
			<dc:creator>Katerina Tsioka</dc:creator>
			<dc:creator>Smaragda Sotiraki</dc:creator>
			<dc:creator>Danai Pervanidou</dc:creator>
			<dc:creator>Styliani Pappa</dc:creator>
			<dc:creator>Konstantina Stoikou</dc:creator>
			<dc:creator>Annita Vakali</dc:creator>
			<dc:creator>Chrisovaladou-Niki Kefaloudi</dc:creator>
			<dc:creator>Christina Sapanidou</dc:creator>
			<dc:creator>Panagiota Ligda</dc:creator>
			<dc:creator>Angeliki Liakata</dc:creator>
			<dc:creator>Anastasios Saratsis</dc:creator>
			<dc:creator>Dimitrios Chatzidimitriou</dc:creator>
			<dc:creator>Anna Papa</dc:creator>
		<dc:identifier>doi: 10.3390/v18050483</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-22</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-22</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>483</prism:startingPage>
		<prism:doi>10.3390/v18050483</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/5/483</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/482">

	<title>Viruses, Vol. 18, Pages 482: Next-Generation Sequencing Strategies During the 2024&amp;ndash;2025 Avian Influenza A(H5N1) Emergency Response in the U.S</title>
	<link>https://www.mdpi.com/1999-4915/18/4/482</link>
	<description>The first influenza A(H5N1) human case associated with the A(H5N1) dairy cattle outbreak in the United States was identified in April 2024. The U.S. CDC response to this outbreak was activated days later and remained active until July 2025. During this time, 70 human cases of influenza A(H5N1) were detected with a range of epidemiological links to sources of exposure. Next-generation sequencing (NGS) of human samples was an effectual mechanism for tracking and analyzing the outbreak evolution throughout the response. Due to the specimens&amp;amp;rsquo; importance and their variable physical quality, an assortment of laboratory methods was utilized including influenza segment-specific amplification, enrichment capture, short-read, and long-read sequencing. Combining these methods allowed for high-quality genomic data production with rapid turnaround times&amp;amp;mdash;typically 2 days from sample receipt to public database submission. By leveraging replicate sequencing, enrichment capture, and sequencing of diagnostic amplicons, valuable genomic data could be produced directly from human clinical specimens that would have normally been considered too weak for routine virologic surveillance sequencing. The resulting assemblies were characterized and analyzed by CDC and shared with local and state public health authorities to facilitate case investigations and risk assessment. These data were further used for phylogenetic analyses of viruses from human cases to investigate likely animal-to-human transmission events and identify clusters within the outbreak that might indicate trends in the types of exposures. Through the adaptable laboratory workflow and the rapid release of viral genomic data, the public health risk mitigation strategies could be evaluated and adjusted in real time.</description>
	<pubDate>2026-04-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 482: Next-Generation Sequencing Strategies During the 2024&amp;ndash;2025 Avian Influenza A(H5N1) Emergency Response in the U.S</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/482">doi: 10.3390/v18040482</a></p>
	<p>Authors:
		Julia C. Frederick
		Kristine A. Lacek
		Matthew J. Wersebe
		Bo Shu
		Lisa M. Keong
		Juliana DaSilva
		Malania M. Wilson
		Sydney R. Sheffield
		Jimma Liddell
		Natasha Burnett
		Reina Chau
		Amanda H. Sullivan
		Yunho Jang
		Juan A. De La Cruz
		Elizabeth A. Pusch
		Dan Cui
		Yasuko Hatta
		Sabrina Schatzman
		Norman Hassell
		Xiao-Yu Zheng
		Ha T. Nguyen
		Larisa Gubareva
		Rebecca Kondor
		Han Di
		Vivien G. Dugan
		Charles T. Davis
		Benjamin L. Rambo-Martin
		Marie K. Kirby
		</p>
	<p>The first influenza A(H5N1) human case associated with the A(H5N1) dairy cattle outbreak in the United States was identified in April 2024. The U.S. CDC response to this outbreak was activated days later and remained active until July 2025. During this time, 70 human cases of influenza A(H5N1) were detected with a range of epidemiological links to sources of exposure. Next-generation sequencing (NGS) of human samples was an effectual mechanism for tracking and analyzing the outbreak evolution throughout the response. Due to the specimens&amp;amp;rsquo; importance and their variable physical quality, an assortment of laboratory methods was utilized including influenza segment-specific amplification, enrichment capture, short-read, and long-read sequencing. Combining these methods allowed for high-quality genomic data production with rapid turnaround times&amp;amp;mdash;typically 2 days from sample receipt to public database submission. By leveraging replicate sequencing, enrichment capture, and sequencing of diagnostic amplicons, valuable genomic data could be produced directly from human clinical specimens that would have normally been considered too weak for routine virologic surveillance sequencing. The resulting assemblies were characterized and analyzed by CDC and shared with local and state public health authorities to facilitate case investigations and risk assessment. These data were further used for phylogenetic analyses of viruses from human cases to investigate likely animal-to-human transmission events and identify clusters within the outbreak that might indicate trends in the types of exposures. Through the adaptable laboratory workflow and the rapid release of viral genomic data, the public health risk mitigation strategies could be evaluated and adjusted in real time.</p>
	]]></content:encoded>

	<dc:title>Next-Generation Sequencing Strategies During the 2024&amp;amp;ndash;2025 Avian Influenza A(H5N1) Emergency Response in the U.S</dc:title>
			<dc:creator>Julia C. Frederick</dc:creator>
			<dc:creator>Kristine A. Lacek</dc:creator>
			<dc:creator>Matthew J. Wersebe</dc:creator>
			<dc:creator>Bo Shu</dc:creator>
			<dc:creator>Lisa M. Keong</dc:creator>
			<dc:creator>Juliana DaSilva</dc:creator>
			<dc:creator>Malania M. Wilson</dc:creator>
			<dc:creator>Sydney R. Sheffield</dc:creator>
			<dc:creator>Jimma Liddell</dc:creator>
			<dc:creator>Natasha Burnett</dc:creator>
			<dc:creator>Reina Chau</dc:creator>
			<dc:creator>Amanda H. Sullivan</dc:creator>
			<dc:creator>Yunho Jang</dc:creator>
			<dc:creator>Juan A. De La Cruz</dc:creator>
			<dc:creator>Elizabeth A. Pusch</dc:creator>
			<dc:creator>Dan Cui</dc:creator>
			<dc:creator>Yasuko Hatta</dc:creator>
			<dc:creator>Sabrina Schatzman</dc:creator>
			<dc:creator>Norman Hassell</dc:creator>
			<dc:creator>Xiao-Yu Zheng</dc:creator>
			<dc:creator>Ha T. Nguyen</dc:creator>
			<dc:creator>Larisa Gubareva</dc:creator>
			<dc:creator>Rebecca Kondor</dc:creator>
			<dc:creator>Han Di</dc:creator>
			<dc:creator>Vivien G. Dugan</dc:creator>
			<dc:creator>Charles T. Davis</dc:creator>
			<dc:creator>Benjamin L. Rambo-Martin</dc:creator>
			<dc:creator>Marie K. Kirby</dc:creator>
		<dc:identifier>doi: 10.3390/v18040482</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-21</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-21</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>482</prism:startingPage>
		<prism:doi>10.3390/v18040482</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/482</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/481">

	<title>Viruses, Vol. 18, Pages 481: High-Throughput Sequencing Reveals Previously Undetected Viruses and Mixed Infections in Pepper (Capsicum annuum) in Hungary</title>
	<link>https://www.mdpi.com/1999-4915/18/4/481</link>
	<description>The increasing global movement of plant material and the complexity of viral communities associated with cultivated crops complicate routine plant virus diagnostics. High-throughput sequencing (HTS) has therefore become an important tool for the comprehensive characterization of plant viromes. In this study, symptomatic pepper (Capsicum annuum) samples submitted to our laboratory between 2020 and 2025 were investigated using HTS following unsuccessful routine diagnostic assays, despite the presence of virus-like symptoms. Virome analysis revealed the presence of multiple viruses with distinct biological characteristics. Eggplant mottled dwarf virus (EMDV) sequences were identified, representing, to our knowledge, the first sequence data from Hungary. In addition, sequences related to tobacco vein clearing virus (TVCV) showed highest similarity to endogenous viral element present in Capsicum annuum genome assemblies. Persistent viruses, including bell pepper alphaendornavirus (BPEV) and pepper cryptic virus 2 (PCV2), were also detected. These findings demonstrate the complex viral communities associated with cultivated pepper and highlight the limitations of strictly targeted diagnostic approaches. The results emphasize the value of HTS for comprehensive virome characterization in horticultural crops.</description>
	<pubDate>2026-04-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 481: High-Throughput Sequencing Reveals Previously Undetected Viruses and Mixed Infections in Pepper (Capsicum annuum) in Hungary</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/481">doi: 10.3390/v18040481</a></p>
	<p>Authors:
		Emese Demián
		Réka Sáray
		Asztéria Almási
		Kata Pogácsás
		Katalin Salánki
		</p>
	<p>The increasing global movement of plant material and the complexity of viral communities associated with cultivated crops complicate routine plant virus diagnostics. High-throughput sequencing (HTS) has therefore become an important tool for the comprehensive characterization of plant viromes. In this study, symptomatic pepper (Capsicum annuum) samples submitted to our laboratory between 2020 and 2025 were investigated using HTS following unsuccessful routine diagnostic assays, despite the presence of virus-like symptoms. Virome analysis revealed the presence of multiple viruses with distinct biological characteristics. Eggplant mottled dwarf virus (EMDV) sequences were identified, representing, to our knowledge, the first sequence data from Hungary. In addition, sequences related to tobacco vein clearing virus (TVCV) showed highest similarity to endogenous viral element present in Capsicum annuum genome assemblies. Persistent viruses, including bell pepper alphaendornavirus (BPEV) and pepper cryptic virus 2 (PCV2), were also detected. These findings demonstrate the complex viral communities associated with cultivated pepper and highlight the limitations of strictly targeted diagnostic approaches. The results emphasize the value of HTS for comprehensive virome characterization in horticultural crops.</p>
	]]></content:encoded>

	<dc:title>High-Throughput Sequencing Reveals Previously Undetected Viruses and Mixed Infections in Pepper (Capsicum annuum) in Hungary</dc:title>
			<dc:creator>Emese Demián</dc:creator>
			<dc:creator>Réka Sáray</dc:creator>
			<dc:creator>Asztéria Almási</dc:creator>
			<dc:creator>Kata Pogácsás</dc:creator>
			<dc:creator>Katalin Salánki</dc:creator>
		<dc:identifier>doi: 10.3390/v18040481</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-21</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-21</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>481</prism:startingPage>
		<prism:doi>10.3390/v18040481</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/481</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/480">

	<title>Viruses, Vol. 18, Pages 480: Testing Control Strategies for Foot-and-Mouth Disease in New England Using the InterSpread Plus Model: Impacts of Regional Zoning, Early Detection, and Enhanced Biosecurity</title>
	<link>https://www.mdpi.com/1999-4915/18/4/480</link>
	<description>Foot-and-mouth disease (FMD) poses a significant threat to the United States dairy industry. This study evaluates the effectiveness of regional zoning, enhanced detection, and biosecurity in controlling FMD spread, focusing on the New England milkshed, using the InterSpread Plus (ISP+) model. We adapted a baseline ISP+ configuration incorporating United States dairy farm data, movement networks, cattle dealers, markets, and slaughterhouses, with milk processing plants as a model addition. Four hypotheses were tested to understand the impact of different biosecurity strategies: (H1) regional zoning limits the interregional spread of FMD post-detection; (H2) earlier detection in New England via increased passive surveillance reduces the overall outbreak impact; (H3) reduced indirect transmission through enhanced biosecurity measures improves FMD outbreak control; (H4) the combination of regional zoning and earlier detection provides synergistic reduction in FMD impact beyond either strategy alone. The four hypotheses were tested using three geographically distinct infection seed sets; 100 iterations of each scenario were simulated over 210 days and compared to the baseline. Key impact metrics included the daily number of infected premises, the outbreak duration, and the total number of infected premises across the outbreak scenarios. Results suggest shorter outbreak durations and reduced total infected premises under the hypothesized scenarios, compared to the baseline scenario. Kruskal&amp;amp;ndash;Wallis H tests confirmed significant differences across the baseline, regional zoning, early detection, enhanced biosecurity, and the combination of heightened passive surveillance with regional zoning scenarios in terms of total infected premises. Post hoc Dunn&amp;amp;rsquo;s tests indicated that enhanced biosecurity outperformed other control strategies tested. These findings demonstrate that layered interventions may substantially curtail both the national amplification and local spread of FMD, and thus protect the consumer milk supply and reduce cascading economic shocks from an outbreak.</description>
	<pubDate>2026-04-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 480: Testing Control Strategies for Foot-and-Mouth Disease in New England Using the InterSpread Plus Model: Impacts of Regional Zoning, Early Detection, and Enhanced Biosecurity</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/480">doi: 10.3390/v18040480</a></p>
	<p>Authors:
		Johnbosco U. Osuagwu
		Julia M. Smith
		Scott C. Merrill
		</p>
	<p>Foot-and-mouth disease (FMD) poses a significant threat to the United States dairy industry. This study evaluates the effectiveness of regional zoning, enhanced detection, and biosecurity in controlling FMD spread, focusing on the New England milkshed, using the InterSpread Plus (ISP+) model. We adapted a baseline ISP+ configuration incorporating United States dairy farm data, movement networks, cattle dealers, markets, and slaughterhouses, with milk processing plants as a model addition. Four hypotheses were tested to understand the impact of different biosecurity strategies: (H1) regional zoning limits the interregional spread of FMD post-detection; (H2) earlier detection in New England via increased passive surveillance reduces the overall outbreak impact; (H3) reduced indirect transmission through enhanced biosecurity measures improves FMD outbreak control; (H4) the combination of regional zoning and earlier detection provides synergistic reduction in FMD impact beyond either strategy alone. The four hypotheses were tested using three geographically distinct infection seed sets; 100 iterations of each scenario were simulated over 210 days and compared to the baseline. Key impact metrics included the daily number of infected premises, the outbreak duration, and the total number of infected premises across the outbreak scenarios. Results suggest shorter outbreak durations and reduced total infected premises under the hypothesized scenarios, compared to the baseline scenario. Kruskal&amp;amp;ndash;Wallis H tests confirmed significant differences across the baseline, regional zoning, early detection, enhanced biosecurity, and the combination of heightened passive surveillance with regional zoning scenarios in terms of total infected premises. Post hoc Dunn&amp;amp;rsquo;s tests indicated that enhanced biosecurity outperformed other control strategies tested. These findings demonstrate that layered interventions may substantially curtail both the national amplification and local spread of FMD, and thus protect the consumer milk supply and reduce cascading economic shocks from an outbreak.</p>
	]]></content:encoded>

	<dc:title>Testing Control Strategies for Foot-and-Mouth Disease in New England Using the InterSpread Plus Model: Impacts of Regional Zoning, Early Detection, and Enhanced Biosecurity</dc:title>
			<dc:creator>Johnbosco U. Osuagwu</dc:creator>
			<dc:creator>Julia M. Smith</dc:creator>
			<dc:creator>Scott C. Merrill</dc:creator>
		<dc:identifier>doi: 10.3390/v18040480</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-21</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-21</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>480</prism:startingPage>
		<prism:doi>10.3390/v18040480</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/480</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/479">

	<title>Viruses, Vol. 18, Pages 479: Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study</title>
	<link>https://www.mdpi.com/1999-4915/18/4/479</link>
	<description>Early initiation of remdesivir (RDV) is recommended to improve COVID-19 outcomes, but real-world studies describing patterns of RDV use and related outcomes among Japanese COVID-19 patients at high-risk of severe outcomes or death are limited. This claims-based cohort study included 60,165 high-risk patients hospitalized with COVID-19 between October 2021 and June 2023 using the DeSC Healthcare claims database. Patients were categorized into early-RDV (within 2 days of hospital admission), late-RDV (between day 3 and day 7), and no-RDV groups based on RDV initiation timing. Descriptive analyses were performed according to RDV groups. Of the study patients, &amp;amp;ge;85% were very elderly (&amp;amp;ge;75 years). Approximately 39% of patients received early RDV, 2% received late RDV, and 59% received no RDV. By day 28, the proportion of alive discharge for early-, late-, and no-RDV groups was 74.9%, 63.1%, and 71.8%, respectively. The mortality for early-, late-, and no-RDV groups was 7.7%, 8.8%, and 8.4%, respectively. Future hypothesis-driven studies with an appropriate adjustment for confounders are needed to formally evaluate the impact of RDV initiation timing on clinical outcomes in this high-risk, predominantly late-elderly population in Japan.</description>
	<pubDate>2026-04-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 479: Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/479">doi: 10.3390/v18040479</a></p>
	<p>Authors:
		Yuichiro Shindo
		Yi Piao
		Mark Berry
		Heribert Ramroth
		Manami Yoshida
		</p>
	<p>Early initiation of remdesivir (RDV) is recommended to improve COVID-19 outcomes, but real-world studies describing patterns of RDV use and related outcomes among Japanese COVID-19 patients at high-risk of severe outcomes or death are limited. This claims-based cohort study included 60,165 high-risk patients hospitalized with COVID-19 between October 2021 and June 2023 using the DeSC Healthcare claims database. Patients were categorized into early-RDV (within 2 days of hospital admission), late-RDV (between day 3 and day 7), and no-RDV groups based on RDV initiation timing. Descriptive analyses were performed according to RDV groups. Of the study patients, &amp;amp;ge;85% were very elderly (&amp;amp;ge;75 years). Approximately 39% of patients received early RDV, 2% received late RDV, and 59% received no RDV. By day 28, the proportion of alive discharge for early-, late-, and no-RDV groups was 74.9%, 63.1%, and 71.8%, respectively. The mortality for early-, late-, and no-RDV groups was 7.7%, 8.8%, and 8.4%, respectively. Future hypothesis-driven studies with an appropriate adjustment for confounders are needed to formally evaluate the impact of RDV initiation timing on clinical outcomes in this high-risk, predominantly late-elderly population in Japan.</p>
	]]></content:encoded>

	<dc:title>Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study</dc:title>
			<dc:creator>Yuichiro Shindo</dc:creator>
			<dc:creator>Yi Piao</dc:creator>
			<dc:creator>Mark Berry</dc:creator>
			<dc:creator>Heribert Ramroth</dc:creator>
			<dc:creator>Manami Yoshida</dc:creator>
		<dc:identifier>doi: 10.3390/v18040479</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-21</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-21</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>479</prism:startingPage>
		<prism:doi>10.3390/v18040479</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/479</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/478">

	<title>Viruses, Vol. 18, Pages 478: Active Participatory Surveillance for Early Detection of Notifiable Pathogens: A Case Study of the U.S. Swine Industry</title>
	<link>https://www.mdpi.com/1999-4915/18/4/478</link>
	<description>The continued global spread of WOAH-listed pathogens via trade, transport, and travel calls for the implementation of biosecurity measures to protect the health of our national livestock industries, plus ongoing surveillance to verify that such measures are operative. Despite this urgency, surveillance must be practical and affordable. Herein, we evaluated the performance and cost of participatory surveillance, a nontraditional surveillance design, using the U.S. swine industry as an example. In this context, &amp;amp;ldquo;participatory&amp;amp;rdquo; meant that herd veterinarians and/or producers collected and submitted samples from the herd to accredited laboratories for testing. To create an infected population (Phase 1), we simulated the introduction and spread of an unspecified notifiable pathogen within the 48 contiguous U.S states (66,637 swine farms, within 8,080,470 km2) using the USDA Animal Disease Spread Model software (v3.5.10.0). In Phase 2, we calculated the probability of detecting &amp;amp;ge;1 infected farm as a function of producer participation, farm-level sensitivity, farm-level prevalence, and sampling frequency. The participatory design was effective: &amp;amp;ge;90% probability of detecting the notifiable pathogen at 0.05% farm prevalence (33 positive farms among 66,637 farms) when farm-level sensitivity was &amp;amp;ge;20% and producer participation was &amp;amp;ge;40%. Depending on the specimen collected, the shipment method, and the test selected, costs ranged from $0.03 to $0.07 USD (&amp;amp;euro;0.02 to &amp;amp;euro;0.06) per pig in inventory. Thus, a surveillance design based on collecting and testing specimens from a few targeted pigs on each of many farms would be both affordable and effective at a national level.</description>
	<pubDate>2026-04-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 478: Active Participatory Surveillance for Early Detection of Notifiable Pathogens: A Case Study of the U.S. Swine Industry</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/478">doi: 10.3390/v18040478</a></p>
	<p>Authors:
		Berenice Munguía-Ramírez
		Giovani Trevisan
		Paul Morris
		Gustavo S. Silva
		Danyang Zhang
		Chong Wang
		Rodger Main
		Jeffrey Zimmerman
		</p>
	<p>The continued global spread of WOAH-listed pathogens via trade, transport, and travel calls for the implementation of biosecurity measures to protect the health of our national livestock industries, plus ongoing surveillance to verify that such measures are operative. Despite this urgency, surveillance must be practical and affordable. Herein, we evaluated the performance and cost of participatory surveillance, a nontraditional surveillance design, using the U.S. swine industry as an example. In this context, &amp;amp;ldquo;participatory&amp;amp;rdquo; meant that herd veterinarians and/or producers collected and submitted samples from the herd to accredited laboratories for testing. To create an infected population (Phase 1), we simulated the introduction and spread of an unspecified notifiable pathogen within the 48 contiguous U.S states (66,637 swine farms, within 8,080,470 km2) using the USDA Animal Disease Spread Model software (v3.5.10.0). In Phase 2, we calculated the probability of detecting &amp;amp;ge;1 infected farm as a function of producer participation, farm-level sensitivity, farm-level prevalence, and sampling frequency. The participatory design was effective: &amp;amp;ge;90% probability of detecting the notifiable pathogen at 0.05% farm prevalence (33 positive farms among 66,637 farms) when farm-level sensitivity was &amp;amp;ge;20% and producer participation was &amp;amp;ge;40%. Depending on the specimen collected, the shipment method, and the test selected, costs ranged from $0.03 to $0.07 USD (&amp;amp;euro;0.02 to &amp;amp;euro;0.06) per pig in inventory. Thus, a surveillance design based on collecting and testing specimens from a few targeted pigs on each of many farms would be both affordable and effective at a national level.</p>
	]]></content:encoded>

	<dc:title>Active Participatory Surveillance for Early Detection of Notifiable Pathogens: A Case Study of the U.S. Swine Industry</dc:title>
			<dc:creator>Berenice Munguía-Ramírez</dc:creator>
			<dc:creator>Giovani Trevisan</dc:creator>
			<dc:creator>Paul Morris</dc:creator>
			<dc:creator>Gustavo S. Silva</dc:creator>
			<dc:creator>Danyang Zhang</dc:creator>
			<dc:creator>Chong Wang</dc:creator>
			<dc:creator>Rodger Main</dc:creator>
			<dc:creator>Jeffrey Zimmerman</dc:creator>
		<dc:identifier>doi: 10.3390/v18040478</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-20</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-20</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>478</prism:startingPage>
		<prism:doi>10.3390/v18040478</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/478</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/477">

	<title>Viruses, Vol. 18, Pages 477: Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection</title>
	<link>https://www.mdpi.com/1999-4915/18/4/477</link>
	<description>This review critically examines the inhibition of viral entry as an emerging disease-modifying strategy in chronic hepatitis B (HBV) and delta (HDV) virus infection, with particular emphasis on bulevirtide, the first-in-class of the sodium taurocholate cotransporting polypeptide entry inhibitor. This paper summarizes the analysis of 7 clinical trials that either underpinned the registration of bulevirtide or are important European real-life trials. We synthesize virological, pathophysiological and clinical evidence, highlighting the impact of this novel bulevirtide-based therapy on virological control, liver inflammation, fibrosis dynamics and long-term prognosis, as well as the limitations of this therapy. The observation of these trials is a greater than 2 log decrease from baseline in hepatitis D virus ribonucleic acid (HDV RNA) in 54&amp;amp;ndash;92% of patients and normalization of alanine transaminase (ALT) in 48.8&amp;amp;ndash;74% of patients after 23&amp;amp;ndash;144 weeks of treatment, and a significant decrease in liver fibrosis, as quantified by Fibroscan, at 12 months of treatment. The conclusion of the study is that this therapy represents an important leap in the etiological approach to chronic HDV infection and in improving the prognosis of these patients, but future clinical studies are needed to define the criteria for discontinuation of therapy, the long-term impact, as well as studies targeting new therapies that can intervene in other stages of the HDV and HBV life cycle not only to achieve HDV RNA negativity but also HBsAg clearance.</description>
	<pubDate>2026-04-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 477: Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/477">doi: 10.3390/v18040477</a></p>
	<p>Authors:
		Raisa Eloise Barbu
		Mariana Daniela Ignat
		Roxana Elena Bogdan Goroftei
		Alexia Anastasia Ștefania Baltă
		Valerii Lutenco
		Valentin Bulza
		Valerian Ionuț Stoian
		Simona Claudia Cambrea
		Elena Dumea
		Liliana Baroiu
		</p>
	<p>This review critically examines the inhibition of viral entry as an emerging disease-modifying strategy in chronic hepatitis B (HBV) and delta (HDV) virus infection, with particular emphasis on bulevirtide, the first-in-class of the sodium taurocholate cotransporting polypeptide entry inhibitor. This paper summarizes the analysis of 7 clinical trials that either underpinned the registration of bulevirtide or are important European real-life trials. We synthesize virological, pathophysiological and clinical evidence, highlighting the impact of this novel bulevirtide-based therapy on virological control, liver inflammation, fibrosis dynamics and long-term prognosis, as well as the limitations of this therapy. The observation of these trials is a greater than 2 log decrease from baseline in hepatitis D virus ribonucleic acid (HDV RNA) in 54&amp;amp;ndash;92% of patients and normalization of alanine transaminase (ALT) in 48.8&amp;amp;ndash;74% of patients after 23&amp;amp;ndash;144 weeks of treatment, and a significant decrease in liver fibrosis, as quantified by Fibroscan, at 12 months of treatment. The conclusion of the study is that this therapy represents an important leap in the etiological approach to chronic HDV infection and in improving the prognosis of these patients, but future clinical studies are needed to define the criteria for discontinuation of therapy, the long-term impact, as well as studies targeting new therapies that can intervene in other stages of the HDV and HBV life cycle not only to achieve HDV RNA negativity but also HBsAg clearance.</p>
	]]></content:encoded>

	<dc:title>Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection</dc:title>
			<dc:creator>Raisa Eloise Barbu</dc:creator>
			<dc:creator>Mariana Daniela Ignat</dc:creator>
			<dc:creator>Roxana Elena Bogdan Goroftei</dc:creator>
			<dc:creator>Alexia Anastasia Ștefania Baltă</dc:creator>
			<dc:creator>Valerii Lutenco</dc:creator>
			<dc:creator>Valentin Bulza</dc:creator>
			<dc:creator>Valerian Ionuț Stoian</dc:creator>
			<dc:creator>Simona Claudia Cambrea</dc:creator>
			<dc:creator>Elena Dumea</dc:creator>
			<dc:creator>Liliana Baroiu</dc:creator>
		<dc:identifier>doi: 10.3390/v18040477</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-19</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-19</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>477</prism:startingPage>
		<prism:doi>10.3390/v18040477</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/477</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/476">

	<title>Viruses, Vol. 18, Pages 476: Advances in Antiviral Drug Development Targeting Enteroviruses: From Viral Proteins to Host Factors</title>
	<link>https://www.mdpi.com/1999-4915/18/4/476</link>
	<description>Enteroviruses represent important human pathogens, posing a substantial disease burden, particularly in children under 5 years of age. Enteroviruses are the primary causative agents of hand-foot-and-mouth disease (HFMD) and are strongly associated with acute flaccid myelitis (AFM), with severe cases potentially resulting in significant neurological complications. Inactivated vaccines against EV-A71 based on the C4 genotype are currently available. However, there are no licensed direct antiviral agents for severe cases. By focusing on viral proteins and host factors, researchers have made great strides in the creation of antiviral medications that target enteroviruses. However, several viral candidates failed to progress in clinical development due to limited efficacy or side effects. This review discusses key findings in enterovirus antiviral research, analyzes the advantages and limitations of each drug target, and highlights knowledge gaps that need to be addressed to advance further development in this field.</description>
	<pubDate>2026-04-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 476: Advances in Antiviral Drug Development Targeting Enteroviruses: From Viral Proteins to Host Factors</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/476">doi: 10.3390/v18040476</a></p>
	<p>Authors:
		Jiaying Lu
		Congyi Li
		Wenzhe Cui
		Yining Du
		Jiayi Geng
		Wenyan Zhang
		</p>
	<p>Enteroviruses represent important human pathogens, posing a substantial disease burden, particularly in children under 5 years of age. Enteroviruses are the primary causative agents of hand-foot-and-mouth disease (HFMD) and are strongly associated with acute flaccid myelitis (AFM), with severe cases potentially resulting in significant neurological complications. Inactivated vaccines against EV-A71 based on the C4 genotype are currently available. However, there are no licensed direct antiviral agents for severe cases. By focusing on viral proteins and host factors, researchers have made great strides in the creation of antiviral medications that target enteroviruses. However, several viral candidates failed to progress in clinical development due to limited efficacy or side effects. This review discusses key findings in enterovirus antiviral research, analyzes the advantages and limitations of each drug target, and highlights knowledge gaps that need to be addressed to advance further development in this field.</p>
	]]></content:encoded>

	<dc:title>Advances in Antiviral Drug Development Targeting Enteroviruses: From Viral Proteins to Host Factors</dc:title>
			<dc:creator>Jiaying Lu</dc:creator>
			<dc:creator>Congyi Li</dc:creator>
			<dc:creator>Wenzhe Cui</dc:creator>
			<dc:creator>Yining Du</dc:creator>
			<dc:creator>Jiayi Geng</dc:creator>
			<dc:creator>Wenyan Zhang</dc:creator>
		<dc:identifier>doi: 10.3390/v18040476</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-18</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-18</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>476</prism:startingPage>
		<prism:doi>10.3390/v18040476</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/476</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/475">

	<title>Viruses, Vol. 18, Pages 475: Diagnostic and Phylogenetic Insights into a Human Rabies Virus Isolate from Romania</title>
	<link>https://www.mdpi.com/1999-4915/18/4/475</link>
	<description>Rabies is a fatal zoonotic disease once clinical symptoms develop. In Europe, sustained animal rabies control programs have led to a marked decline in animal rabies and subsequently human rabies cases; however, sporadic infections continue to occur. In July 2025, a fatal case of autochthonous (locally acquired) human rabies was confirmed in Romania following a stray dog bite in a patient who did not receive post-exposure prophylaxis (PEP). Here, we report the first molecular characterization of a human rabies virus (RABV) strain isolated in Romania and place it in the context of contemporaneously circulating animal-derived RABV strains. Rabies virus infection was confirmed intra vitam by fluorescent antibody testing and both conventional and real-time RT-PCR on cerebrospinal fluid and saliva, with postmortem confirmation on skin and brain tissue. Whole-genome sequencing was performed on the human isolate and on 22 animal-derived RABV strains collected in northern Romania in 2025. Phylogenetic analyses revealed that all recent Romanian sequences clustered within the North-East European (NEE) rabies virus phylogenetic group and segregated into two geographically distinct genetic clusters: a north-western cluster, closely related to strains from Slovakia and Poland, and a larger north-eastern cluster, linked to viruses circulating in eastern Romania and the Republic of Moldova. The human-derived RABV genome was grouped within the north-eastern cluster and showed the highest genetic similarity to animal viral strains from the same geographical area, supporting a local transmission event. This demonstrates the importance of integrating human viral genomic data into the national rabies surveillance framework.</description>
	<pubDate>2026-04-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 475: Diagnostic and Phylogenetic Insights into a Human Rabies Virus Isolate from Romania</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/475">doi: 10.3390/v18040475</a></p>
	<p>Authors:
		Vlad Vuta
		Maria Gradinaru
		Mihnea Hurmuzache
		Florica Bărbuceanu
		Lenuta Zamfir
		Răzvan Moțiu
		Laura Schmid
		Dirk Höper
		Sten Calvelage
		Thomas Müller
		Conrad M. Freuling
		</p>
	<p>Rabies is a fatal zoonotic disease once clinical symptoms develop. In Europe, sustained animal rabies control programs have led to a marked decline in animal rabies and subsequently human rabies cases; however, sporadic infections continue to occur. In July 2025, a fatal case of autochthonous (locally acquired) human rabies was confirmed in Romania following a stray dog bite in a patient who did not receive post-exposure prophylaxis (PEP). Here, we report the first molecular characterization of a human rabies virus (RABV) strain isolated in Romania and place it in the context of contemporaneously circulating animal-derived RABV strains. Rabies virus infection was confirmed intra vitam by fluorescent antibody testing and both conventional and real-time RT-PCR on cerebrospinal fluid and saliva, with postmortem confirmation on skin and brain tissue. Whole-genome sequencing was performed on the human isolate and on 22 animal-derived RABV strains collected in northern Romania in 2025. Phylogenetic analyses revealed that all recent Romanian sequences clustered within the North-East European (NEE) rabies virus phylogenetic group and segregated into two geographically distinct genetic clusters: a north-western cluster, closely related to strains from Slovakia and Poland, and a larger north-eastern cluster, linked to viruses circulating in eastern Romania and the Republic of Moldova. The human-derived RABV genome was grouped within the north-eastern cluster and showed the highest genetic similarity to animal viral strains from the same geographical area, supporting a local transmission event. This demonstrates the importance of integrating human viral genomic data into the national rabies surveillance framework.</p>
	]]></content:encoded>

	<dc:title>Diagnostic and Phylogenetic Insights into a Human Rabies Virus Isolate from Romania</dc:title>
			<dc:creator>Vlad Vuta</dc:creator>
			<dc:creator>Maria Gradinaru</dc:creator>
			<dc:creator>Mihnea Hurmuzache</dc:creator>
			<dc:creator>Florica Bărbuceanu</dc:creator>
			<dc:creator>Lenuta Zamfir</dc:creator>
			<dc:creator>Răzvan Moțiu</dc:creator>
			<dc:creator>Laura Schmid</dc:creator>
			<dc:creator>Dirk Höper</dc:creator>
			<dc:creator>Sten Calvelage</dc:creator>
			<dc:creator>Thomas Müller</dc:creator>
			<dc:creator>Conrad M. Freuling</dc:creator>
		<dc:identifier>doi: 10.3390/v18040475</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-17</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-17</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>475</prism:startingPage>
		<prism:doi>10.3390/v18040475</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/475</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/474">

	<title>Viruses, Vol. 18, Pages 474: Investigation of the Viromes of Solanaceous Weeds in Hungary Using High-Throughput Sequencing Adds New Insights to Their Hidden Complexity</title>
	<link>https://www.mdpi.com/1999-4915/18/4/474</link>
	<description>Weed control of solanaceous weeds growing with solanaceous crops is a constant challenge. Infected by viruses, they can also act as virus reservoirs, complicating this problem further. Viromes of annual Solanum nigrum, Datura stramonium, and Solanum dulcamara, a perennial climbing shrub, were investigated using RNA sequencing and validated using RT-PCR, revealing infection with nine viruses. Broad bean wilt virus 1 (BBWV1), cucumber mosaic virus (CMV), and potato virus M (PVM) were found to infect S. nigrum. Investigating only 46 plants revealed infection with Solanum dulcamara yellow fleck virus (SDYFV) not only in S. dulcamara but in a new host, D. stramonium, which also represents a new host of turnip yellows virus (TuYV). We described the first presence of a potato virus H (PVH)-like, and Oxybasis rubra mitovirus 1 (OxruMV1)-like virus in Europe, in S. dulcamara as a new host. Our results highlight the unexpected complexity of the viromes of solanaceous weeds, which should be considered during reliable and efficient plant protection strategies, in order to alleviate the virus reservoir role of the weeds.</description>
	<pubDate>2026-04-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 474: Investigation of the Viromes of Solanaceous Weeds in Hungary Using High-Throughput Sequencing Adds New Insights to Their Hidden Complexity</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/474">doi: 10.3390/v18040474</a></p>
	<p>Authors:
		Burim Ismajli
		Zsuzsanna N. Galbács
		Lilla Dorottya Péri
		György Pasztor
		András Péter Takács
		Éva Várallyay
		</p>
	<p>Weed control of solanaceous weeds growing with solanaceous crops is a constant challenge. Infected by viruses, they can also act as virus reservoirs, complicating this problem further. Viromes of annual Solanum nigrum, Datura stramonium, and Solanum dulcamara, a perennial climbing shrub, were investigated using RNA sequencing and validated using RT-PCR, revealing infection with nine viruses. Broad bean wilt virus 1 (BBWV1), cucumber mosaic virus (CMV), and potato virus M (PVM) were found to infect S. nigrum. Investigating only 46 plants revealed infection with Solanum dulcamara yellow fleck virus (SDYFV) not only in S. dulcamara but in a new host, D. stramonium, which also represents a new host of turnip yellows virus (TuYV). We described the first presence of a potato virus H (PVH)-like, and Oxybasis rubra mitovirus 1 (OxruMV1)-like virus in Europe, in S. dulcamara as a new host. Our results highlight the unexpected complexity of the viromes of solanaceous weeds, which should be considered during reliable and efficient plant protection strategies, in order to alleviate the virus reservoir role of the weeds.</p>
	]]></content:encoded>

	<dc:title>Investigation of the Viromes of Solanaceous Weeds in Hungary Using High-Throughput Sequencing Adds New Insights to Their Hidden Complexity</dc:title>
			<dc:creator>Burim Ismajli</dc:creator>
			<dc:creator>Zsuzsanna N. Galbács</dc:creator>
			<dc:creator>Lilla Dorottya Péri</dc:creator>
			<dc:creator>György Pasztor</dc:creator>
			<dc:creator>András Péter Takács</dc:creator>
			<dc:creator>Éva Várallyay</dc:creator>
		<dc:identifier>doi: 10.3390/v18040474</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-17</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-17</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>474</prism:startingPage>
		<prism:doi>10.3390/v18040474</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/474</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/473">

	<title>Viruses, Vol. 18, Pages 473: The Key Role of Complement Receptor CRIg in Kupffer Cell-Mediated Liver Disease Progression</title>
	<link>https://www.mdpi.com/1999-4915/18/4/473</link>
	<description>Liver diseases, ranging from chronic hepatitis and metabolic dysfunction to cirrhosis and hepatocellular carcinoma, represent a major global public health burden. As an immune-privileged organ, the liver harbors a unique and intricate immune microenvironment, which plays a dual role in pathogen clearance and chronicity. Kupffer cells (KCs), the primary resident macrophages in the liver, constitute the first line of defense in liver innate immunity and play complex and important roles in pathogen recognition, phagocytosis, and the regulation of liver inflammation and immune responses. The complement receptor of the immunoglobulin superfamily (CRIg) is a membrane receptor that is specifically expressed on KCs. It serves not only as a sentinel for the liver against pathogen invasion but also as a sophisticated regulator for maintaining immune homeostasis. As a key component of the liver&amp;amp;rsquo;s immune system, CRIg can efficiently mediate the clearance of complement-opsonized particles, thereby playing multidimensional roles in pathogen clearance, antigen cross-presentation, and the establishment of immune tolerance, functioning as both a &amp;amp;ldquo;pathogen catcher&amp;amp;rdquo; and an &amp;amp;ldquo;immune brake.&amp;amp;rdquo; This review focuses on the CRIg molecule, detailing its mechanisms in the recognition and phagocytic clearance by KCs, and its subsequent impact on hepatic immune responses. Furthermore, we explored the potential involvement of CRIg in the pathological progression of diverse liver diseases, including persistent inflammation, fibrosis, and hepatocarcinogenesis. This synthesis provides novel insights into the immunopathology of liver diseases and establishes a theoretical foundation for developing CRIg-targeted therapeutic strategies.</description>
	<pubDate>2026-04-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 473: The Key Role of Complement Receptor CRIg in Kupffer Cell-Mediated Liver Disease Progression</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/473">doi: 10.3390/v18040473</a></p>
	<p>Authors:
		Xin-Zhou Sun
		Yan Liu
		</p>
	<p>Liver diseases, ranging from chronic hepatitis and metabolic dysfunction to cirrhosis and hepatocellular carcinoma, represent a major global public health burden. As an immune-privileged organ, the liver harbors a unique and intricate immune microenvironment, which plays a dual role in pathogen clearance and chronicity. Kupffer cells (KCs), the primary resident macrophages in the liver, constitute the first line of defense in liver innate immunity and play complex and important roles in pathogen recognition, phagocytosis, and the regulation of liver inflammation and immune responses. The complement receptor of the immunoglobulin superfamily (CRIg) is a membrane receptor that is specifically expressed on KCs. It serves not only as a sentinel for the liver against pathogen invasion but also as a sophisticated regulator for maintaining immune homeostasis. As a key component of the liver&amp;amp;rsquo;s immune system, CRIg can efficiently mediate the clearance of complement-opsonized particles, thereby playing multidimensional roles in pathogen clearance, antigen cross-presentation, and the establishment of immune tolerance, functioning as both a &amp;amp;ldquo;pathogen catcher&amp;amp;rdquo; and an &amp;amp;ldquo;immune brake.&amp;amp;rdquo; This review focuses on the CRIg molecule, detailing its mechanisms in the recognition and phagocytic clearance by KCs, and its subsequent impact on hepatic immune responses. Furthermore, we explored the potential involvement of CRIg in the pathological progression of diverse liver diseases, including persistent inflammation, fibrosis, and hepatocarcinogenesis. This synthesis provides novel insights into the immunopathology of liver diseases and establishes a theoretical foundation for developing CRIg-targeted therapeutic strategies.</p>
	]]></content:encoded>

	<dc:title>The Key Role of Complement Receptor CRIg in Kupffer Cell-Mediated Liver Disease Progression</dc:title>
			<dc:creator>Xin-Zhou Sun</dc:creator>
			<dc:creator>Yan Liu</dc:creator>
		<dc:identifier>doi: 10.3390/v18040473</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-17</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-17</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>473</prism:startingPage>
		<prism:doi>10.3390/v18040473</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/473</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/472">

	<title>Viruses, Vol. 18, Pages 472: Immunogenicity and Safety of Biological E&amp;rsquo;s Monovalent rDNA Hepatitis B Vaccine (BEVAC&amp;reg;) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial</title>
	<link>https://www.mdpi.com/1999-4915/18/4/472</link>
	<description>Biological E&amp;amp;rsquo;s BEVAC&amp;amp;reg; is a recombinant DNA hepatitis B vaccine that has been used in India for more than a decade in routine early-life immunization and has recently been prequalified by the World Health Organization (WHO). This multicentre, single-blind, parallel-group, randomized phase IV trial, conducted at seven study sites in India, compared the immunogenicity and safety of BEVAC&amp;amp;reg; with a licensed comparator vaccine (GeneVac-B&amp;amp;reg;, Serum Institute of India Pvt. Ltd, Pune, India.) in healthy term neonates and infants. Participants received three 0.5 mL doses administered intramuscularly at birth (within 24 h), 6 weeks of age, and 14 weeks of age. The primary endpoint was seroprotection (anti-HBs IgG &amp;amp;ge;10 mIU/mL) at 28 days after the third dose (Day 126), compared using a non-inferiority margin of &amp;amp;minus;10%. Secondary endpoints included safety and tolerability outcomes through Day 126. A total of 468 neonates were randomized (234 per group), of whom 44% were female. At Day 126, seroprotection rates were 98.2% (95% CI: 95.39, 99.50) with BEVAC&amp;amp;reg; and 99.1% (95% CI: 96.78, 99.89) with the comparator; the between-group difference was &amp;amp;minus;0.9% (95% CI: &amp;amp;minus;3.09, 1.24), meeting the prespecified non-inferiority criterion. Solicited adverse events within 7 days after any dose occurred in 29.1% (95% CI: 23.3, 35.3) of BEVAC&amp;amp;reg; recipients and 35.0% (95% CI: 28.9, 41.5) of comparator recipients, most commonly pyrexia, injection-site pain, and swelling; all were mild-to-moderate. No serious adverse events were reported. BEVAC&amp;amp;reg; demonstrated non-inferior immunogenicity to the licensed comparator and a comparable safety profile.</description>
	<pubDate>2026-04-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 472: Immunogenicity and Safety of Biological E&amp;rsquo;s Monovalent rDNA Hepatitis B Vaccine (BEVAC&amp;reg;) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/472">doi: 10.3390/v18040472</a></p>
	<p>Authors:
		Subhash Thuluva
		Subbareddy Gunneri
		Siddalingaiah Ningaiah
		Vijay Yerroju
		Rammohan Reddy Mogulla
		Chirag Dhar
		Kamal Thammireddy
		Raju Esanakarra
		Pradeep Nanjappa
		Niranjana S. Mahantshetti
		</p>
	<p>Biological E&amp;amp;rsquo;s BEVAC&amp;amp;reg; is a recombinant DNA hepatitis B vaccine that has been used in India for more than a decade in routine early-life immunization and has recently been prequalified by the World Health Organization (WHO). This multicentre, single-blind, parallel-group, randomized phase IV trial, conducted at seven study sites in India, compared the immunogenicity and safety of BEVAC&amp;amp;reg; with a licensed comparator vaccine (GeneVac-B&amp;amp;reg;, Serum Institute of India Pvt. Ltd, Pune, India.) in healthy term neonates and infants. Participants received three 0.5 mL doses administered intramuscularly at birth (within 24 h), 6 weeks of age, and 14 weeks of age. The primary endpoint was seroprotection (anti-HBs IgG &amp;amp;ge;10 mIU/mL) at 28 days after the third dose (Day 126), compared using a non-inferiority margin of &amp;amp;minus;10%. Secondary endpoints included safety and tolerability outcomes through Day 126. A total of 468 neonates were randomized (234 per group), of whom 44% were female. At Day 126, seroprotection rates were 98.2% (95% CI: 95.39, 99.50) with BEVAC&amp;amp;reg; and 99.1% (95% CI: 96.78, 99.89) with the comparator; the between-group difference was &amp;amp;minus;0.9% (95% CI: &amp;amp;minus;3.09, 1.24), meeting the prespecified non-inferiority criterion. Solicited adverse events within 7 days after any dose occurred in 29.1% (95% CI: 23.3, 35.3) of BEVAC&amp;amp;reg; recipients and 35.0% (95% CI: 28.9, 41.5) of comparator recipients, most commonly pyrexia, injection-site pain, and swelling; all were mild-to-moderate. No serious adverse events were reported. BEVAC&amp;amp;reg; demonstrated non-inferior immunogenicity to the licensed comparator and a comparable safety profile.</p>
	]]></content:encoded>

	<dc:title>Immunogenicity and Safety of Biological E&amp;amp;rsquo;s Monovalent rDNA Hepatitis B Vaccine (BEVAC&amp;amp;reg;) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial</dc:title>
			<dc:creator>Subhash Thuluva</dc:creator>
			<dc:creator>Subbareddy Gunneri</dc:creator>
			<dc:creator>Siddalingaiah Ningaiah</dc:creator>
			<dc:creator>Vijay Yerroju</dc:creator>
			<dc:creator>Rammohan Reddy Mogulla</dc:creator>
			<dc:creator>Chirag Dhar</dc:creator>
			<dc:creator>Kamal Thammireddy</dc:creator>
			<dc:creator>Raju Esanakarra</dc:creator>
			<dc:creator>Pradeep Nanjappa</dc:creator>
			<dc:creator>Niranjana S. Mahantshetti</dc:creator>
		<dc:identifier>doi: 10.3390/v18040472</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-17</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-17</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>472</prism:startingPage>
		<prism:doi>10.3390/v18040472</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/472</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/471">

	<title>Viruses, Vol. 18, Pages 471: Development of a Multiplex PCR Method for Efficient Differential Diagnosis of Clinical Cases and Vaccine Immunization of Marek&amp;rsquo;s Disease</title>
	<link>https://www.mdpi.com/1999-4915/18/4/471</link>
	<description>Marek&amp;amp;rsquo;s disease (MD), caused by pathogenic Marek&amp;amp;rsquo;s disease virus serotype 1 (MDV-1), is one of the most important avian immunosuppressive and neoplastic diseases and has led to huge economic losses to the poultry industry worldwide. Rapid and accurate clinical diagnosis is of great significance for efficient control of the disease. Herein, we have established a multiplex PCR (mPCR) method to simply differentiate all of the three types of MDV, using five specific primers targeting to MDV-1 oncogene meq or MDV-2 and MDV-3/HVT gB genes. Simultaneously, it can detect any type of virulent or vaccine MDV strains in one PCR reaction, with amplicons of the short (S) and long (L)-meq of MDV-1 strains, and the gB of MDV-2 and HVT vaccine strains. Non-specific amplifications of avian leukosis virus (ALV), reticuloendotheliosis virus (REV), or fowl adenovirus virus 4 (FAdV-4) were not observed, indicating a good specificity of this method. A total of 522 clinical samples of tumor-bearing or suspected diseased birds collected from 30 poultry farms were detected. The results demonstrated that the newly developed mPCR method accurately detected and differentiated epidemic MDV-1 infections and vaccine strains, and provided nearly 100% consistency for detecting clinical wild-type infections compared with conventional PCR amplification of the meq gene. Collectively, our data has provided a highly efficient method for early differential diagnosis of MD clinical cases, virus identification and future evaluation of vaccination efficacy in healthy chicken flocks, which would be meaningful for efficient control of the disease.</description>
	<pubDate>2026-04-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 471: Development of a Multiplex PCR Method for Efficient Differential Diagnosis of Clinical Cases and Vaccine Immunization of Marek&amp;rsquo;s Disease</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/471">doi: 10.3390/v18040471</a></p>
	<p>Authors:
		Wen-Kai Zhang
		Man Teng
		Lu-Ping Zheng
		Bin Shi
		Wei-Dong Wang
		Gui-Xi Li
		Yong-Xu Zhao
		Zhen Yang
		Zu-Hua Yu
		Jun Luo
		</p>
	<p>Marek&amp;amp;rsquo;s disease (MD), caused by pathogenic Marek&amp;amp;rsquo;s disease virus serotype 1 (MDV-1), is one of the most important avian immunosuppressive and neoplastic diseases and has led to huge economic losses to the poultry industry worldwide. Rapid and accurate clinical diagnosis is of great significance for efficient control of the disease. Herein, we have established a multiplex PCR (mPCR) method to simply differentiate all of the three types of MDV, using five specific primers targeting to MDV-1 oncogene meq or MDV-2 and MDV-3/HVT gB genes. Simultaneously, it can detect any type of virulent or vaccine MDV strains in one PCR reaction, with amplicons of the short (S) and long (L)-meq of MDV-1 strains, and the gB of MDV-2 and HVT vaccine strains. Non-specific amplifications of avian leukosis virus (ALV), reticuloendotheliosis virus (REV), or fowl adenovirus virus 4 (FAdV-4) were not observed, indicating a good specificity of this method. A total of 522 clinical samples of tumor-bearing or suspected diseased birds collected from 30 poultry farms were detected. The results demonstrated that the newly developed mPCR method accurately detected and differentiated epidemic MDV-1 infections and vaccine strains, and provided nearly 100% consistency for detecting clinical wild-type infections compared with conventional PCR amplification of the meq gene. Collectively, our data has provided a highly efficient method for early differential diagnosis of MD clinical cases, virus identification and future evaluation of vaccination efficacy in healthy chicken flocks, which would be meaningful for efficient control of the disease.</p>
	]]></content:encoded>

	<dc:title>Development of a Multiplex PCR Method for Efficient Differential Diagnosis of Clinical Cases and Vaccine Immunization of Marek&amp;amp;rsquo;s Disease</dc:title>
			<dc:creator>Wen-Kai Zhang</dc:creator>
			<dc:creator>Man Teng</dc:creator>
			<dc:creator>Lu-Ping Zheng</dc:creator>
			<dc:creator>Bin Shi</dc:creator>
			<dc:creator>Wei-Dong Wang</dc:creator>
			<dc:creator>Gui-Xi Li</dc:creator>
			<dc:creator>Yong-Xu Zhao</dc:creator>
			<dc:creator>Zhen Yang</dc:creator>
			<dc:creator>Zu-Hua Yu</dc:creator>
			<dc:creator>Jun Luo</dc:creator>
		<dc:identifier>doi: 10.3390/v18040471</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-16</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-16</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>471</prism:startingPage>
		<prism:doi>10.3390/v18040471</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/471</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/470">

	<title>Viruses, Vol. 18, Pages 470: SHAPE-MaP-Based Assessment of the Structure of Citrus Tristeza Virus Long Non-Coding RNA</title>
	<link>https://www.mdpi.com/1999-4915/18/4/470</link>
	<description>The 5&amp;amp;prime;-proximal region of the citrus tristeza virus (CTV) RNA genome is a hub where several elements involved in different facets of the virus cycle reside, including the sequences driving the production of the viral long non-coding RNA (lncRNA) LMT1. The sequence of this region is one of the most divergent genome areas, allowing for strain differentiation. Beyond its use in assessing viral population diversity, the region provides a valuable model for studying the conservation of RNA structure and function despite sequence variation. Here, we integrated comparative in silico analysis of the LMT1 region from variants of eight CTV strains with selective 2&amp;amp;prime;-hydroxyl acylation, analyzed by primer extension and mutational profiling (SHAPE-MaP) probing of in vitro&amp;amp;ndash;generated LMT1 RNAs from two divergent strains, T36 and T68. The predicted consensus structures revealed 19 putative, conserved stem-loops. The SHAPE-MaP reactivity data supported and substantiated the thermodynamics-based predictions for the 15 previously uncharacterized stem-loops and two functional elements identified earlier. The strong structural conservation across strains highlights that the LMT1 RNA structure contributes to its function during CTV infection. These results provide the first experimentally supported structure of this viral lncRNA and lay the foundation for defining how individual RNA motifs influence CTV biology.</description>
	<pubDate>2026-04-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 470: SHAPE-MaP-Based Assessment of the Structure of Citrus Tristeza Virus Long Non-Coding RNA</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/470">doi: 10.3390/v18040470</a></p>
	<p>Authors:
		Arianna Spellman-Kruse
		Jodi L. Bubenik
		Tathiana Ferreira Sa Antunes
		Alexander J. Lawrence
		Maurice S. Swanson
		Ying Wang
		Svetlana Y. Folimonova
		</p>
	<p>The 5&amp;amp;prime;-proximal region of the citrus tristeza virus (CTV) RNA genome is a hub where several elements involved in different facets of the virus cycle reside, including the sequences driving the production of the viral long non-coding RNA (lncRNA) LMT1. The sequence of this region is one of the most divergent genome areas, allowing for strain differentiation. Beyond its use in assessing viral population diversity, the region provides a valuable model for studying the conservation of RNA structure and function despite sequence variation. Here, we integrated comparative in silico analysis of the LMT1 region from variants of eight CTV strains with selective 2&amp;amp;prime;-hydroxyl acylation, analyzed by primer extension and mutational profiling (SHAPE-MaP) probing of in vitro&amp;amp;ndash;generated LMT1 RNAs from two divergent strains, T36 and T68. The predicted consensus structures revealed 19 putative, conserved stem-loops. The SHAPE-MaP reactivity data supported and substantiated the thermodynamics-based predictions for the 15 previously uncharacterized stem-loops and two functional elements identified earlier. The strong structural conservation across strains highlights that the LMT1 RNA structure contributes to its function during CTV infection. These results provide the first experimentally supported structure of this viral lncRNA and lay the foundation for defining how individual RNA motifs influence CTV biology.</p>
	]]></content:encoded>

	<dc:title>SHAPE-MaP-Based Assessment of the Structure of Citrus Tristeza Virus Long Non-Coding RNA</dc:title>
			<dc:creator>Arianna Spellman-Kruse</dc:creator>
			<dc:creator>Jodi L. Bubenik</dc:creator>
			<dc:creator>Tathiana Ferreira Sa Antunes</dc:creator>
			<dc:creator>Alexander J. Lawrence</dc:creator>
			<dc:creator>Maurice S. Swanson</dc:creator>
			<dc:creator>Ying Wang</dc:creator>
			<dc:creator>Svetlana Y. Folimonova</dc:creator>
		<dc:identifier>doi: 10.3390/v18040470</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-16</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-16</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>470</prism:startingPage>
		<prism:doi>10.3390/v18040470</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/470</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/469">

	<title>Viruses, Vol. 18, Pages 469: Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study</title>
	<link>https://www.mdpi.com/1999-4915/18/4/469</link>
	<description>Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in children &amp;amp;lt; 24 months and a major public health concern, causing high rates of Emergency Department (ED) visits, hospitalizations, and Pediatric Intensive Care Unit (PICU) admissions. Nirsevimab is a recombinant monoclonal antibody recommended for all infants and high-risk children &amp;amp;lt; 24 months. A retrospective single-center cohort study was conducted to evaluate the impact of nirsevimab introduction on bronchiolitis epidemiology in an Italian tertiary pediatric ED, accounting for 40,000 admissions/year. All children &amp;amp;lt; 24 months who presented to our ED with bronchiolitis during two consecutive RSV seasons (first season: 1 October 2023 to 30 April 2024; second season: 1 October 2024 to 30 April 2025) were included. Descriptive and multivariate analyses are reported. Overall, 484 patients were analyzed (336 in 2023&amp;amp;ndash;2024; 148 in 2024&amp;amp;ndash;2025), with immunization coverage reaching 87.5% by April 2025. Compared with the previous season, RSV positivity decreased significantly (32.4% vs. 47.9%; p = 0.003) and was lower in immunized children (16.2% vs. 51.5%; p &amp;amp;lt; 0.001). Immunization was associated with a reduced risk of RSV-positive swab in the second season (OR = 0.159, 95% CI: 0.059&amp;amp;ndash;0.397). Among RSV-negative patients, other respiratory viruses increased (p &amp;amp;lt; 0.001), while co-infections increased in RSV-positive cases (p = 0.021). Hospitalization rates remained stable, though absolute admissions were halved. In conclusion, nirsevimab immunization reduced RSV burden, supporting its inclusion in universal prevention programs and the need for multicenter prospective studies to assess long-term outcomes.</description>
	<pubDate>2026-04-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 469: Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/469">doi: 10.3390/v18040469</a></p>
	<p>Authors:
		Emanuele Castagno
		Carola Aschieri
		Irene Ferri
		Sara El Khbazi
		Lorenzo Milani
		Rosanna Irene Comoretto
		Irene Raffaldi
		Irene Tardivo
		Marco Spada
		Claudia Bondone
		Franca Fagioli
		</p>
	<p>Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in children &amp;amp;lt; 24 months and a major public health concern, causing high rates of Emergency Department (ED) visits, hospitalizations, and Pediatric Intensive Care Unit (PICU) admissions. Nirsevimab is a recombinant monoclonal antibody recommended for all infants and high-risk children &amp;amp;lt; 24 months. A retrospective single-center cohort study was conducted to evaluate the impact of nirsevimab introduction on bronchiolitis epidemiology in an Italian tertiary pediatric ED, accounting for 40,000 admissions/year. All children &amp;amp;lt; 24 months who presented to our ED with bronchiolitis during two consecutive RSV seasons (first season: 1 October 2023 to 30 April 2024; second season: 1 October 2024 to 30 April 2025) were included. Descriptive and multivariate analyses are reported. Overall, 484 patients were analyzed (336 in 2023&amp;amp;ndash;2024; 148 in 2024&amp;amp;ndash;2025), with immunization coverage reaching 87.5% by April 2025. Compared with the previous season, RSV positivity decreased significantly (32.4% vs. 47.9%; p = 0.003) and was lower in immunized children (16.2% vs. 51.5%; p &amp;amp;lt; 0.001). Immunization was associated with a reduced risk of RSV-positive swab in the second season (OR = 0.159, 95% CI: 0.059&amp;amp;ndash;0.397). Among RSV-negative patients, other respiratory viruses increased (p &amp;amp;lt; 0.001), while co-infections increased in RSV-positive cases (p = 0.021). Hospitalization rates remained stable, though absolute admissions were halved. In conclusion, nirsevimab immunization reduced RSV burden, supporting its inclusion in universal prevention programs and the need for multicenter prospective studies to assess long-term outcomes.</p>
	]]></content:encoded>

	<dc:title>Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study</dc:title>
			<dc:creator>Emanuele Castagno</dc:creator>
			<dc:creator>Carola Aschieri</dc:creator>
			<dc:creator>Irene Ferri</dc:creator>
			<dc:creator>Sara El Khbazi</dc:creator>
			<dc:creator>Lorenzo Milani</dc:creator>
			<dc:creator>Rosanna Irene Comoretto</dc:creator>
			<dc:creator>Irene Raffaldi</dc:creator>
			<dc:creator>Irene Tardivo</dc:creator>
			<dc:creator>Marco Spada</dc:creator>
			<dc:creator>Claudia Bondone</dc:creator>
			<dc:creator>Franca Fagioli</dc:creator>
		<dc:identifier>doi: 10.3390/v18040469</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-16</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-16</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>469</prism:startingPage>
		<prism:doi>10.3390/v18040469</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/469</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/468">

	<title>Viruses, Vol. 18, Pages 468: Epidemiology, Genetic Evolution, and Capsid Protein Variation of Porcine Circovirus 2 in China (2023&amp;ndash;2024): Sustained Dominance of Genotype PCV2d</title>
	<link>https://www.mdpi.com/1999-4915/18/4/468</link>
	<description>Porcine circovirus type 2 (PCV2) is a pathogen of major importance in swine that is characterized by ongoing genetic evolution. To provide an updated epidemiological assessment for China, our study analyzed 1051 clinical samples collected from 27 provincial-level regions between 2023 and 2024. The overall PCV2 positivity rate was 65.18%, with detection rates showing significant seasonal variation, with higher rates in spring and summer. Genotypic analysis of 379 open reading frame 2 (ORF2) sequences identified PCV2d as the dominant genotype (78.89%), and no significant geographic clustering was observed. Coinfection with porcine reproductive and respiratory syndrome virus (PRRSV) is common, yet statistical tests have revealed an epidemiologically independent relationship between the two viruses. Notably, analysis of the capsid (Cap) protein revealed that high-frequency amino acid mutations were concentrated in immunodominant loop regions. These mutations resulted in genotype-specific substitutions within key neutralizing epitopes. This study provides the latest large-scale national baseline data on PCV2 in China for 2023&amp;amp;ndash;2024. It systematically analyzes the epidemiological characteristics of the dominant PCV2d genotype in the post-African Swine Fever era, the patterns of antigenic epitope mutations in the Cap protein, and their potential impact on vaccine efficacy. The study fills a gap in recent national epidemiological data on PCV2 in China and provides a basis for the targeted prevention and control of PCV2 and the updating of vaccine strains.</description>
	<pubDate>2026-04-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 468: Epidemiology, Genetic Evolution, and Capsid Protein Variation of Porcine Circovirus 2 in China (2023&amp;ndash;2024): Sustained Dominance of Genotype PCV2d</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/468">doi: 10.3390/v18040468</a></p>
	<p>Authors:
		Ze Tong
		Shiting Ni
		Jiaqi Liu
		Pingxuan Liu
		Daisheng Shi
		Guosheng Chen
		Xin Zong
		Yaning Lv
		Renhang Xiao
		Chen Tan
		</p>
	<p>Porcine circovirus type 2 (PCV2) is a pathogen of major importance in swine that is characterized by ongoing genetic evolution. To provide an updated epidemiological assessment for China, our study analyzed 1051 clinical samples collected from 27 provincial-level regions between 2023 and 2024. The overall PCV2 positivity rate was 65.18%, with detection rates showing significant seasonal variation, with higher rates in spring and summer. Genotypic analysis of 379 open reading frame 2 (ORF2) sequences identified PCV2d as the dominant genotype (78.89%), and no significant geographic clustering was observed. Coinfection with porcine reproductive and respiratory syndrome virus (PRRSV) is common, yet statistical tests have revealed an epidemiologically independent relationship between the two viruses. Notably, analysis of the capsid (Cap) protein revealed that high-frequency amino acid mutations were concentrated in immunodominant loop regions. These mutations resulted in genotype-specific substitutions within key neutralizing epitopes. This study provides the latest large-scale national baseline data on PCV2 in China for 2023&amp;amp;ndash;2024. It systematically analyzes the epidemiological characteristics of the dominant PCV2d genotype in the post-African Swine Fever era, the patterns of antigenic epitope mutations in the Cap protein, and their potential impact on vaccine efficacy. The study fills a gap in recent national epidemiological data on PCV2 in China and provides a basis for the targeted prevention and control of PCV2 and the updating of vaccine strains.</p>
	]]></content:encoded>

	<dc:title>Epidemiology, Genetic Evolution, and Capsid Protein Variation of Porcine Circovirus 2 in China (2023&amp;amp;ndash;2024): Sustained Dominance of Genotype PCV2d</dc:title>
			<dc:creator>Ze Tong</dc:creator>
			<dc:creator>Shiting Ni</dc:creator>
			<dc:creator>Jiaqi Liu</dc:creator>
			<dc:creator>Pingxuan Liu</dc:creator>
			<dc:creator>Daisheng Shi</dc:creator>
			<dc:creator>Guosheng Chen</dc:creator>
			<dc:creator>Xin Zong</dc:creator>
			<dc:creator>Yaning Lv</dc:creator>
			<dc:creator>Renhang Xiao</dc:creator>
			<dc:creator>Chen Tan</dc:creator>
		<dc:identifier>doi: 10.3390/v18040468</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-15</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-15</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>468</prism:startingPage>
		<prism:doi>10.3390/v18040468</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/468</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/467">

	<title>Viruses, Vol. 18, Pages 467: Effect of Acid-Stabilizing Hemagglutinin Mutations on Immunogenicity and Heterologous Protection by H1N1 Influenza Virus mRNA-LNP Vaccines</title>
	<link>https://www.mdpi.com/1999-4915/18/4/467</link>
	<description>While current influenza vaccines often lack broad protection against antigenically drifted strains, some modified hemagglutinin (HA) protein antigens have shown promise in eliciting broadly neutralizing antibodies against conserved epitopes. During infection, the mildly acidic environment of the late endosome triggers irreversible HA conformational changes resulting in a post-fusion structure with altered antigenicity. While enhancing the stability of other structural class I viral fusion protein antigens has been instrumental in improving the effectiveness of COVID-19 and RSV vaccines, the role of HA stability in influenza vaccine immunogenicity is relatively unclear. Here, we used the nucleoside-modified mRNA-LNP platform to test engineered HA antigens with specific acid-stabilizing mutations (E47K, K58I, R106K, and K153E) in the HA stalk. All mutations increased HA acid stability, but E47K and R106K did not increase immunogenicity. K153E and K58I, but not E47K and R106K, enhanced the cell-surface expression of the HA protein in vitro. In mice, K153E- and K58I-containing mRNA-LNP vaccines elicited increased neutralizing antibody titers against homologous virus. K153E conferred greater protection than wild-type vaccine against lethal heterologous A/PR/8/34 challenge at low doses (0.5&amp;amp;ndash;1.0 &amp;amp;micro;g), despite the absence of neutralizing antibodies against the challenge strain. K153E also elicited greater expansion of antigen-specific antibody-secreting cells (ASCs) in the bone marrow, as well as cross-reactive T follicular helper (Tfh) cells in the spleen. For the vaccines studied, increased HA expression was a stronger correlate of mRNA-LNP enhancement than increased HA stability.</description>
	<pubDate>2026-04-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 467: Effect of Acid-Stabilizing Hemagglutinin Mutations on Immunogenicity and Heterologous Protection by H1N1 Influenza Virus mRNA-LNP Vaccines</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/467">doi: 10.3390/v18040467</a></p>
	<p>Authors:
		Chet R. Ojha
		Samuel W. Rovito
		Balaji Banoth
		Hyunsuh Kim
		Jeremy C. Jones
		Mohamad-Gabriel Alameh
		Po-Ling Chen
		Richard J. Webby
		Drew Weissman
		Charles J. Russell
		</p>
	<p>While current influenza vaccines often lack broad protection against antigenically drifted strains, some modified hemagglutinin (HA) protein antigens have shown promise in eliciting broadly neutralizing antibodies against conserved epitopes. During infection, the mildly acidic environment of the late endosome triggers irreversible HA conformational changes resulting in a post-fusion structure with altered antigenicity. While enhancing the stability of other structural class I viral fusion protein antigens has been instrumental in improving the effectiveness of COVID-19 and RSV vaccines, the role of HA stability in influenza vaccine immunogenicity is relatively unclear. Here, we used the nucleoside-modified mRNA-LNP platform to test engineered HA antigens with specific acid-stabilizing mutations (E47K, K58I, R106K, and K153E) in the HA stalk. All mutations increased HA acid stability, but E47K and R106K did not increase immunogenicity. K153E and K58I, but not E47K and R106K, enhanced the cell-surface expression of the HA protein in vitro. In mice, K153E- and K58I-containing mRNA-LNP vaccines elicited increased neutralizing antibody titers against homologous virus. K153E conferred greater protection than wild-type vaccine against lethal heterologous A/PR/8/34 challenge at low doses (0.5&amp;amp;ndash;1.0 &amp;amp;micro;g), despite the absence of neutralizing antibodies against the challenge strain. K153E also elicited greater expansion of antigen-specific antibody-secreting cells (ASCs) in the bone marrow, as well as cross-reactive T follicular helper (Tfh) cells in the spleen. For the vaccines studied, increased HA expression was a stronger correlate of mRNA-LNP enhancement than increased HA stability.</p>
	]]></content:encoded>

	<dc:title>Effect of Acid-Stabilizing Hemagglutinin Mutations on Immunogenicity and Heterologous Protection by H1N1 Influenza Virus mRNA-LNP Vaccines</dc:title>
			<dc:creator>Chet R. Ojha</dc:creator>
			<dc:creator>Samuel W. Rovito</dc:creator>
			<dc:creator>Balaji Banoth</dc:creator>
			<dc:creator>Hyunsuh Kim</dc:creator>
			<dc:creator>Jeremy C. Jones</dc:creator>
			<dc:creator>Mohamad-Gabriel Alameh</dc:creator>
			<dc:creator>Po-Ling Chen</dc:creator>
			<dc:creator>Richard J. Webby</dc:creator>
			<dc:creator>Drew Weissman</dc:creator>
			<dc:creator>Charles J. Russell</dc:creator>
		<dc:identifier>doi: 10.3390/v18040467</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-15</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-15</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>467</prism:startingPage>
		<prism:doi>10.3390/v18040467</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/467</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/466">

	<title>Viruses, Vol. 18, Pages 466: TRIM13 Positively Regulates the NF-&amp;kappa;B Signaling Pathway Induced by Encephalomyocarditis Virus</title>
	<link>https://www.mdpi.com/1999-4915/18/4/466</link>
	<description>Encephalomyocarditis virus (EMCV) belongs to the genus Cardiovirus of the family Picornaviridae. It is a non-enveloped, positive-sense, single-stranded RNA virus and an important pathogen causing encephalomyocarditis (EMC). Tripartite motif 13 (TRIM13) is a member of the tripartite motif (TRIM) family and serves as an important effector molecule in antiviral innate immunity. However, its antiviral activity and underlying molecular mechanisms during EMCV infection remain unknown. In this study, we identified TRIM13 as a regulator of NF-&amp;amp;kappa;B activation. TRIM13, dependent on its E3 ubiquitin ligase activity, directly binds to I&amp;amp;kappa;B&amp;amp;alpha; and dose-dependently increases its phosphorylation level. To determine the chain type of I&amp;amp;kappa;B&amp;amp;alpha; polyubiquitination, antibodies specific for K48-linked and K63-linked ubiquitin were used. Our data indicated that I&amp;amp;kappa;B&amp;amp;alpha; was subjected to polyubiquitination independent of K48 and K63 linkages. This interaction promotes non-K48/K63-linked polyubiquitination of I&amp;amp;kappa;B&amp;amp;alpha;, thereby inducing NF-&amp;amp;kappa;B nuclear translocation. Subsequently, nuclear NF-&amp;amp;kappa;B activates the secretion of pro-inflammatory cytokines, exacerbating inflammatory responses and ultimately facilitating EMCV infection.</description>
	<pubDate>2026-04-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 466: TRIM13 Positively Regulates the NF-&amp;kappa;B Signaling Pathway Induced by Encephalomyocarditis Virus</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/466">doi: 10.3390/v18040466</a></p>
	<p>Authors:
		Xiaolan Ji
		Donglin Bi
		Mingqi Liu
		Xiangru Du
		Zhiqi Wang
		Haiqing Li
		Jinluan Wang
		Yiyang Fan
		Hao Gao
		Derong Zhang
		Jialin Bai
		Qiongyi Li
		</p>
	<p>Encephalomyocarditis virus (EMCV) belongs to the genus Cardiovirus of the family Picornaviridae. It is a non-enveloped, positive-sense, single-stranded RNA virus and an important pathogen causing encephalomyocarditis (EMC). Tripartite motif 13 (TRIM13) is a member of the tripartite motif (TRIM) family and serves as an important effector molecule in antiviral innate immunity. However, its antiviral activity and underlying molecular mechanisms during EMCV infection remain unknown. In this study, we identified TRIM13 as a regulator of NF-&amp;amp;kappa;B activation. TRIM13, dependent on its E3 ubiquitin ligase activity, directly binds to I&amp;amp;kappa;B&amp;amp;alpha; and dose-dependently increases its phosphorylation level. To determine the chain type of I&amp;amp;kappa;B&amp;amp;alpha; polyubiquitination, antibodies specific for K48-linked and K63-linked ubiquitin were used. Our data indicated that I&amp;amp;kappa;B&amp;amp;alpha; was subjected to polyubiquitination independent of K48 and K63 linkages. This interaction promotes non-K48/K63-linked polyubiquitination of I&amp;amp;kappa;B&amp;amp;alpha;, thereby inducing NF-&amp;amp;kappa;B nuclear translocation. Subsequently, nuclear NF-&amp;amp;kappa;B activates the secretion of pro-inflammatory cytokines, exacerbating inflammatory responses and ultimately facilitating EMCV infection.</p>
	]]></content:encoded>

	<dc:title>TRIM13 Positively Regulates the NF-&amp;amp;kappa;B Signaling Pathway Induced by Encephalomyocarditis Virus</dc:title>
			<dc:creator>Xiaolan Ji</dc:creator>
			<dc:creator>Donglin Bi</dc:creator>
			<dc:creator>Mingqi Liu</dc:creator>
			<dc:creator>Xiangru Du</dc:creator>
			<dc:creator>Zhiqi Wang</dc:creator>
			<dc:creator>Haiqing Li</dc:creator>
			<dc:creator>Jinluan Wang</dc:creator>
			<dc:creator>Yiyang Fan</dc:creator>
			<dc:creator>Hao Gao</dc:creator>
			<dc:creator>Derong Zhang</dc:creator>
			<dc:creator>Jialin Bai</dc:creator>
			<dc:creator>Qiongyi Li</dc:creator>
		<dc:identifier>doi: 10.3390/v18040466</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-14</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-14</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>466</prism:startingPage>
		<prism:doi>10.3390/v18040466</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/466</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/465">

	<title>Viruses, Vol. 18, Pages 465: Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-19</title>
	<link>https://www.mdpi.com/1999-4915/18/4/465</link>
	<description>Objective: The COVID-19 pandemic has strained healthcare systems and has been associated with substantial morbidity and mortality. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2), implicating dysregulation of the renin&amp;amp;ndash;angiotensin system (RAS) in COVID-19 pathophysiology. Measurement of circulating RAS components, including ACE and ACE2, may therefore provide an insight into disease severity and underlying mechanisms. Subjects and Methods: In this retrospective cohort study, 224 adults with PCR-confirmed COVID-19 were stratified by World Health Organization disease-severity criteria into asymptomatic, mild, mild-pneumonia, severe, and critical groups. Plasma ACE and ACE2 concentrations were quantified by ELISA. Demographic, clinical, and laboratory data were extracted from electronic medical records. Results and Conclusions: Increasing disease severity was associated with higher mortality, elevated body mass index, and higher viral load estimates. Severe and critical illness was characterized by leukocytosis with neutrophilia, marked lymphopenia, anemia, elevated inflammatory and coagulation markers, renal dysfunction, and hypoalbuminemia. Plasma ACE2 levels declined progressively with increasing severity and were significantly lower in patients with mild-pneumonia, severe, or critical illness compared with asymptomatic or mild cases, showing a strong inverse correlation with severity. In contrast, plasma ACE levels increased significantly with disease severity. The resulting increase in the ACE/ACE2 ratio indicates a progressive shift toward the pro-inflammatory arm of the RAS, providing mechanistic insight into the COVID-19 pathophysiology.</description>
	<pubDate>2026-04-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 465: Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-19</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/465">doi: 10.3390/v18040465</a></p>
	<p>Authors:
		Murat Oz
		Wassim Chehadeh
		Omamah Alfarisi
		Farhan S. Cyprian
		</p>
	<p>Objective: The COVID-19 pandemic has strained healthcare systems and has been associated with substantial morbidity and mortality. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2), implicating dysregulation of the renin&amp;amp;ndash;angiotensin system (RAS) in COVID-19 pathophysiology. Measurement of circulating RAS components, including ACE and ACE2, may therefore provide an insight into disease severity and underlying mechanisms. Subjects and Methods: In this retrospective cohort study, 224 adults with PCR-confirmed COVID-19 were stratified by World Health Organization disease-severity criteria into asymptomatic, mild, mild-pneumonia, severe, and critical groups. Plasma ACE and ACE2 concentrations were quantified by ELISA. Demographic, clinical, and laboratory data were extracted from electronic medical records. Results and Conclusions: Increasing disease severity was associated with higher mortality, elevated body mass index, and higher viral load estimates. Severe and critical illness was characterized by leukocytosis with neutrophilia, marked lymphopenia, anemia, elevated inflammatory and coagulation markers, renal dysfunction, and hypoalbuminemia. Plasma ACE2 levels declined progressively with increasing severity and were significantly lower in patients with mild-pneumonia, severe, or critical illness compared with asymptomatic or mild cases, showing a strong inverse correlation with severity. In contrast, plasma ACE levels increased significantly with disease severity. The resulting increase in the ACE/ACE2 ratio indicates a progressive shift toward the pro-inflammatory arm of the RAS, providing mechanistic insight into the COVID-19 pathophysiology.</p>
	]]></content:encoded>

	<dc:title>Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-19</dc:title>
			<dc:creator>Murat Oz</dc:creator>
			<dc:creator>Wassim Chehadeh</dc:creator>
			<dc:creator>Omamah Alfarisi</dc:creator>
			<dc:creator>Farhan S. Cyprian</dc:creator>
		<dc:identifier>doi: 10.3390/v18040465</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-14</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-14</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>465</prism:startingPage>
		<prism:doi>10.3390/v18040465</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/465</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/464">

	<title>Viruses, Vol. 18, Pages 464: 25th Annual Meeting of the Rocky Mountain Virology Association</title>
	<link>https://www.mdpi.com/1999-4915/18/4/464</link>
	<description>Located on the traditional and ancestral homelands of the Arapaho, Cheyenne, and Ute Nations, Colorado State University&amp;amp;rsquo;s Mountain Campus hosted the 25th Annual Rocky Mountain Virology Association meeting. The three-day event, held from 26 September to 28 September 2025, welcomed 152 participants focused on the following topics: viruses, prions, immunology, transmission, structural biology, and vector biology. This year&amp;amp;rsquo;s Randall Jay Cohrs Keynote Presentation summarized ongoing research on viral glycoproteins in relation to viral entry and assembly. Understanding the role of viral glycoproteins is essential in vaccine and antiviral development for enveloped RNA viruses. Alongside rigorous scientific discourse and networking, attendees made the most of their time by hiking amidst beautiful fall colors, wildlife, and young aspens starting the forest anew. On behalf of the Rocky Mountain Virology Association, this report summarizes select presentations from the 25th annual meeting.</description>
	<pubDate>2026-04-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 464: 25th Annual Meeting of the Rocky Mountain Virology Association</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/464">doi: 10.3390/v18040464</a></p>
	<p>Authors:
		Talia J. Byrne-Haber
		Kylee N. Pham
		Arianna Joob
		Samantha M. Pinto
		Oshani C. Ratnayake
		Ryan Thompson
		Joel Rovnak
		Rushika Perera
		</p>
	<p>Located on the traditional and ancestral homelands of the Arapaho, Cheyenne, and Ute Nations, Colorado State University&amp;amp;rsquo;s Mountain Campus hosted the 25th Annual Rocky Mountain Virology Association meeting. The three-day event, held from 26 September to 28 September 2025, welcomed 152 participants focused on the following topics: viruses, prions, immunology, transmission, structural biology, and vector biology. This year&amp;amp;rsquo;s Randall Jay Cohrs Keynote Presentation summarized ongoing research on viral glycoproteins in relation to viral entry and assembly. Understanding the role of viral glycoproteins is essential in vaccine and antiviral development for enveloped RNA viruses. Alongside rigorous scientific discourse and networking, attendees made the most of their time by hiking amidst beautiful fall colors, wildlife, and young aspens starting the forest anew. On behalf of the Rocky Mountain Virology Association, this report summarizes select presentations from the 25th annual meeting.</p>
	]]></content:encoded>

	<dc:title>25th Annual Meeting of the Rocky Mountain Virology Association</dc:title>
			<dc:creator>Talia J. Byrne-Haber</dc:creator>
			<dc:creator>Kylee N. Pham</dc:creator>
			<dc:creator>Arianna Joob</dc:creator>
			<dc:creator>Samantha M. Pinto</dc:creator>
			<dc:creator>Oshani C. Ratnayake</dc:creator>
			<dc:creator>Ryan Thompson</dc:creator>
			<dc:creator>Joel Rovnak</dc:creator>
			<dc:creator>Rushika Perera</dc:creator>
		<dc:identifier>doi: 10.3390/v18040464</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-14</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-14</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Conference Report</prism:section>
	<prism:startingPage>464</prism:startingPage>
		<prism:doi>10.3390/v18040464</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/464</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/463">

	<title>Viruses, Vol. 18, Pages 463: Roles of the Chemokine Receptor CX3CR1 in the Pathogenesis of RSV Infections</title>
	<link>https://www.mdpi.com/1999-4915/18/4/463</link>
	<description>CX3CR1 is a chemokine receptor expressed on respiratory epithelial and immune cells and has been identified as a host factor important for infections with respiratory syncytial virus (RSV). In this review, we discuss the roles CX3CR1 plays in the pathogenesis of RSV infections as a viral entry receptor and regulator of immune cell trafficking. The conserved CX3C motif of the RSV G glycoprotein binds to CX3CR1 to mediate viral attachment and entry into respiratory epithelial cells. Furthermore, soluble G protein (sG) can bind to CX3CR1 and competitively interfere with cell signaling induced by the chemokine CX3CL1, resulting in inhibition of immune cell recruitment to the site of infection. In addition, sG engages TLR2 on epithelial cells, activating MyD88-NF-&amp;amp;kappa;B signaling and priming the NLRP3 inflammasome, which enhances viral dissemination through pyroptotic cell death. CX3CR1 signaling should be viewed as one of several overlapping host factors that&amp;amp;mdash;along with developmental changes in interferon and STAT3 signaling, airway anatomy, inflammasome activity, and tissue-resident memory responses&amp;amp;mdash;contribute to differential disease outcomes of RSV infection. A more complete molecular understanding of RSV-CX3CR1 interactions and downstream host responses may enable the development of improved prevention and treatment strategies.</description>
	<pubDate>2026-04-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 463: Roles of the Chemokine Receptor CX3CR1 in the Pathogenesis of RSV Infections</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/463">doi: 10.3390/v18040463</a></p>
	<p>Authors:
		Robert Meineke
		Martin Ludlow
		Albert D. M. E. Osterhaus
		Guus F. Rimmelzwaan
		</p>
	<p>CX3CR1 is a chemokine receptor expressed on respiratory epithelial and immune cells and has been identified as a host factor important for infections with respiratory syncytial virus (RSV). In this review, we discuss the roles CX3CR1 plays in the pathogenesis of RSV infections as a viral entry receptor and regulator of immune cell trafficking. The conserved CX3C motif of the RSV G glycoprotein binds to CX3CR1 to mediate viral attachment and entry into respiratory epithelial cells. Furthermore, soluble G protein (sG) can bind to CX3CR1 and competitively interfere with cell signaling induced by the chemokine CX3CL1, resulting in inhibition of immune cell recruitment to the site of infection. In addition, sG engages TLR2 on epithelial cells, activating MyD88-NF-&amp;amp;kappa;B signaling and priming the NLRP3 inflammasome, which enhances viral dissemination through pyroptotic cell death. CX3CR1 signaling should be viewed as one of several overlapping host factors that&amp;amp;mdash;along with developmental changes in interferon and STAT3 signaling, airway anatomy, inflammasome activity, and tissue-resident memory responses&amp;amp;mdash;contribute to differential disease outcomes of RSV infection. A more complete molecular understanding of RSV-CX3CR1 interactions and downstream host responses may enable the development of improved prevention and treatment strategies.</p>
	]]></content:encoded>

	<dc:title>Roles of the Chemokine Receptor CX3CR1 in the Pathogenesis of RSV Infections</dc:title>
			<dc:creator>Robert Meineke</dc:creator>
			<dc:creator>Martin Ludlow</dc:creator>
			<dc:creator>Albert D. M. E. Osterhaus</dc:creator>
			<dc:creator>Guus F. Rimmelzwaan</dc:creator>
		<dc:identifier>doi: 10.3390/v18040463</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-13</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>463</prism:startingPage>
		<prism:doi>10.3390/v18040463</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/463</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/462">

	<title>Viruses, Vol. 18, Pages 462: In Vitro Antiviral Properties of Two Recombinant Sendai Virus Vectors Encoding ORFV 011 and ORFV 059 Genes</title>
	<link>https://www.mdpi.com/1999-4915/18/4/462</link>
	<description>Orf virus (ORFV) is a globally distributed zoonotic parapoxvirus that causes a highly contagious mucocutaneous disease in small ruminants. Despite the urgent demand for vaccination-based control, no licensed vaccines are currently available universally. In this study, we generated two recombinant Sendai virus (SeV) vectors expressing ORFV 011 (rSeV-GFP-B2L) and ORFV 059 (rSeV-GFP-059) genes and evaluated their ability to stimulate antiviral responses in vitro. Following the transduction, we assessed transgene expression, innate immune activation, induction of interferon-stimulated genes (A3Z1, OBST2, SAMHD1), and antiviral activity. Both vectors significantly upregulated pattern recognition receptors (TLRs, RIG-I) and type I interferon (IFN-&amp;amp;beta;) genes, with rSeV-GFP-059 inducing the strongest response. Remarkably, OBST2 was robustly upregulated, suggesting a potential role in restricting ORFV replication. Antiviral activity assays revealed a marked reduction in ORFV DNA copies and a mild decrease in ORFV RNA transcription in rSeV-GFP-059-transduced cells, particularly at later time points, accompanied by complete abrogation of the typical cytopathic effect. Collectively, these results demonstrate that SeV-based vectors, particularly rSeV-GFP-059, efficiently prime antiviral immunity and suppress ORFV replication, establishing a promising platform for further in vivo vaccine evaluation in sheep.</description>
	<pubDate>2026-04-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 462: In Vitro Antiviral Properties of Two Recombinant Sendai Virus Vectors Encoding ORFV 011 and ORFV 059 Genes</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/462">doi: 10.3390/v18040462</a></p>
	<p>Authors:
		Álex Gómez
		Idoia Glaria
		Irati Moncayola
		Leonor Puzol
		Laura Arriazu
		Ainhoa Calero
		Ignacio de Blas
		Mikel Nazábal
		Itziar Hualde
		Benhur Lee
		Lluís Luján
		Ralf Amann
		Irache Echeverría
		Ramsés Reina
		</p>
	<p>Orf virus (ORFV) is a globally distributed zoonotic parapoxvirus that causes a highly contagious mucocutaneous disease in small ruminants. Despite the urgent demand for vaccination-based control, no licensed vaccines are currently available universally. In this study, we generated two recombinant Sendai virus (SeV) vectors expressing ORFV 011 (rSeV-GFP-B2L) and ORFV 059 (rSeV-GFP-059) genes and evaluated their ability to stimulate antiviral responses in vitro. Following the transduction, we assessed transgene expression, innate immune activation, induction of interferon-stimulated genes (A3Z1, OBST2, SAMHD1), and antiviral activity. Both vectors significantly upregulated pattern recognition receptors (TLRs, RIG-I) and type I interferon (IFN-&amp;amp;beta;) genes, with rSeV-GFP-059 inducing the strongest response. Remarkably, OBST2 was robustly upregulated, suggesting a potential role in restricting ORFV replication. Antiviral activity assays revealed a marked reduction in ORFV DNA copies and a mild decrease in ORFV RNA transcription in rSeV-GFP-059-transduced cells, particularly at later time points, accompanied by complete abrogation of the typical cytopathic effect. Collectively, these results demonstrate that SeV-based vectors, particularly rSeV-GFP-059, efficiently prime antiviral immunity and suppress ORFV replication, establishing a promising platform for further in vivo vaccine evaluation in sheep.</p>
	]]></content:encoded>

	<dc:title>In Vitro Antiviral Properties of Two Recombinant Sendai Virus Vectors Encoding ORFV 011 and ORFV 059 Genes</dc:title>
			<dc:creator>Álex Gómez</dc:creator>
			<dc:creator>Idoia Glaria</dc:creator>
			<dc:creator>Irati Moncayola</dc:creator>
			<dc:creator>Leonor Puzol</dc:creator>
			<dc:creator>Laura Arriazu</dc:creator>
			<dc:creator>Ainhoa Calero</dc:creator>
			<dc:creator>Ignacio de Blas</dc:creator>
			<dc:creator>Mikel Nazábal</dc:creator>
			<dc:creator>Itziar Hualde</dc:creator>
			<dc:creator>Benhur Lee</dc:creator>
			<dc:creator>Lluís Luján</dc:creator>
			<dc:creator>Ralf Amann</dc:creator>
			<dc:creator>Irache Echeverría</dc:creator>
			<dc:creator>Ramsés Reina</dc:creator>
		<dc:identifier>doi: 10.3390/v18040462</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-13</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>462</prism:startingPage>
		<prism:doi>10.3390/v18040462</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/462</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/461">

	<title>Viruses, Vol. 18, Pages 461: Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation</title>
	<link>https://www.mdpi.com/1999-4915/18/4/461</link>
	<description>Oncolytic viruses represent a paradigm-shifting approach to cancer immunotherapy, functioning as in situ vaccines that convert immunologically &amp;amp;ldquo;cold&amp;amp;rdquo; tumors into &amp;amp;ldquo;hot&amp;amp;rdquo; tumors through induction of immunogenic cell death (ICD). Despite the clinical success of checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), many patients exhibit primary or acquired resistance due to insufficient tumor immunogenicity and exclusion of tumor-infiltrating lymphocytes. Oncolytic viruses address this limitation by selectively replicating in tumor cells, inducing robust ICD characterized by four cardinal hallmarks: calreticulin exposure, ATP secretion, HMGB1 release, and type I interferon production. This review systematically examines the molecular mechanisms underlying virus-induced ICD, compares DNA virus platforms (Vaccinia, HSV-1, Adenovirus) with RNA virus platforms (Coxsackieviruses A21, A11, and B3), and analyzes clinical trial data demonstrating synergistic efficacy when combined with checkpoint inhibitors. Notably, RNA viruses generate higher type I interferon responses compared to DNA viruses, correlating with superior clinical outcomes. Coxsackievirus A21 combined with pembrolizumab achieved a 47% objective response rate in melanoma in the CAPRA trial, representing notable efficacy exceeding either monotherapy. Coxsackievirus A11 demonstrates exceptional selectivity for thoracic cancers through ICAM-1-dependent receptor tropism and potent immunogenic cell death induction. Japanese researchers have pioneered microRNA-targeted Coxsackievirus B3, achieving cardiac safety attenuation while preserving complete oncolytic potency and ICD-inducing capacity. This comprehensive analysis synthesizes molecular mechanisms, platform comparisons, clinical efficacy data, and translational challenges to guide future development of oncolytic virotherapy as a cornerstone of cancer immunotherapy.</description>
	<pubDate>2026-04-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 461: Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/461">doi: 10.3390/v18040461</a></p>
	<p>Authors:
		Hiroyuki Inoue
		</p>
	<p>Oncolytic viruses represent a paradigm-shifting approach to cancer immunotherapy, functioning as in situ vaccines that convert immunologically &amp;amp;ldquo;cold&amp;amp;rdquo; tumors into &amp;amp;ldquo;hot&amp;amp;rdquo; tumors through induction of immunogenic cell death (ICD). Despite the clinical success of checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), many patients exhibit primary or acquired resistance due to insufficient tumor immunogenicity and exclusion of tumor-infiltrating lymphocytes. Oncolytic viruses address this limitation by selectively replicating in tumor cells, inducing robust ICD characterized by four cardinal hallmarks: calreticulin exposure, ATP secretion, HMGB1 release, and type I interferon production. This review systematically examines the molecular mechanisms underlying virus-induced ICD, compares DNA virus platforms (Vaccinia, HSV-1, Adenovirus) with RNA virus platforms (Coxsackieviruses A21, A11, and B3), and analyzes clinical trial data demonstrating synergistic efficacy when combined with checkpoint inhibitors. Notably, RNA viruses generate higher type I interferon responses compared to DNA viruses, correlating with superior clinical outcomes. Coxsackievirus A21 combined with pembrolizumab achieved a 47% objective response rate in melanoma in the CAPRA trial, representing notable efficacy exceeding either monotherapy. Coxsackievirus A11 demonstrates exceptional selectivity for thoracic cancers through ICAM-1-dependent receptor tropism and potent immunogenic cell death induction. Japanese researchers have pioneered microRNA-targeted Coxsackievirus B3, achieving cardiac safety attenuation while preserving complete oncolytic potency and ICD-inducing capacity. This comprehensive analysis synthesizes molecular mechanisms, platform comparisons, clinical efficacy data, and translational challenges to guide future development of oncolytic virotherapy as a cornerstone of cancer immunotherapy.</p>
	]]></content:encoded>

	<dc:title>Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation</dc:title>
			<dc:creator>Hiroyuki Inoue</dc:creator>
		<dc:identifier>doi: 10.3390/v18040461</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-13</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>461</prism:startingPage>
		<prism:doi>10.3390/v18040461</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/461</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/460">

	<title>Viruses, Vol. 18, Pages 460: Sorting Nexin 10 Mediates Endosomal Acidification and Autophagy to Promote Influenza A Virus Infection</title>
	<link>https://www.mdpi.com/1999-4915/18/4/460</link>
	<description>The infection cycle of the Influenza A Virus (IAV) typically requires host factors to regulate replication and proliferation. However, the roles of these factors remain undiscovered. This study focuses on Sorting Nexin 10 (SNX10), which is involved in regulating membrane trafficking and endosomal stabilization. Our previous study identified that SNX10 facilitates the replication of human coronavirus OC43 through enhancing clathrin-mediated endocytosis. In our present study, we found that SNX10 significantly promoted IAV infection in host cells. The conditional knockout of Snx10 in mice lungs prolonged survival following IAV challenge. Mechanistically, SNX10 facilitated the production of acidic endosomal vesicles and promoted the accumulation of pro-viral autophagic structures, a process supported by the specific interaction between SNX10 and the viral NP and M2 protein of IAV. Blocking SNX10-mediated acidic endosomal vesicles and autophagosome formation demonstrated antiviral effects. Moreover, IAV infection increased SNX10 protein levels by suppressing its ubiquitination, suggesting that SNX10 could serve as a potential host-derived antiviral drug target.</description>
	<pubDate>2026-04-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 460: Sorting Nexin 10 Mediates Endosomal Acidification and Autophagy to Promote Influenza A Virus Infection</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/460">doi: 10.3390/v18040460</a></p>
	<p>Authors:
		Lizhu Chen
		Haobin Li
		Huiyi Guo
		Jinlong Liang
		Yingyuan Zhong
		Xucheng He
		Wenjiao Wu
		Shuwen Liu
		</p>
	<p>The infection cycle of the Influenza A Virus (IAV) typically requires host factors to regulate replication and proliferation. However, the roles of these factors remain undiscovered. This study focuses on Sorting Nexin 10 (SNX10), which is involved in regulating membrane trafficking and endosomal stabilization. Our previous study identified that SNX10 facilitates the replication of human coronavirus OC43 through enhancing clathrin-mediated endocytosis. In our present study, we found that SNX10 significantly promoted IAV infection in host cells. The conditional knockout of Snx10 in mice lungs prolonged survival following IAV challenge. Mechanistically, SNX10 facilitated the production of acidic endosomal vesicles and promoted the accumulation of pro-viral autophagic structures, a process supported by the specific interaction between SNX10 and the viral NP and M2 protein of IAV. Blocking SNX10-mediated acidic endosomal vesicles and autophagosome formation demonstrated antiviral effects. Moreover, IAV infection increased SNX10 protein levels by suppressing its ubiquitination, suggesting that SNX10 could serve as a potential host-derived antiviral drug target.</p>
	]]></content:encoded>

	<dc:title>Sorting Nexin 10 Mediates Endosomal Acidification and Autophagy to Promote Influenza A Virus Infection</dc:title>
			<dc:creator>Lizhu Chen</dc:creator>
			<dc:creator>Haobin Li</dc:creator>
			<dc:creator>Huiyi Guo</dc:creator>
			<dc:creator>Jinlong Liang</dc:creator>
			<dc:creator>Yingyuan Zhong</dc:creator>
			<dc:creator>Xucheng He</dc:creator>
			<dc:creator>Wenjiao Wu</dc:creator>
			<dc:creator>Shuwen Liu</dc:creator>
		<dc:identifier>doi: 10.3390/v18040460</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-12</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>460</prism:startingPage>
		<prism:doi>10.3390/v18040460</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/460</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/459">

	<title>Viruses, Vol. 18, Pages 459: A Mouse-Adapted CHIKV Strain Harboring E2-K200R and Non-Structural Mutations Exhibits Enhanced Pathogenicity in Multiple Rodent Models</title>
	<link>https://www.mdpi.com/1999-4915/18/4/459</link>
	<description>Chikungunya virus (CHIKV) pathogenesis research has long been constrained by the lack of suitable immunocompetent rodent models. Through serial passaging in A129 and C57BL/6 mice, we obtained an adapted strain (CHIKV-Adapt) harboring an E2-K200R substitution along with non-structural protein mutations. Phenotypic analysis in C57BL/6 mice, BALB/c mice, and hamster models demonstrated that compared to the wild-type virus CHIKV-Adapt induced significantly higher and more prolonged viremia, broader tissue tropism, and more severe internal joint inflammation, without exacerbating external swelling. Notably, the K200R mutation did not alter the viral replication kinetics in vitro and was predicted not to affect its binding pattern to the MXRA8 receptor. Furthermore, mice challenged 160 days after primary infection exhibited nearly complete protective immunity. These findings indicate that E2-K200R is a critical adaptive mutation that, together with accompanying non-structural mutations, significantly enhances CHIKV replication capacity and pathogenicity in immunocompetent rodents without changing its in vitro replication ability or predicted receptor-binding mode. The acquisition of this adapted strain provides a new tool for CHIKV pathogenesis research and vaccine evaluation.</description>
	<pubDate>2026-04-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 459: A Mouse-Adapted CHIKV Strain Harboring E2-K200R and Non-Structural Mutations Exhibits Enhanced Pathogenicity in Multiple Rodent Models</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/459">doi: 10.3390/v18040459</a></p>
	<p>Authors:
		Cong Tang
		Bai Li
		Qing Huang
		Yun Yang
		Wenhai Yu
		Yanan Zhou
		Daoju Wu
		Hao Yang
		Haixuan Wang
		Junbin Wang
		Shuaiyao Lu
		</p>
	<p>Chikungunya virus (CHIKV) pathogenesis research has long been constrained by the lack of suitable immunocompetent rodent models. Through serial passaging in A129 and C57BL/6 mice, we obtained an adapted strain (CHIKV-Adapt) harboring an E2-K200R substitution along with non-structural protein mutations. Phenotypic analysis in C57BL/6 mice, BALB/c mice, and hamster models demonstrated that compared to the wild-type virus CHIKV-Adapt induced significantly higher and more prolonged viremia, broader tissue tropism, and more severe internal joint inflammation, without exacerbating external swelling. Notably, the K200R mutation did not alter the viral replication kinetics in vitro and was predicted not to affect its binding pattern to the MXRA8 receptor. Furthermore, mice challenged 160 days after primary infection exhibited nearly complete protective immunity. These findings indicate that E2-K200R is a critical adaptive mutation that, together with accompanying non-structural mutations, significantly enhances CHIKV replication capacity and pathogenicity in immunocompetent rodents without changing its in vitro replication ability or predicted receptor-binding mode. The acquisition of this adapted strain provides a new tool for CHIKV pathogenesis research and vaccine evaluation.</p>
	]]></content:encoded>

	<dc:title>A Mouse-Adapted CHIKV Strain Harboring E2-K200R and Non-Structural Mutations Exhibits Enhanced Pathogenicity in Multiple Rodent Models</dc:title>
			<dc:creator>Cong Tang</dc:creator>
			<dc:creator>Bai Li</dc:creator>
			<dc:creator>Qing Huang</dc:creator>
			<dc:creator>Yun Yang</dc:creator>
			<dc:creator>Wenhai Yu</dc:creator>
			<dc:creator>Yanan Zhou</dc:creator>
			<dc:creator>Daoju Wu</dc:creator>
			<dc:creator>Hao Yang</dc:creator>
			<dc:creator>Haixuan Wang</dc:creator>
			<dc:creator>Junbin Wang</dc:creator>
			<dc:creator>Shuaiyao Lu</dc:creator>
		<dc:identifier>doi: 10.3390/v18040459</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-12</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>459</prism:startingPage>
		<prism:doi>10.3390/v18040459</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/459</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/458">

	<title>Viruses, Vol. 18, Pages 458: Integrative Insights into the Immunopathogenesis and Organ-Specific Immunological Mechanisms of Long COVID: A Narrative Review</title>
	<link>https://www.mdpi.com/1999-4915/18/4/458</link>
	<description>Long COVID (LC), also referred to as post-acute sequelae of SARS-CoV-2 infection, is characterized by persistent symptoms originating 3 months following acute COVID-19, lasting for at least two months and frequently affecting individuals who initially experienced mild to moderate disease. The clinical spectrum is heterogeneous, involving respiratory, cardiovascular, neurological, renal, gastrointestinal, and endocrine systems, thereby posing substantial diagnostic and therapeutic challenges. Despite extensive investigation, the precise immunopathogenic mechanisms underlying LC remain incompletely defined. Accumulating evidence suggests that LC is driven by a multifactorial interplay of persistent viral antigen reservoirs, chronic immune activation, dysregulated innate and adaptive immune responses, autoimmunity, endothelial dysfunction, microvascular injury, and aberrant tissue repair. These systemic immune perturbations manifest variably across different organs, contributing to the diverse clinical phenotypes observed. However, mechanistic clarity is hindered by heterogeneity in study designs, limited longitudinal data, and the absence of standardized immunological profiling. This narrative review provides integrative insights into the immunopathogenesis of LC, synthesizing current evidence on systemic immune dysregulation and organ-specific immunological mechanisms. A conceptual framework is proposed to facilitate a structured understanding of this complex syndrome and to guide future research toward targeted immunomodulatory strategies.</description>
	<pubDate>2026-04-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 458: Integrative Insights into the Immunopathogenesis and Organ-Specific Immunological Mechanisms of Long COVID: A Narrative Review</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/458">doi: 10.3390/v18040458</a></p>
	<p>Authors:
		Supriya Mahajan
		Saurabh Mahajan
		Nidhi Kaushik
		</p>
	<p>Long COVID (LC), also referred to as post-acute sequelae of SARS-CoV-2 infection, is characterized by persistent symptoms originating 3 months following acute COVID-19, lasting for at least two months and frequently affecting individuals who initially experienced mild to moderate disease. The clinical spectrum is heterogeneous, involving respiratory, cardiovascular, neurological, renal, gastrointestinal, and endocrine systems, thereby posing substantial diagnostic and therapeutic challenges. Despite extensive investigation, the precise immunopathogenic mechanisms underlying LC remain incompletely defined. Accumulating evidence suggests that LC is driven by a multifactorial interplay of persistent viral antigen reservoirs, chronic immune activation, dysregulated innate and adaptive immune responses, autoimmunity, endothelial dysfunction, microvascular injury, and aberrant tissue repair. These systemic immune perturbations manifest variably across different organs, contributing to the diverse clinical phenotypes observed. However, mechanistic clarity is hindered by heterogeneity in study designs, limited longitudinal data, and the absence of standardized immunological profiling. This narrative review provides integrative insights into the immunopathogenesis of LC, synthesizing current evidence on systemic immune dysregulation and organ-specific immunological mechanisms. A conceptual framework is proposed to facilitate a structured understanding of this complex syndrome and to guide future research toward targeted immunomodulatory strategies.</p>
	]]></content:encoded>

	<dc:title>Integrative Insights into the Immunopathogenesis and Organ-Specific Immunological Mechanisms of Long COVID: A Narrative Review</dc:title>
			<dc:creator>Supriya Mahajan</dc:creator>
			<dc:creator>Saurabh Mahajan</dc:creator>
			<dc:creator>Nidhi Kaushik</dc:creator>
		<dc:identifier>doi: 10.3390/v18040458</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-10</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-10</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>458</prism:startingPage>
		<prism:doi>10.3390/v18040458</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/458</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/457">

	<title>Viruses, Vol. 18, Pages 457: Viruses in Extreme Marine Environments and Their Potential Existence in Extraterrestrial Environments</title>
	<link>https://www.mdpi.com/1999-4915/18/4/457</link>
	<description>Viruses are abundant and widespread in extreme marine environments, such as sea ice, hydrothermal vents, and ocean trenches. They occur at temperatures up to 122 &amp;amp;deg;C and down to &amp;amp;minus;30 &amp;amp;deg;C and pressures exceeding 100 MPa. Their distribution in these environments is closely correlated with that of their extremophile hosts, which are mostly bacteria, archaea, and microeukaryotes. Viruses have been shown to be capable of long-term survival in conditions simulating interstellar conditions. However, for them to reproduce, they would still need a host. Many recent astro-biological investigations have focused on habitability, specifically the ability of a planet to support the activity of at least one lifeform. The most likely candidates for extraterrestrial habitability in our solar system are the sea ice moons of Jupiter and Saturn, namely Europa and Enceladus. These are both thought to contain subsurface oceans of liquid water and potentially access to the necessary elements for microbial growth. If microorganisms were to be detected in these extraterrestrial environments, viruses might also be found coexisting with their host cells.</description>
	<pubDate>2026-04-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 457: Viruses in Extreme Marine Environments and Their Potential Existence in Extraterrestrial Environments</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/457">doi: 10.3390/v18040457</a></p>
	<p>Authors:
		Andrew McMinn
		Yantao Liang
		Ziyue Wang
		Min Wang
		</p>
	<p>Viruses are abundant and widespread in extreme marine environments, such as sea ice, hydrothermal vents, and ocean trenches. They occur at temperatures up to 122 &amp;amp;deg;C and down to &amp;amp;minus;30 &amp;amp;deg;C and pressures exceeding 100 MPa. Their distribution in these environments is closely correlated with that of their extremophile hosts, which are mostly bacteria, archaea, and microeukaryotes. Viruses have been shown to be capable of long-term survival in conditions simulating interstellar conditions. However, for them to reproduce, they would still need a host. Many recent astro-biological investigations have focused on habitability, specifically the ability of a planet to support the activity of at least one lifeform. The most likely candidates for extraterrestrial habitability in our solar system are the sea ice moons of Jupiter and Saturn, namely Europa and Enceladus. These are both thought to contain subsurface oceans of liquid water and potentially access to the necessary elements for microbial growth. If microorganisms were to be detected in these extraterrestrial environments, viruses might also be found coexisting with their host cells.</p>
	]]></content:encoded>

	<dc:title>Viruses in Extreme Marine Environments and Their Potential Existence in Extraterrestrial Environments</dc:title>
			<dc:creator>Andrew McMinn</dc:creator>
			<dc:creator>Yantao Liang</dc:creator>
			<dc:creator>Ziyue Wang</dc:creator>
			<dc:creator>Min Wang</dc:creator>
		<dc:identifier>doi: 10.3390/v18040457</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-10</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-10</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Commentary</prism:section>
	<prism:startingPage>457</prism:startingPage>
		<prism:doi>10.3390/v18040457</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/457</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/456">

	<title>Viruses, Vol. 18, Pages 456: Molecular Mimics: How Viral Genomes Dupe Their Host by Usurping CTCF to Establish Infection</title>
	<link>https://www.mdpi.com/1999-4915/18/4/456</link>
	<description>The eukaryotic genome is organized into distinct structural units dictated by architectural proteins. The major host architectural protein CCCTC-binding factor (CTCF) is usurped by DNA viruses to regulate viral gene expression. This review will discuss the major ways large (EBV, HSV, HCMV) and small (HPV, HBV, AAV) DNA viruses mimic eukaryotic genome topology using CTCF to regulate viral gene expression. We will further discuss how changes in genome topology can drive virally induced oncogenic progression. Knowledge gained from studying viral genome folding mechanisms will inform the development of targeted anti-viral agents and inform the modification of viruses to serve as gene therapy vectors.</description>
	<pubDate>2026-04-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 456: Molecular Mimics: How Viral Genomes Dupe Their Host by Usurping CTCF to Establish Infection</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/456">doi: 10.3390/v18040456</a></p>
	<p>Authors:
		Clairine I. S. Larsen
		Rhiannon R. Abrahams
		Kinjal Majumder
		</p>
	<p>The eukaryotic genome is organized into distinct structural units dictated by architectural proteins. The major host architectural protein CCCTC-binding factor (CTCF) is usurped by DNA viruses to regulate viral gene expression. This review will discuss the major ways large (EBV, HSV, HCMV) and small (HPV, HBV, AAV) DNA viruses mimic eukaryotic genome topology using CTCF to regulate viral gene expression. We will further discuss how changes in genome topology can drive virally induced oncogenic progression. Knowledge gained from studying viral genome folding mechanisms will inform the development of targeted anti-viral agents and inform the modification of viruses to serve as gene therapy vectors.</p>
	]]></content:encoded>

	<dc:title>Molecular Mimics: How Viral Genomes Dupe Their Host by Usurping CTCF to Establish Infection</dc:title>
			<dc:creator>Clairine I. S. Larsen</dc:creator>
			<dc:creator>Rhiannon R. Abrahams</dc:creator>
			<dc:creator>Kinjal Majumder</dc:creator>
		<dc:identifier>doi: 10.3390/v18040456</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-10</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-10</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>456</prism:startingPage>
		<prism:doi>10.3390/v18040456</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/456</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/1999-4915/18/4/455">

	<title>Viruses, Vol. 18, Pages 455: Association of Oral Papivir/Pavirona&amp;reg; Supplementation with HPV DNA Clearance</title>
	<link>https://www.mdpi.com/1999-4915/18/4/455</link>
	<description>Background: Persistent cervical human papillomavirus (Human papillomavirus) infection remains a significant public health concern, as it is the primary etiological factor in the development of cervical cancer and its precursor lesions. While prophylactic vaccination and standard screening programs are cornerstones of prevention, a substantial proportion of women with established infection are managed conservatively, often with prolonged follow-up and associated psychological burden. Interest has therefore grown in supportive interventions that may facilitate viral clearance during routine clinical management. Methods: This retrospective cohort study included 239 women with confirmed cervical Human papillomavirus infection followed at a tertiary referral center between February 2023 and August 2025. Participants were classified into a treatment group receiving oral Papivir/Pavirona&amp;amp;reg; twice daily for six months (n = 119) and a control group managed with routine clinical follow-up alone (n = 120). Human papillomavirus DNA testing and cervical cytology were evaluated at baseline and at 6 and 12 months. Results: Human papillomavirus clearance rates were significantly higher in the Papivir/Pavirona&amp;amp;reg; group compared with controls at both 6 and 12 months. Cytological regression was also more frequent in the treatment group at both time points. In multivariate logistic regression analysis, Papivir/Pavirona&amp;amp;reg; use emerged as the only independent predictor of both Human papillomavirus clearance and cytological regression, while demographic, reproductive, behavioral, and virological baseline characteristics were not significantly associated with outcomes. Conclusions: Papivir/Pavirona&amp;amp;reg; supplementation was associated with increased Human papillomavirus clearance and cytological regression rates in women with cervical Human papillomavirus infection, suggesting a potential supportive role alongside standard clinical follow-up.</description>
	<pubDate>2026-04-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Viruses, Vol. 18, Pages 455: Association of Oral Papivir/Pavirona&amp;reg; Supplementation with HPV DNA Clearance</b></p>
	<p>Viruses <a href="https://www.mdpi.com/1999-4915/18/4/455">doi: 10.3390/v18040455</a></p>
	<p>Authors:
		Betul Gungor Serin
		Bilal Esat Temiz
		Haticegul Tuncer
		Muhammed Onur Atakul
		Ali Can Gunes
		Taylan Onat
		Utku Akgor
		Derman Basaran
		Zafer Selcuk Tuncer
		Murat Gultekin
		</p>
	<p>Background: Persistent cervical human papillomavirus (Human papillomavirus) infection remains a significant public health concern, as it is the primary etiological factor in the development of cervical cancer and its precursor lesions. While prophylactic vaccination and standard screening programs are cornerstones of prevention, a substantial proportion of women with established infection are managed conservatively, often with prolonged follow-up and associated psychological burden. Interest has therefore grown in supportive interventions that may facilitate viral clearance during routine clinical management. Methods: This retrospective cohort study included 239 women with confirmed cervical Human papillomavirus infection followed at a tertiary referral center between February 2023 and August 2025. Participants were classified into a treatment group receiving oral Papivir/Pavirona&amp;amp;reg; twice daily for six months (n = 119) and a control group managed with routine clinical follow-up alone (n = 120). Human papillomavirus DNA testing and cervical cytology were evaluated at baseline and at 6 and 12 months. Results: Human papillomavirus clearance rates were significantly higher in the Papivir/Pavirona&amp;amp;reg; group compared with controls at both 6 and 12 months. Cytological regression was also more frequent in the treatment group at both time points. In multivariate logistic regression analysis, Papivir/Pavirona&amp;amp;reg; use emerged as the only independent predictor of both Human papillomavirus clearance and cytological regression, while demographic, reproductive, behavioral, and virological baseline characteristics were not significantly associated with outcomes. Conclusions: Papivir/Pavirona&amp;amp;reg; supplementation was associated with increased Human papillomavirus clearance and cytological regression rates in women with cervical Human papillomavirus infection, suggesting a potential supportive role alongside standard clinical follow-up.</p>
	]]></content:encoded>

	<dc:title>Association of Oral Papivir/Pavirona&amp;amp;reg; Supplementation with HPV DNA Clearance</dc:title>
			<dc:creator>Betul Gungor Serin</dc:creator>
			<dc:creator>Bilal Esat Temiz</dc:creator>
			<dc:creator>Haticegul Tuncer</dc:creator>
			<dc:creator>Muhammed Onur Atakul</dc:creator>
			<dc:creator>Ali Can Gunes</dc:creator>
			<dc:creator>Taylan Onat</dc:creator>
			<dc:creator>Utku Akgor</dc:creator>
			<dc:creator>Derman Basaran</dc:creator>
			<dc:creator>Zafer Selcuk Tuncer</dc:creator>
			<dc:creator>Murat Gultekin</dc:creator>
		<dc:identifier>doi: 10.3390/v18040455</dc:identifier>
	<dc:source>Viruses</dc:source>
	<dc:date>2026-04-09</dc:date>

	<prism:publicationName>Viruses</prism:publicationName>
	<prism:publicationDate>2026-04-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>455</prism:startingPage>
		<prism:doi>10.3390/v18040455</prism:doi>
	<prism:url>https://www.mdpi.com/1999-4915/18/4/455</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
    
<cc:License rdf:about="https://creativecommons.org/licenses/by/4.0/">
	<cc:permits rdf:resource="https://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
